=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehaf192.pdf",
  "converted_date": "2026-01-31T14:47:50.458235",
  "file_size_bytes": 9359638,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehaf192.pdf"
}

=== СОДЕРЖАНИЕ ===

ESC GUIDELINES
European Heart Journal (2025) 46, 3952–4041

2025 ESC Guidelines for the management
of myocarditis and pericarditis
Developed by the task for ce for the management of myocarditis and
pericarditis of the European Society of Cardiology (ESC)
Endorsed by the Association for European Paediatric and
Congenital Cardiology (AEPC) and the European Association
for Cardio-Thoracic Surgery (EACTS)
Authors/Task Force Members: Jeanette Schulz-Menger †,*, (Chairperson)
(Germany), Valentino Collini ‡, (Task Force Co-ordinator) (Italy),
Jan Gröschel ‡, (Task Force Co-ordinator) (Germany), Yehuda Adler (Israel),
Antonio Brucato (Italy), Vanessa Christian (United Kingdom),
Vanessa M. Ferreira (United Kingdom), Estelle Gandjbakhch (France),
Bettina Heidecker (Germany), Mathieu Kerneis (France), Allan L. Klein
(United States of America), Karin Klingel (Germany), George Lazaros
(Greece), Roberto Lorusso (Netherlands), Elena G. Nesukay (Ukraine),
Kazem Rahimi (United Kingdom), Arsen D. Ristić (Serbia), Marcin Rucinski
(Poland), Leyla Elif Sade (United States of America), Hannah Schaubroeck
(Belgium), Anne Grete Semb (Norway), Gianfranco Sinagra (Italy),
Jens Jakob Thune (Denmark), Massimo Imazio †,*, (Chairperson) (Italy), and
the ESC Scientific Document Group
* Corresponding authors: Jeanette Schulz-Menger, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, ECRC
Experimental and Clinical Research Center, Berlin, Germany, and DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany, and Deutsches
Herzzentrum der Charité Berlin, Germany, and Cardiology and Nephrology, HELIOS Hospital Berlin-Buch, Berlin, Germany. Tel: +4930450540611, E-mail: jeanette.schulz-
menger@charite.de
Massimo Imazio, Department of Medicine, University of Udine, and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine, Italy. Tel: +393296524271,
E-mail: massimo.imazio@uniud.it
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging
(EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council of Cardio-Oncology, Council on Basic Cardiovascular Science.
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, Pulmonary Circulation and Right Ventricular Function.
Patient Forum
© The European Society of Cardiology 2025. All rights reserved.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3953
Document Reviewers: Elena Arbelo, (CPG Review Co-ordinator) (Spain), Cristina Basso, (CPG Review
Co-ordinator) (Italy), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), Enrico Ammirati (Italy),
Lisa Anderson (United Kingdom), Eloisa Arbustini (Italy), Emanuele Bobbio (Sweden), Giuseppe Boriani (Italy),
Margarita Brida (Croatia), Robert A. Byrne (Ireland), Alida L.P. Caforio (Italy), Gh.-Andrei Dan (Romania),
Fernando Domínguez (Spain), Suzanne Fredericks (Canada), Geeta Gulati (Norway), Borja Ibanez (Spain),
Stefan James (Sweden), Alexander Kharlamov (Netherlands), Sabine Klaassen (Germany), Jolanda Kluin
(Netherlands), Konstantinos C. Koskinas (Switzerland), Petr Kuchynka (Czech Republic), Vijay Kunadian (United
Kingdom), Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), Bernhard Maisch (Germany),
Federica Marelli-Berg (United Kingdom), Pilar Martin (Spain), John William McEvoy (Ireland), Borislava Mihaylova
(United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark), Saidi A. Mohiddin (United
Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Giovanni Peretto (Italy), Kalliopi Pilichou
(Italy), Nicolas Piriou (France), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy),
Xavier Rossello (Spain), Anna Sannino (Germany), Franziska Seidel1 (Germany), Felix C. Tanner (Switzerland),
Witold Zbyszek Tomkowski (Poland), Ilonca Vaartjes (Netherlands), Sophie Van Linthout (Germany),
Christiaan Vrints (Belgium), Romuald Wojnicz (Poland), and Katja Zeppenfeld (Netherlands)
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC).
All experts involved in the development of these guidelines have submitted declarations of interest,
which are reported in a supplementary document to the guidelines. See the European Heart Journal online
or  for supplementary documents as well as evidence tables.
Disclaimer: The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were produced after careful
consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in
the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines
issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals
are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s
health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC
Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or
guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data
pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and
regulations relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this
document exists. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions: The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is
authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC.
Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal
and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Guidelines • Myocarditis • Pericarditis • Myopericarditis • Perimyocarditis • Diagnosis • Therapy •
Echocardiography • Cardiac magnetic resonance • Multimodality imaging • Endomyocardial biopsy
Table of contents 3.3.2. Diagnostic criteria for pericarditis........................................... 3966
3.4. Aetiology of myocarditis and pericarditis.................................... 3966
1. Preamble.............................................................................................................. 3958 3.4.1. Aetiology of myocarditis ............................................................. 3966
2. Introduction ....................................................................................................... 3959 3.4.2. Aetiology of pericarditis .............................................................. 3966
2.1. What is new ............................................................................................. 3959 4. Clinical presentation of inflammatory myopericardial syndrome 3966
3. Epidemiology, classification, stages, diagnostic criteria and 4.1. General symptoms and signs............................................................. 3970
aetiology.................................................................................................................... 3962 4.2. Clinical stages of myocarditis ............................................................ 3970
3.1. Epidemiology............................................................................................ 3962 4.2.1. Acute myocarditis .......................................................................... 3970
3.2. Classification and stages ...................................................................... 3962 4.2.2. Fulminant myocarditis................................................................... 3971
3.3. Diagnostic criteria .................................................................................. 3963 4.2.3. Subacute myocarditis .................................................................... 3971
3.3.1. Diagnostic criteria for myocarditis.......................................... 3963 4.2.4. Chronic myocarditis...................................................................... 3971
Downloaded
from

by
guest
on
22
January
2026

3954 E S C G u id e l in e s
4.3. Clinical presentations of myocarditis............................................. 3971 6.3.1.2. Intra-aortic balloon pump .................................................. 3993
4.3.1. Chest pain presentation .............................................................. 3971 6.3.2. Pericarditis ......................................................................................... 3993
4.3.2. Heart failure presentation........................................................... 3973 6.3.2.1. Pericardiocentesis and pericardial drainage................ 3993
4.3.3. Presentation with arrhythmias.................................................. 3973 6.3.2.2. Percutaneous balloon pericardiotomy.......................... 3994
4.3.4. Sudden cardiac death.................................................................... 3973 6.3.2.3. Intrapericardial drug administration............................... 3994
4.3.5. Presentation of myocarditis with a potential genetic 6.3.2.4. Pericardioscopy....................................................................... 3994
background .................................................................................................... 3973 6.3.2.5. Pericardial fluid analysis, pericardial and epicardial
4.4. Clinical stages of pericarditis ............................................................. 3973 biopsy.......................................................................................................... 3994
4.4.1. Acute pericarditis............................................................................ 3973 6.3.2.6. Circulatory support .............................................................. 3994
4.4.2. Subacute pericarditis ..................................................................... 3976 6.4. Surgical therapy....................................................................................... 3994
4.4.3. Chronic pericarditis....................................................................... 3976 6.4.1. Myocarditis ........................................................................................ 3994
4.5. Clinical presentations of pericarditis.............................................. 3976 6.4.2. Pericarditis ......................................................................................... 3994
4.5.1. Dry pericarditis................................................................................ 3976 6.4.2.1. Surgical pericardiocentesis ................................................. 3994
4.5.2. Effusive pericarditis ........................................................................ 3976 6.4.2.2. Pericardiotomy/pericardial window............................... 3994
4.5.3. Effusive–constrictive pericarditis.............................................. 3976 6.4.2.3. Pericardiectomy...................................................................... 3995
4.5.4. Pericarditis with cardiac tamponade ...................................... 3976 6.5. Management of arrhythmias and prevention of sudden
4.5.5. Constrictive pericarditis............................................................... 3977 cardiac death in myocarditis....................................................................... 3995
4.5.6. Transient constrictive pericarditis ........................................... 3978 6.5.1. Role of active devices (wearable and implanted devices) in
4.5.6.1. Constrictive pathophysiology ........................................... 3978 acute myocarditis........................................................................................ 3996
4.5.7. Pericarditis with polyserositis.................................................... 3979 7. Prognosis ............................................................................................................. 3996
4.5.8. Inflammatory vs non-inflammatory pericarditis................. 3979 7.1. Complications and outcomes for myocarditis .......................... 3996
4.5.8.1. Inflammatory phenotype of pericarditis....................... 3979 7.1.1. Sequela and mortality in myocarditis..................................... 3997
4.5.8.2. Non-inflammatory phenotype of pericarditis............ 3979 7.1.2. Follow-up ........................................................................................... 3997
5. Diagnosis and diagnostic work-up............................................................ 3979 7.2. Complications and outcomes for pericarditis ........................... 3998
5.1. Electrocardiogram.................................................................................. 3980 8. Inflammatory myopericardial syndrome overlapping types:
5.2. Biomarkers ................................................................................................ 3980 myopericarditis and perimyocarditis ............................................................ 3999
5.2.1. Biomarkers in clinical routine.................................................... 3980 8.1. Inflammatory myopericardial syndrome in systemic
5.2.2. Biomarkers beyond clinical routine ........................................ 3980 disorders............................................................................................................. 4000
5.3. Genetics...................................................................................................... 3981 8.1.1. Rheumatoid arthritis ..................................................................... 4000
5.4. Multimodality imaging........................................................................... 3982 8.1.2. Systemic lupus erythematosus.................................................. 4000
5.5. Echocardiography................................................................................... 3982 8.1.3. Antiphospholipid syndrome....................................................... 4000
5.5.1. Echocardiography in myocarditis............................................. 3982 8.1.4. Sjögren’s syndrome........................................................................ 4000
5.5.2. Echocardiography in pericarditis.............................................. 3982 8.1.5. Systemic sclerosis ........................................................................... 4000
5.6. Cardiovascular magnetic resonance............................................... 3983 8.1.6. Polymyositis and dermatomyositis.......................................... 4000
5.7. Computed tomography....................................................................... 3983 8.1.7. Vasculitis ............................................................................................. 4000
5.8. Nuclear medicine ................................................................................... 3984 8.2. Inflammatory myopericardial syndrome in COVID-19
5.9. Endomyocardial and pericardial biopsy ........................................ 3984 disease.................................................................................................................. 4000
5.9.1. Endomyocardial biopsy ................................................................ 3984 9. Specific types of myocarditis....................................................................... 4001
5.9.2. Pericardial biopsy............................................................................ 3986 9.1. Lymphocytic myocarditis .................................................................... 4001
5.10. Role of autopsy .................................................................................... 3986 9.1.1. Presentation...................................................................................... 4001
5.11. Role of cardiac catheterization and coronary angiography 3986 9.1.2. Diagnosis and therapy .................................................................. 4001
5.12. Electro-anatomical mapping............................................................ 3987 9.2. Eosinophilic myocarditis...................................................................... 4001
6. Therapy................................................................................................................ 3987 9.2.1. Presentation...................................................................................... 4001
6.1. Non-pharmacological therapy for inflammatory 9.2.2. Diagnosis ............................................................................................ 4001
myopericardial syndrome............................................................................ 3987 9.2.3. Therapy............................................................................................... 4001
6.2. Pharmacological therapy ..................................................................... 3987 9.3. Giant-cell myocarditis........................................................................... 4001
6.2.1. Pharmacological therapy for myocarditis............................. 3987 9.3.1. Presentation...................................................................................... 4002
6.2.1.1. General principles.................................................................. 3987 9.3.2. Diagnosis ............................................................................................ 4002
6.2.1.2. Fulminant myocarditis .......................................................... 3989 9.3.3. Therapy............................................................................................... 4002
6.2.1.3. Acute myocarditis.................................................................. 3989 9.4. Myocarditis in sarcoidosis................................................................... 4003
6.2.1.4. Subacute and chronic myocarditis.................................. 3990 9.4.1. Presentation...................................................................................... 4003
6.2.2. Pharmacological therapy for pericarditis.............................. 3990 9.4.2. Diagnosis ............................................................................................ 4003
6.2.2.1. General principles.................................................................. 3990 9.4.3. Therapy............................................................................................... 4003
6.2.2.1.1. Acute pericarditis (first episode) ............................ 3990 9.5. Specific infectious myocarditis (Viruses, Lyme, Chagas) ....... 4004
6.2.2.2. Incessant and recurrent pericarditis .............................. 3990 9.5.1. Viruses................................................................................................. 4004
6.3. Interventional techniques including circulatory support ....... 3993 9.5.1.1. Presentation ............................................................................. 4004
6.3.1. Myocarditis ........................................................................................ 3993 9.5.1.2. Diagnosis.................................................................................... 4004
6.3.1.1. Short-term mechanical circulatory support ............... 3993 9.5.1.3. Therapy ...................................................................................... 4004
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3955
9.5.1.3.1. Influenza virus.................................................................. 4004 11.9.1. Introduction.................................................................................... 4014
9.5.1.3.2. Human immunodeficiency virus.............................. 4004 11.9.2. Presentation ................................................................................... 4014
9.5.2. Lyme carditis..................................................................................... 4004 11.9.3. Diagnosis.......................................................................................... 4014
9.5.2.1. Presentation ............................................................................. 4004 11.9.4. Therapy ............................................................................................ 4015
9.5.2.2. Diagnosis.................................................................................... 4004 11.10. Effusive–constrictive pericarditis ................................................ 4015
9.5.2.3. Therapy ...................................................................................... 4004 11.10.1. Introduction................................................................................. 4015
9.5.3. Chagas disease ................................................................................. 4005 11.10.2. Aetiology....................................................................................... 4015
9.5.3.1. Presentation ............................................................................. 4005 11.10.3. Presentation................................................................................. 4015
9.5.3.2. Diagnosis.................................................................................... 4005 11.10.4. Diagnosis ....................................................................................... 4015
9.5.3.3. Therapy ...................................................................................... 4005 11.10.5. Treatment..................................................................................... 4015
9.6. Drug- or vaccine-induced myocarditis.......................................... 4005 12. Age- and sex-related aspects in inflammatory myopericardial
9.6.1. Drug-induced myocarditis........................................................... 4005 syndrome.................................................................................................................. 4015
9.6.1.1. Immune checkpoint inhibitor-induced myocarditis. 4005 12.1. Sex distribution..................................................................................... 4015
9.6.1.1.1. Presentation..................................................................... 4005 12.2. Paediatric patients ............................................................................... 4016
9.6.1.1.2. Diagnosis ........................................................................... 4005 12.2.1. Myocarditis...................................................................................... 4016
9.6.1.1.3. Therapy.............................................................................. 4005 12.2.2. Pericarditis....................................................................................... 4016
9.6.1.2. Other drugs associated with myocarditis.................... 4006 12.3. Pregnancy, lactation, and reproductive issues......................... 4016
9.6.2. Vaccine-induced myocarditis ..................................................... 4006 12.4. The elderly.............................................................................................. 4017
9.7. Pregnancy-associated myocarditis................................................... 4006 12.5. Physical activity in inflammatory myopericardial syndrome 4017
9.7.1. Presentation...................................................................................... 4006 12.5.1. Mental health effect of restricting exercise ...................... 4017
9.7.2. Diagnosis ............................................................................................ 4006 12.6. Multidisciplinary teams for the management of inflammatory
9.7.3. Therapy............................................................................................... 4006 myopericardial syndrome............................................................................ 4017
10. Inflammatory cardiomyopathy ................................................................ 4006 13. Advice for patients ....................................................................................... 4018
10.1. Presentation........................................................................................... 4007 14. Tertiary referral centres for inflammatory myopericardial
10.2. Diagnosis ................................................................................................. 4007 syndrome: feature and volume of activity.................................................. 4018
10.3. Therapy.................................................................................................... 4007 14.1. Tertiary care centres.......................................................................... 4018
11. Specific types of pericarditis..................................................................... 4007 14.2. Inflammatory myopericardial syndrome in regional centres 4018
11.1. Tuberculous pericarditis................................................................... 4007 14.3. Hub-and-spoke model....................................................................... 4018
11.1.1. Presentation ................................................................................... 4007 14.4. Teamwork, competencies, and advances in imaging
11.1.2. Diagnosis.......................................................................................... 4007 techniques .......................................................................................................... 4019
11.1.3. Therapy ............................................................................................ 4008 15. Key messages .................................................................................................. 4019
11.2. Pericardial involvement in neoplastic disease.......................... 4009 15.1. Aetiology ................................................................................................. 4019
11.2.1. Presentation ................................................................................... 4009 15.2. Clinical presentation and diagnosis .............................................. 4019
11.2.2. Diagnosis.......................................................................................... 4009 15.3. Therapy.................................................................................................... 4019
11.2.3. Therapy ............................................................................................ 4009 15.4. Prognosis and outcomes .................................................................. 4019
11.3. Post-cardiac injury syndrome......................................................... 4009 15.5. Multidisciplinary team ........................................................................ 4019
11.3.1. Diagnosis.......................................................................................... 4010 16. Gaps in evidence............................................................................................ 4019
11.3.2. Therapy ............................................................................................ 4010 16.1. Myocarditis ............................................................................................. 4019
11.4. Pericarditis and autoinflammatory diseases ............................. 4010 16.2. Pericarditis .............................................................................................. 4020
11.5. Purulent pericarditis ........................................................................... 4010 17. Sex differences ............................................................................................... 4020
11.5.1. Presentation ................................................................................... 4011 18. ‘What to do’ and ‘What not to do’ messages from the
11.5.2. Diagnosis.......................................................................................... 4011 Guidelines................................................................................................................. 4020
11.5.3. Therapy ............................................................................................ 4011 19. Evidence tables ............................................................................................... 4023
11.6. Incessant and recurrent pericarditis............................................ 4011 20. Data availability statement......................................................................... 4023
11.7. Inflammatory and non-inflammatory pericardial effusion .. 4011 21. Author information...................................................................................... 4023
11.7.1. Classification and aetiology...................................................... 4011 22. Appendix........................................................................................................... 4024
11.7.2. Presentation ................................................................................... 4011 ESC Scientific Document Group ................................................................... 4024
11.7.3. Diagnosis.......................................................................................... 4012 23. References........................................................................................................ 4025
11.7.4. Therapy ............................................................................................ 4013
11.7.5. Prognosis and follow-up ........................................................... 4013
Tables of Recommendations
11.8. Cardiac tamponade............................................................................. 4013
11.8.1. Presentation ................................................................................... 4013 Recommendation Table 1 — Recommendations for clinical
11.8.2. Aetiology and diagnosis............................................................. 4013 evaluation of myocarditis and pericarditis (see Evidence Table 1). 3979
11.8.3. Therapy ............................................................................................ 4014 Recommendation Table 2 — Recommendations for genetic testing
11.8.4. Outcomes and prognosis ......................................................... 4014 (see Evidence Table 2)........................................................................................ 3981
11.9. Pericardial constriction and constrictive pericarditis Recommendation Table 3 — Recommendations for the use of
(calcified and non-calcified)......................................................................... 4014 cardiovascular magnetic resonance imaging (see Evidence Table 3) 3983
Downloaded
from

by
guest
on
22
January
2026

3956 E S C G u id e l in e s
Recommendation Table 4 — Recommendations for computed Table 4 Diagnostic criteria and classification for inflammatory
tomography (see Evidence Table 4)............................................................. 3983 myopericardial syndrome.................................................................................. 3964
Recommendation Table 5 — Recommendations for nuclear Table 5 Histopathological criteria for myocarditis................................. 3964
medicine (see Evidence Table 5).................................................................... 3984 Table 6 Red flags for the clinical diagnosis of myocarditis and
Recommendation Table 6 — Recommendations for pericarditis................................................................................................................ 3967
endomyocardial biopsy (see Evidence Table 6)....................................... 3985 Table 7 Clinical risk stratification to guide work-up in inflammatory
Recommendation Table 7 — Recommendations for autopsy (see myopericardial syndrome.................................................................................. 3967
Evidence Table 7).................................................................................................. 3986 Table 8 Causes of cardiac tamponade......................................................... 3976
Recommendation Table 8 — Recommendations for Table 9 Basic and advanced level assessment........................................... 3980
electro-anatomical mapping (see Evidence Table 8) ............................. 3987 Table 10 Classification of pericardial effusion .......................................... 3982
Recommendation Table 9 — Recommendations for medical Table 11 Parameters for reporting by endomyocardial biopsy........ 3986
therapy in myocarditis (see Evidence Table 9) ........................................ 3990 Table 12 Therapy for specific forms of myocarditis ............................. 3988
Recommendation Table 10 — Recommendations for medical Table 13 Specific initial dosing and duration of therapy for acute and
therapy in pericarditis (see Evidence Table 10)....................................... 3993 recurrent pericarditis .......................................................................................... 3991
Recommendation Table 11 — Recommendations for interventional Table 14 Tapering of corticosteroids .......................................................... 3991
techniques including circulatory support in myocarditis (see Table 15 Follow-up in inflammatory myopericardial syndrome after
Evidence Table 11)............................................................................................... 3993 discharge ................................................................................................................... 3998
Recommendation Table 12 — Recommendations for interventional Table 16 Indicators of non-viral aetiologies and complications
techniques in pericarditis (see Evidence Table 12) ................................ 3994 (high-risk features or red flags in acute pericarditis)............................. 3999
Recommendation Table 13 — Recommendations for surgical Table 17 Echocardiographic signs of cardiac tamponade............................... 4013
therapy (see Evidence Table 13).................................................................... 3995 Table 18 Definitions and therapy of main constrictive pericardial
Recommendation Table 14 — Recommendations for management syndromes................................................................................................................ 4014
of arrhythmias and prevention of sudden cardiac death in Table 19 ‘What to do’ and ‘What not to do’ .......................................... 4020
myocarditis (see Evidence Table 14)............................................................ 3996
Recommendation Table 15 — Recommendations for risk List of figures
stratification, complications, and outcomes of inflammatory
myopericardial syndrome (see Evidence Table 15) ............................... 3998 Figure 1 Central illustration of the ESC guidelines on myocarditis and
Recommendation Table 16 — Recommendations for giant-cell pericarditis................................................................................................................ 3960
myocarditis (see Evidence Table 16)............................................................ 4002 Figure 2 Paradigm change in the clinical diagnosis of myocarditis... 3961
Recommendation Table 17 — Recommendations for myocarditis in Figure 3 Stages of inflammatory myopericardial syndrome ............... 3963
sarcoidosis (see Evidence Table 17) ............................................................. 4003 Figure 4 Diagnostic criteria by cardiovascular magnetic resonance
Recommendation Table 18 — Recommendations for immune based on the updated Lake Louise criteria................................................ 3965
checkpoint inhibitor-associated myocarditis (see Evidence Figure 5 Diagnostic algorithm and triage for inpatient myocarditis 3968
Table 18)................................................................................................................... 4006 Figure 6 Diagnostic algorithm and triage for outpatient myocarditis 3969
Recommendation Table 19 — Recommendations for inflammatory Figure 7 Diagnostic algorithm and triage for pericarditis .................... 3970
cardiomyopathy (see Evidence Table 19) .................................................. 4007 Figure 8 Spectrum of myocarditis presentations and outcomes ..... 3971
Recommendation Table 20 — Recommendations for tuberculous Figure 9 Diagnostic algorithm for acute chest pain presentation.... 3972
pericarditis (see Evidence Table 20)............................................................. 4008 Figure 10 Diagnostic algorithm for acute heart failure presentation 3974
Recommendation Table 21 — Recommendations for neoplastic Figure 11 Diagnostic algorithm for arrhythmia presentation ............ 3975
pericardial involvement (see Evidence Table 21).................................... 4009 Figure 12 Management of cardiac tamponade......................................... 3977
Recommendation Table 22 — Recommendations for post-cardiac Figure 13 Management of constriction........................................................ 3978
injury syndrome (see Evidence Table 22) .................................................. 4010 Figure 14 The different courses of inflammatory myopericardial
Recommendation Table 23 — Recommendations for purulent syndrome and the interplay between genetic background
pericarditis (see Evidence Table 23)............................................................. 4011 inflammation and autoimmunity beyond the initial infectious trigger 3982
Recommendation Table 24 — Recommendations for constrictive Figure 15 Histopathological findings in myocarditis............................... 3985
pericarditis (see Evidence Table 24)............................................................. 4015 Figure 16 Proposed algorithm of medical therapy for pericarditis in
Recommendation Table 25 — Recommendations for pregnancy, adults (not including interventional therapies and pericardiectomy) 3992
lactation, and reproductive issues (see Evidence Table 25)............... 4016 Figure 17 Follow-up and risk stratification after acute myocarditis
Recommendation Table 26 — Recommendations for physical with arrhythmic presentation.......................................................................... 3999
activity and myocarditis/pericarditis (see Evidence Table 26) ........... 4017 Figure 18 Stages of tuberculous pericarditis ............................................. 4008
Recommendation Table 27 — Recommendations for Figure 19 Triage and management of pericardial effusion .................. 4012
multidisciplinary teams in myopericardial syndromes (see Evidence Figure 20 Multidisciplinary teams for inflammatory myopericardial
Table 27)................................................................................................................... 4017 syndrome.................................................................................................................. 4018
List of tables Abbreviations and acronyms
Table 1 Classes of recommendations.......................................................... 3958 ACC American College of Cardiology
Table 2 Levels of evidence................................................................................ 3959 ACS Acute coronary syndrome
Table 3 Terminology and stages..................................................................... 3962 ADA Adenosine deaminase
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3957
AF Atrial fibrillation ICU Intensive care unit
AM Acute myocarditis IFN Interferon
AMI Acute myocardial infarction IL Interleukin
AP Acute pericarditis IL-1RA Interleukin-1 receptor antagonist
ARVC Arrhythmogenic right ventricular cardiomyopathy IL-1RL1 IL-1 receptor-like 1
ATG Anti-thymocyte globulin IMPS Inflammatory myopericardial syndrome
AVB Atrioventricular block i.v. Intravenous
B19V Parvovirus B19 IVIG Intravenous immunoglobulins
CAD Coronary artery disease JVP Jugular venous pressure
CD Chagas disease LA Left atrial
CI Confidence interval LAG-3 Lymphocyte activation gene 3
CK Creatinine kinase LC Lyme carditis
CK-MB Creatinine kinase muscle-brain type LGE Late gadolinium enhancement
CMP Cardiomyopathy LLC Lake Louise criteria
CMR Cardiovascular magnetic resonance LM Lymphocytic myocarditis
CMV Cytomegalovirus LV Left ventricle
COVID-19 Coronavirus disease 2019 LVAD Left ventricular assist device
CP Constrictive pericarditis LVEF Left ventricular ejection fraction
CPB Cardiopulmonary bypass MACE Major adverse cardiac events
CRT Cardiac resynchronization therapy MCS Mechanical circulatory support
CS Cardiac sarcoidosis miRNAs MicroRNAs
CT Computed tomography NDLVC Non-dilated left ventricular cardiomyopathy
CTLA-4 Cytotoxic T-lymphocyte antigen 4 NLRP3 NLR family pyrin domain containing 3
CTP Cardiac tamponade NSAID Non-steroidal anti-inflammatory drug
DCM Dilated cardiomyopathy NSVT Non-sustained ventricular tachycardia
DNA Deoxyribonucleic acid NT-proBNP N-terminal prohormone of brain natriuretic
DSP Desmoplakin peptide
EAM Electro-anatomical mapping OR Odds ratio
EBV Epstein–Barr virus P/LP Pathogenic/likely pathogenic
ECG Electrocardiogram PaM Pregnancy-associated myocarditis
ECP Effusive–constrictive pericarditis PCIS Post-cardiac injury syndrome
ECV Extracellular volume PCR Polymerase chain reaction
EF Ejection fraction PD-1 Programmed cell death protein 1
EGPA Eosinophilic granulomatosis with polyangiitis PD-L1 Programmed death ligand 1
EM Eosinophilic myocarditis PEff Pericardial effusion
EMB Endomyocardial biopsy PPCM Peripartum cardiomyopathy
ESC European Society of Cardiology PPS Post-pericardiotomy syndrome
ESR Erythrocyte sedimentation rate PVS Programmed ventricular stimulation
FDG-PET Fluorodeoxyglucose positron emission RA Rheumatoid arthritis
tomography RAP Right atrial pressure
FM Fulminant myocarditis RCM Restrictive cardiomyopathy
FMF Familial Mediterranean fever RCT Randomized controlled trial
GCM Giant-cell myocarditis RNA Ribonucleic acid
GDMT Guideline-directed medical therapy RP Recurrent pericarditis
GLS Global longitudinal strain RV Right ventricle
HAART Highly active antiretroviral therapy SARS-CoV-2 Severe acute respiratory syndrome
HCM Hypertrophic cardiomyopathy coronavirus 2
HCV Hepatitis C virus SCD Sudden cardiac death
HES Hypereosinophilic syndrome SLE Systemic lupus erythematosus
HF Heart failure SSc Systemic sclerosis
HHV-6 Human herpesvirus 6 TB Tuberculosis
HIV Human immunodeficiency virus TDI Tissue Doppler imaging
HR Hazard ratio TF Task Force
hs-TnI High-sensitivity troponin I TNF-α Tumour necrosis factor alpha
hs-TnT High-sensitivity troponin T TRAPS Tumour necrosis factor receptor-associated
HT Heart transplantation periodic syndrome
IABP Intra-aortic balloon pump TTE Transthoracic echocardiography
ICD Implantable cardioverter-defibrillator uIFN-γ Unstimulated interferon gamma
ICI Immune checkpoint inhibitor VA Ventricular arrhythmias
Downloaded
from

by
guest
on
22
January
2026

3958 E S C G u id e l in e s
VA-ECMO Veno-arterial extracorporeal membrane oxygenation members from across the whole of the ESC region and from relevant
VAD Ventricular assist device ESC Subspecialty Communities. Consideration was given to diversity
VF Ventricular fibrillation and inclusion.
VT Ventricular tachycardia Guidelines Task Forces perform a critical review and evaluation of
WCD Wearable cardioverter-defibrillator the published literature on diagnostic and therapeutic approaches in-
WMA Wall motion abnormalities cluding assessment of the risk–benefit ratio. Recommendations are
based on major randomized trials and relevant systematic reviews
and meta-analyses, when available. Systematic literature searches are
1. Preamble
conducted in cases of controversy or uncertainty to ensure that all
key studies were considered. For recommendations related to diagno-
Guidelines evaluate and summarize available evidence with the aim of as-
sis and prognosis, additional types of evidence are included, such as
sisting health professionals in proposing the best diagnostic or therapeutic
diagnostic accuracy studies and studies focused on the development
approach for an individual patient with a given condition. ESC Guidelines
and validation of prognostic models. The strength of each recommen- are intended for use by health professionals but do not override their in-
dation and the level of evidence supporting it are weighed and scored
dividual responsibility to make appropriate and accurate decisions in con-
according to predefined criteria as outlined in Tables 1 and 2.
sideration of each patient’s health condition and in consultation with the
Patient-reported outcome measures (PROMs) and patient-reported
patient or the patient’s caregiver where appropriate and/or necessary. It is
experience measures (PREMs) are also evaluated when available as also the health professional’s responsibility to verify the rules and regula-
the basis for recommendations and/or discussion in these guidelines.
tions applicable in each country to drugs and devices at the time of pre-
Evidence tables summarizing key information from relevant studies
scription and to respect the ethical rules of their profession.
are generated to facilitate the formulation of recommendations, to en-
ESC Guidelines represent the official position of the ESC on a given
hance comprehension of recommendations after publication, and to
topic. Guideline topics are selected for updating after annual expert re-
reinforce transparency in the guidelines development process. The ta-
view of new evidence conducted by the ESC Clinical Practice
bles are published in their own section of ESC Guidelines and reference
Guidelines (CPG) Committee. ESC Policies and Procedures for formu-
specific recommendation tables.
lating and issuing ESC Guidelines can be found on the ESC website
After an iterative process of deliberations, a first Task Force vote
(
on all recommendations is conducted prior to the initiation of rounds
Guidelines-development/Writing-ESC-Guidelines).
of review. A second Task Force vote on all recommendations is con-
This guideline updates and replaces the previous version of the ESC
ducted after the final round of review and revision. For each vote, the
Guidelines on pericarditis from 2015. For the first time it also covers
Task Force follows ESC voting procedures and all recommendations
myocarditis. This Task Force was selected by the ESC to include profes-
require at least 75% agreement among voting members to be ap-
sionals involved with the medical care of patients with this pathology
proved. Voting restrictions may be applied based on declarations of
and to include patient representatives and methodologists. The selec-
interests.
tion procedure included an open call for authors and aimed to include
Table 1 Classes of recommendations
(cid:157)(cid:21)(cid:3)(cid:15)(cid:12)(cid:13)(cid:12)(cid:20)(cid:15) (cid:144)(cid:20)(cid:18)(cid:14)(cid:12)(cid:15)(cid:8)(cid:28)(cid:13)(cid:20)(cid:28)(cid:5)(cid:22)(cid:21)
(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:28) (cid:31)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:23)(cid:15)(cid:14)(cid:9)(cid:20)(cid:18)(cid:28)(cid:8)(cid:21)(cid:15)(cid:21)(cid:18)(cid:23)(cid:24)(cid:28)(cid:23)(cid:8)(cid:18)(cid:21)(cid:21)(cid:16)(cid:21)(cid:15)(cid:13) (cid:11)(cid:22)(cid:28)(cid:18)(cid:21)(cid:17)(cid:20)(cid:16)(cid:16)(cid:21)(cid:15)(cid:14)(cid:21)(cid:14)(cid:28)(cid:20)(cid:18)(cid:28)(cid:12)(cid:22)(cid:28)(cid:12)(cid:15)(cid:14)(cid:12)(cid:17)(cid:23)(cid:13)(cid:21)(cid:14)
(cid:13)(cid:7)(cid:23)(cid:13)(cid:28)(cid:23)(cid:28)(cid:8)(cid:12)(cid:10)(cid:21)(cid:15)(cid:28)(cid:13)(cid:18)(cid:21)(cid:23)(cid:13)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:20)(cid:18)(cid:28)(cid:6)(cid:18)(cid:20)(cid:17)(cid:21)(cid:14)(cid:5)(cid:18)(cid:21)(cid:28)(cid:12)(cid:22)
(cid:4)(cid:21)(cid:15)(cid:21)(cid:3)(cid:17)(cid:12)(cid:23)(cid:24)(cid:2)(cid:28)(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:2)(cid:28)(cid:21)(cid:1)(cid:21)(cid:17)(cid:13)(cid:12)(cid:10)(cid:21)(cid:127)(cid:28)
(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:28) (cid:29)(cid:20)(cid:15)(cid:129)(cid:12)(cid:17)(cid:13)(cid:12)(cid:15)(cid:8)(cid:28)(cid:21)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:23)(cid:15)(cid:14)(cid:9)(cid:20)(cid:18)(cid:28)(cid:23)(cid:28)(cid:14)(cid:12)(cid:10)(cid:21)(cid:18)(cid:8)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:20)(cid:19)(cid:28)(cid:20)(cid:6)(cid:12)(cid:15)(cid:12)(cid:20)(cid:15)(cid:28)(cid:23)(cid:4)(cid:20)(cid:5)(cid:13)(cid:28)(cid:13)(cid:7)(cid:21)(cid:28)(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:15)(cid:21)(cid:22)(cid:22)(cid:9)(cid:28)
(cid:21)(cid:141)(cid:17)(cid:23)(cid:17)(cid:143)(cid:28)(cid:20)(cid:19)(cid:28)(cid:13)(cid:7)(cid:21)(cid:28)(cid:8)(cid:12)(cid:10)(cid:21)(cid:15)(cid:28)(cid:13)(cid:18)(cid:21)(cid:23)(cid:13)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:20)(cid:18)(cid:28)(cid:6)(cid:18)(cid:20)(cid:17)(cid:21)(cid:14)(cid:5)(cid:18)(cid:21)(cid:127)(cid:28)
(cid:28)(cid:28)(cid:28)(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:23) (cid:144)(cid:21)(cid:12)(cid:8)(cid:7)(cid:13)(cid:28)(cid:20)(cid:19)(cid:28)(cid:21)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:9)(cid:20)(cid:6)(cid:12)(cid:15)(cid:12)(cid:20)(cid:15)(cid:28)(cid:12)(cid:22)(cid:28)(cid:12)(cid:15) (cid:30)(cid:7)(cid:20)(cid:5)(cid:24)(cid:14)(cid:28)(cid:4)(cid:21)(cid:28)(cid:17)(cid:20)(cid:15)(cid:22)(cid:12)(cid:14)(cid:21)(cid:18)(cid:21)(cid:14)
(cid:28)
(cid:19)(cid:23)(cid:10)(cid:20)(cid:5)(cid:18)(cid:28)(cid:20)(cid:19)(cid:28)(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:15)(cid:21)(cid:22)(cid:22)(cid:9)(cid:21)(cid:141)(cid:17)(cid:23)(cid:17)(cid:143)(cid:127)(cid:28)
(cid:28)(cid:28) (cid:28)(cid:28)(cid:28)(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:4) (cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:15)(cid:21)(cid:22)(cid:22)(cid:9)(cid:21)(cid:141)(cid:17)(cid:23)(cid:17)(cid:143)(cid:28)(cid:12)(cid:22)(cid:28)(cid:24)(cid:21)(cid:22)(cid:22)(cid:28) (cid:21)(cid:24)(cid:24) €(cid:23)(cid:143)(cid:28)(cid:4)(cid:21)(cid:28)(cid:17)(cid:20)(cid:15)(cid:22)(cid:12)(cid:14)(cid:21)(cid:18)(cid:21)(cid:14)
(cid:21)(cid:22)(cid:13)(cid:23)(cid:4)(cid:24)(cid:12)(cid:22)(cid:7)(cid:21)(cid:14)(cid:28)(cid:4)(cid:143)(cid:28)(cid:21)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:9)(cid:20)(cid:6)(cid:12)(cid:15)(cid:12)(cid:20)(cid:15)(cid:127)
(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:11)(cid:28) (cid:31)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:20)(cid:18)(cid:28)(cid:8)(cid:21)(cid:15)(cid:21)(cid:18)(cid:23)(cid:24)(cid:28)(cid:23)(cid:8)(cid:18)(cid:21)(cid:21)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:13)(cid:7)(cid:23)(cid:13)(cid:28)(cid:13)(cid:7)(cid:21) (cid:11)(cid:22)(cid:28)(cid:15)(cid:20)(cid:13)(cid:28)(cid:18)(cid:21)(cid:17)(cid:20)(cid:16)(cid:16)(cid:21)(cid:15)(cid:14)(cid:21)(cid:14)
(cid:8)(cid:12)(cid:10)(cid:21)(cid:15)(cid:28)(cid:13)(cid:18)(cid:21)(cid:23)(cid:13)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:20)(cid:18)(cid:28)(cid:6)(cid:18)(cid:20)(cid:17)(cid:21)(cid:14)(cid:5)(cid:18)(cid:21)(cid:28)(cid:12)(cid:22)(cid:28)(cid:15)(cid:20)(cid:13)
(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:9)(cid:21)(cid:1)(cid:21)(cid:17)(cid:13)(cid:12)(cid:10)(cid:21)(cid:2)(cid:28)(cid:23)(cid:15)(cid:14)(cid:28)(cid:12)(cid:15)(cid:28)(cid:22)(cid:20)(cid:16)(cid:21)(cid:28)(cid:17)(cid:23)(cid:22)(cid:21)(cid:22)
(cid:16)(cid:23)(cid:143)(cid:28)(cid:4)(cid:21)(cid:28)(cid:7)(cid:23)(cid:18)(cid:16)(cid:19)(cid:5)(cid:24)(cid:127)(cid:28)
(cid:22)(cid:15)(cid:20)(cid:12)(cid:13)(cid:23)(cid:14)(cid:15)(cid:21)(cid:16)(cid:16)(cid:20)(cid:17)(cid:21)(cid:18)(cid:28)(cid:19)(cid:20)(cid:28)(cid:22)(cid:21)(cid:22)(cid:22)(cid:23)(cid:24)(cid:29)
(cid:25)(cid:27)(cid:26)(cid:27)(cid:28)(cid:29)(cid:30)(cid:31)©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3959
Table 2 Levels of evidence
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:13)(cid:12)(cid:28)(cid:15)(cid:24)(cid:11)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)(cid:9)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:20) (cid:26)(cid:14)(cid:27)(cid:13)(cid:30)(cid:15)(cid:16)(cid:8)(cid:16)(cid:22)(cid:16)(cid:28)(cid:7)(cid:9)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:16)(cid:27)(cid:9)(cid:24)(cid:22)(cid:5)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:19) (cid:26)(cid:14)(cid:27)(cid:28)(cid:16)(cid:14)(cid:5)(cid:30)(cid:27)(cid:22)(cid:26)(cid:22)(cid:8)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:18)(cid:26)(cid:22)(cid:9)(cid:30)(cid:22)(cid:9)(cid:12)(cid:9)(cid:27)(cid:26)(cid:25)(cid:27)(cid:26)(cid:11)(cid:24)(cid:22)(cid:24)(cid:26)(cid:22)(cid:27)(cid:26)(cid:25)(cid:27)(cid:15)(cid:4)(cid:30)(cid:27)(cid:30)(cid:3)(cid:11)(cid:30)(cid:14)(cid:15)(cid:9)(cid:27)(cid:16)(cid:22)(cid:23)(cid:2)(cid:26)(cid:14)(cid:27)(cid:9)(cid:13)(cid:16)(cid:28)(cid:28)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:18) (cid:14)(cid:30)(cid:15)(cid:14)(cid:26)(cid:9)(cid:11)(cid:30)(cid:21)(cid:15)(cid:24)(cid:29)(cid:30)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)(cid:27)(cid:14)(cid:30)(cid:5)(cid:24)(cid:9)(cid:15)(cid:14)(cid:24)(cid:30)(cid:9)(cid:6)
The writing and reviewing panels provide declaration of interest diagnostic process until a final diagnosis is made (Figure 1). It reflects the
forms for all relationships that might be perceived as real or potential possible myocarditis–pericarditis overlap, aiming to increase the aware-
sources of conflicts of interest. Their declarations of interest are re- ness of the spectrum of disease, and to allow timely diagnosis and better
viewed according to the ESC declaration of interest rules, which can management. IMPS ranges from isolated myocarditis to isolated pericar-
be found on the ESC website ( and are ditis through mixed forms with possible reciprocal involvement, such as
compiled in a report published in a supplementary document with myopericarditis and perimyocarditis. Both terms are commonly used in
the guidelines. Funding for the development of ESC Guidelines is de- the medical literature, and defined in the 2015 ESC Guidelines for the
rived entirely from the ESC with no involvement of the healthcare diagnosis and management of pericardial diseases (see Section 8).1
industry. The rationale for the introduction of IMPS is that myocarditis and
The CPG Committee supervises and co-ordinates the preparation of pericarditis have similar aetiologies and are anatomical contiguous
new guidelines and approves their publication. In addition to review by structures with possible secondary involvement.2–5
the CPG Committee, ESC Guidelines undergo multiple rounds of The field has experienced rapid growth, with position statements
double-blind peer review on a dedicated online review platform. The proposed by different cardiac societies.6–10 In the past, several consen-
review is conducted by topic experts, including members from ESC sus statements were provided, usually defining a proven myocarditis
National Cardiac Societies and from relevant ESC Subspecialty based on endomyocardial biopsy (EMB). Endomyocardial biopsy is
Communities. Guideline Task Forces consider all review comments able to detect the histological type, can identify some specific aetiolo-
and are required to respond to all those classified as major. After ap- gies, and can help to differentiate from non-inflammatory cardiomyop-
propriate revisions, the Task Force and the CPG Committee members athies (CMPs).10 But nowadays multimodality imaging has become a
approve the final document for publication in the European Heart cornerstone for the diagnosis of myocardial and pericardial inflamma-
Journal. tion and cardiovascular magnetic resonance (CMR) plays a crucial
Unless otherwise stated, ESC Guidelines content refers to sex, role, as reported in other ESC guidelines11–13 (Figure 2).
understood as the biological condition of being male or female, defined The aim of these guidelines is to provide evidence-based guidance for
by genes, hormones and sexual organs. Off-label use of medication may clinical management of IMPS, to guide clinicians of all subspecialties
be presented in this guideline if a sufficient level of evidence shows that from a clinical point of view, and to ensure qualified shared decision-
it can be considered medically appropriate for a given condition. making with patients (see Section 13 and Supplementary data online,
However, decisions on off-label use must be made by the responsible Section 8).
health professional giving special consideration to ethical rules concern-
ing healthcare, the specific situation of the patient, patient consent, and
2.1. What is new
country-specific health regulations.
Guidelines on pericarditis have been published twice before,1,15 while
myocarditis will be covered for the first time in a guideline. The TF be-
2. Introduction lieves that combined guidelines with the recognition of the spectrum of
disease are a step in a new direction, enabling a paradigm shift towards
Myocarditis and pericarditis are inflammatory diseases of the myocar- therapy based on the combined input from experts in inflammatory
dium and pericardium, respectively, with potential overlap. These are diseases of the myocardium and pericardium, with the support of a
the first ESC clinical practice guidelines covering the whole spectrum multidisciplinary team. In order to improve the awareness of the spec-
of these diseases. trum of disease, a new category, ‘inflammatory myopericardial syn-
Herein, the Task Force (TF) introduces the term ‘inflammatory myo- drome (IMPS)’, will be introduced as an umbrella term to increase
pericardial syndrome’ (IMPS). IMPS is an umbrella term during the initial the understanding of the potential myocarditis–pericarditis overlap.
(cid:144)(cid:141)(cid:143)(cid:141)(cid:27)(cid:18)(cid:129)(cid:127)©
Downloaded
from

by
guest
on
22
January
2026

3960 E S C G u id e l in e s
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:20)(cid:19)(cid:23)(cid:18)(cid:23)(cid:17)(cid:16)(cid:27)(cid:23)(cid:15)(cid:14)(cid:27)(cid:13)(cid:12)(cid:28)(cid:11)(cid:30)(cid:23)(cid:10)(cid:9)(cid:23)(cid:12)(cid:16)(cid:27)(cid:23)(cid:8)(cid:7)(cid:6)(cid:25)(cid:30)(cid:30)(cid:25)(cid:12)(cid:10)(cid:28)(cid:5)(cid:23)(cid:30)(cid:5)(cid:10)(cid:14)(cid:27)(cid:28)(cid:8)(cid:13)(cid:25)(cid:28)(cid:4)(cid:8)(cid:25)(cid:26)(cid:23)(cid:15)(cid:5)(cid:7)(cid:4)(cid:28)(cid:10)(cid:30)(cid:27)
(cid:22)(cid:21)(cid:20)(cid:19)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23)(cid:18)(cid:31)(cid:30)(cid:29)(cid:28)(cid:17)(cid:21)(cid:20)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23) (cid:22)(cid:21)(cid:20)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23)
(cid:3)(cid:26)(cid:8)(cid:7)(cid:8)(cid:13)(cid:25)(cid:26)(cid:23)(cid:13)(cid:26)(cid:25)(cid:15)(cid:15)(cid:8)(cid:2)(cid:13)(cid:25)(cid:12)(cid:8)(cid:10)(cid:7)
(cid:14)(cid:20)(cid:7)(cid:22)(cid:17) (cid:10)(cid:7)(cid:12)(cid:21)(cid:20)(cid:7)(cid:22)(cid:17) (cid:19)(cid:18)(cid:13)(cid:27)(cid:15)(cid:29)(cid:20) (cid:127)(cid:17)(cid:20)(cid:7)(cid:13)(cid:13)(cid:17)(cid:15)(cid:22) (cid:127)(cid:17)(cid:24)(cid:29)(cid:26)(cid:26)(cid:29)(cid:27)(cid:15)(cid:16)(cid:129)(cid:29)(cid:22)(cid:18)(cid:141)(cid:129)(cid:29)(cid:22)(cid:18)(cid:27)(cid:7)(cid:22)(cid:16)(cid:13)(cid:17)(cid:26)(cid:29)(cid:11)(cid:7)(cid:21)(cid:30)(cid:26)
(cid:4)(cid:3)(cid:17)(cid:20)(cid:10)(cid:24)(cid:2) (cid:1)(cid:127)(cid:17)(cid:20)(cid:10)(cid:24)(cid:2)(cid:23)
(cid:3)(cid:10)(cid:30)(cid:30)(cid:10)(cid:7)(cid:23)(cid:25)(cid:27)(cid:12)(cid:8)(cid:10)(cid:26)(cid:10)(cid:1)(cid:8)(cid:27)(cid:15)
(cid:3)(cid:15)(cid:4)(cid:17)(cid:20)(cid:22)(cid:29)(cid:27)(cid:7)(cid:26) (cid:2)(cid:27)(cid:15)(cid:1)(cid:29)(cid:15)(cid:4)(cid:17)(cid:20)(cid:22)(cid:29)(cid:27)(cid:7)(cid:26)
(cid:11)(cid:15)(cid:24)(cid:20)(cid:28)(cid:10)(cid:9)(cid:26)(cid:17)(cid:17)(cid:26)(cid:24)(cid:20)(cid:29)(cid:21) (cid:8)(cid:30)(cid:10)(cid:30)(cid:24)(cid:28)(cid:27)
(cid:16)(cid:28)(cid:29)(cid:15)(cid:23)(cid:30)(cid:23) (cid:12)(cid:26)(cid:27)(cid:24)(cid:30)(cid:29)(cid:28)(cid:26) (cid:31)(cid:26)(cid:29)(cid:26)(cid:23)(cid:28)(cid:24)(cid:30)(cid:23) (cid:11)(cid:15)(cid:24)(cid:20)(cid:28)(cid:17)(cid:17)(cid:15)(cid:10)(cid:30) (cid:27)(cid:20)(cid:10)(cid:25)(cid:28)(cid:24)(cid:28)(cid:20)(cid:10)(cid:23) (cid:7)(cid:26)(cid:10)(cid:27)(cid:30)(cid:29)(cid:6)(cid:29)(cid:30)(cid:5)(cid:26)(cid:24)(cid:30)(cid:25) (cid:14)(cid:29)(cid:15)(cid:13)(cid:23)
(cid:3)(cid:26)(cid:8)(cid:7)(cid:8)(cid:13)(cid:25)(cid:26)(cid:23)(cid:14)(cid:28)(cid:27)(cid:15)(cid:27)(cid:7)(cid:12)(cid:25)(cid:12)(cid:8)(cid:10)(cid:7)
(cid:8)(cid:14)(cid:20)(cid:7)(cid:22)(cid:17)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:27)(cid:24)(cid:21)(cid:22)(cid:29)(cid:20) (cid:19)(cid:18)(cid:17)(cid:26)(cid:22)(cid:16)(cid:23)(cid:21)(cid:29)(cid:15) (cid:14)(cid:13)(cid:13)(cid:18)(cid:25)(cid:22)(cid:18)(cid:24)(cid:29)(cid:21)(cid:26) (cid:143)(cid:7)(cid:30)(cid:24)(cid:29)(cid:15)(cid:21)(cid:15)(cid:22) (cid:14)(cid:12)(cid:27)(cid:13)(cid:22)(cid:17)(cid:11)(cid:16)(cid:10)(cid:19)(cid:9) (cid:10)(cid:19)(cid:9)
(cid:5)(cid:17)(cid:21)(cid:13)(cid:22)(cid:16)(cid:4)(cid:21)(cid:29)(cid:30)(cid:7)(cid:13)(cid:17)
(cid:22)(cid:7)(cid:8)(cid:12)(cid:8)(cid:25)(cid:26)(cid:23)(cid:22)(cid:21)(cid:20)(cid:19)(cid:23)(cid:25)(cid:15)(cid:15)(cid:27)(cid:15)(cid:15)(cid:30)(cid:27)(cid:7)(cid:12)
(cid:7)(cid:5)(cid:28)(cid:10)(cid:28)(cid:27)(cid:26)(cid:5)(cid:129)(cid:2)(cid:28)(cid:23)(cid:24)(cid:20)(cid:29)(cid:21)(cid:18)
(cid:23)(cid:21)(cid:17)(cid:19)(cid:24)(cid:20)(cid:17)(cid:23) (cid:31)(cid:2)(cid:21)(cid:23)(cid:28)(cid:27)(cid:26)(cid:5)(cid:129)(cid:30) (cid:26)(cid:17) (cid:16)(cid:28)(cid:24)(cid:26)(cid:5)(cid:129)(cid:23)(cid:28)(cid:13)(cid:10)(cid:23) (cid:143)(cid:7)(cid:8) (cid:26)(cid:144)(cid:129)€(cid:26)(cid:5)(cid:15)(cid:30)(cid:23) (cid:143)(cid:27)(cid:2)(cid:20)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:20)(cid:13)(cid:29)(cid:26)(cid:19)(cid:2)(cid:21)
(cid:127)(cid:11)(cid:26)(cid:27)(cid:23)(cid:10)(cid:11)(cid:12)(cid:23)(cid:10)(cid:29)(cid:15)(cid:12)(cid:28)(cid:11)(cid:13)(cid:12)(cid:8)(cid:129)(cid:27)(cid:23)(cid:13)(cid:10)(cid:28)(cid:10)(cid:7)(cid:25)(cid:28)(cid:5)(cid:23)(cid:25)(cid:28)(cid:12)(cid:27)(cid:28)(cid:5)(cid:23)(cid:4)(cid:8)(cid:15)(cid:27)(cid:25)(cid:15)(cid:27)(cid:23)(cid:18)(cid:23)(cid:25)(cid:13)(cid:13)(cid:10)(cid:28)(cid:4)(cid:8)(cid:7)(cid:1)(cid:23)(cid:12)(cid:10)(cid:23)(cid:13)(cid:26)(cid:8)(cid:7)(cid:8)(cid:13)(cid:25)(cid:26)(cid:23)(cid:26)(cid:8)(cid:141)(cid:27)(cid:26)(cid:8)(cid:16)(cid:10)(cid:10)(cid:4)(cid:143)(cid:14)(cid:28)(cid:10)(cid:29)(cid:25)(cid:29)(cid:8)(cid:26)(cid:8)(cid:12)(cid:5)
(cid:144)(cid:27)(cid:129) (cid:157)(cid:27)(cid:11)(cid:17)(cid:13)(cid:21)(cid:22)(cid:17) (cid:5)(cid:29)(cid:28)(cid:18)
(cid:7)(cid:5)(cid:28)(cid:10)(cid:28)(cid:27)(cid:26)(cid:5)
(cid:141)(cid:141)(cid:143)(cid:129)(cid:6)(cid:129)(cid:144)(cid:28)(cid:20)(cid:17)(cid:26)(cid:29)(cid:157)(cid:30)(cid:29)(cid:23)(cid:129)(cid:6)(cid:129)(cid:143)(cid:7)(cid:8) (cid:7)(cid:20)(cid:29)(cid:20)(cid:10)(cid:26)(cid:29)(cid:21)
(cid:27)(cid:20)(cid:17)(cid:19)(cid:15)(cid:24)(cid:30)(cid:25) (cid:7)(cid:20)(cid:29)(cid:20)(cid:10)(cid:26)(cid:29)(cid:21)
(cid:24)(cid:20)(cid:17)(cid:20)(cid:13)(cid:29)(cid:26)(cid:19)(cid:2)(cid:21) (cid:26)(cid:10)(cid:13)(cid:28)(cid:20)(cid:13)(cid:29)(cid:26)(cid:19)(cid:2)(cid:21)
(cid:127)(cid:8)(cid:15)(cid:141)(cid:23)(cid:14)(cid:28)(cid:10)(cid:2)(cid:26)(cid:27)(cid:23)(cid:25)(cid:7)(cid:4)(cid:23)(cid:28)(cid:8)(cid:15)(cid:141)(cid:23)(cid:18)(cid:23)(cid:25)(cid:4)(cid:144)(cid:11)(cid:15)(cid:12)(cid:27)(cid:4)(cid:23)(cid:25)(cid:15)(cid:15)(cid:27)(cid:15)(cid:15)(cid:30)(cid:27)(cid:7)(cid:12)
(cid:144)(cid:27)(cid:129)(cid:16)(cid:13)(cid:29)(cid:26) (cid:3)(cid:15)(cid:22)(cid:17)(cid:13)(cid:24)(cid:17)(cid:11)(cid:29)(cid:21)(cid:22)(cid:17)(cid:16)(cid:13)(cid:29)(cid:26) (cid:5)(cid:29)(cid:28)(cid:18)(cid:16)(cid:13)(cid:29)(cid:26)
(cid:19)(cid:21)(cid:13)(cid:11)(cid:29)(cid:27) (cid:21)(cid:26)(cid:20)(cid:7)(cid:30)(cid:21)(cid:13)(cid:16)(cid:24)(cid:21)(cid:28)(cid:15)(cid:17)(cid:22)(cid:29)(cid:20)(cid:16)(cid:13)(cid:17)(cid:26)(cid:27)(cid:15)(cid:21)(cid:15)(cid:20)(cid:17) (cid:3)(cid:15) (cid:21)(cid:26)(cid:29) (cid:17)(cid:16)(cid:23)(cid:13)(cid:27)(cid:20)(cid:17)(cid:11)(cid:7)(cid:13)(cid:17)(cid:26)(cid:16)(cid:8)€(cid:157)‚(cid:6)
‚(cid:15)(cid:10)(cid:27)(cid:24)(cid:28)(cid:20)(cid:10) (cid:11)(cid:27)(cid:24)(cid:28)€(cid:28)(cid:24)(cid:21) (cid:22)(cid:21)(cid:20)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:26)(cid:5) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:26)(cid:5) ƒ(cid:28)(cid:23)(cid:24)(cid:20)(cid:19)(cid:26)(cid:24)(cid:2)(cid:20)(cid:5)(cid:20)(cid:13)(cid:21)
(cid:28)(cid:10)€(cid:20)(cid:5)€(cid:30)(cid:17)(cid:30)(cid:10)(cid:24) (cid:28)(cid:10)€(cid:20)(cid:5)€(cid:30)(cid:17)(cid:30)(cid:10)(cid:24)
(cid:143)(cid:7)(cid:13)(cid:22)(cid:18)(cid:17)(cid:13)(cid:16)(cid:21)(cid:26)(cid:26)(cid:17)(cid:26)(cid:26)(cid:24)(cid:17)(cid:15)(cid:22)(cid:16)(cid:8)(cid:29)(cid:4)(cid:16)(cid:129)(cid:21)(cid:13)(cid:13)(cid:21)(cid:15)(cid:22)(cid:17)(cid:11)(cid:6)
(cid:10)(cid:17)(cid:21)(cid:13)(cid:20)(cid:18)(cid:16)(cid:4)(cid:27)(cid:13)(cid:16)(cid:21)(cid:17)(cid:22)(cid:29)(cid:27)(cid:30)(cid:27)(cid:28)(cid:25) (cid:157)(cid:7)(cid:30)(cid:22)(cid:29)(cid:24)(cid:27)(cid:11)(cid:21)(cid:30)(cid:29)(cid:22)(cid:25)(cid:16)(cid:29)(cid:24)(cid:21)(cid:28)(cid:29)(cid:15)(cid:28) €(cid:30)(cid:17)(cid:20)(cid:22)(cid:13)(cid:27)(cid:21)(cid:15)(cid:21)(cid:22)(cid:27)(cid:24)(cid:29)(cid:20)(cid:21)(cid:30)(cid:16)(cid:24)(cid:21)(cid:23)(cid:23)(cid:29)(cid:15)(cid:28)
(cid:157)(cid:8)(cid:7)(cid:25)(cid:26)(cid:23)(cid:4)(cid:8)(cid:25)(cid:1)(cid:7)(cid:10)(cid:15)(cid:8)(cid:15)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23) (cid:22)(cid:21)(cid:20)(cid:19)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23)(cid:18)(cid:31)(cid:30)(cid:29)(cid:28)(cid:17)(cid:21)(cid:20)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23) (cid:22)(cid:21)(cid:20)(cid:27)(cid:26)(cid:29)(cid:25)(cid:28)(cid:24)(cid:28)(cid:23)
(cid:141)(cid:2)(cid:30)(cid:29)(cid:26)(cid:19)(cid:21)(cid:6)(cid:25)(cid:30)(cid:19)(cid:30)(cid:10)(cid:25)(cid:30)(cid:10)(cid:24)(cid:129)(cid:20)(cid:10)(cid:129)„(cid:10)(cid:26)(cid:5)(cid:129)(cid:25)(cid:28)(cid:26)(cid:13)(cid:10)(cid:20)(cid:23)(cid:28)(cid:23)
(cid:26)(cid:10)(cid:25)(cid:129)(cid:29)(cid:28)(cid:23)(cid:157)(cid:18)(cid:27)(cid:20)(cid:17)(cid:19)(cid:5)(cid:28)(cid:27)(cid:26)(cid:24)(cid:28)(cid:20)(cid:10)(cid:23)(cid:129)
Figure 1 Central illustration of the ESC guidelines on myocarditis and pericarditis. ECG, electrocardiogram; EMB, endomyocardial biopsy; IMPS,
inflammatory myopericardial syndrome; SCD, sudden cardiac death; TTE, transthoracic echocardiography.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3961
(cid:15)(cid:27)(cid:24)(cid:26)(cid:14)(cid:16)(cid:27)
(cid:31)(cid:29)(cid:19)(cid:19)(cid:14)(cid:13)(cid:12)(cid:27)
(cid:11)(cid:26)(cid:12)(cid:14)(cid:10)(cid:27)(cid:12)(cid:9)(cid:8)(cid:30)(cid:27)(cid:7)(cid:27)(cid:17)(cid:16)(cid:27)(cid:22)
(cid:31)(cid:30)(cid:29)(cid:28)
(cid:27)(cid:26)(cid:25)(cid:24)(cid:30)(cid:23)(cid:28)
(cid:31)(cid:30)(cid:29) (cid:22)(cid:26)(cid:27)(cid:21)(cid:20)(cid:19)
(cid:31)(cid:30)(cid:29) (cid:24)(cid:30)(cid:23) (cid:31)(cid:30)(cid:29)(cid:25)(cid:18)(cid:19)(cid:17)(cid:25)(cid:24)(cid:30)(cid:23)
(cid:16)(cid:15)(cid:14)(cid:13)(cid:25)(cid:12)(cid:19)(cid:11)(cid:20)(cid:26)(cid:14)(cid:18)(cid:15)(cid:19)(cid:25)(cid:26)(cid:20)(cid:10)(cid:12)(cid:9)(cid:14)(cid:10)
(cid:31)(cid:30)(cid:29)(cid:25)(cid:18)(cid:19)(cid:17)(cid:25)(cid:24)(cid:30)(cid:23)(cid:25)(cid:19)(cid:20)(cid:8)(cid:18)(cid:14)(cid:15)(cid:21)(cid:20)
(cid:24)(cid:9)(cid:15)(cid:19)(cid:15)(cid:11)(cid:18)(cid:9)
(cid:6)(cid:5)(cid:6)(cid:1)
(cid:24)(cid:30)(cid:23)(cid:25)(cid:7)(cid:25)(cid:11)(cid:9)(cid:15)(cid:19)(cid:15)(cid:11)(cid:18)(cid:9)
(cid:6)(cid:5)(cid:6)(cid:4)(cid:2)(cid:6)(cid:5)(cid:6)(cid:3)
(cid:6)(cid:5)(cid:4)(cid:3)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)
(cid:25)(cid:29)(cid:26)(cid:24)(cid:30)(cid:23)(cid:27)(cid:22)
(cid:21)(cid:20)(cid:19)(cid:18)(cid:27)(cid:17)(cid:16)(cid:27)(cid:22)
Figure 2 Paradigm change in the clinical diagnosis of myocarditis. CMR, cardiovascular magnetic resonance; EMB, endomyocardial biopsy. Both EMB
and CMR can provide a definitive clinical diagnosis but with different indications. Details are given in Section 5. 2013 Reference: Caforio et al.10 2021 and
2023 References: Keren et al., Law et al.6,14
It is introduced as an entering diagnostic term to lead to a tailored work- of the pathogenesis of pericarditis has greatly improved with new evi-
up and individualized therapy. Patient-oriented case management is pro- dence on the importance of the interplay between inflammation and
posed in different settings such as diagnosis and therapy, as well as return autoinflammatory mechanisms, the role of genetic background, and
to work and play avoiding strict time definitions, since the remission path- immune responses in patients with multiple recurrences. The identi-
way differs from patient to patient. In addition, a novelty in the field of fication of a positive family history, a poor response to colchicine, and
IMPS is the improved knowledge on its possible genetic background a clinical presentation with an inflammatory or non-inflammatory
and its link to specific inherited CMPs. Furthermore, a paradigm shift phenotype are useful tools to guide the selection of patients for gen-
will be introduced in its diagnostic management. This is reflecting the etic testing and specific pharmacological options. A new class of drugs
new capabilities of multimodality imaging, especially CMR, as it has chan- targeting interleukin-1 (IL-1), the so-called anti-IL-1 agents, has be-
ged clinical workflow during recent years. A similar change was intro- come available and is used in recurrent cases with a poor response
duced in the American College of Cardiology (ACC) consensus to other conventional therapies. Nevertheless, we need to further im-
statement in 2024.9 Endomyocardial biopsy has its place and is needed prove our understanding of the pathogenesis of non-inflammatory dis-
if specific decisions are warranted. ease forms.
In comparison with the last ESC Guidelines for the diagnosis Moreover, diagnostic capabilities have increased, thanks to the role
and management of pericardial diseases,1 the current understanding of multimodality imaging, allowing improved diagnostic accuracy and
Downloaded
from

by
guest
on
22
January
2026

3962 E S C G u id e l in e s
individualized duration of therapies according to clinical and imaging Table 3 Terminology and stages
findings.
The TF recommends establishing a multidisciplinary IMPS team to Terminology Definition
ensure optimal patient care in complicated cases.
IMPS Umbrella term for inflammatory myocardial
We firmly believe that recognizing IMPS will enhance the under-
and pericardial syndromes
standing of these inflammatory conditions and hope it will inspire fur-
Myopericarditis Predominant pericarditisa
ther research to advance personalized diagnostic and therapeutic
approaches. Perimyocarditis Predominant myocarditisb
Acute myocarditis Duration of symptoms ≤4 weeks
Fulminant if:
3. Epidemiology, classification,
• Acute onset28 and haemodynamically
stages, diagnostic criteria and unstable patients requiring inotropes or
aetiology mechanical circulatory support
Complicated myocarditis AM and ≥1 of the following:28
3.1. Epidemiology • LVEF <50% on echocardiogram
• Sustained ventricular arrhythmias
Population-based studies of the incidence or prevalence of IMPS are
• Advanced heart block
limited, and most epidemiological studies assess disease burden and
sequelae in selected patient groups, such as those admitted to hos- • Heart failure
pital. However, such studies might underestimate the true disease • Cardiogenic shock
burden. For example, the rate of patients diagnosed with acute myo- Acute pericarditis Duration of symptoms ≤4 weeks
carditis (AM) increases from 5% to 13% with the use of CMR among Subacute/ongoing Duration of symptoms >4 weeks to
patients with angina-like symptoms and increased high-sensitivity myocarditis ≤3 months
troponin T (hs-TnT).16 A different registry reported an incidence Subacute/incessant Duration of symptoms >4 weeks to
of 6.3–8.6 per 100 000 inhabitants, mostly in young men.17 The cur- pericarditisc ≤3 months
rent global burden of cardiovascular disease data reports a preva-
Chronic myocarditis/ Duration of symptoms >3 months
lence of 4.2–8.7 per 100 000 in the age range between 35 and
pericarditis
39 years.18 Men and younger patients are more likely to be diag-
Inflammatory Chronic myocarditis in association with cardiac
nosed, although this could reflect the diagnostic bias towards these
patient groups.19 cardiomyopathy dysfunction and ventricular remodelling with
clinical phenotype of hypokinetic, either dilated
In children <2 years of age, the sex distribution is balanced; in ado-
lescents there is a male prevalence (about two-thirds of cases),20,21 or non-dilated cardiomyopathy with/without
which is also maintained in adult patients, suggesting the importance arrhythmogenic substrate
of hormonal factors. Recurrent myocarditis/ New symptoms or disease activity after clinical
The incidence of acute pericarditis (AP) is estimated to be about 3– pericarditis remission
32 cases per 100 000 person-years.22,23 Similar to myocarditis, men and Remission without Regression/absence of symptoms,
younger individuals are more likely to be diagnosed. Recurrence occurs residuals normalization of ECG, biomarkers, imaging
in about 20%–30% of patients within 18 months after a first episode abnormalities (echocardiography and CMR)
of AP.24 The recurrence rate increases up to 50% after the first recur-
Remission with residuals Regression/absence of symptoms, persistence
rence.25 Pericarditis is diagnosed in 0.2% of all cardiovascular in-hospital
of abnormalities on ECG, biomarkers and/or
admissions and is responsible for 5% of emergency room admissions for
imaging (functional and/or structural
chest pain.23 In the observational Epidémiologie de la Douleur
abnormalities in echocardiography or CMR)
Thoracique (EPIDOULTHO) study, 3% of patients received a final diag-
nosis of IMPS.26 AM, acute myocarditis; CK-MB, creatine kinase muscle-brain type; CMR, cardiovascular
magnetic resonance; ECG, electrocardiogram; IMPS, inflammatory myopericardial
syndrome; LVEF, left ventricular ejection fraction.
3.2. Classification and stages aPatients with definite criteria for pericarditis and elevated biomarkers of myocardial injury
(high-sensitivity troponin I or T, CK-MB fraction) without newly developed regional or
The field of IMPS gained increasing awareness and interest during the
global impairment of left ventricular function in echocardiography or CMR.
coronavirus disease 2019 (COVID-19) pandemic.27 Research in the bPatients with definite criteria for pericarditis and elevated biomarkers of myocardial injury
field of all forms of IMPS has a long history, and several terminologies (high-sensitivity troponin I or T, CK-MB fraction) with newly developed regional or global
exist. This is also reflected in the definition of stages. We are proposing impairment of left ventricular function in echocardiography or CMR.
cIncessant/ongoing pericarditis: the term incessant pericarditis describes patients with
a terminology from a clinical point of view with the intention of guiding
persistent symptoms without a symptom-free interval of >4 weeks despite full-dose
the appropriate management of patients (Table 3). In addition, time guideline-directed medical therapy (including corticosteroids), or those relapsing early
frames for the stages (acute, subacute, and chronic) are suggested to during the tapering.
be used for myocarditis and pericarditis. However, it is not always pos-
sible from a clinical point of view to identify the disease onset, for in-
stance in subacute cases.1 cases leading to death. Patients may not experience every stage.
IMPS is characterized by different stages (see Figure 3). The course of Complete remission can occur at every timepoint. However, a deep
the disease differs among patients. A patient may recover completely understanding of the respective stages is essential for appropriate
without any residuals, but others may develop complications, in some therapeutic guidance.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3963
(cid:127)(cid:27)(cid:23)(cid:26)(cid:28)(cid:18)(cid:22)(cid:26)(cid:15)(cid:19)(cid:28) ‹(cid:23)(cid:4)(cid:15)(cid:27)(cid:23)(cid:26)(cid:28)(cid:18)(cid:22)(cid:26)(cid:15)(cid:19)(cid:28) (cid:12)(cid:6)(cid:16)(cid:24)(cid:30)(cid:25)(cid:27)(cid:18)(cid:22)(cid:26)(cid:15)(cid:19)(cid:28)
ƒ„(cid:18)(cid:7)(cid:24)(cid:30)(cid:26)(cid:6) „ŒŽ(cid:18)(cid:7)(cid:24)(cid:30)(cid:26)(cid:6)(cid:22) ‘Ž(cid:18)(cid:7)(cid:24)(cid:30)(cid:26)(cid:6)(cid:22)
(cid:12)(cid:15)(cid:16)(cid:11)(cid:25)(cid:24)(cid:26)(cid:16)(cid:24)(cid:10)(cid:25)(cid:27) (cid:5)(cid:25)(cid:16)(cid:15)(cid:14)(cid:18)(cid:25)(cid:30)(cid:11)(cid:23)(cid:27)(cid:28)(cid:11)
(cid:15)(cid:30)(cid:11) (cid:11)(cid:15)(cid:7)(cid:15)(cid:19)(cid:28)(cid:18)(cid:15)(cid:30)(cid:11)
(cid:17)(cid:15)(cid:22)(cid:27)(cid:23)(cid:14)(cid:24)(cid:26)(cid:16)(cid:24)(cid:10)(cid:25)(cid:27) (cid:25)(cid:30)(cid:30)(cid:15)(cid:26)(cid:28)(cid:18)(cid:25)(cid:7)(cid:7)(cid:23)(cid:30)(cid:28)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22) (cid:17)(cid:25)(cid:16)(cid:23)(cid:22)(cid:28)(cid:22) (cid:16)(cid:28)(cid:22)(cid:10)(cid:24)(cid:30)(cid:22)(cid:28)
(cid:127)(cid:11)(cid:15)(cid:10)(cid:26)(cid:25)(cid:17)(cid:28) (cid:5)(cid:25)(cid:16)(cid:15)(cid:14)(cid:18)(cid:10)(cid:28)(cid:16)(cid:22)(cid:25)(cid:22)(cid:26)(cid:28)(cid:30)(cid:27)(cid:28)(cid:18) (cid:25)(cid:26)(cid:6)(cid:18)(cid:27)(cid:6)(cid:16)(cid:24)(cid:30)(cid:25)(cid:27)
(cid:21)(cid:28)(cid:20)(cid:19)(cid:20)(cid:18)(cid:17)(cid:25)(cid:16)(cid:15)(cid:14)(cid:13)
(cid:25)(cid:7)(cid:7)(cid:23)(cid:30)(cid:28)(cid:18)(cid:16)(cid:28)(cid:22)(cid:10)(cid:24)(cid:30)(cid:22)(cid:28) (cid:25)(cid:30)(cid:2)(cid:15)(cid:7)(cid:7)(cid:15)(cid:26)(cid:25)(cid:24)(cid:30)(cid:18)(cid:15)(cid:30)(cid:11)€(cid:24)(cid:16)(cid:18)‚(cid:4)(cid:16)(cid:24)(cid:22)(cid:25)(cid:22)(cid:18)(cid:24)(cid:16)(cid:18)(cid:16)(cid:28)(cid:27)(cid:24)(cid:17)(cid:28)(cid:16)(cid:8)
(cid:31)(cid:30)(cid:11)(cid:25)(cid:16)(cid:28)(cid:27)(cid:26)(cid:18)(cid:11)(cid:15)(cid:7)(cid:15)(cid:19)(cid:28)
(cid:9)(cid:8)(cid:7)(cid:10)(cid:6)(cid:24)(cid:26)(cid:16)(cid:24)(cid:10)(cid:25)(cid:27)
(cid:17)(cid:25)(cid:15)(cid:18)(cid:27)(cid:28)(cid:14)(cid:14)(cid:23)(cid:14)(cid:15)(cid:16)
(cid:17)(cid:25)(cid:16)(cid:23)(cid:22)(cid:28)(cid:22)
(cid:25)(cid:7)(cid:7)(cid:23)(cid:30)(cid:28)(cid:18)(cid:16)(cid:28)(cid:22)(cid:10)(cid:24)(cid:30)(cid:22)(cid:28)
…(cid:24)†(cid:15)‡(cid:18)(cid:15)(cid:30)(cid:8)(cid:18)(cid:15)(cid:19)(cid:28)(cid:30)(cid:26)
‰(cid:28)(cid:30)(cid:28)(cid:26)(cid:25)(cid:27)
(cid:27)(cid:15)(cid:10)(cid:15)(cid:4)(cid:14)(cid:28)(cid:18)(cid:24)(cid:29)(cid:18)(cid:25)(cid:30)ˆ(cid:23)(cid:16)(cid:25)(cid:30)(cid:19) (cid:157) (cid:157)
(cid:22)(cid:23)(cid:22)(cid:27)(cid:28)(cid:10)(cid:26)(cid:25)(cid:4)(cid:25)(cid:14)(cid:25)(cid:26)(cid:8)
(cid:26)(cid:6)(cid:28)(cid:18)(cid:7)(cid:8)(cid:24)(cid:10)(cid:28)(cid:16)(cid:25)(cid:27)(cid:15)(cid:16)(cid:11)(cid:25)(cid:23)(cid:7)
(cid:157)(cid:28)(cid:7)(cid:25)(cid:22)(cid:22)(cid:25)(cid:24)(cid:30)(cid:18) (cid:157)(cid:28)(cid:7)(cid:25)(cid:22)(cid:22)(cid:25)(cid:24)(cid:30)(cid:18) (cid:25)(cid:26)(cid:6) (cid:144)(cid:25)(cid:14)(cid:15)(cid:26)(cid:28)(cid:11)(cid:18) (cid:12)(cid:24)(cid:30)(cid:22)(cid:26)(cid:16)(cid:25)(cid:27)(cid:26)(cid:25)(cid:17)(cid:28)(cid:18)
(cid:25)(cid:26)(cid:6)(cid:24)(cid:23)(cid:26)(cid:18)(cid:16)(cid:28)(cid:22)(cid:25)(cid:11)(cid:23)(cid:15)(cid:14)(cid:22) (cid:16)(cid:28)(cid:22)(cid:25)(cid:11)(cid:23)(cid:15)(cid:14)(cid:22) (cid:27)(cid:15)(cid:16)(cid:11)(cid:25)(cid:24)(cid:7)(cid:8)(cid:24)(cid:10)(cid:15)(cid:26)(cid:6)(cid:8) (cid:10)(cid:28)(cid:16)(cid:25)(cid:27)(cid:15)(cid:16)(cid:11)(cid:25)(cid:26)(cid:25)(cid:22)
(cid:31)(cid:7)(cid:4)(cid:15)(cid:14)(cid:15)(cid:30)(cid:27)(cid:28)(cid:18)(cid:24)(cid:29)(cid:18)(cid:10)(cid:16)(cid:24)(cid:3)(cid:18)(cid:15)(cid:30)(cid:11)
(cid:15)(cid:30)(cid:26)(cid:25)(cid:3)(cid:25)(cid:30)(cid:2)(cid:15)(cid:7)(cid:7)(cid:15)(cid:26)(cid:24)(cid:16)(cid:8)(cid:18)(cid:27)(cid:8)(cid:26)(cid:24)(cid:1)(cid:25)(cid:30)(cid:28)(cid:22)
…(cid:24)(cid:30)(cid:3)(cid:25)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)
(cid:21)(cid:28)(cid:20)(cid:19)(cid:20)(cid:18)(cid:15)(cid:23)(cid:26)(cid:24)(cid:25)(cid:7)(cid:7)(cid:23)(cid:30)(cid:28)
(cid:127)(cid:23)(cid:26)(cid:24)(cid:16)(cid:28)(cid:15)(cid:27)(cid:26)(cid:25)(cid:17)(cid:28)(cid:18)(cid:129)(cid:3)(cid:27)(cid:28)(cid:14)(cid:14)(cid:22)
(cid:11)(cid:25)(cid:22)(cid:24)(cid:16)(cid:11)(cid:28)(cid:16)(cid:22)(cid:143)(cid:18)(cid:11)(cid:16)(cid:23)(cid:19)(cid:22)(cid:143)
(cid:26)(cid:24)†(cid:25)(cid:30)(cid:22)(cid:18)(cid:28)(cid:26)(cid:27)(cid:20)(cid:13)
(cid:127)(cid:23)(cid:26)(cid:24)(cid:15)(cid:30)(cid:26)(cid:25)(cid:4)(cid:24)(cid:11)(cid:25)(cid:28)(cid:22)
(cid:21)(cid:28)(cid:20)(cid:19)(cid:20)(cid:18)(cid:127)(cid:141)(cid:127)(cid:143)(cid:18)(cid:127)(cid:31)(cid:144)(cid:127)(cid:13)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:18)(cid:15)(cid:19)(cid:28)(cid:30)(cid:26) (cid:12)(cid:28)(cid:14)(cid:14)(cid:23)(cid:14)(cid:15)(cid:16)(cid:18)(cid:25)(cid:30)‚(cid:14)(cid:26)(cid:16)(cid:15)(cid:26)(cid:25)(cid:24)(cid:30) (cid:21)(cid:127)(cid:30)(cid:26)(cid:25)(cid:3)(cid:17)(cid:25)(cid:16)(cid:15)(cid:14)(cid:13)(cid:18)(cid:15)(cid:30)(cid:26)(cid:25)(cid:4)(cid:24)(cid:11)(cid:25)(cid:28)(cid:22) Š(cid:8)(cid:24)(cid:3)(cid:15)(cid:30)(cid:11)€(cid:24)(cid:16)(cid:18)(cid:10)(cid:28)(cid:16)(cid:25)(cid:27)(cid:15)(cid:16)(cid:11)(cid:25)(cid:15)(cid:14)(cid:18)(cid:25)(cid:30)ˆ(cid:23)(cid:16)(cid:8)
Figure 3 Stages of inflammatory myopericardial syndrome. AHA, anti-heart antibodies; AIDA, anti-intercalated disc antibodies.
3.3. Diagnostic criteria CMR-proven or EMB-proven result (see details in Table 4). The add-
itional criteria include common parameters in basic work-up, such as
After the original proposed diagnostic criteria from the consensus paper
in 2013,10 multimodality imaging, in particular CMR, has made a clinical, an electrocardiogram (ECG), which may show unspecific changes, in-
non-invasive diagnosis of myocarditis feasible. In accordance with the cluding the whole spectrum of presentations from mimicking a myocar-
paradigm change (Figure 2), the TF proposes new diagnostic criteria and dial infarction with ST elevation in non-coronary distribution, as well as
a new classification, following the system introduced in the 2023 ESC rhythm abnormalities, or findings in echocardiography (see Section 5.5).
Guidelines for the management of endocarditis (Table 4).29 This clinically Laboratory analysis of serum biomarkers usually shows elevation of
driven approach is based on a clinical presentation, with additional support- markers of myocardial lesion, such as hs-TnT or high-sensitivity tropo-
ive findings, and positive CMR or EMB for myocarditis. Histopathological nin I (hs-TnI). Biomarkers of heart failure (HF) (such as N-terminal pro-
criteria and updated CMR Lake Louise criteria (LLC)30 are given in hormone of brain natriuretic peptide, NT-proBNP) are also needed to
Table 5 and Figure 4, respectively. Similarly, diagnosis of pericarditis can identify the severity of the disease, and suggest myocardial involvement.
be made with a clinical presentation, and more than one additional criter- Depending on the individual case and risk (see Section 4), definitive
ion. Cardiovascular magnetic resonance can also provide the non-invasive diagnosis of myocarditis can be based on CMR (Figure 4) or EMB
confirmation of the presence of pericarditis beyond clinical criteria. (Table 5). For EMB analysis quantitative immunohistochemistry criteria
for inflammatory cells in lymphocytic myocarditis (LM) are under devel-
3.3.1. Diagnostic criteria for myocarditis opment. Asymptomatic cases may exist, e.g. vaccine- or drug-related
Myocarditis can be clinically diagnosed as definite/possible with an cases, such as immune checkpoint inhibitor (ICI)-induced myocarditis,
appropriate clinical presentation and additional criterion, including and are often underdiagnosed.
Downloaded
from

by
guest
on
22
January
2026

3964 E S C G u id e l in e s
Table 4 Diagnostic criteria and classification for inflammatory myopericardial syndrome
IMPS
If diagnostic criteria for myocarditis and/or pericarditis are fulfilleda
Myocarditis Pericarditis
Definite Clinical presentationb and CMR- or EMB-proven Clinical presentationb with >1 additional criterion
Possible Clinical presentationb with at least 1 additional criterion Clinical presentationb with 1 additional criterion
CMR- or EMB-uncertain or not available
Unlikely/rejected Only clinical presentationb without additional criteria Only clinical presentationb without additional criteria
Additional criteria beyond clinical presentationsb
Myocarditis Pericarditis
Clinicalb Non-specific findings Pericardial rubs
ECGc ST-T changes PR depression, widespread ST-segment elevation
Biomarkers Troponin elevation C-reactive protein elevation
Imagingd Abnormal strain, wall motion, reduced EF New or worsening pericardial effusion
Myocardial oedema and/or LGE (CMR findings) Pericardial oedema and/or LGE (CMR findings)
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; EF, ejection fraction; EMB, endomyocardial biopsy; IMPS, inflammatory myopericardial syndrome; LGE, late gadolinium
enhancement; LLC, Lake Louise criteria.
Clinical presentations include chest pain or infarct-like symptoms, arrhythmias, heart failure, aborted sudden cardiac death.
Cardiovascular magnetic resonance categories: proven = 2 out of 2 updated LLC fulfilled (Figure 4); uncertain = only 1 out of 2 updated LLC fulfilled; rejected = negative CMR.
EMB categories: proven, uncertain, rejected (according to pathologist consensus).
aOne condition may be leading (see Section 8).
bSee detailed description of clinical presentation in Section 4; rarely asymptomatic cases may be detected (e.g. drug-related with a distinct history, such as immune checkpoint inhibitors).
cIf ECG changes always consider/exclude myocarditis.
dSee additional Sections 5.4–5.7 for detailed description of imaging findings.
Table 5 Histopathological criteria for myocarditis
Term Predominant inflammatory cells Myocyte necrosis Infections
PCR positive (viruses, etc.)
Active lymphocytic myocarditis CD3+ T lymphocytes yes yes/no
>7/mm2,
CD68+ macrophages
Persistent lymphocytic myocarditis CD3+ T lymphocytes yes yes/no
>7/mm2, CD68+ macrophages
Resolved lymphocytic myocarditis – no yes/no
Eosinophilic myocarditis (acute stage) Eosinophils, CD3+ T lymphocytes, yes yes/no
CD68+ macrophages
Giant-cell myocarditis (acute stage) Eosinophils, yes no
CD68+ giant cells, CD3+ T lymphocytes,
CD68+ macrophages
Sarcoidosis CD68+ giant cells, granuloma, yes/no no
CD3+ T lymphocytes,
CD68+ macrophages
PCR, polymerase chain reaction.
Non-ischaemic myocardial inflammation can be diagnosed by CMR still be made by having only one (i.e. T2-based or T1-based) criterion
according to the updated LLC30 (see Figure 4). This is based on at least in an appropriate clinical scenario, although with less specificity.
one T2-based criterion plus ideally one T1-based criterion. Having both Supportive criteria include pericardial abnormalities (which, however,
a positive T2-based criterion and a T1-based criterion will increase spe- suggest concomitant pericarditis), and global or regional left ventricular
cificity for diagnosing AM, but a diagnosis of possible myocarditis can (LV) systolic dysfunction on cine imaging.
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3965
(cid:11)(cid:18)(cid:30)(cid:18)(cid:17)(cid:27)(cid:28)(cid:27)(cid:30)(cid:21)(cid:14)(cid:10)(cid:26)(cid:30)(cid:14)(cid:30)(cid:27)(cid:16)(cid:26)(cid:30)(cid:28)(cid:29)(cid:25)(cid:13)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:26)(cid:25) (cid:24)(cid:27)(cid:28)(cid:23)(cid:26)(cid:22)(cid:21) (cid:20)(cid:19)(cid:18)(cid:17)(cid:16)(cid:15)(cid:27)(cid:14)(cid:29)(cid:17)(cid:18)(cid:13)(cid:27)(cid:21)(cid:14)(cid:18)(cid:25)(cid:22)(cid:14)(cid:16)(cid:18)(cid:28)(cid:23)(cid:26)(cid:15)(cid:26)(cid:13)(cid:12)
(cid:3)(cid:26)(cid:30)(cid:14)(cid:17)(cid:12)(cid:26)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:28)(cid:29)(cid:21) (cid:3)(cid:26)(cid:30)(cid:14)(cid:16)(cid:27)(cid:30)(cid:29)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:18)(cid:15)(cid:14)(cid:29)(cid:25)(cid:2)(cid:26)(cid:15)(cid:2)(cid:27)(cid:17)(cid:27)(cid:25)(cid:28)
(cid:24)(cid:12)(cid:26)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:18)(cid:15) (cid:11)(cid:27)(cid:30)(cid:29)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:18)(cid:15) (cid:143)(cid:16)(cid:27)(cid:9)(cid:27)(cid:19)(cid:8)(cid:27)(cid:144)(cid:18)(cid:27)(cid:157)(cid:23)(cid:27)(cid:19)(cid:23)(cid:144)(cid:18)(cid:20)(cid:19)(cid:22)(cid:18) (cid:127)(cid:26)(cid:25)(cid:24)(cid:18)(cid:9)(cid:26)(cid:25)(cid:19)(cid:20)(cid:2)(cid:18)(cid:26)(cid:19)(cid:23)(cid:27)(cid:19)(cid:9)(cid:26)(cid:23)(cid:129)(cid:18)
(cid:26)(cid:27)(cid:22)(cid:27)(cid:17)(cid:18) (cid:26)(cid:27)(cid:22)(cid:27)(cid:17)(cid:18) (cid:2)(cid:17)(cid:8)(cid:20)(cid:23)(cid:26)(cid:17)(cid:19)(cid:18)(cid:17)(cid:141)(cid:18)(cid:17)(cid:27)(cid:22)(cid:27)(cid:21)(cid:20)(cid:18)(cid:7)(cid:31)(cid:30)(cid:18) (cid:17)(cid:141)(cid:18)(cid:23)(cid:24)(cid:27)(cid:18)(cid:15)(cid:27)(cid:16)(cid:26)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:1)(cid:21)(cid:18)
(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22)(cid:4) (cid:26)(cid:19)(cid:18)(cid:31)(cid:30)(cid:29)(cid:21)(cid:20)(cid:15)(cid:15)(cid:26)(cid:19)(cid:25)(cid:18)(cid:17)(cid:16)(cid:18)
(cid:27)(cid:25)(cid:26)(cid:17)(cid:19)(cid:20)(cid:2)(cid:18)(cid:24)(cid:26)(cid:25)(cid:24)(cid:18)(cid:31)(cid:30)(cid:18) (cid:2)(cid:18)(cid:17)(cid:16)(cid:18) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22)(cid:18)
(cid:9)(cid:8)(cid:7)(cid:6)(cid:18)(cid:21)(cid:27)(cid:22) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22) (cid:25)(cid:2)(cid:17)€(cid:20)(cid:2)(cid:18)(cid:24)(cid:26)(cid:25)(cid:24)(cid:18)(cid:31)(cid:30)(cid:18) ‚(cid:18) (cid:26)(cid:21)(cid:20)(cid:25)(cid:26)(cid:19)(cid:25)
(cid:26)(cid:21)(cid:20)(cid:25)(cid:26)(cid:19)(cid:25)(cid:18)(cid:17)(cid:16) (cid:7)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22)(cid:4)
(cid:5)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:26)(cid:25)
(cid:31)(cid:30)(cid:31)(cid:21)(cid:20)(cid:15)(cid:15)(cid:26)(cid:19)(cid:25) (cid:27)(cid:25)(cid:26)(cid:17)(cid:19)(cid:20)(cid:2)(cid:18)(cid:17)(cid:16)(cid:18)(cid:25)(cid:2)(cid:17)€(cid:20)(cid:2)(cid:18)
(cid:26)(cid:19)(cid:8)(cid:16)(cid:27)(cid:20)(cid:9)(cid:27)(cid:18)(cid:17)(cid:141)(cid:18)(cid:21)(cid:129)(cid:17)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)
(cid:31)(cid:30)(cid:18)(cid:23)(cid:26)(cid:21)(cid:27)(cid:9)
(cid:24)(cid:12)(cid:26)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:18)(cid:15)(cid:14)(cid:26)(cid:27)(cid:22)(cid:27)(cid:17)(cid:18)(cid:1) (cid:11)(cid:27)(cid:30)(cid:29)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:18)(cid:15)(cid:14)(cid:26)(cid:27)(cid:22)(cid:27)(cid:17)(cid:18)(cid:1) ƒ(cid:27)(cid:9)(cid:8)(cid:16)(cid:26)(cid:15)(cid:23)(cid:26)(cid:17)(cid:19)(cid:18)(cid:17)(cid:141)(cid:18)(cid:141)(cid:17)(cid:8)(cid:20)(cid:2)(cid:18) (cid:127)(cid:26)(cid:25)(cid:24)(cid:18)(cid:9)(cid:26)(cid:25)(cid:19)(cid:20)(cid:2)(cid:18)(cid:26)(cid:19)(cid:23)(cid:27)(cid:19)(cid:9)(cid:26)(cid:23)(cid:129)(cid:18)
(cid:22)(cid:29)(cid:127)(cid:129)(cid:21)(cid:27)(cid:14)(cid:141)(cid:6)(cid:30)(cid:26)(cid:21)(cid:29)(cid:21) (cid:22)(cid:29)(cid:127)(cid:129)(cid:21)(cid:27)(cid:14)(cid:141)(cid:6)(cid:30)(cid:26)(cid:21)(cid:29)(cid:21) (cid:26)(cid:19)(cid:8)(cid:16)(cid:27)(cid:20)(cid:9)(cid:27)(cid:9) (cid:17)(cid:141)(cid:18)(cid:23)(cid:24)(cid:27)(cid:18)(cid:15)(cid:27)(cid:16)(cid:26)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:1)(cid:21)(cid:18)
(cid:27)(cid:25)(cid:26)(cid:17)(cid:19)(cid:20)(cid:2)(cid:18)(cid:17)(cid:16)(cid:18)(cid:25)(cid:2)(cid:17)€(cid:20)(cid:2)(cid:18) (cid:26)(cid:19)(cid:18)(cid:31)(cid:11)(cid:29)(cid:21)(cid:20)(cid:15)(cid:15)(cid:26)(cid:19)(cid:25)
(cid:13)(cid:20)(cid:23)(cid:26)(cid:12)(cid:27)(cid:18)(cid:31)(cid:11)(cid:31)(cid:21)(cid:20)(cid:15)(cid:15)(cid:26)(cid:19)(cid:25)(cid:10) (cid:26)(cid:19)(cid:8)(cid:16)(cid:27)(cid:20)(cid:9)(cid:27)(cid:18)(cid:17)(cid:141)(cid:18)(cid:19)(cid:20)(cid:23)(cid:26)(cid:12)(cid:27)(cid:18)
(cid:15)(cid:17)(cid:9)(cid:23)(cid:29)(cid:8)(cid:17)(cid:19)(cid:23)(cid:16)(cid:20)(cid:9)(cid:23)(cid:18)(cid:31)(cid:11) (cid:21)(cid:129)(cid:17)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)(cid:18)(cid:31)(cid:11)(cid:31)(cid:23)(cid:26)(cid:21)(cid:27)(cid:9)
(cid:21)(cid:20)(cid:15)(cid:15)(cid:26)(cid:19)(cid:25)(cid:18)(cid:7)(cid:6)(cid:14)(cid:5)(cid:4)(cid:10) (cid:27)(cid:25)(cid:26)(cid:17)(cid:19)(cid:20)(cid:2)(cid:18)(cid:17)(cid:16)(cid:18)(cid:25)(cid:2)(cid:17)€(cid:20)(cid:2)(cid:18)
(cid:31)(cid:11)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22) (cid:26)(cid:19)(cid:8)(cid:16)(cid:27)(cid:20)(cid:9)(cid:27)(cid:18)(cid:6)(cid:14)(cid:5)(cid:18)(cid:12)(cid:20)(cid:2)(cid:1)(cid:27)(cid:9)
(cid:26)(cid:21)(cid:20)(cid:25)(cid:26)(cid:19)(cid:25)
(cid:9)(cid:4)(cid:7)(cid:6)(cid:18)(cid:21)(cid:27)(cid:22)
(cid:5)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:26)(cid:25) (cid:3)(cid:26)(cid:5)(cid:18)(cid:15)(cid:14)(cid:17)(cid:12)(cid:26)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:18)(cid:15) (cid:11)(cid:27)(cid:30)(cid:29)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:18)(cid:15) (cid:143)(cid:16)(cid:27)(cid:9)(cid:27)(cid:19)(cid:8)(cid:27)(cid:144)(cid:18)(cid:15)(cid:20)(cid:23)(cid:23)(cid:27)(cid:16)(cid:19)(cid:144)(cid:18) (cid:127)(cid:26)(cid:25)(cid:24)(cid:18)(cid:9)(cid:26)(cid:25)(cid:19)(cid:20)(cid:2)(cid:18)(cid:26)(cid:19)(cid:23)(cid:27)(cid:19)(cid:9)(cid:26)(cid:23)(cid:129)(cid:18)
(cid:141)(cid:6)(cid:30)(cid:26)(cid:21)(cid:29)(cid:21)(cid:1)(cid:21)(cid:5)(cid:18)(cid:30) (cid:29)(cid:25)(cid:143)(cid:18)(cid:17)(cid:17)(cid:18)(cid:28)(cid:29)(cid:26)(cid:25)(cid:1)(cid:21)(cid:5)(cid:18)(cid:30) (cid:27)(cid:157)(cid:23)(cid:27)(cid:19)(cid:23)(cid:144)(cid:18)(cid:20)(cid:19)(cid:22)(cid:18)(cid:2)(cid:17)(cid:8)(cid:20)(cid:23)(cid:26)(cid:17)(cid:19)(cid:18)(cid:17)(cid:141)(cid:18) (cid:17)(cid:141)(cid:18)(cid:23)(cid:24)(cid:27)(cid:18)(cid:15)(cid:27)(cid:16)(cid:26)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:1)(cid:21)(cid:18)
(cid:3)„(cid:6)(cid:18)(cid:7)(cid:15)(cid:17)(cid:9)(cid:26)(cid:23)(cid:26)(cid:12)(cid:27)(cid:18)(cid:26)(cid:141)(cid:18)(cid:20)(cid:16)(cid:27)(cid:20)(cid:9)(cid:18) (cid:26)(cid:19)(cid:18)(cid:3)„(cid:6)(cid:18)(cid:26)(cid:21)(cid:20)(cid:25)(cid:27)(cid:9)
(cid:28)(cid:26)(cid:23)(cid:24)(cid:18)(cid:24)(cid:26)(cid:25)(cid:24)(cid:18) ‚(cid:18)(cid:26)(cid:19)(cid:18)(cid:20)(cid:18)
(cid:3)(cid:20)(cid:23)(cid:27)(cid:18)(cid:25)(cid:20)(cid:22)(cid:17)(cid:2)(cid:26)(cid:19)(cid:26)(cid:1)(cid:21) (cid:19)(cid:17)(cid:19)(cid:26)(cid:9)(cid:8)(cid:24)(cid:20)(cid:27)(cid:21)(cid:26)(cid:8)(cid:18)
(cid:27)(cid:19)(cid:24)(cid:20)(cid:19)(cid:8)(cid:27)(cid:21)(cid:27)(cid:19)(cid:23) (cid:22)(cid:26)(cid:9)(cid:23)(cid:16)(cid:26)€(cid:1)(cid:23)(cid:26)(cid:17)(cid:19)(cid:18)(cid:15)(cid:20)(cid:23)(cid:23)(cid:27)(cid:16)(cid:19)(cid:4)
(cid:31)(cid:24)(cid:16)(cid:17)(cid:21)€(cid:26)(cid:18)(cid:7)(cid:26)(cid:141)(cid:18)(cid:15)(cid:16)(cid:27)(cid:9)(cid:27)(cid:19)(cid:23)(cid:4)
(cid:31)(cid:17)(cid:23)(cid:20)(cid:2)(cid:18)(cid:3)„(cid:6)(cid:10)(cid:3)(cid:5)(cid:18)(cid:21)(cid:20)(cid:9)(cid:9)(cid:18)(cid:7)…(cid:4)
(cid:7)(cid:19)(cid:17)(cid:18)(cid:16)(cid:17)(cid:1)(cid:23)(cid:26)(cid:19)(cid:27)(cid:4)
(cid:3)(cid:129)(cid:25)(cid:5)(cid:28)(cid:29)(cid:26)(cid:25)(cid:18)(cid:15)(cid:14)(cid:18)(cid:25)(cid:22)(cid:14)(cid:144)(cid:18)(cid:15)(cid:15) (cid:157)(cid:18)(cid:27)(cid:17)(cid:26)(cid:22)(cid:12)(cid:25)(cid:18)(cid:17)(cid:29)(cid:5) (cid:27)(cid:25)(cid:26)(cid:17)(cid:19)(cid:20)(cid:2)(cid:18)(cid:28)(cid:20)(cid:2)(cid:2)(cid:29)(cid:21)(cid:17)(cid:23)(cid:26)(cid:17)(cid:19)(cid:18) (cid:143)(cid:16)(cid:27)(cid:9)(cid:27)(cid:19)(cid:8)(cid:27)(cid:144)(cid:18)
(cid:17)(cid:26)(cid:28)(cid:29)(cid:26)(cid:25)(cid:14)(cid:18)(cid:6)(cid:25)(cid:26)(cid:30)(cid:17)(cid:18)(cid:15)(cid:29)(cid:28)(cid:29)(cid:27)(cid:21) (cid:5)(cid:26)(cid:17)(cid:16)(cid:30)(cid:26)(cid:17)(cid:29)(cid:21)(cid:27) (cid:20)€(cid:19)(cid:17)(cid:16)(cid:21)(cid:20)(cid:2)(cid:26)(cid:23)(cid:26)(cid:27)(cid:9) (cid:8)(cid:17)(cid:21)(cid:15)(cid:17)(cid:9)(cid:26)(cid:23)(cid:26)(cid:17)(cid:19)(cid:144)(cid:18)(cid:20)(cid:19)(cid:22)(cid:18)
(cid:14)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:8)(cid:18)(cid:141)(cid:1)(cid:19)(cid:8)(cid:23)(cid:26)(cid:17)(cid:19)(cid:18)(cid:7)(cid:27)‡(cid:25)‡(cid:18) (cid:27)(cid:157)(cid:23)(cid:27)(cid:19)(cid:23)(cid:18)(cid:17)(cid:141)(cid:18)(cid:15)(cid:27)(cid:16)(cid:26)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)(cid:18)
(cid:3)(cid:5)(cid:6)ˆ(cid:144)(cid:18) (cid:5)(cid:6)ˆ(cid:4)(cid:18)(cid:20)(cid:19)(cid:22)(cid:18)(cid:12)(cid:17)(cid:2)(cid:1)(cid:21)(cid:27)(cid:18) (cid:27)†(cid:1)(cid:9)(cid:26)(cid:17)(cid:19)
(cid:129)(cid:16)(cid:16)(cid:26)(cid:30)(cid:28)(cid:29)(cid:2)(cid:27) (cid:14)(cid:26)(cid:19)(cid:27) (cid:15)(cid:20)(cid:16)(cid:20)(cid:21)(cid:27)(cid:23)(cid:27)(cid:16)(cid:9) (cid:127)(cid:20)(cid:27)(cid:21)(cid:17)(cid:22)(cid:129)(cid:19)(cid:20)(cid:21)(cid:26)(cid:8)(cid:18)
(cid:16)(cid:27)(cid:2)(cid:27)(cid:12)(cid:20)(cid:19)(cid:8)(cid:27)(cid:18)(cid:17)(cid:141)
(cid:5)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:26)(cid:25) (cid:26)(cid:21)(cid:20)(cid:25)(cid:26)(cid:19)(cid:25)
(cid:15)(cid:27)(cid:16)(cid:26)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)(cid:18)(cid:27)†(cid:1)(cid:9)(cid:26)(cid:17)(cid:19)
ƒ(cid:26)(cid:20)(cid:21)(cid:27)(cid:23)(cid:27)(cid:16)(cid:18)(cid:17)(cid:141)(cid:18)(cid:15)(cid:27)(cid:16)(cid:26)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)(cid:18)
(cid:27)†(cid:1)(cid:9)(cid:26)(cid:17)(cid:19)
‚(cid:16)(cid:22)(cid:18)(cid:28)(cid:27)(cid:22)(cid:14)ƒ(cid:18)„(cid:27)(cid:14)ƒ(cid:26)(cid:129)(cid:29)(cid:21)(cid:27)(cid:14)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:18)(cid:14)…ƒƒ(cid:31)†(cid:14)(cid:10)(cid:26)(cid:30)(cid:14)(cid:17)(cid:12)(cid:26)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:28)(cid:29)(cid:21)
(cid:31)(cid:24) (cid:7)(cid:16)(cid:30)(cid:26)(cid:2)(cid:27)(cid:25)(cid:14)(cid:17)(cid:12)(cid:26)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:28)(cid:29)(cid:21)€
(cid:9)(cid:8)(cid:7)(cid:6)(cid:18)(cid:21)(cid:27)(cid:22)(cid:14)(cid:5)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:26)(cid:25) Œ€(cid:19)(cid:17)(cid:16)(cid:21)(cid:20)(cid:2)(cid:18)(cid:31)(cid:30)(cid:29)(cid:21)(cid:20)(cid:15)(cid:15)(cid:26)(cid:19)(cid:25)
(cid:30)(cid:18)(cid:17)(cid:1)(cid:23)(cid:18)(cid:17)(cid:141)(cid:18)(cid:30)(cid:18)(cid:1)(cid:15)(cid:22)(cid:20)(cid:23)(cid:27)(cid:22)(cid:18)(cid:3)(cid:3)(cid:14)(cid:18)(cid:21)(cid:20)(cid:26)(cid:19) (cid:143)(cid:27)(cid:16)(cid:26)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)(cid:18)(cid:20)€(cid:19)(cid:17)(cid:16)(cid:21)(cid:20)(cid:2)(cid:26)(cid:23)(cid:26)(cid:27)(cid:9)
Š(cid:129)(cid:17)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)(cid:18)(cid:17)(cid:27)(cid:22)(cid:27)(cid:21)(cid:20) (cid:17)(cid:16)(cid:18)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22)(cid:18)(cid:26)(cid:21)(cid:20)(cid:25)(cid:26)(cid:19)(cid:25)
(cid:8)(cid:16)(cid:26)(cid:23)(cid:27)(cid:16)(cid:26)(cid:20)(cid:18)(cid:141)(cid:1)(cid:2)‰(cid:2)(cid:2)(cid:27)(cid:22)
(cid:24)(cid:18)(cid:29)(cid:25)(cid:14)(cid:5)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:18) (cid:129)(cid:16)(cid:16)(cid:26)(cid:30)(cid:28)(cid:29)(cid:2)(cid:27)(cid:14)(cid:5)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:18)
(cid:31)(cid:24) (cid:7)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:29)(cid:14)(cid:17)(cid:12)(cid:26)(cid:5)(cid:18)(cid:30)(cid:22)(cid:29)(cid:28)(cid:29)(cid:21)€ (cid:9)(cid:22)(cid:7)(cid:6)(cid:18)(cid:21)(cid:27)(cid:22)(cid:14)(cid:5)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:26)(cid:25)
Œ€(cid:19)(cid:17)(cid:16)(cid:21)(cid:20)(cid:2)(cid:18)(cid:31)(cid:11)(cid:29)(cid:21)(cid:20)(cid:15)(cid:15)(cid:26)(cid:19)(cid:25)(cid:144)
(cid:17)(cid:19)(cid:2)(cid:129)(cid:18)(cid:11)(cid:18)(cid:17)(cid:1)(cid:23)(cid:18)(cid:17)(cid:141)(cid:18)(cid:30)(cid:18)(cid:1)(cid:15)(cid:22)(cid:20)(cid:23)(cid:27)(cid:22)(cid:18)(cid:3)(cid:3)(cid:14)(cid:18)(cid:21)(cid:20)(cid:26)(cid:19) (cid:13)(cid:17)(cid:19)(cid:29)(cid:26)(cid:9)(cid:8)(cid:24)(cid:20)(cid:27)(cid:21)(cid:26)(cid:8) (cid:129)(cid:9)(cid:23)(cid:17)(cid:2)(cid:26)(cid:8)(cid:18)(cid:3)(cid:5)(cid:29)(cid:22)(cid:129)(cid:9)(cid:141)(cid:1)(cid:19)(cid:8)(cid:23)(cid:26)(cid:17)(cid:19)
(cid:6)(cid:14)(cid:5)(cid:18)(cid:17)(cid:16)(cid:18)(cid:3)„(cid:6)
(cid:8)(cid:16)(cid:26)(cid:23)(cid:27)(cid:16)(cid:26)(cid:20)(cid:18)(cid:141)(cid:1)(cid:2)‰(cid:2)(cid:2)(cid:27)(cid:22) (cid:21)(cid:129)(cid:17)(cid:8)(cid:20)(cid:16)(cid:22)(cid:26)(cid:20)(cid:2)(cid:18)(cid:26)(cid:19)‹(cid:1)(cid:16)(cid:129)
Figure 4 Diagnostic criteria by cardiovascular magnetic resonance based on the updated Lake Louise criteria. CMR, cardiovascular magnetic reson-
ance; ECV, extracellular volume; LGE, late gadolinium enhancement; LLC, Lake Louise criteria; LV, left ventricle; LVEF, left ventricular ejection fraction;
RVEF, right ventricular ejection fraction; SI, signal intensity ratio.30 Presence of pericardial effusion suggests concomitant pericarditis.
Downloaded
from

by
guest
on
22
January
2026

3966 E S C G u id e l in e s
Histopathological Dallas criteria,31 in addition to immunohistological herpesviruses [Epstein–Barr virus (EBV), human herpesvirus 6 (HHV-6)],
staining to detect CD3+ T cells and CD68+ macrophages, are required as well as influenza and coronaviruses, are the most common viruses
to identify specific histological subtypes of myocarditis and to differen- associated with myocarditis (Supplementary data online, Table S1).
tiate from phenocopies [e.g. arrhythmogenic right ventricular cardio- Non-cytotoxic viruses trigger myocarditis indirectly by activating the im-
myopathy (ARVC)].32,33 New quantitative criteria are presently mune system.41,42 Bacterial infection with Borrelia species [Lyme carditis
required, since the ESC criteria of ≥14 leucocytes/mm2 including (LC)] and parasitic infections, such as Trypanosoma cruzi [Chagas disease
≥7 CD3+ T cells/mm2 have been questioned by cardiopathologists.10 (CD)], are additional important aetiologies in specific regions of the globe.
In addition, molecular analysis of EMB and blood [including assessment However, several non-infectious aetiologies should be recognized,
of viral deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in per- including systemic diseases, autoimmune (or likely autoimmune) disor-
ipheral leucocytes and in plasma] using quantitative polymerase chain ders [systemic lupus erythematosus (SLE), systemic sclerosis (SSc),
reaction (PCR) is necessary to identify the aetiopathogenesis of myo- rheumatoid arthritis (RA), eosinophilic granulomatosis with polyangii-
carditis and allow targeted therapies (antiviral or immunosuppressive/ tis (EGPA), hypereosinophilic syndrome (HES)], immune-mediated
immunomodulatory), if clinically useful.10,32,34 Examples are given in forms [such as LM, giant-cell myocarditis (GCM), eosinophilic myocar-
Section 5.9.1. ditis (EM), and cardiac sarcoidosis (CS)], inflammatory bowel disor-
ders, drugs and toxic reactions (including ICI-associated myocarditis,
3.3.2. Diagnostic criteria for pericarditis see Section 9.6.1.1) and chest radiation, as well as genetic conditions
Pericarditis is an inflammatory pericardial syndrome with or without such as inherited CMP (see Section 5.3);10,39 see Supplementary data
pericardial effusion (PEff). The definite clinical diagnosis can be made online, Table S1.10
with a clinical presentation and more than one additional criterion
(Table 4). The main presenting symptom is usually chest pain 3.4.2. Aetiology of pericarditis
(85%–90% of cases), which is typically sharp and pleuritic, improves
The aetiology largely depends on the epidemiological background,
by sitting up and leaning forward, and is exacerbated by inspiration, patient population, and clinical setting.1,10 Idiopathic or viral peri-
lying down, and deglutition, due to increased attrition between in-
carditis is the most frequent aetiology in developed countries,
flamed pericardial layers. Dyspnoea can be reported by the elderly,
ranging from 50% in inpatient settings to >80% in outpatient
or right HF signs and symptoms in the case of pericarditis with con- settings.43–48 Tuberculosis (TB) is responsible for about 70% of
striction. Arrhythmic presentations are rare and are usually asso-
all cases, especially in human immunodeficiency (HIV)-infected pa-
ciated with atrial fibrillation (AF). Additional criteria include a
tients, in regions where the disease is endemic. An increasing num-
pericardial friction rub (≤33% of cases), which is a superficial scratchy
ber of cases are related to interventional procedures and surgery
or squeaking sound, caused by friction between the two inflamed
[post-cardiac injury syndrome (PCIS)] due to the increased number
pericardial layers. Electrocardiogram changes have been historically of procedures performed and the ageing population.49 Other com-
reported as a typical hallmark of AP; however, the pericardium is
mon causes include systemic inflammatory/autoimmune diseases
electrically silent, so ECG changes imply concomitant inflammation
and cancer (especially lung and breast cancer or lymphomas and
of the myocardium, warranting investigation for concurrent myocar- leukaemia) (see Supplementary data online, Table S1).1
ditis.35 On imaging, new or worsening PEff (up to 60% of cases),
About 5%–15% of patients with recurrence have genetic mutations,
which is generally mild, might be detected. As pericarditis classically
sometimes related to a monogenic autoinflammatory disease, mainly fa-
manifests with an inflammatory syndrome, elevated laboratory mar-
milial Mediterranean fever (FMF) and tumour necrosis factor receptor-
kers of inflammation, such as C-reactive protein (79%–90%),36 associated periodic syndrome (TRAPS).50,51 A genetic predisposition
erythrocyte sedimentation rate (ESR), and neutrophilic leucocyt- and an autoinflammatory/immune-mediated pathogenesis are also sus-
osis,37,38 can provide additional supportive criteria. The inflamed pected in patients with multiple recurrences. For additional information
pericardium is neovascularized and contrast-enhanced on computed see Supplementary data online, Tables S2 and S3.50–52
tomography (CT) and CMR. Cardiovascular magnetic resonance is
superior for tissue characterization and can reveal pericardial oe-
dema and/or pericardial late gadolinium enhancement (LGE), provid- 4. Clinical presentation of
ing additional imaging criteria for the diagnosis.
inflammatory myopericardial
3.4. Aetiology of myocarditis and syndrome
pericarditis
The term IMPS includes a spectrum of inflammatory diseases from
Myocardial and pericardial diseases share mostly similar aetiologies (see isolated myocarditis to isolated pericarditis through a combination
Supplementary data online, Table S1). The aetiology of IMPS can be ei- of both. IMPS should be used as an umbrella term during the initial
ther infectious or non-infectious. These can trigger IMPS in a genetically diagnostic work-up until the final diagnosis is made. One of the ma-
predisposed individual by inflammatory/autoimmune mechanisms. jor challenges for the diagnosis of IMPS is recognition itself, there-
However, the prevalence of each aetiology and the impact of the causa- fore the TF highlighted red flags (Table 6). These symptoms and
tive agent on the clinical course, prognosis, and therapeutic approach signs should suggest IMPS. The red flags for IMPS are mainly clinical
may differ between the two entities.1,10 signs, accompanied by serological and/or imaging biomarkers, and
are not equivalent to the risk. Red flags for IMPS are warning signs,
3.4.1. Aetiology of myocarditis aiming to raise the awareness of the disease. If there is a suspicion
The most common infectious aetiology is presumed to be viral.10,39,40 of IMPS, staging based on the risk assessment should be performed
Enteroviruses, adenoviruses, parvovirus B19 (B19V) and some (Table 7).
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3967
Table 6 Red flags for the clinical diagnosis of myocarditis and pericarditis
Myocarditis Pericarditis
Recent or concomitant flu-like syndrome or gastroenteritis Recent or concomitant flu-like syndrome or gastroenteritis
Infarct-like chest pain Pleuritic/infarct-like chest pain
Palpitations Right HF symptoms and signs of constriction
HF symptoms Fever
ECG changesa Pericardial rubs
Ventricular arrhythmias (isolated, complex) C-reactive protein elevation
Syncope Pericardial effusion
Haemodynamic instability Pleural effusion
Elevated markers of myocardial lesion (hs-Tn, CK-MB elevation) Polyserositis
Elevated markers of HF (NT-proBNP) CMR imaging with pericardial oedema and/or LGE
Abnormal wall motion, increased wall thickness and/or impaired systolic function
on imaging
CMR imaging with myocardial oedema and/or LGE
CK-MB, creatinine kinase muscle-brain type; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; HF, heart failure; hs-Tn; high-sensitivity troponin; LGE, late gadolinium
enhancement; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
aSee Section 5.1.
Table 7 Clinical risk stratification to guide work-up in inflammatory myopericardial syndrome
Risk High risk Intermediate risk Low risk
Myocarditis • Acute HF/cardiogenic shock • New/progressive dyspnoea Stable symptoms or oligosymptomatic
• Dyspnoea NYHA III–IV refractory • Non-sustained ventricular arrhythmias
to medical therapy • Persistent release or relapsing troponin
• Cardiac arrest/syncopea
• Ventricular fibrillation/sustained
ventricular tachycardiaa
• High-level AV blocka
Imaging criteria: Imaging criteria: Imaging criteria:
• Newly reduced LVEF (<40%)a • Newly mildly reduced LVEF (41%–49%) • Preserved LVEF (≥50%) without LGE or limited
• Extensive LGE on CMRa and/or WMA LGE (<2 segments) on CMR
• Preserved LVEF (≥50%) and
LGE ≥2 segments on CMR
Pericarditis • Signs and symptoms of cardiac • Signs and symptoms of right HF • Response to adequate therapy within 1–2 weeks
tamponade
• Fever (temperature >38°C)
• Effusive–constrictive pericarditis
• Failure of NSAID therapy
• Incessant pericarditis
Imaging criteria: Imaging criteria: Imaging criteria:
• Large PEff (>20 mm end-diastole) • Moderate–large PEff • Absence or mild PEff
• Cardiac tamponade (10–20 mm end-diastole) • Absence of pericardial LGE on CMR
• Extensive pericardial LGE on CMR • Constrictive physiology regardless of the
size of the effusion
AV, atrioventricular; CMR, cardiovascular magnetic resonance; HF, heart failure; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; NSAID, non-steroidal
anti-inflammatory drug; NYHA, New York Heart Association classification; PEff, pericardial effusion; WMA, wall motion abnormalities.
aThese criteria do not lead directly towards endomyocardial biopsy; in these scenarios it is a case-by-case decision depending on the suspected underlying cause.
A fast and reliable diagnosis is crucial for proper management. The ini- warrants consideration whether the first contact was inpatient or
tial step involves triaging patients by assessing their risk factors and ruling outpatient.53,54 This approach is based on the different national
out acute coronary syndrome (ACS), whenever indicated by the pa- healthcare systems, given that a patient may be first seen in an out-
tient’s characteristics and clinical presentation. In addition, myocarditis patient or inpatient setting (Figures 5–7).
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3968 E S C G u id e l in e s
Patient with symptoms and signsa of myocarditis presenting to the emergency room
First-line assessment with history, physical examination, ECG,
transthoracic echocardiography, chest X-ray, laboratory assessmentb
(Class I)
Treat CAD Obstructive CADc
Admit to ward/ICU
(Class I)
High-risk clinical featuresd
Cardiovascular magnetic
Endomyocardial biopsyf
resonancee
(Class I)
(Class I)
Possible Diagnosis Rejected/unlikely
Definitive
Further assessmentg Complete risk classificationd Further work-up
Low risk Intermediate risk High risk
Stay on ward and
Stay on ward/ICU
discharge when possible
(Class I)
Establish HF/AA therapy and/or
treatment of specific aetiology
Improvement
Discharge Cardiovascular magnetic resonance
if possible (if not done before)
Multidisciplinary
Outpatient
IMPS team
follow-up
discussion
Figure 5 Diagnostic algorithm and triage for inpatient myocarditis. AA, anti-arrhythmic therapy; CAD, coronary artery disease; CRP, C-reactive pro-
tein; ECG, electrocardiogram; HF, heart failure; ICU, intensive care unit; IMPS, inflammatory myopericardial syndrome; N, no; NT-proBNP, N-terminal
prohormone of brain natriuretic peptide; Y, yes. aSee Table 6. bLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood
count. cInvasive coronary angiography or computed tomography angiography depending on clinical likelihood/probability. dSee Table 7. eConsider en-
domyocardial biopsy. fConsider cardiovascular magnetic resonance. gSee Table 9.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3969
Patient with symptoms and signsa of myocarditis presenting to the outpatient clinic
First-line assessment with history, physical examination, ECG, transthoracic echocardiography,
laboratory assessmentb
(Class I)
Elevated troponin Refer to hospital
See inpatient
algorithmc
Treat CAD Obstructive CADd
Cardiovascular magnetic resonancee
(Class I)
Possible Diagnosis Rejected/unlikely
Definitive
Further assessmentf Complete risk classificationg Further work-up
Low risk Intermediate risk High risk
Outpatient treatment Admit to ward
(Class I)
Outpatient follow-up See inpatient algorithmc
Figure 6 Diagnostic algorithm and triage for outpatient myocarditis. CAD, coronary artery disease; CRP, C-reactive protein; ECG, electrocardio-
gram; N, no; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; Y, yes. aSee Table 6. bLaboratory testing including troponin,
NT-proBNP, C-reactive protein, differential blood count. cSee Figure 5. dInvasive coronary angiography or computed tomography angiography depend-
ing on clinical likelihood/probability. eDepending on clinical situation (heart failure, arrhythmias) admit to ward. fSee Table 9. gSee Table 7.
Downloaded
from

by
guest
on
22
January
2026

3970 E S C G u id e l in e s
Patient with symptoms and signs of pericarditisa
First-line assessment with history, physical examination,
ECG, transthoracic echocardiography,
X-ray, routine blood test including CRP and troponin
(Class I)
High-risk featuresb
Outpatient follow-up
Response to therapy after 1−2 week
Risk evaluationb
Low risk Intermediate risk High risk
Admission,
Admission or close
Outpatient aetiology search
follow-up
treatment and anti-inflammatory
and aetiology search.
therapy
Figure 7 Diagnostic algorithm and triage for pericarditis. CRP, C-reactive protein; ECG, electrocardiogram; N, no; Y, yes. asee Table 6. bIf a patient has
one or more prognostic predictors, as reported in Table 7, a high-risk patient must be admitted to hospital, and an aetiology search should be per-
formed. Patients without high-risk features can be managed as outpatients without an aetiology search and admission if there is a good response to
empirical anti-inflammatory therapy.
4.1. General symptoms and signs The presentation of AM can vary from very mild symptoms
to a life-threatening condition.10 The typical symptoms and signs at
The most common symptom of myocarditis and pericarditis is chest
presentation include chest pain in >80% of cases, and dyspnoea in
pain (sometimes with infarct-like features, especially for myocarditis,
20%–50%, while fatigue, palpitations, and syncope are less common
or pleuritic with respiratory changes, especially for pericarditis).
and are reported in about 5%.28,32,55 In the majority of cases (80%),
Other common presentations include dyspnoea (myocarditis with HF
symptoms are preceded by prodromes, such as fever (60%), gastro-
presentation, but it is also the most common symptom in the elderly
intestinal complaints (30%), or respiratory symptoms (25%).28,55,56
with pericarditis) and/or arrhythmias of different degrees (mainly ven-
Other extracardiac symptoms, depending on the underlying disease,
tricular for myocarditis and supraventricular and AF for pericarditis)
can be present. Electrocardiogram is normal in a minority of patients
and, less frequently, syncope. Flow charts are provided for each type
(about 15%); most frequently, ST-segment elevation is present
to guide the diagnostic pathway (see Section 4.3).
(57.5%), but other ST/T-segment changes can be found (23.5%), as
Some patients may present with persistent symptoms without re-
well as conduction blocks (10%).28,55
mission and are labelled as patients with incessant/ongoing IMPS.
In most patients with acute presentation, cardiac enzymes [troponin
T/I and creatinine kinase muscle-brain type (CK-MB)] are elevated.28,55
4.2. Clinical stages of myocarditis
Echocardiography is important for clinical evaluation as it might reveal
4.2.1. Acute myocarditis signs of myocarditis, including increased wall thickness and echogenicity
Acute onset is defined as symptoms and signs lasting ≤4 weeks.28 In myo- due to myocardial oedema. PEff is seen in up to 25% of patients, reflect-
carditis, this entails AM and the subtype fulminant myocarditis (FM). ing concomitant pericarditis or related to haemodynamic factors.28,55
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3971
4.2.2. Fulminant myocarditis myocardial inflammation in patients with non-ischaemic HF.60 New
Fulminant myocarditis (occurring in 3%–9%) is characterized by cardio- quantitative CMR techniques have improved the diagnostic yield in pa-
genic shock at presentation for which haemodynamic support is tients with chronic myocarditis.61
needed.28 Isolated right ventricle (RV) dysfunction is uncommon; how-
4.3. Clinical presentations of myocarditis
ever, biventricular failure occurs frequently in FM. Sustained ventricular
arrhythmias (VA) may also occur in these patients (46.9%) and some Myocarditis is characterized by the heterogeneity of clinical manifesta-
present with sudden cardiac death (SCD) (25.8%).28,56,57 tions (Figure 8); therefore, the diagnosis requires a high level of suspi-
In the majority of children with FM (usually <2 years of age), LV dys- cion. The main patterns of clinical presentation are infarct-like chest
function with dilatation is present at initial presentation,40 while there is pain (most frequent symptom), arrhythmias, and HF. Severity may
usually no LV dilatation in the early phase for adults. Concurrent viral range from asymptomatic/oligosymptomatic to severe life-threatening
infections can be common in these children. scenarios, such as severe HF or VA (potentially leading to SCD). A clin-
ical classification based on presentation as high-risk or non-high-risk
myocarditis (see Table 7) has been shown to meaningfully predict out-
4.2.3. Subacute myocarditis
comes in large cohorts.28,62,63 Moreover, myocarditis, especially when
The subacute stage refers to cases with symptoms lasting >1 month
recurrent, may represent the ‘hot phase’ of some CMPs [e.g. desmopla-
but ≤3 months. The symptoms are unspecific, and patients might either kin (DSP)-related ARVC].64 Details are given in Section 4.3.5.
have a remission without residuals or might progress to chronic myo-
carditis or inflammatory CMP (see Section 10).
4.3.1. Chest pain presentation
Chest pain is the most common form of clinical presentation (about 75%
4.2.4. Chronic myocarditis of unselected cases) in adolescents and adults.28 It is commonly associated
Chronic myocarditis is myocarditis persisting beyond 3 months.39 with an increase in necrosis biomarkers, such as troponin, often with ECG
Chronic myocarditis might reflect an intermediate stage possibly lead- alterations (especially ST-segment elevation), which may mimic ACS, des-
ing to inflammatory CMP, characterized by cardiac remodelling and pite the absence of significant obstructive coronary artery disease (CAD).
some degree of ventricular dysfunction.10,39 These cases are often labelled as infarct-like.65 Patients with this presen-
Milder forms may appear as hypokinetic non-dilated forms of CMP.39 tation usually report a recent or concomitant viral infection, such as a re-
Moreover, an arrhythmogenic substrate, due to fibrosis, should be con- spiratory tract infection or gastroenteritis, which often precedes
sidered for the management of these patients.39,58 myocarditis by several days to weeks (2–4 weeks). Usually, the presence
Symptoms may be unremarkable in chronic myocarditis.10,39 of troponin release in the context of IMPS is not a negative prognostic
Dyspnoea and palpitations might be the leading symptoms.10,39 marker, when associated with preserved biventricular function.4,66
Biomarkers of myocardial injury are usually within normal limits.59 Patients presenting with chest pain and normal left ventricular ejection
Notably, elevated C-reactive protein, hs-TnT, and impaired global lon- fraction (LVEF) without wall motion abnormalities (WMA), no VA,
gitudinal strain (GLS) have been associated with EMB-proven and complete resolution of ECG abnormalities in the short term can
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:23)(cid:24)(cid:20)(cid:22)(cid:28)(cid:19)(cid:26)(cid:18)(cid:17)(cid:27)(cid:17)(cid:16)(cid:23)(cid:30)(cid:26)(cid:29)(cid:16)(cid:29)(cid:15)(cid:27)(cid:19)(cid:27)(cid:17)(cid:22)(cid:15)(cid:16)(cid:23)(cid:19)(cid:15)(cid:18)(cid:23)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:24)(cid:29)(cid:16)
(cid:5)(cid:29)(cid:17)(cid:4)(cid:30)(cid:24)(cid:27)(cid:28)(cid:3)(cid:30)(cid:24)(cid:13)(cid:26)(cid:19)(cid:19)(cid:30)(cid:16)(cid:17)(cid:22)(cid:30)(cid:27)
(cid:23)(cid:28)(cid:22)(cid:21)(cid:24)(cid:12)(cid:19)(cid:30)(cid:2)(cid:20)(cid:30)(cid:25)(cid:13)(cid:6)
(cid:8)(cid:14)(cid:20)(cid:7)(cid:22)(cid:17)(cid:6) (cid:14)(cid:12)(cid:27)(cid:13)(cid:22)(cid:17)(cid:11)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:27)(cid:24)(cid:21)(cid:22)(cid:29)(cid:20) (cid:19)(cid:18)(cid:17)(cid:26)(cid:22)(cid:16)(cid:23)(cid:21)(cid:29)(cid:15) (cid:14)(cid:13)(cid:13)(cid:18)(cid:25)(cid:22)(cid:18)(cid:24)(cid:29)(cid:21)(cid:26) (cid:3)(cid:7)(cid:30)(cid:24)(cid:29)(cid:15)(cid:21)(cid:15)(cid:22) (cid:10)(cid:19)(cid:9)
(cid:5)(cid:17)(cid:21)(cid:13)(cid:22)(cid:16)(cid:4)(cid:21)(cid:29)(cid:30)(cid:7)(cid:13)(cid:17) (cid:10)(cid:19)(cid:9)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:27)(cid:28)(cid:26)(cid:25)(cid:24)(cid:23)(cid:28)(cid:22)(cid:21)(cid:26)(cid:20)(cid:22)(cid:24)(cid:26)(cid:19)(cid:24)(cid:23)(cid:28)(cid:22)(cid:21)(cid:24)(cid:19)(cid:30)(cid:27)(cid:28)(cid:18)(cid:20)(cid:17)(cid:16)(cid:27) (cid:7)(cid:28)(cid:16)(cid:17)(cid:22)(cid:30)(cid:18)
(cid:7)(cid:30)(cid:17)(cid:22)(cid:21)
(cid:15)(cid:14)(cid:19)(cid:30)(cid:27)(cid:30)(cid:25)(cid:13)(cid:30)(cid:24)(cid:26)(cid:12)(cid:24)(cid:19)(cid:30)(cid:18)(cid:20)(cid:13)(cid:30)(cid:18)(cid:24)(cid:12)(cid:20)(cid:25)(cid:13)(cid:22)(cid:28)(cid:26)(cid:25)(cid:24)(cid:17)(cid:25)(cid:18)(cid:24)(cid:26)(cid:19)(cid:24)(cid:11)(cid:10)(cid:9)(cid:8) (cid:13)(cid:17)(cid:19)(cid:18)(cid:28)(cid:26)(cid:29)(cid:6)(cid:26)(cid:14)(cid:17)(cid:22)(cid:21)(cid:6)
Figure 8 Spectrum of myocarditis presentations and outcomes. LGE, late gadolinium enhancement; SCD, sudden cardiac death. Image size correlates
with presentation frequency (e.g. chest pain being the most common). Uncomplicated cases of myocarditis (about 75% of unselected cases) usually have
spontaneous remission.28 In acute myocarditis diagnosed by endomyocardial biopsy, up to 50% of patients have spontaneous recovery, but up to 25%
may have a persistent stable cardiac dysfunction, while 10%–25% have a progressive ventricular dysfunction, which could lead to end-stage dilated car-
diomyopathy, heart transplantation, or death.9
Downloaded
from

by
guest
on
22
January
2026

3972 E S C G u id e l in e s
be considered as having a low-risk presentation with an excellent long- of any cause was shown to be relevant for outcome, and small scars (e.g.
term prognosis.4,28,62,66,67 There are possible exceptions to this general <2 segments) after >6 months seemed to be more benign.71
rule in a few cases with EM and GCM. Myocardial scarring as detected Nevertheless, long-term outcome data are missing. For a proposed work-
by CMR can be present in cases with preserved LVEF.3,68–70 Focal scarring flow see Figure 9.
Patient with acute chest pain
Clinical history and vital signs, 12-lead ECG, laboratory testinga, transthoracic echocardiography
(Class I)
Clinical likelihood/probability of obstructive coronary artery disease
High Moderate Low
Invasive coronary
CT angiography Clinical exclusion
angiography
(Class I)
(Class I)
Further
Red flags for IMPSb aetiological
work-up
Coronary artery disease Diagnostic criteria Diagnostic criteria
suggestive of suggestive of
myocarditis pericarditis
Treat according to Go to pericarditis
ACS GLc Risk stratificationd algorithme
If CAD not Non-high risk High riskf
the sole
explanation
for the
symptoms Cardiovascular Before discharge Endomyocardial
magnetic resonanceg biopsy
(Class I) (Class I)
Suggestive of
Definite Normal findings non cardiac causes
myocarditis
or cardiomyopathies
No further Aetiological Further aetiological
work-up work-up work-up requiredh
Further No further
work-upi work-up
Figure 9 Diagnostic algorithm for acute chest pain presentation. ACS, acute coronary syndrome; CAD, coronary artery disease; CRP, C-reactive
protein; CT, computed tomography; ECG, electrocardiogram; GL, guideline; IMPS, inflammatory myopericardial syndrome; N, no; NT-proBNP,
N-terminal prohormone of brain natriuretic peptide; Y, yes. aLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood
count. bSee Table 6. cReference: Byrne et al.72 dSee Table 7. eSee Figure 7. fConsider cardiovascular magnetic resonance. gConsider endomyocardial
biopsy on a case-by-case basis. hDepending on the underlying cause and clinical need. iSee Sections 5, 8, 9, 10.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3973
4.3.2. Heart failure presentation patients present with symptoms, including viral illness/malaise, syn-
Patients with myocarditis presenting with acute HF, in particular when cope, nausea/abdominal pain, chest pain, and palpitations.87,88 Only
associated with left ventricular dysfunction (LVEF ≤ 40%), should be 5% show cardiac symptoms in conjunction with an infective pro-
considered as a high-risk group, and their prognosis largely depends cess.87 These data highlight the need to suspect a diagnosis of myo-
on the short-term response to therapy.28,62 Clinical presentation carditis early enough. Late gadolinium enhancement in the mid-wall
may range from unexplained impaired ventricular function (with or layer of the anteroseptal myocardial segments has been associated
without dilated LV), new onset or worsening HF (usually over with higher rates of mortality and major VA, including SCD,3,89,90
2 weeks to 3 months), to rapidly progressive refractory HF and car- even in the presence of preserved LVEF. Septal involvement in myo-
diogenic shock. Fulminant myocarditis presenting with HF has a higher carditis can be associated with a worse prognosis in the presence of
rate of cardiac death and heart transplantation (HT) both in the short a specific genetic background, such as pathogenic desmosomal gene
and long term, compared with patients with LV dysfunction without variants (see Section 5.3).91,92 Further studies are necessary to con-
FM (see Section 4.2.2).56,73,74 In these scenarios, GCM and EM are in- firm these data.
dependently associated with increased mortality.56,75 An algorithm
for the proposed workflow is shown in Figure 10. As a central scheme,
4.3.5. Presentation of myocarditis with a potential
the workflow follows the CHAMPIT approach, provided in the 2021
genetic background
ESC Guidelines for the diagnosis and treatment of acute and chronic
heart failure.12 One should be aware that arrhythmias can be a pres- A complex interaction between genetic background and inflammation
might be responsible for the heterogeneity of the clinical presentation
entation of myocarditis, as well as an ‘alternative cause’ of HF outside
of myocarditis. An inflammatory stimulus of the heart might unveil an
the suspicion of myocarditis.
increased genetic susceptibility to develop overt LV dysfunction or ar-
rhythmogenic phenotypes. In this setting it is important to consider
4.3.3. Presentation with arrhythmias additional features, such as a family history of myocarditis/pericarditis,
Patients with AM with new, recurrent, or unexplained arrhythmias CMP, or SCD. Autosomal dominant gene defects may be associated
may have a wide spectrum of symptoms, ranging from palpitations with myocarditis.93–95 Certain autosomal recessive defects in genes en-
to syncope or life-threatening arrhythmias causing aborted coding various components of the cardiac structure can predispose
SCD.10,76 Supraventricular arrhythmias, especially AF,63,77 are young individuals to myocarditis.95,96
more common in the presence of concomitant pericarditis and Different studies reported that patients with myocarditis and evi-
PEff, while atrioventricular blocks (AVBs) or sustained VA are gener- dence of pathogenic/likely pathogenic (P/LP) desmosomal gene var-
ally, but not exclusively, associated with LV dysfunction and HF. iants (mostly with DSP variants) have a higher incidence of adverse
Patients with advanced AVB or sustained VA should be considered cardiovascular events, especially myocarditis recurrence and VA,
as high risk, even in the absence of LV dysfunction. Ventricular fibril- than patients without.91,94 Episodes of acute chest pain with troponin
lation (VF)/cardiac arrest occurs in about 2.5% of myocarditis-related elevation and normal coronary arteries may occur in about 15% of
hospitalizations.78 Patients with sustained VA during AM have a high patients with DSP mutations and are associated with LV LGE in about
risk of recurrence.79 90% of cases.97 Specific genetic P/LP variants may increase the sus-
Patients with GCM (see Section 9.3) or CS (see Section 9.4) are at a ceptibility to superimposed myocarditis in ARVC, which may be
high risk of VA, with a prevalence of >25%.80–82 the first clinical presentation in the natural history of the disease.64,98
Scar-related VA can occur at any time during follow-up, even after The presence of so-called ‘hot phases’ (chest pain episodes accom-
inflammation resolution. However, polymorphic and irregular VA are panied by ECG changes and troponin release) represents a possible
more common during the active inflammatory phase, whereas mono- clinical presentation of ARVC, which often occurs in paediatric and
morphic and regular VA are associated with healed myocarditis with re- young patients, as well as carriers of DSP genetic variants.99–101
siduals.83 Consistently, catheter ablation of ventricular tachycardia (VT) Currently, the role of ‘hot phases’ in disease progression, as well as
is more effective when performed in the post-inflammatory stage of the in arrhythmic risk stratification, remains to be clarified. For more de-
disease rather than during AM.84 tails see Section 5.3.
AVB is a common feature of myocarditis related to non-viral infec-
tions (i.e. CD, LC, diphtheria),85 and can also be an initial presentation
4.4. Clinical stages of pericarditis
of CS. In patients with arrhythmic presentation, genetic testing for CMP
4.4.1. Acute pericarditis
[ARVC/dilated CMP (DCM)/non-dilated left ventricular CMP
(NDLVC)] should be considered (see Section 5.3). Acute pericarditis is an inflammatory pericardial syndrome with or without
An algorithm for the proposed workflow is shown in Figure 11. PEff with an onset of ≤4 weeks. The clinical diagnosis is usually character-
ized by pleuritic and/or positional chest pain (>80% of cases). Dyspnoea is
more common in the elderly.45,102 Physical examination may be character-
4.3.4. Sudden cardiac death ized by pericardial friction rubs in up to one-third of cases, which could dis-
One of the causes of SCD in young adults is myocardial inflamma- appear with the presence of PEff. Pericardial effusion has been reported in
tion associated with fatal arrhythmias. Sudden cardiac death attrib- up to 60% of cases, and it is usually mild. ECG changes, especially PR
uted to myocarditis among autopsied patients ranged from 1.1% to depression as an early sign and widespread ST-segment elevations,
12%,87,88 and males show higher incidence rates of SCD than fe- have been reported in up to 60% of cases, especially in young patients.
males, with an incidence rate ratio of 2.2.88 Most individuals are This is suggestive of concomitant myocardial involvement, at least of
asymptomatic before SCD; however, between 18% and 48% of mild degree.
Downloaded
from

by
guest
on
22
January
2026

3974 E S C G u id e l in e s
Patient with signs and symptoms of acute heart failure
Cardiogenic shock and/or respiratory failure Admission to ICU
Clinical history and vital signs, 12-lead ECG, laboratory testinga, transthoracic echocardiography
(Class I)
Simultaneously use CHAMPIT approach and whether congestion/apparent HF
acute Coronary syndrome Congestion/apparent HF
Hypertensive emergency
Arrhythmia
Mechanical
Pulmonary embolism
Infections HF treatment
Tamponade (Class I)
Further
Red flags for myocarditisb
work-up
Suspected fulminant myocarditis
Risk stratificationc High riskd
Non-high risk
Cardiovascular magnetic Endomyocardial
Before
resonancee biopsy
(Class I) discharge (Class I)
Normal Suggestive of non cardiac causes Definite
findings or cardiomyopathies myocarditis
No further Aetiological Further aetiological
work-up work-up work-up requiredf
Further work-up
No further
including
work-up
geneticsg
Figure 10 Diagnostic algorithm for acute heart failure presentation. CRP, C-reactive protein; ECG, electrocardiogram; HF, heart failure; ICU, inten-
sive care unit; N, no; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; Y, yes. aLaboratory testing including troponin, NT-proBNP,
C-reactive protein, differential blood count. bSee Table 6. cSee Table 7. dConsider cardiovascular magnetic resonance. eIn stabilized heart failure patients,
endomyocardial biopsy may be performed on a case-by-case basis. fDepending on the underlying cause and clinical need. gSee Sections 5, 8, 9, 10.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3975
Patient with new, recurrent or unexplained arrhythmias (any type)
Identify arrhythmia
Cardioversion/defibrillation/
transcutaneous pacing/ALS Haemodynamic instability
(Class I)
Clinical history and vital signs, 12-lead ECG, laboratory
Obstructive CADa evaluationb, transthoracic echocardiography
(Class I)
Further aetiological
Treat CAD Red flags for myocardial involvementc
work-up
Risk stratificationd High riske
Non-high risk
Cardiovascular magnetic resonancef Before Endomyocardial biopsy
(Class I) discharge (Class I)
Suggestive of non-cardiac causes
Normal findings Definite myocarditis
or cardiomyopathies
No further work-up Aetiological work-up Specific aetiology
Type of initial arrhythmia at presentation See specific sections
Conduction blocks
Ventricular arrhythmiag
Further aetiological work-uph
Active myocarditis (based on initial CMR/EMB)
PM indicationi
Repeat CMR
within 6 months
(Class I)
Catheter ablation
(Class IIa)
Further work-up depending on activity
(genetics, systemic disorders) ICD indicationsj
(Class I) (Class IIa) (Class IIb)
Figure 11 Diagnostic algorithm for arrhythmia presentation. ALS, advanced life support; CAD, coronary artery disease; CMR, cardiovascular mag-
netic resonance; CRP, C-reactive protein; ECG, electrocardiogram; EMB, endomyocardial biopsy; ICD, implantable cardioverter-defibrillator; N, no;
NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PM, pacemaker; Y, yes. aInvasive coronary angiography or computed tomography
angiography depending on clinical likelihood/probability. bLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood
count. cSee Table 6. dSee Table 7. eConsider cardiovascular magnetic resonance. fConsider endomyocardial biopsy on a case-by-case basis. gSee
Section 6.5 for wearable cardioverter-defibrillator. hSee Sections 5, 8, 9, 10. iSee Section 6.5 and Reference Glikson et al.86 jSee Section 6.5,
Recommendation Table 14 and Reference Zeppenfeld et al.58
Downloaded
from

by
guest
on
22
January
2026

3976 E S C G u id e l in e s
An inflammatory syndrome is usually present with fever of >38°C congestive HF, pneumonia with pleuritis, pulmonary embolism, chronic
(70%),37 elevated markers of inflammation (C-reactive protein) (80%– obstructive pulmonary disease, and vasculitis.
90%),36,37 ESR, neutrophil leucocytosis,37,38 and pericardial and/or pleur-
al effusion (approximately 50%), often with lung atelectasis, leading to a
4.5.1. Dry pericarditis
possible diagnosis of pleuro-pneumonia,37,103 and less commonly, peri-
Dry pericarditis (40%–50% of cases), also referred to as ‘pericarditis sic-
toneal involvement (13%).38 This presentation is labelled ‘inflammatory
ca’, is a form of pericarditis that is characterized by inflammation of the
phenotype’ of AP.
pericardium without the presence of PEff. It can begin insidiously or
Cardiac enzymes are usually normal, but troponin may be ele-
abruptly. It is usually not associated with a specific cause or a worse
vated in 20%–30% of cases, due to concomitant myocarditis
prognosis.
(myopericarditis).4
4.5.2. Effusive pericarditis
4.4.2. Subacute pericarditis
Effusive pericarditis (50%–60% of cases) is characterized by the concur- Subacute pericarditis refers to cases with persistent symptoms lasting
rent presence of effusion.115 A moderate to large PEff is more com-
>1 month and <3 months. This condition may directly progress to
monly associated with a non-idiopathic aetiology.
constrictive pericarditis (CP) within a few months and requires timely
optimal medical therapy and close follow-up to prevent chronic
evolution.104 4.5.3. Effusive–constrictive pericarditis
Effusive–constrictive pericarditis (ECP) is characterized by the con-
4.4.3. Chronic pericarditis current presence of PEff, along with thickening and constriction of
Chronic pericarditis refers to cases lasting >3 months. In pericarditis, the pericardium that restricts the normal filling of the heart.116
management of the patient during the acute phase is of paramount im- Effusive–constrictive pericarditis occurs when constrictive physi-
portance, not only for symptom relief but, most importantly, for prog- ology is uncovered following the drainage of a PEff with tamponade.
nostic purposes. Hospitalization of patients with AP and high-risk The exact haemodynamic definition involves the right atrial pressure
features allows the prompt identification and treatment of potentially (RAP) failing to fall by ≥50% or to a level of <10 mmHg despite intra-
life-threatening complications, such as cardiac tamponade (CTP).105 pericardial pressure being lowered to near 0 mmHg with removal of
Moreover, appropriate screening for specific aetiologies is the basis pericardial fluid via pericardiocentesis.110,116,117 Current multimodal-
for tailored therapy. Progression of AP to subacute or chronic disease ity imaging allows a clinical diagnosis of ECP without cardiac
is sometimes unpredictable. Omission of colchicine administration and catheterization.
the use of high doses of corticosteroids with fast tapering are risk fac-
tors for recurrences or a chronic course of the disease.24,106–109 4.5.4. Pericarditis with cardiac tamponade
Recently, scores that predict the individual risk of complicated pericar-
The two most serious complications of pericarditis are CTP and CP.
ditis and chronicity have been proposed for the identification of sub-
Pericarditis with CTP is a life-threatening condition where inflammation
jects who require intensive therapy in terms of medication dose and
of the pericardium leads to the accumulation of compressive pericardial
length, as well as close follow-up.43,44,110 They require further validation fluid (Table 8).110,115 Symptoms may include chest discomfort, fatigue,
in prospective, multicentre studies.
and dyspnoea. Clinical signs include hypotension, tachycardia, raised
In chronic forms, symptoms are similar to previous attack(s),
JVP, pulsus paradoxus, muffled heart sounds, electrical alternans with
but often milder.1 In unclear cases or in difficult-to-treat patients,
decreased ECG voltage, and an enlarged cardiac silhouette on chest
CMR may be performed to assess the degree of inflammation and
X-ray. The magnitude of clinical and haemodynamic abnormalities de-
individualize medical therapy, especially before drug tapering or
pends on the amount of pericardial fluid and rate of accumulation,
discontinuation.111,112
the distensibility of the pericardium, and the compliance and filling pres-
Paradoxically, although chronic pericarditis significantly impairs qual- sures of the cardiac chambers118 (Figure 12).
ity of life, the rate of progression to CP is negligible (<1%) and is lower
than the risk imposed by a single episode of AP, unless a specific aeti-
ology is identified.105,113,114 Table 8 Causes of cardiac tamponade
4.5. Clinical presentations of pericarditis Common causes (in order of relative frequency):
(1) Neoplasm/malignancy
Pericarditis is characterized by a wide spectrum of clinical presentations.
(2) Iatrogenic/trauma
The main presenting symptom of pericarditis is positional chest pain,
(3) Pericarditis
which is reported in most affected individuals. Typical pericardial pain
(4) Tuberculosis (most common in developing countries)
is sharp and is worse when coughing and taking a deep breath (pleuritic).
Less common causes (in order of relative frequency):
Left trapezius ridge pain is a classic symptom of pericardial irritation and is
transmitted through the phrenic nerve. Other less common symptoms (1) Collagen vascular diseases (systemic lupus erythematosus, rheumatoid
include shortness of breath, fever, fatigue, and arrhythmia (e.g. AF). arthritis, scleroderma)
Pericardial effusion often accompanies pericarditis (>50% of cases). (2) Pericardial injury syndrome
Other presentations include right HF-like symptoms [elevated jugular (3) Acute myocardial infarction
venous pressure (JVP), peripheral oedema, ascites] when constriction (4) Aortic dissection
is present. Hypotension is a sign of CTP (which presents with Beck’s (5) Uraemia
triad: hypotension, jugular venous distension, and muffled heart sounds). (6) Bacterial infection
It is crucial to differentiate pericarditis from other diseases, such as ACS, (7) Pneumopericardium
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3977
Patient with definite diagnosis of cardiac tamponade
High-risk features Postpone pericardiocentesis
(with cumulative score ≥6) Empiric anti-inflammatory therapy
Pericardiocentesis with drainage
Improvement
Outpatient follow-up Pericardial window
Criteria for triage for patients with pericardial effusion at risk for progression to cardiac tamponade
Aetiology Clinical presentation Imaging
Malignant disease 2 Dyspnoea/tachypnoea 1 Cardiomegaly on chest x-ray 1
Tuberculosis 2 Orthopnoea 3 Electrical alternans on ECG 0.5
Recent radiotherapy 1 Hypotension (CBP <95 mmHg) 0.5 Microvoltage on ECG 1
Recent viral infection 1 Progressive sinus tachycardia 1 Circumferential large PEff 3
Recurrent PEff 1 Oliguria 1 Moderate PEff 1
Chronic terminal renal failure 1 Pulsus paradoxus (>10 mmHg) 2 Small PEff -1
Immunosuppression 1 Pericardial chest pain 0.5 Right atrial collapse 1
Dysthyroidism -1 Pericardial friction rub 0.5 IVC dilated not collapsible 1.5
Systemic autoimmune disease -1 Rapid worsening of symptoms 2 Right ventricular collapse 1.5
Slow disease evolution -1 Left atrial collapse 2
Mitral/tricuspid respiratory
flow variations 1
Swinging heart 1
Figure 12 Management of cardiac tamponade. CBP, central blood pressure; ECG, electrocardiogram; IVC, inferior vena cava; N, no; PEff, pericardial
effusion; Y, yes. Criteria are listed for the evaluation of patients by immediate or delayed pericardiocentesis based on expert consensus. Immediate
pericardiocentesis should be considered if there are >6 points from at least two categories.
4.5.5. Constrictive pericarditis oedema, orthopnoea, and fatigue. The classic clinical picture is usually
Pericardial constriction is a chronic condition characterized by a thick- characterized by isolated right HF with normal or nearly normal natri-
ened, fibrotic, and often calcified pericardium that leads to impaired dia- uretic peptide levels. Venous congestion, hepatomegaly, pleural effu-
stolic filling of the heart. It should be named CP when associated with sions, and ascites may occur.110,115,119 Constrictive pericarditis should
pericarditis. Constrictive pericarditis is a consequence of chronic peri- be treated empirically with anti-inflammatory therapy. Cases after fail-
cardial inflammation and is characterized by scarring, fibrosis, and loss ure of medical therapy and pericardial constriction without pericarditis
of elasticity of the pericardium. The main symptoms are dyspnoea, should be referred for pericardiectomy without delay (Figure 13).
Downloaded
from

by
guest
on
22
January
2026

3978 E S C G u id e l in e s
Patient with symptoms and signs of constrictiona
First-line assessment with history, physical examination,
ECG, transthoracic echocardiography, laboratory assessment,
CT (calcifications) and CMR (inflammation)
(Class I)
Admission and
Definite diagnosis of constriction
cardiac catheterization
Concomitant pericarditis
Pericardiectomy Empiric anti-inflammatory therapy for at least 3–6 months
(Class I) (Class IIa)
Persistence of constriction
Outpatient follow-up
Low riskb Intermediate riskb High risk
Outpatient treatment Close follow-up within 1 month Admission
(Class I)
Outpatient follow-up Improvement
Pericardiectomy
(Class I)
Figure 13 Management of constriction. CMR, cardiovascular magnetic resonance; CT, computed tomography; ECG, electrocardiogram; N, no; Y, yes.
Empirical anti-inflammatory therapy is warranted only for those with evidence of pericarditis (by clinical criteria, biomarkers, and/or imaging). Low risk:
clinical remission after therapy/normalization of imaging findings. Intermediate risk: improved symptoms without complete remission/partial regression.
High risk: persistent symptoms/persistent imaging signs of constriction. aSee Table 6. bSee Table 7.
4.5.6. Transient constrictive pericarditis pericardiectomy.122,123 Biomarkers (e.g. elevated C-reactive protein)
Transient constriction is CP with ongoing inflammation that can be re- and multimodality imaging, including CMR, are mandatory to detect
versed following anti-inflammatory treatment or that heals spontaneously. pericardial inflammation.
It develops with pericarditis with or without PEff (about 10% of
cases) and resolves with anti-inflammatory therapy in >50% of 4.5.6.1. Constrictive pathophysiology
cases.120,121 A trial of 3–6 months of anti-inflammatory therapy is re- It is important to distinguish constrictive pathophysiology from actual
commended in patients with newly diagnosed CP before referral for HF symptoms.115,120,121,124 There may be features of septal bounce,
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3979
respiratory phase-dependent shift of the ventricular septum, and Recommendation Table 1 — Recommendations for
Doppler features of constriction without HF symptoms (see clinical evaluation of myocarditis and pericarditis (see
Supplementary data online, Section 2.4 and Figure S1). Evidence Table 1)
Recommendations Classa Levelb
4.5.7. Pericarditis with polyserositis
Pericarditis with polyserositis is characterized by inflammation of the Complete clinical evaluation, including history,
pericardium and concurrent inflammation of other serous membranes physical examination, chest X-ray, biomarkersc, ECG,
lining major body cavities, such as the pleura and peritoneum.37,103,125,126 and echocardiography is recommended in all patients I C
with a suspicion of myocarditis and/or pericarditis for
4.5.8. Inflammatory vs non-inflammatory pericarditis the initial diagnostic assessment.
In the context of pericarditis, the terms ‘inflammatory’ and ‘non- CMR is recommended in patients with the clinical
inflammatory’ phenotype refer to two distinct clinical presentations suspicion of myocarditis (using updated LL criteria)30
I B
based on the underlying pathophysiological mechanisms. and/or pericarditis for the non-invasive diagnosis of
inflammatory reaction.110,115,129
4.5.8.1. Inflammatory phenotype of pericarditis Hospital admission is recommended for patients
The inflammatory phenotype is characterized by inflammation of the with high-risk pericarditisd for monitoring and I B
pericardium with evidence of systemic inflammation. This phenotype treatment.105,130
is often associated with fever, and/or elevated systemic inflammatory Hospital admission is recommended for patients
markers (e.g. C-reactive protein), PEff, and/or pleural effusion. These with moderate- to high-risk myocarditisd for I C
forms typically respond well to targeted anti-inflammatory therapies,
monitoring and treatment.
including colchicine and anti-IL-1 agents.37,127
EMBe is recommended in patients with high-risk
myocarditisd and/or haemodynamic instability,
4.5.8.2. Non-inflammatory phenotype of pericarditis
and/or in patients with intermediate-risk myocarditis
I C
The non-inflammatory phenotype refers to the manifestation of pericar-
not responding to conventional therapy in order to
ditis without C-reactive protein elevation or low elevation of markers of
detect a specific histologic subtype and to assess the
systemic inflammation (e.g. high-sensitivity C-reactive protein).127 This oc- presence of viral genome for treatment.34,63,73,131
curs in 10%–20% of patients with pericarditis.36 The pathogenesis of peri-
Invasive coronary angiography or coronary CT,
carditis with normal C-reactive protein is unknown and these cases are
depending on clinical likelihood, is recommended in
often difficult to treat. C-reactive protein is a sensitive albeit unspecific bio-
patients with IMPS if an acute coronary syndrome is I C
marker of inflammation mainly driven by IL-6. Moreover, in autoimmune
suspected to rule out obstructive coronary artery
diseases characterized by the type I interferon (IFN) gene signature,
C-reactive protein appears to be an unreliable marker of inflammation.52 disease.
Hospital admission should be considered for patients
with low-risk myocarditisd for monitoring and IIa C
5. Diagnosis and diagnostic
treatment.
work-up Pericardial or epicardial biopsy may be considered in
relapsing pericardial effusion as part of the diagnostic
The diagnostic work-up in patients with suspected IMPS should be tai- IIb C
work-up when the diagnosis cannot be reached with
lored based on the severity of clinical presentation, response to medical
multimodality imaging and laboratory examinations.
therapy, and individual risk (Table 7). It includes medical history, clinical/
Routine serology is not recommended in patients
physical exam, biomarkers (myocardial injury, systemic inflammation,
with myocarditis and/or pericarditis for the
and HF), ECG, and multimodality imaging. Endomyocardial biopsy has III C
evaluation of viral aetiology except for hepatitis C,
its place in dedicated clinical scenarios. For IMPS, routine viral serology
is not recommended,1 except for HIV and hepatitis C virus (HCV), as HIV, and Lyme disease.
well as for suspected bacterial infections (such as Borrelia spp., rickett- CMR, cardiovascular magnetic resonance; CT, computed tomography; ECG,
sial, and T. cruzi infections). Echocardiography is the basic imaging meth- electrocardiogram; EMB, endomyocardial biopsy; HIV, human immunodeficiency virus;
od, followed by other techniques. Cardiovascular magnetic resonance hs-TnI, high-sensitivity troponin I; hs-TnT, high-sensitivity troponin T; IMPS,
inflammatory myopericardial syndrome; LL, Lake Louise; NT-proBNP, N-terminal
is an advanced imaging test of increasing importance for detection of
prohormone of brain natriuretic peptide.
myocardial as well as pericardial injury.115,128 Most important is a aClass of recommendation.
patient-tailored approach, usually driven by the dominant symptoms. bLevel of evidence.
cIncluding hs-TnT or hs-TnI, C-reactive protein, NT-proBNP.
Flow charts (Figures 5–7 and 9–13) illustrate the proposed workflow
dSee Table 7.
in different clinical scenarios. If a patient presents with clinical symp- eContemporary evaluation of EMB should be based on histology, immunohistology, and
toms suggestive of IMPS (Table 6), basic and advanced diagnostic assess- molecular pathology for detection of viral infections in myocardial and blood samples
ments are recommended (see Table 9). (see also Table 11).
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3980 E S C G u id e l in e s
Table 9 Basic and advanced level assessment inflammation of the subepicardium.35 These changes are more com-
mon in the initial phase and may be more frequent in younger pa-
Basic assessment: tients. ST-segment depression and T-wave inversion may also be
present, albeit less frequently than in patients with acute myocardial
History: potential causes and triggers (viral infection of upper respiratory or
ischaemia,132 and may be related to the extent of myocardial
gastrointestinal tract, toxins, drug use, medications), recurrent symptoms,
damage.133,134 Diffuse depression of the PR segment is a classic early
family history of IMPS/cardiomyopathy/SCD, and systemic
finding in AP.
inflammatory/autoimmune diseases
A decrease in the amplitude of QRS complexes on ECG can be
Physical examination: assess clinical stability, symptoms (chest pain, HF observed in cases of AP and/or AM, especially with large effusions or
symptoms, palpitations, syncope), malaise, general weakness and fatigue, extensive myocardial injury. Electrical alternans of the QRS complexes
pericardial friction rub, clinical symptoms/signs of CTP has been reported, attributed to fluctuation of the heart within a
ECG: PR-segment depression, ST/T-wave changes, AVB, and ventricular large effusion (swinging heart). Lengthening of the QT interval might oc-
arrhythmias cur in AM.
Chest X-ray Atrial fibrillation can occur in AP, especially in predisposed patients,
in whom pericardial inflammation may be a trigger for supraventricular
Basic laboratory data:
arrhythmias.77 In contrast, VA are more common in myocarditis.
Markers of myocardial lesion (e.g. hs-TnT/TnI)
AVBs and intraventricular conduction defects, particularly right bun- Markers of systemic inflammation (e.g. C-reactive protein, ESR, WBC count)
dle branch blocks, are not uncommon (see Section 4.3.3, and
Markers of heart failure (e.g. NT-proBNP)
Supplementary data online, Table S4) and may be associated with
Complete blood count (including eosinophilic count)
more severe presentations.135–137
Renal function and electrolytes (e.g. sodium, potassium, creatinine)
Electrocardiogram changes are highly dynamic and may evolve over a
Thyroid function (e.g. TSH)
span of hours or days, with temporal progression varying significantly
Hepatic function and additional testing (e.g. lactate dehydrogenase, aspartate
among patients. Typically, ST changes resolve; however, it is important
aminotransferase, alanine aminotransferase)
to note that a normal ECG at presentation does not exclude the pos-
Echocardiography including strain imaging sibility of IMPS.
Advanced assessment usually after admission:
Coronary anatomy evaluation (if needed for differential diagnosis by invasive
5.2. Biomarkers
coronary angiography or coronary CT depending on the clinical likelihood of
ACS) 5.2.1. Biomarkers in clinical routine
CMR to assess signs of myocardial and pericardial inflammation and/or fibrosis Recommended biomarkers in IMPS include:
Arrhythmia screening depending on risk stratification (e.g. Holter-ECG) • Markers of inflammation (e.g. C-reactive protein): C-reactive
Additional laboratory parameters guided by clinical suspicion (e.g. if protein is often increased in patients with pericarditis (up to 80%)
therapeutic consequences are expected) and AM (up to 80%), and contributes to the diagnosis.28,36,138
Dedicated genetic testing if indicated Negative results, however, do not exclude the diagnosis. In pericar-
CT to assess concomitant pleuropulmonary diseases ditis, C-reactive protein is a marker of disease activity that could be
used to guide the duration of anti-inflammatory therapy.36
Specific myocarditis: EMB in high-risk cases and in intermediate-risk
D-dimers are currently being investigated for their diagnostic and cases on a case-by-case decision to detect specific histology and some prognostic relevance.36,139,140
aetiologies if needed
• Markers of myocardial lesions (e.g. troponin): Troponin is ele-
Specific pericarditis: diagnostic pericardiocentesis when indicateda
vated in myocardial involvement, usually indicating cardiomyocyte
ACS, acute coronary syndrome; AVB, atrioventricular block; CMR, cardiovascular magnetic necrosis. Assessment of baseline troponin is crucial to diagnose the
resonance; CT, computed tomography; CTP, cardiac tamponade; ECG, electrocardiogram; severity of myocarditis. It is typically increased in infarct-like
EMB, endomyocardial biopsy; ESR, erythrocyte sedimentation rate; HF, heart failure;
myocarditis.
hs-TnT/TnI, high-sensitivity troponin T/I; IMPS, inflammatory myopericardial syndrome;
NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SCD, sudden cardiac • Markers of HF (BNP or NT-proBNP): Assessment of baseline level
death; TSH, thyroid-stimulating hormone; WBC, white blood cell. is recommended among patients with suspected myocarditis. This
aSee Recommendation Table 12 measurement can be repeated at discharge and during follow-up in
an outpatient setting to assess the risk of clinical events.
NT-proBNP can be used in patients with myocarditis as a predictive
5.1. Electrocardiogram marker of HF among patients with normal or impaired LVEF.12
Dynamic changes in the ST segment are classic hallmarks of pericar-
ditis and myocarditis. The most typical pattern includes widespread
ST-segment elevation, reported in 20%–60% of cases (see 5.2.2. Biomarkers beyond clinical routine
Supplementary data online, Table S4). In pericarditis, ECG changes Different biomarkers may help to identify a specific aetiology and to
suggest concomitant myocardial involvement, and are indicative of guide risk stratification. Most of them are not part of clinical routine,
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3981
but could help based on a strong clinical suspicion,73 e.g. miR721 was As scientific knowledge about gene variants and their potential
shown to have a discriminatory capacity.141 pathophysiological role has been continuously increasing over re-
In specific circumstances, tumour necrosis factor alpha (TNF-α), IL-1β, cent years, comprehensive screening includes desmosomal and sar-
IL-6, and IL-17A may be of value. Similarly, in some cases, evaluation of comeric genes and some DCM-associated genes.64,91,96,146,150 For
cardio-specific antibodies may be helpful, according to the local labora- details, see 2023 ESC Guidelines for the management of cardiomy-
tory availability. These include organ-specific anti-heart autoantibodies opathies.13 Nevertheless, it is not clear whether the inflammatory
and anti-intercalated disc autoantibodies, as well as non-organ-specific process acts as a trigger or is fully part of the pathophysiological pro-
serum autoantibodies.10 These autoantibodies, especially if found at cess in inherited CMP.151
high titres, may have a negative prognostic value.73,142 Pathogenic/likely pathogenic variants have been identified in patients
Furthermore, a specific serum biomarker, i.e. the soluble form of the with recurrent pericarditis (RP), especially young patients, with a family
IL-1 receptor-like 1 (IL-1RL1), also known as ST2, was associated with a history, multiple recurrences, inflammatory phenotype, and refractory
higher risk of severe HF among male myocarditis patients.143 Other or dependent on medical treatments. Recurrent pericarditis has been
biomarkers have been studied in myocarditis, including procollagen associated with genetic variants for monogenic autoinflammatory dis-
type III, gelsolin, soluble VCAM-1, galectin-3, serum alarmin S100A8/ eases (e.g. FMF, TRAPS), but also with genes related to the inflamma-
S100A9, immunoglobulin free light chain, and heparin-binding protein, tory response (Figure 14).50,51,152,153
for both diagnostic and prognostic purposes. However, these biomar- A recent study performed whole-exome sequencing in 108 patients
kers were evaluated among limited small cohorts and are clinically not with RP. Overall, about 15% of patients had variants in genes related to
routinely used.144,145 the inflammatory response, while up to 30% of patients carried variants
in different cardiac genes, worthy of a deeper investigation.51 These
data suggest a genetic predisposition in at least a subset of patients
5.3. Genetics (positive family history of pericarditis or periodic fever, poor response
to colchicine, multiple recurrences with inflammatory phenotype), and
Genetic testing is relatively new in the field of IMPS. There is a potential
counselling may be offered.51,152 In these clinical scenarios, prolonged
overlap with CMPs. Myocarditis and pericarditis will be discussed
therapy with specific biological agents (e.g. anti-IL-1 agents) should be
separately.
considered.
There has been increasing evidence that gene variants coding for struc-
tural proteins, particularly desmosomal and sarcomeric proteins, may
overlap with acute and recurrent myocarditis and affect disease sever-
ity.94,95 Furthermore, it has been shown that there is an overlap of gene
Recommendation Table 2 — Recommendations for
variants predisposing to myocardial inflammation and inherited CMP genetic testing (see Evidence Table 2)
(ARVC and NDLVC).13 In particular, myocardial inflammation may be de-
tected in patients with inherited CMP using serum and imaging biomar- Recommendations Classa Levelb
kers.13 There is evidence that these patients are at higher risk for
complicated myocarditis (Section 4.3.5).13,91,93,94 In a meta-analysis, the It is recommended to obtain family history
including pedigrees in cases of recurrent IMPS
pooled prevalence of P/LP variants was 4.2% for uncomplicated myocar-
ditis, whereas for complicated myocarditis the pooled prevalence was 22% to provide clues to the underlying aetiology, I C
and 45% in adults and children, respectively.95 Pathogenic/likely pathogenic determine inheritance pattern, and identify
variants in desmosomal genes were more common in uncomplicated relatives at risk.
myocarditis (64%), while variants in sarcomeric genes were more preva- Genetic testing should be considered in patients
lent in complicated myocarditis (58% in adults and 71% in children).95 with definite myocarditis/pericarditis in
A case series demonstrated a high proportion of definite or prob- cases of:50,51,64,94,150
able pathogenic variants in patients with myocarditis with RV in- • family history of IMPS, inherited or suspected
volvement or sustained VA.146 Furthermore, DSP variants have cardiomyopathy
been reported in familial recurrent myocarditis.147 Another study • severe ventricular arrhythmiac
demonstrated overlap of gene variants in myocarditis and inherited • significant left/right LGE (e.g. ring-like pattern or IIa B
CMP.96
septal LGE) or persistent LVEF systolic dysfunction
Identifying such gene variants has several clinical implications:
• recurrent myocarditis or persistent troponin
elevation
(1) While in myocarditis there is a recommendation to defer on im-
• recurrent pericarditis with an inflammatory
plantable cardioverter-defibrillator (ICD) placement during the
phenotype, refractory to conventional treatmentd,
acute phase of the disease, the threshold for ICD placement is low-
er in ARVC in cases of primary prevention.58 with the aim to detect an underlying genetic cause.
(2) Gene variants predisposing to myocarditis have relevant implica- IMPS, inflammatory myopericardial syndrome; IL, interleukin; LGE, late gadolinium
tions for patients.147,148 Details are given in the 2023 ESC enhancement; LVEF, left ventricular ejection fraction.
Guidelines for the management of cardiomyopathies.13 aClass of recommendation.
bLevel of evidence.
(3) Cascade clinical and genetic screening for relatives and familial gen- cSee Section 4.
etic counselling should be offered.93,149 dEspecially poor response to colchicine and anti-IL-1 agents.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3982 E S C G u id e l in e s
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22) (cid:21)(cid:27)(cid:30)(cid:29)(cid:20)(cid:20)(cid:27)(cid:19)(cid:28)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)
(cid:23)(cid:18)(cid:28)(cid:17)(cid:27)(cid:19)(cid:28)(cid:26)(cid:16)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:30)
(cid:23)(cid:22)(cid:25)(cid:30)(cid:21)(cid:20)(cid:28)(cid:19)(cid:28)(cid:18)(cid:25)(cid:22)(cid:24)(cid:17)(cid:28)(cid:16)
(cid:7)(cid:28)(cid:30)(cid:28)(cid:26)(cid:25)(cid:27)
(cid:6)(cid:10)(cid:27)(cid:5)(cid:21)(cid:15)(cid:24)(cid:14)(cid:30)(cid:17)
(cid:23)(cid:18)(cid:28)(cid:17)(cid:27)(cid:19)(cid:28)(cid:26)(cid:15) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:30)
(cid:12)(cid:14)(cid:26)(cid:24)(cid:25)(cid:30)(cid:11)(cid:10)(cid:13)(cid:13)(cid:10)(cid:26)(cid:24)(cid:15)(cid:9)(cid:8)
(cid:23)(cid:24)(cid:30)(cid:28)(cid:19)(cid:15)(cid:28)(cid:27)(cid:14)(cid:15)(cid:15)(cid:28)(cid:30)(cid:27)(cid:28)(cid:16)
(cid:10)(cid:14)(cid:26)(cid:24)(cid:25)(cid:13)(cid:13)(cid:14)(cid:30)(cid:28)
(cid:7)(cid:28)(cid:30)(cid:28)(cid:26)(cid:25)(cid:27)
(cid:6)(cid:10)(cid:27)(cid:5)(cid:21)(cid:15)(cid:24)(cid:14)(cid:30)(cid:17)
(cid:23)(cid:18)(cid:28)(cid:17)(cid:27)(cid:19)(cid:28)(cid:26)(cid:14)
(cid:12)(cid:14)(cid:26)(cid:24)(cid:25)(cid:30)(cid:11)(cid:10)(cid:13)(cid:13)(cid:10)(cid:26)(cid:24)(cid:15)(cid:9)(cid:8)
(cid:23)(cid:13)(cid:14)(cid:20)(cid:26)(cid:25)(cid:18)(cid:20)(cid:28)(cid:19)(cid:15)(cid:28)(cid:27)(cid:14)(cid:15)(cid:15)(cid:28)(cid:30)(cid:27)(cid:28)(cid:22)(cid:16) (cid:10)(cid:14)(cid:26)(cid:24)(cid:25)(cid:13)(cid:13)(cid:14)(cid:30)(cid:28)
Figure 14 The different courses of inflammatory myopericardial syndrome and the interplay between genetic background inflammation and auto-
immunity beyond the initial infectious trigger. IMPS, inflammatory myopericardial syndrome.
5.4. Multimodality imaging Tissue Doppler imaging or strain imaging can be used in the setting of
myocarditis and may indicate myocardial injury.156,157 Recent studies
The non-invasive diagnosis of IMPS relies on advanced cardiovascular im-
have shown that global longitudinal and circumferential strain (GLS
aging. An overview of the capabilities of different imaging modalities for
and GCS) and strain rate were decreased in patients with AM, even
the identification of pathophysiological components is provided in
with preserved EF.156 Strain may provide important prognostic infor-
Supplementary data online, Table S5. Echocardiography is usually the
mation in AM.157 Regional GLS can be associated with scarring on
first-step imaging modality and provides functional and morphological in-
CMR and can predict VA and outcomes in patients with AM.157
formation. Cardiovascular magnetic resonance can better differentiate
Abnormal RV strain158 and left atrial (LA) strain159 have been detected
myocardial tissue and shows myocardial and pericardial inflammation,
in AM with preserved EF.
as well as different patterns of fibrosis. Fluorodeoxyglucose positron
emission tomography (FDG-PET) is useful to detect disease activity, es-
pecially for CS (see Section 5.8). Computed tomography allows detection 5.5.2. Echocardiography in pericarditis
of calcification of the pericardium and its extent, as well as exclusion of
Transthoracic echocardiography can detect the presence of PEff and
CAD. The application of non-invasive imaging should guide therapeutic
assess its haemodynamic importance, as well as constrictive patho-
decision-making (see Section 4).
physiology (Supplementary data online, Figure S1 and Table S6).
5.5. Echocardiography
Table 10 Classification of pericardial effusion
Transthoracic echocardiography (TTE) is usually the initial imaging mo-
dality of choice for individuals with suspected IMPS, given its ability to Onset Acute (≤4 weeks)
identify myocardial and pericardial abnormalities, as well as concomi-
Subacute (>4 weeks to ≤3 months)
tant valvular disease.115,124
Chronic (>3 months)
Sizea Mild: <10 mm
5.5.1. Echocardiography in myocarditis
Moderate: 10–20 mm
Patients with a suspicion of myocarditis should usually undergo standard
Large: >20 mm
TTE including speckle tracking or tissue Doppler imaging (TDI) at pres-
Distribution Circumferential/loculated
entation. Transthoracic echocardiography helps monitor changes in car-
diac chamber size, ventricular function, wall thickness, and PEff. In Composition Transudate/exudate
myocarditis, global ventricular dysfunction, diastolic dysfunction with aMaximal end-diastolic diameter.
preserved ejection fraction (EF), and regional WMA may occur.154,155
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3983
Acute pericarditis patients may have a normal-appearing TTE (40%– Recommendation Table 3 — Recommendations for the
50% of cases in first episodes); however, the presence of new or wor- use of cardiovascular magnetic resonance imaging (see
sening PEff is a diagnostic criterion for pericarditis.24,115,160 The size of Evidence Table 3)
PEff is assessed by the end-diastolic distance of the echo-free space be-
tween the epicardium and parietal pericardium (Table 10).115,128 It is re- Recommendations Classa Levelb
commended that images should include the extent and location of each Myocarditis
effusion measurement, as this allows follow-up studies. Transthoracic
CMR is recommended in patients with suspected
echocardiography enables the recognition of CTP and the presence
myocarditis to reach a clinical diagnosis and to
of constriction.115
determine the cause of acute myocardial injury, I B
including assessment of oedema, ischaemia, and
5.6. Cardiovascular magnetic resonance
necrosis/fibrosis/scarring.115,164,169–183
Cardiovascular magnetic resonance is the accepted gold standard for
CMR is recommended for follow-up at least within
the quantification of biventricular function and detection of WMA.
the first 6 months in patients with myocarditis to
Cardiovascular magnetic resonance has the advantage of tissue differ-
identify a healed or ongoing process, for risk I C
entiation, non-invasively detecting myocardial and pericardial inflamma-
stratification and personalized therapy, and to enable
tion, as well as fibrosis.30 The diagnostic targets in non-ischaemic
a return to exercise.10,62,184–186
myocardial inflammation include myocardial oedema, hyperaemia and
Pericarditis
capillary leak, and necrosis/fibrosis (see Supplementary data online,
Figure S2).161–164 The diagnostic accuracy of CMR is higher if performed CMR is recommended in patients with suspected
early in the time course of disease (best within the first 2 weeks). pericarditis when a diagnosis cannot be made using
Myocardial oedema and changes due to inflammation lead to increased clinical criteria to assess evidence of pericardial
I B
tissue water content that can be detected as increased signal intensities thickening, oedema, LGE, and to assess the
on T2-weighted imaging and/or T2 mapping; increased tissue free- persistence of disease during follow-up in selected
water content will also lead to an increased signal in T1 mapping and cases.110,129,165,187–194
extracellular volume (ECV) quantification. Myocyte necrosis and fibro-
CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement.
sis can result in non-ischaemic (e.g. mid-wall, subepicardial, patchy) pat- aClass of recommendation.
terns of LGE, which do not typically follow a coronary artery bLevel of evidence.
distribution. The identification of myocarditis with chest pain presenta-
tion is less challenging than in HF and arrhythmic scenarios. The up-
dated LLC, which include parametric mapping methods (T1/T2/ECV), 5.7. Computed tomography
should be applied for diagnosis, as the combined approach increases Computed tomography is an established tool for excluding CAD de-
the diagnostic accuracy (see Figure 4).30 It is important to note that im- pending on the risk score and can be used in the diagnostic work-up
aging evidence of myocardial inflammation does not provide the under- according to current ESC guidelines.65,72,195
lying histotype (see Supplementary data online, Figure S2). Contrast-enhanced CT may be very useful to make an aetiological
In the case of pericarditis, CMR detects thickening, oedema, and LGE diagnosis in patients presenting with large PEff including tamponade.196
of the pericardium.110,129,165 It is important to note that pericardial Computed tomography is important before pericardiectomy for con-
LGE may imply ongoing inflammation and neovascularization rather striction to evaluate the anatomy and extent of calcifications as a higher
than simple scarring (see Supplementary data online, Figure S2). burden of pericardial calcification has been associated with a better
Cardiovascular magnetic resonance is helpful for an objective assess- post-surgical outcome.197 Furthermore, anatomical abnormalities,
ment of the degree of inflammatory involvement of the pericardium, such as pectus excavatum, can be identified.198 Meanwhile, CT in com-
either for first diagnoses or follow-up (for details see Figure 7 and bination with FDG-PET plays a crucial role in the detection of CS
Table 9). (Section 9.4).
Given its physical properties, CMR is affected by ferromagnetic ob-
jects, such as valvular prosthesis and implants, resulting in artefacts.
Recommendation Table 4 — Recommendations for
The same holds true for active MR-conditional devices, such as pace-
computed tomography (see Evidence Table 4)
makers, ICDs, and cardiac resynchronization therapy (CRT) pace-
makers/defibrillators (P/Ds), but dedicated techniques are now
Recommendations Classa Levelb
available to achieve better diagnostic image quality in many cases.166
Cardiovascular magnetic resonance could also be used in patients CT is recommended to evaluate pericardial
with non-conditional devices with a clear clinical indication if other im- thickness, calcifications, masses, and loculated
aging modalities are not helpful. In all cases, programming of the im- pericardial effusions, as well as concomitant I C
planted device before and after the scan is warranted, as well as pleuropulmonary diseases and chest
patient monitoring. abnormalities.193,197,199,200
Even in intubated patients, CMR scans are feasible in order to detect
inflammation.167 If breath-hold capacities are reduced or the patient is CT, computed tomography. Remaining recommendations for CT can be found in
Recommendation Table 1.
uncooperative, fast imaging techniques and/or motion-corrected im- aClass of recommendation.
aging have to be applied.168 bLevel of evidence.
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3984 E S C G u id e l in e s
5.8. Nuclear medicine glycogenosis), different CMPs, and genetic heart diseases33,216 if non-
invasive imaging is inconclusive. This approach is consistent with other
Fluorodeoxyglucose uptake reflects metabolically active inflammatory
cells in AM.201 international position statements.9,210 Endomyocardial biopsy can be use-
ful in cases of chronic CMP that is progressive or unresponsive to stand-
Fluorodeoxyglucose positron emission tomography can be consid-
ard therapy. When FM, GCM or EM are suspected, early EMB is required
ered as an alternative in patients when CMR is unsuitable because of
an irregular heartbeat or device-related artefacts.202 Simultaneous/hybrid to start immunosuppressive therapy rapidly and improve outcomes.57 In
GCM, EMB has high sensitivity (80%–93%) and a positive predictive value
cardiac PET-CT/CMR imaging complement each other in the assess-
ment of myocarditis compared with either approach alone.201,203 (71%), especially if performed within 2–4 weeks from symptom onset.217
In CS, EMB may have a low sensitivity (20%–30%) due to the focal nature
Fluorodeoxyglucose positron emission tomography is also a powerful
of inflammatory lesions, but can be improved by guiding the EMB using
tool to detect and assess the extent of extracardiac involvement in sar-
CMR or electro-anatomical mapping (EAM).218–222
coidosis (see Section 9.4).
Historically, diagnosis by EMB was based on the histological Dallas cri-
Appropriate fasting before FDG-PET is a must to obtain reliable re-
sults.204 Typical preparation protocols include a high-fat and low- teria in HE-stained heart tissue sections revealing myocytolysis and inter-
stitial immune cells.223 However, since there is high interobserver
carbohydrate diet for 12–24 h followed by complete fasting other
variability, immunohistochemical detection of lymphocytes (CD3) and
than water for the 6–12-h period prior to FDG injection.
macrophages (CD68) can definitely increase sensitivity for the diagnosis
The role of nuclear imaging in pericarditis is less well established. The
of myocarditis.10,224–226 A recent meta-analysis indicates that the use of use of FDG-PET/CT in pericarditis is generally complementary and is
most often implemented in cases where CMR cannot be used.205 immunohistochemistry can increase the detection rate of inflammation
in EMB specimens to ∼51%.227 A value of ≥14 leucocytes/mm2 with T
lymphocytes of ≥7 cells/mm2 has been considered as the cut-off for
Recommendation Table 5 — Recommendations for nu- the diagnosis of myocarditis.10 In acute LM, the number of T lymphocytes
clear medicine (see Evidence Table 5) is generally higher (>25 cells/mm2).228 Additionally, the expression of
MHC class II molecules in antigen-presenting macrophages and endothe-
Recommendations Classa Levelb lial cells is routinely observed in EMB with myocarditis.33 Endomyocardial
biopsy also enables the detection of viruses, such as enteroviruses,
Carb-free 18F-FDG-PET or 18F-FDG-PET/CT should
B19V,228 and herpesviruses, e.g. EBV and HHV-6, using quantitative real-
be considered for the diagnostic work-up in patients
time (RT)-PCR and in situ hybridization. It is likely that advances in mo-
with suspected myocarditis and/or pericarditis in IIa C
lecular diagnostic techniques, such as next-generation sequencing, will
whom echocardiography and CMR are inconclusive
help to identify potential new pathogens. Positive PCR results obtained
for the clinical diagnosis.201,206
on EMB have to be accompanied by a parallel investigation of blood sam-
CMR, cardiovascular magnetic resonance; CT, computed tomography; 18F-FDG-PET, ples collected at the time of the EMB to exclude acute systemic virus in-
[18F]-fluorodeoxyglucose positron emission tomography. fection. In cases of acute cardiac and systemic virus infection,
aClass of recommendation. immunosuppressive therapy must be avoided.
bLevel of evidence.
The most common site of EMB is the RV septum, but occasionally LV
or biventricular EMB may be needed. The decision of the EMB site should
be based on the clinical indication, findings of pre-procedural imaging, and
5.9. Endomyocardial and pericardial biopsy
operator expertise.229 A study of 755 patients with suspected myocardi-
5.9.1. Endomyocardial biopsy tis and non-ischaemic CMP (including infiltrative and storage disorders)
Endomyocardial biopsy enables the identification of the underlying indicated that biventricular EMB can increase diagnostic accuracy com-
histological subtype of cardiac inflammation.10,34,207,208 However, non- pared with selective LV or RV EMB.211 Sampling error is the major limi-
invasive imaging methods have significantly improved, allowing the diag- tation of the diagnostic accuracy of EMB. The minimal number of
nosis of myocarditis by CMR. Therefore, the role of EMB in clinical required EMB samples for each technique is reported in Table 11.33
practice has changed. Endomyocardial biopsy remains important for It should be emphasized that PCR in EMB tissue and in situ hybridiza-
high-risk patients and in some intermediate cases when the knowledge tion can be used for identification of the viral agent, because viral ser-
of the histological subtype and the identification of a possible viral aeti- ology concurs with the results of PCR in a minority of patients
ology are important for targeted therapies (Figure 15).207,209 (∼4%) with myocarditis.230 With PCR, the rate of viral sequences de-
Endomyocardial biopsy has potential complications (e.g. cardiac per- tected in EMB specimens is up to 67%, although the rate varies widely
foration/tamponade, thromboembolism, valvular trauma, severe arrhyth- among studies.63,228,231 The PCR tests for the detection of infectious
mias, and death).9,210 Rates depend on the setting and centre experience agents must be performed in laboratories that are accredited and cer-
and range between 0.6% and 5%,63,211 and increase up to 26% in FM tified for the identification of viruses, bacteria, and parasites. The evalu-
cases on mechanical circulatory support (MCS).212 Children may have ation of these PCR results must be done in the context of histological/
higher complication rates depending on age, the experience of the cen- immunohistological findings by pathologists with expertise in cardiovas-
tre, and the site of the biopsy (LV or RV).63,213 On this basis, the clinical cular diseases.
use of EMB should be tailored according to the risk–benefit ratio. The timely communication of biopsy results is crucial for optimal
Histological and immunohistological investigations, as well as viral gen- therapeutic guidance.
ome analysis, allow the identification of viral or immune-mediated LM, EM, Targeted biopsies of an inflamed heart diagnosed using histology, immu-
GCM, and sarcoidosis.33,214,215 Moreover, EMB allows the identification of nohistochemistry, and molecular virology could be correlated with mod-
the inflammatory stages in association with the degree of myocardial ne- ern technologies, such as genomics, epigenomics, proteomics, and
crosis and fibrosis. Endomyocardial biopsy is useful in the differential diag- metabolomics to improve the diagnosis and therapy. Recommendations
nosis of infiltrative/storage diseases (amyloidosis, haemochromatosis, for EMB can be found in Recommendation Table 1.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3985
Recommendation Table 6 — Recommendations for endomyocardial biopsy (see Evidence Table 6)
Recommendations Classa Levelb
EMBc is recommended in patients with high-risk myocarditisd, and/or haemodynamic instability, and/or in patients with intermediate-risk
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral I C
genome for treatment.34,63,73,131
EMB, endomyocardial biopsy.
aClass of recommendation.
bLevel of evidence.
cContemporary evaluation of EMB should be based on histology, immunohistology, and molecular pathology for detection of viral infections in myocardial and blood samples (see also
Table 11).
dSee Table 7.
(cid:31) (cid:30) (cid:29)
(cid:31)(cid:16)(cid:15)(cid:14)(cid:13)
(cid:12)(cid:11)(cid:10)(cid:9)(cid:8)(cid:7)(cid:16)(cid:11)(cid:14)(cid:6)(cid:16)
(cid:10)(cid:11)(cid:7)(cid:16)(cid:5)(cid:4)(cid:3)(cid:6)(cid:14)(cid:6)(cid:2)
(cid:28) (cid:18) (cid:17)
(cid:29)(cid:8)(cid:4)(cid:7)(cid:1)(cid:6)(cid:16)
(cid:12)(cid:11)(cid:10)(cid:9)(cid:8)(cid:7)(cid:16)(cid:11)(cid:14)(cid:6)(cid:16)
(cid:10)(cid:11)(cid:7)(cid:16)(cid:5)(cid:4)(cid:3)(cid:6)(cid:14)(cid:6)(cid:2)
(cid:27) (cid:26) (cid:25)
(cid:18)(cid:7)(cid:2)(cid:6)(cid:1)(cid:7)(cid:9)(cid:8)(cid:6)(cid:12)(cid:6)(cid:16)
(cid:10)(cid:11)(cid:7)(cid:16)(cid:5)(cid:4)(cid:3)(cid:6)(cid:14)(cid:6)(cid:2)
(cid:24) (cid:23) (cid:22)
(cid:27)(cid:6)(cid:5)(cid:1)(cid:14)(cid:127)(cid:16)(cid:13)(cid:12)(cid:12)
(cid:10)(cid:11)(cid:7)(cid:16)(cid:5)(cid:4)(cid:3)(cid:6)(cid:14)(cid:6)(cid:2)
(cid:21) (cid:20) (cid:19)
(cid:29)(cid:5)(cid:4)(cid:3)(cid:6)(cid:5)(cid:16)
(cid:2)(cid:5)(cid:4)(cid:16)(cid:7)(cid:6)(cid:3)(cid:7)(cid:2)(cid:6)(cid:2)
(cid:26)(cid:18)(cid:127)(cid:129)(cid:127)(cid:27)(cid:6)(cid:13)(cid:10)(cid:2)(cid:5) (cid:29)(cid:28)(cid:141) (cid:29)(cid:28)(cid:143)(cid:144)
(cid:31)(cid:30)(cid:30)(cid:29)µm
Figure 15 Histopathological findings in myocarditis. HE, haematoxylin eosin. (A–C) Endomyocardial biopsy for acute lymphocytic myocarditis reveals
cardiomyocyte necrosis (A, HE stain) and severe focal infiltration of CD3+ T cells (B) and CD68+ macrophages (C), as detected by immunohistochem-
istry. (D–F) In chronic lymphocytic myocarditis, no cardiomyocyte injury is observed, but there is focal replacement fibrosis (D, HE) in the presence of
CD3+ T cells (E) and CD68+ macrophages (F). (G–I) In acute eosinophilic myocarditis, necrosis of cardiomyocytes is associated with numerous eosino-
philic granulocytes (G, Giemsa stain), some CD3+ T cells (H), and numerous CD68+ macrophages (I). (J–L) Areas with severe cardiomyocyte necrosis in
the presence of extensive focal and diffuse infiltration of eosinophilic granulocytes (J, Giemsa stain), CD3+ T cells (K), and CD68+ macrophages and
CD68+ giant cells (L) are typical of giant-cell myocarditis. (M–O) Cardiac sarcoidosis is histologically characterized by the presence of granulomas, usu-
ally in the absence of cardiomyocyte necrosis (M, Giemsa stain), but with focal infiltration of CD3+ T cells (N) and numerous CD68+ macrophages and
CD68+ giant cells (O).
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3986 E S C G u id e l in e s
Table 11 Parameters for reporting by endomyocardial of SCD. Here, the most common reported form was LM (56%), which
biopsy corresponds well with data obtained from EMBs of patients with sus-
pected myocarditis.10,63,87,238
Criteria Parameters for reporting In the guidelines for the histopathological diagnosis of myocarditis,
‘fulminant’ or ‘multifocal’ myocarditis can be generally considered as a
Histology (paraffin-embedded EMB, Presence and extent of
reliable or acceptable cause of death, especially when inflammation is
at least 3 EMB) cardiomyocyte necrosis,
the only substantial histopathological finding. This approach is endorsed
inflammation, fibrosis
by the Association of European Cardiovascular Pathology.239
Immunohistology Presence, extent, localization, and
In addition to LM, other types of cardiac inflammation are observed
(paraffin-embedded EMB, at least 3 typing of immune cells in the
in autopsies. In 558 of 49 612 (1.1%) forensic autopsies, myocarditis
myocardial samples) myocardium: CD3+ T lymphocytes,
was detected by histology. In a Finnish study consisting of 351 patients
CD68+ macrophages
with CS, 14% experienced fatal and aborted SCD as a presenting mani-
(≥14 leucocytes/mm2 with T festation. In 64%, undiagnosed granulomas in the heart were the cause
lymphocytes ≥7 cells/mm),10 of fatalities.240 The likelihood that a case of unexplained SCD is caused
HLA-DR expression in immune by an underlying inherited disorder has led to the emerging role of gen-
cells and endothelial cells etic testing of DNA obtained at autopsy (also called molecular autopsy
Molecular pathology [infections: Presence, typing, and quantification or post-mortem genetic testing).239 Therefore, pathologists play an im-
RNAlater, snap-frozen tissue (1–2 of DNA/RNA from infectious portant role in the identification of families at risk by reporting whether
EMB), paraffin-embedded EMB] agents by q(RT)-PCR it is recommended to refer first-degree family members for clinical
Viruses: mainly enteroviruses, screening and/or to perform additional post-mortem genetic testing
parvovirus B19, human herpesvirus 6, to identify the underlying cause of cardiac inflammation.241,242 Legal
Epstein–Barr virus; Borrelia spp., and ethical issues related to genetic testing in deceased subjects who
Trypanosoma cruzia did not give their consent are not universally regulated by law.
Blood q(RT)-PCR for detection of
systemic infections Recommendation Table 7 — Recommendations for
autopsy (see Evidence Table 7)
Molecular pathology (genetics: NGS for detection of pathogenic
RNAlater, frozen tissue, variants in cardiac genes,
Recommendations Classa Levelb
paraffin-embedded EMB, blood) traditionally associated with
cardiomyopathies (especially Comprehensive autopsy is recommended in all
desmosomal and sarcomeric/ patients <50 years of age with SCD to evaluate the
cytoskeletal genes) presence of acute myocarditis as a cause and to I B
detect potential underlying inherited cardiac
DNA, deoxyribonucleic acid; EMB, endomyocardial biopsy; HLA-DR, human leucocyte
antigen—DR isotype; NGS, next-generation sequencing; q(RT)-PCR, quantitative
diseases.87,243–246c
(real-time) polymerase chain reaction; RNA, ribonucleic acid. Retaining samples suitable for DNA extraction and
aSee Supplementary data online, Table S1.
consulting a cardiac pathologist is recommended in
I B
cases of SCD, when an inherited cause is suspected,
or the cause of death remains unexplained.243,247c
5.9.2. Pericardial biopsy
DNA, deoxyribonucleic acid; SCD, sudden cardiac death.
In clinical practice, pericardial biopsy is rarely indicated in complicated aClass of recommendation.
cases not responding to conventional anti-inflammatory therapy and bLevel of evidence.
with a high suspicion of a specific aetiology (e.g. primary pericardial tu- cIn line with the 2022 ESC Guidelines for the management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death.58
mours and metastases), which cannot be determined by non-invasive
diagnostic methods. Pericardial biopsy can be performed by pericardio-
scopy (an endoscopic study of the pericardium that is available in a lim- 5.11. Role of cardiac catheterization and
ited number of tertiary referral centres). It is more commonly
coronary angiography
performed with a thoracoscopic or surgical approach, usually during
a pericardial drainage or a pericardial window.1,232 Given the overlap of symptoms (especially chest pain), as well as the
elevation of biomarkers (such as troponin in the case of myocardial in-
volvement and NT-proBNP) and ECG changes, ACS is the main differ-
5.10. Role of autopsy
ential diagnosis for IMPS. Depending on the initial clinical assessment,
In autopsy studies of SCD, myocarditis has been described as a com- ACS should be ruled out according to current guidelines (Figure 9).
mon finding, with incidences of myocarditis in children and adults ran- The recommended methods are coronary CT or invasive coronary
ging from 0.3% to 14.8%.87,88,233–235 In the majority of these studies, the angiography depending on likelihood of obstructive CAD.72,248
incidence of myocarditis in SCD was higher in people aged under Coronary angiography is preferable in patients with a high likelihood
35 years.236,237 A nationwide unselected cohort of 14 294 deaths in of ACS. It should be noted that CAD may coexist with myocarditis
Denmark suggested that 6% of all autopsied SCD was caused by myo- in particular scenarios, including EM and ICI-induced myocarditis.249–251
carditis. Males have a significantly higher incidence.88 In the UK, be- Cardiac catheterization is also indicated to monitor and guide HF
tween 1994 and 2022, myocarditis was reported as a rare cause of therapy, as well as the early need for more advanced support (HT or
SCD in non-hospitalized individuals (1.1%) in 7702 consecutive cases MCS) in the case of refractory haemodynamic deterioration.12
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3987
For pericarditis, specific indications for cardiac catheterization in- constriction (in cases of pericarditis). Treatments are individualized ac-
clude the differential diagnosis between restrictive CMP (RCM) or cording to the specific case and the presumed or diagnosed pathogen-
CP,252 when this differentiation cannot be done by multimodality im- esis, and specific therapeutic concepts will be discussed in the section
aging (see Supplementary data online, Section 2.6). covering specific causes. There may be differences depending on
whether an isolated or a combined form is present. The current evi-
dence is more focused on the isolated cases. For combined conditions,
5.12. Electro-anatomical mapping the leading one (myopericarditis or perimyocarditis) should guide the
The diagnostic yield of traditional fluoroscopy-guided EMB in patients therapeutic decision-making and subsequent follow-up.
with suspected myocarditis may decrease with segmental or patchy
myocardial involvement, as seen in CS. Electro-anatomical mapping, 6.1. Non-pharmacological therapy for
using bipolar and unipolar voltage mapping, allows the identification inflammatory myopericardial syndrome
of low-voltage areas, which reflects abnormal myocardial tissue (scar-
An important non-pharmacological concept is the restriction of physical
ring, inflammation), and therefore guides EMB.218–222 Unipolar
activity beyond sedentary activities until symptom resolution and clinical
EAM-guided EMB demonstrated a higher diagnostic yield than bipolar
remission with normalization of inflammatory markers. This temporary
EAM (83% compared with 63%), consistent with the epicardial
limitation of physical activities should be individualized according to each
substrate.84,218,221
patient, and the response to therapy until clinical remission. According
A meta-analysis of 148 patients showed a higher diagnostic perform-
to clinical presentation, at least 1 month is needed to reach clinical re-
ance of EAM-guided EMB in CS compared with other forms of myocar-
mission, but it can last longer. Depending on the stage and risk of the
ditis. The sensitivity of any abnormal electrogram for a positive EMB
IMPS, physical activity should be tailored, and temporary restriction of
was high (92%) but was associated with moderate specificity (58%).221
physical activity is necessary in the acute phase of the disease (see
Electro-anatomical mapping has demonstrated good sensitivity and Section 7). Previous consensus statements and guidelines11 have tried
specificity compared with CMR for the detection of pathological areas
to provide a fixed time interval. This TF suggests personalizing the treat-
of the myocardium.218 The value of EAM to guide biopsy may be lower
ment until clinical remission based on a multiparametric assessment,
in AM as low-voltage areas correlate well with LGE, but not with oe- which was also supported by the 2024 ACC expert consensus paper.9
dema.253 There may also be discordance between low-voltage areas
Clinical remission is defined as full regression of symptoms, as well as
and LGE on CMR. However, the combination of unipolar/bipolar EAM
normalization of laboratory results (e.g. C-reactive protein, troponin le-
with CMR findings increased the diagnosis yield of EMB,218 especially in
vels) and investigations (ECG, evidence of PEff, CMR evidence of active
CS.220 The EAM pattern may also help to differentiate between differen-
inflammation) (Table 3). Additional testing (e.g. exercise testing and
tial diagnoses, especially between CS and ARVC,254 as CS often involves
Holter monitoring) is recommended for patients with myocarditis for
the basal septum and exhibits a higher bipolar/unipolar low-voltage area
the detection of clinical remission. After a prolonged rest period, a grad-
ratio. The reported complication rate of EAM-guided EMB is <5%.218,221
ual, monitored return to work and physical activity may be helpful, if ne-
Programmed ventricular stimulation (PVS) has not been evaluated in
cessary, guided by a qualified rehabilitation. Currently, evidence-based
the acute setting and should not be performed in the acute phase. It
data are missing on this topic, and the decision must be individualized.
could be useful for arrhythmia stratification in selected patients with
non-active myocarditis, with LGE and risk factors for ventricular arryth- 6.2. Pharmacological therapy
mias (Section 6.5).255
6.2.1. Pharmacological therapy for myocarditis
Recommendation Table 8 — Recommendations for 6.2.1.1. General principles
electro-anatomical mapping (see Evidence Table 8)
This section will focus on general aspects and non-aetiology-directed
therapy. It should be recognized that evidence is very limited in this field
Recommendations Classa Levelb
and this document will provide guidance for clinical practice.
Electro-anatomical mapping should be considered in Medical therapy of myocarditis is based on clinical presentation, case se-
cases of suspected myocarditis (especially cardiac verity, and aetiology. It includes general supportive, non-aetiology-directed
sarcoidosis) to guide endomyocardial IIa C therapy (e.g. HF therapy),12,259 anti-arrhythmic therapy, and specific ther-
biopsy.218,220,221,253,256–258 apy (aetiology-directed therapy).58,260,261 Corticosteroids are considered
for autoimmunity-associated cases to suppress the immune system, as first-
aClass of recommendation. line therapy in most cases. Severe cases are considered for MCS and HT.
bLevel of evidence.
Uncomplicated cases of myocarditis usually present with chest pain
and can be empirically treated with aspirin or non-steroidal anti-
6. Therapy inflammatory drugs (NSAIDs) for the control of chest pain, if needed.
This is supported by a small study showing no harm for patients treated
The aim of medical therapy for IMPS is to relieve symptoms and to pre- with anti-inflammatory drugs.262 Concomitant use of colchicine is safe
vent complications, especially recurrences and mortality in complicated in patients with myopericarditis, preventing recurrences.263 In clinical
cases. Medical therapy targets include: (i) infectious agents; (ii) inflam- practice, β-blockers are often used in patients with myocarditis. In a
mation; (iii) immune-mediated processes; (iv) HF and ventricular small study, β-blockers were associated with better outcomes, defined
dysfunction (in cases of myocarditis); (v) arrhythmias; and (vi) as freedom from cardiac death or HT.264
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3988 E S C G u id e l in e s
Several viruses can cause myocarditis and are mentioned in aetiologies, refer to the subsections on LM (Section 9.1), EM
Section 3.4. The specific therapies for viral aetiologies can be found in (Section 9.2), GCM (Section 9.3), CS (Section 9.4), LC (Section 9.5.2),
Section 9.5 for influenza-, severe acute respiratory syndrome corona- CD (Section 9.5.3), and ICI-associated myocarditis (Section 9.6.1.1).
virus 2 (SARS-CoV-2)-, and HIV-associated myocarditis. For specific Specific medical therapies are summarized in Table 12.
Table 12 Therapy for specific forms of myocarditis
Lymphocytic myocarditis (virus-negative)
1st line therapy Non-severe: prednisone 1 mg/kg/day p.o. then tapered
Severe: i.v. methylprednisolone 7–14 mg/kg/day for 3 days, then 1 mg/kg/day p.o.
2nd line therapy Oral corticosteroids + azathioprinea or mycophenolate mofetilb, cyclosporinec, methotrexated
3rd line therapy IVIGe or plasmapheresisf
Eosinophilic myocarditis
1st line therapy Same as lymphocytic myocarditis + Treat EM-associated condition if identified
2nd line therapy Same as lymphocytic myocarditis + Treat EM-associated condition if identified
3rd line therapy –
Giant-cell myocarditis
1st line therapy Non-severe: prednisone 1 mg/kg/day p.o. then tapered
Severe: i.v. methylprednisolone 7–14 mg/kg/day for 3 days, then 1 mg/kg/day p.o. + immunosuppressive
(azathioprinea or mycophenolate mofetilb, cyclosporinec)
2nd line therapy Antithymocyte Globulin (ATG)g cyclophosphamideh, rituximabi
3rd line therapy –
Cardiac sarcoidosis
1st line therapy Non-severe: prednisone 1 mg/kg/day p.o., tapering from 40–60 mg daily
Severe: i.v. methylprednisolone 7–14 mg/kg/day for 3 days, then 1 mg/kg/day p.o.
2nd line therapy Methotrexated (1st choice), or azathioprinea mycophenolate mofetilb, cyclophosphamideh
3rd line therapy Infliximabj or adalimumabk, rituximabi
Lyme carditis
1st line therapy (a) Oral antibiotics (mild cases):
– Doxycycline 100 mg b.i.d. (14–21 days)
– Amoxicillin 500 mg t.i.d. (14–21 days)
– Cefuroxime axetil 500 mg b.i.d. (14–21 days)
(b) i.v. antibiotics (severe cases):
– Ceftriaxone 2 g/day (14–21 days)
2nd line therapy i.v. antibiotics:
Cefotaxime (2 g q8h × 14–21 days) or Penicillin G (18–24 MU/day i.v. q4h × 14–21 day)
3rd line therapy –
Chagas disease
1st line therapy Benznidazole 5–7 mg/kg/day in 2 doses for 60 days
Nifurtimox 8–10 mg/kg/day in 3 doses for 60–90 days
2nd line therapy –
3rd line therapy –
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3989
ICI-induced myocarditis
1st line therapy Withdraw ICI, reassess
Non-severe: methylprednisolone 500–1000 mg/day × 3 days, then taper with oral prednisone
Severe: i.v. methylprednisolone 7–14 mg/kg/day × 3 days, then 1 mg/kg/day
2nd line therapy If no response in 24–48 h: mycophenolate mofetilb, ATGg abataceptl, alemtuzumabm
3rd line therapy Infliximabj or adalimumabk, rituximabi
ATG, anti-thymocyte globulins; b.i.d., twice daily; CTLA-4, cytotoxic T-lymphocyte antigen 4; EM, eosinophilic myocarditis; ICI, immune checkpoint inhibitor; IgG, immunoglobulin; IL,
interleukin; i.v., intravenous; IVIG, intravenous immunoglobulins; p.o., by mouth; s.c., subcutaneous; t.i.d., three times daily; TNF-α, tumour necrosis factor alpha.
aAzathioprine (immunosuppressant purine analog): 1–2 mg/kg per day p.o. (typically 100–150 mg daily, in 1–2 divided doses, main target: lymphocytes).
bMycophenolate mofetil (immunosuppressant that inhibits inosine monophosphate dehydrogenase, main target: lymphocytes): 500–1000 mg p.o. b.i.d. (total 1–2 g/day).
cCyclosporine (calcineurin inhibitor that prevents IL-2 transcription in activated T-cells): ∼3–5 mg/kg/day p.o. (divided b.i.d.) adjusted to target trough levels ∼150–250 ng/mL.
dMethotreaxate (antimetabolite that inhibits dihydrofolate reductase and other folate-dependent steps, reducing proliferation of active lymphocytes): 15–20 mg/week p.o. or s.c. (low-dose
weekly, with folic acid supplementation).
eIVIG (immunomodulatory therapy providing pooled IgG antibodies) = standard dose off-label 2 g/kg total dose, typically administered over 1 to 2 days; alternative dosing: 0.4 g/kg/day for 5
consecutive days (less commonly used in myocarditis but sometimes used in autoimmune settings).
fPlasmapheresis (therapeutic plasma exchange that filters out and removes circulating autoantibodies, immune complexes, and inflammatory mediators) 3–5 sessions in 5–10 days.
gAntithymocyte Globulin (ATG; polyclonal anti-T-lymphocyte antibody that causes profound T-cell depletion): ∼1 mg/kg i.v., often given daily for 3–5 days.
hCyclophosphamide (cytotoxic alkylating agent that crosslinks DNA in rapidly dividing cells, main target: lymphocytes): 600 mg/m² i.v. bolus on days 1, 15, and 30 (pulse therapy).
iRituximab (monoclonal antibody against CD20 on B cells): 375 mg/m² i.v. weekly × 4 doses (1 month).
jInfliximab (monoclonal antibody against TNF-α): 5 mg/kg i.v. at weeks 0, 2, 6, then every ∼8 weeks (maintenance).
kAdalimumab (anti-TNF-α fully human monoclonal antibody) 40 mg SC every week (or every 2 weeks, per clinical response).
lAbatacept (CTLA-4 Ig fusion protein that binds CD80/86 on antigen-presenting cells, blocking the CD28 co-stimulatory signal required for full T-cell activation): 500 mg i.v. every 2 weeks × 5
doses (approximately 10 weeks).
mAlemtuzumab (monoclonal antibody against CD52 on lymphocytes): 30 mg i.v. once (alternative: 15 mg i.v. daily for 2 days).
Main mechanisms of action:
• T-cell suppression (e.g., corticosteroids, cyclosporine, abatacept)
• B-cell depletion (rituximab)
• Cytokine inhibition (TNF-α blockers like infliximab, adalimumab)
• DNA synthesis inhibition (azathioprine, mycophenolate, methotrexate)
• Immunoglobulin replacement/modulation (IVIG)
• Plasma filtration (plasmapheresis)
6.2.1.2. Fulminant myocarditis avenue to stop the development of viral myocarditis. The evidence
Fulminant myocarditis is a rare and severe presentation of myocarditis on clinical application of antiviral agents is limited, and antiviral treat-
and a cause of cardiogenic shock, and should be treated accordingly ments should be agreed upon with an infectious disease expert as
with inotropic or vasopressor support or, if needed, MCS (see part of the IMPS team.
Section 6.3).265 It is crucial to be aware of the condition and, when Patients with AM show significant activation of the NLR family pyrin
needed, to refer patients to tertiary referral centres that can institute domain containing 3 (NLRP3) inflammasome in the heart, thus it is a
temporary MCS and perform early EMB. Early EMB has been independ- potential therapeutic target in the acute phase of myocarditis.267
ently associated with a lower rate of death or HT/left ventricular assist Activation of NLRP3 functions as a rapid inducer of an inflammatory re-
device (LVAD) at 1 year.57 The timely communication of biopsy results sponse through the production of IL-1β and IL-18. Theoretically, prom-
is crucial. Specific subtypes of FM (e.g. biopsy-proven non-infectious ising agents are anti-IL-1 agents (anakinra, rilonacept, canakinumab) and
forms) may respond to immunosuppressive therapy in addition to colchicine,267 although human data on the effect of such agents in myo-
guideline-directed medical care.12,34 An ongoing trial is evaluating cor- carditis are still limited.
ticosteroids for FM (ClinicalTrials.gov Identifier: NCT05150704). In humans, the first evidence has been reported using anakinra, an
IL-1 receptor antagonist (IL-1RA) that improved heart function in se-
lected cases of AM refractory to standard treatment. However, in
6.2.1.3. Acute myocarditis the ARAMIS trial, anakinra failed to demonstrate a benefit in patients
Acute myocarditis has a high rate of spontaneous recovery, especially in with suspected AM without a specific aetiology (NCT03018834).268
uncomplicated cases. In cases of AM diagnosed by EMB, up to 50% of The primary endpoint was the number of days alive free from any com-
patients have spontaneous recovery and up to 25% may have a persist- plication due to AM. The study had potential limitations related to the
ent stable cardiac dysfunction. Only 10%–25% have a progressive ven- limited sample size, the inclusion of a low-risk population, and the short
tricular dysfunction, which could lead to end-stage DCM, HT, or follow-up, but it proved that anakinra was safe in this setting.
death.9 Treatment of AM depends on severity and clinical presentation. Regarding modulation of the immune response, further randomized
Risk stratification of these patients is mandatory to assess the required studies are needed to assess treatment with intravenous immunoglobu-
level of care. lins (IVIG) in AM for adults,269 since case series and retrospective ana-
The acute phase of viral myocarditis (e.g. induced by cytolytic enter- lyses suggest a benefit in terms of transplant-free survival. Intravenous
oviruses) is characterized by intense virus replication and myocyte ne- immunoglobulins are commonly prescribed in paediatric patients.269 In
crosis and usually lasts for only a few days.266 Thus, early antiviral general, treatment of AM with corticosteroids is controversial, with the
therapy directed against an identified virus is a potential therapeutic exception of ICI-induced myocarditis270 and EM.271
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3990 E S C G u id e l in e s
The efficacy of combined immunosuppression (prednisone with ei- Corticosteroids may be considered in patients with
ther cyclosporine or azathioprine), compared with placebo, was as- acute myocarditis with impaired LVEF if refractory to IIb C
sessed in a single randomized controlled trial (RCT) in patients with
standard HF therapy to stabilize patients.
biopsy-proven AM of unspecified aetiology, since infectious causes
Routine use of immunosuppressive therapy is not
were not excluded by PCR.272 The trial was designed to determine
recommended in acute myocarditis with preserved
whether immunosuppressive therapy improved LV function in patients III C
LV function because no outcome benefit has been
with AM. There was no significant difference in survival between the
shown.
two groups (P = 0.96). The study had several limitations, such as small
sample size and incomplete analysis of EMB based only on histopath- ESC, European Society of Cardiology; HF, heart failure; LV, left ventricle; LVEF, left
ology. However, in specific histopathological forms of AM, such as ventricular ejection fraction; NSAID, non-steroidal anti-inflammatory drug; VT,
ventricular tachycardia.
GCM, immunosuppressive drugs are recommended (see Sections 9.2
aClass of recommendation.
and 9.3). bLevel of evidence.
6.2.1.4. Subacute and chronic myocarditis
6.2.2. Pharmacological therapy for pericarditis
Chronic myocarditis may represent an intermediate stage between
6.2.2.1. General principles
subacute myocarditis and inflammatory CMP. During chronic myo-
carditis, HF may develop, and guideline-directed medical therapy The aims of medical therapy for pericarditis are to provide: (i) symp-
(GDMT) for HF is the cornerstone in the treatment of chronic myo- tomatic care (mainly control of pericarditis chest pain); (ii) clinical re-
carditis.12,259 Antiviral therapy has little benefit in the subacute and mission; and (iii) prevention of complications, especially recurrences
chronic stages of myocarditis,273 and the effects of immunomodula- and constriction.
tory drugs on chronic myocarditis of unspecified aetiology are still Exercise restriction limits the heart rate and may be useful to reduce
controversial. pericardial friction, which can be improved using drugs that reduce it
(e.g. β-blockers or ivabradine for those who cannot receive or tolerate
β-blockers) for patients with a resting heart rate of >75 b.p.m., and
symptoms despite empirical anti-inflammatory therapy.274
Recommendation Table 9 — Recommendations for
medical therapy in myocarditis (see Evidence Table 9)
6.2.2.1.1. Acute pericarditis (first episode). The mainstay of medical
Recommendations Classa Levelb
therapy is empirical anti-inflammatory therapy using aspirin or NSAIDs
Management of symptoms at full anti-inflammatory doses with appropriate time intervals of ad-
ministration (usually every 8 h) plus colchicine to reduce the risk of re-
NSAIDs (together with proton pump inhibition)
currences.24,25,108,275–278 Gastroprotection with a proton pump
should be considered in patients with associated IIa C
inhibitor is recommended using NSAIDs.279
symptoms of pericarditis to reduce symptoms.
When aspirin and NSAIDs are contraindicated, or for specific indica-
Colchicine should be considered in patients with
IIa B tions, corticosteroids should be considered at low to moderate doses
myopericarditis to reduce recurrences.263
plus colchicine (see Tables 13 and 14).
Management of heart failure In cases of incomplete response to aspirin/NSAIDs and colchicine,
Adherence to the ESC HF guidelines is corticosteroids may be added at low to moderate doses as triple ther-
recommended in cases of myocarditis with LV apy.1 In cases of recurrence, every effort should be made not to in-
I C
systolic dysfunction and/or HF to reduce symptoms crease the dose or to reinstate corticosteroids.
and to improve LV function.12 The use of colchicine on top of empirical anti-inflammatory therapy
HF therapy should be considered in patients with is supported by most of the published evidence, with the single excep-
myocarditis and LV systolic dysfunction for at least tion of a small open-label trial that was probably underpowered to
6 months upon complete LV functional recovery to IIa C test the study hypothesis for patients with AP.281 Specific dosing
and duration of therapy are summarized in Table 13. Monitoring of
stabilize LV function.
serum C-reactive protein and CMR imaging is recommended to assess
Management of arrhythmias
clinical remission, guide the treatment length, and evaluate the re-
β-Blockers, with a continuation for at least 6 months,
sponse to therapy in more complicated and difficult-to-treat cases.
should be considered in patients with acute
IIa C In uncomplicated cases, clinical follow-up with/without echocardiog-
myocarditis, especially those with troponin elevation,
raphy is sufficient.
to control symptoms and prevent arrhythmias.
Anti-arrhythmic treatment should be considered in
6.2.2.2. Incessant and recurrent pericarditis
post-myocarditis patients with recurrent, IIa C
symptomatic VT to reduce arrhythmic burden.58 In patients with incessant pericarditis or RP, the mainstay of therapy
is always colchicine in association with aspirin/NSAID or low to
Immunosuppressive therapy
moderate doses of corticosteroids. For more difficult cases, chest
Corticosteroids should be considered in patients
pain can be controlled by a combination of aspirin or an NSAID
with fulminant, non-infectious forms of myocarditis IIa C
plus corticosteroids at low to moderate doses and colchicine (triple
to stabilize the patients.
therapy). The i.v. route should be considered to ensure a clinical re-
Continued sponse or to control symptoms in more difficult or resistant cases.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3991
Table 13 Specific initial dosing and duration of therapy for acute and recurrent pericarditis
Therapy Dosing Durationa Taperinga
Aspirinb 750–1000 mg 3 times daily 1–2 weeks Decrease by 250 mg every 1–2 weeks
Ibuprofenb 600–800 mg 3 times daily 1–2 weeks Decrease by 200 mg every 1–2 weeks
Indomethacin 25–50 mg 3 times daily 1–2 weeks Decrease by 25 mg every 1–2 weeks
Colchicineb 0.5 mg once daily (<70 kg or severe renal impairment) or 0.5 mg 3–6 months Not required
twice daily
Prednisone 0.2–0.5 mg/kg/day 2–4 weeks Several months
Treatment for recurrences only:
Azathioprine Starting with 1 mg/kg/day then gradually increased to 2–3 mg/kg/day Several months Several months
IVIG 400–500 mg/kg i.v. daily for 5 days 5 days Not required
Anakinra 1–2 mg/kg/day up to 100 mg/day in adults At least 6 months/ Needed (at least 3–6 months)/
>12 months unknown
Rilonaceptc 320 mg once daily followed by 160 mg weekly
IVIG, intravenous immunoglobulins; NSAID, non-steroidal anti-inflammatory drug.
Treatment for recurrences only is highlighted in grey.
aTherapy duration as initial dosing; for all treatments the attack dose is maintained until symptom resolution and normalization of inflammatory markers (e.g. C-reactive protein) and other
investigations (electrocardiogram, echocardiogram) then tapering is recommended. It should be tailored to the single patient according to disease severity and patient response. Tapering is
especially important for corticosteroids where tapering is particularly slow, especially below 15 mg/day, the common threshold for recurrences (see Table 14). Monitoring is essentially based
on the assessment of blood count, creatinine, creatine kinase, transaminases, C-reactive protein, echocardiography. Anakinra should be tapered after clinical remission. Different schemes are
adopted: e.g. reducing one dose per week every month; every other day full dose for at least 3 months then half-dose every other day for at least 3 months.
bAspirin and ibuprofen are common first-level treatments for the first episode of pericarditis (acute pericarditis) associated with colchicine for at least 3 months. Aspirin is the preferred
choice for patients with ischaemic heart disease. Indomethacin is usually considered for incessant/recurrent cases. In incessant/recurrent cases, colchicine is maintained for at least
6 months. Aspirin/NSAID full dose is recommended for patients with normal or mildly reduced renal function. For those with moderate to severe renal impairment, dose adjustment or
use of corticosteroids is recommended.
cRilonacept is registered in the USA but is not currently available in Europe. Anakinra, due to its short half-life, may be the preferable choice in patients at increased risk of infections.
Table 14 Tapering of corticosteroids advantage of these agents is the rapid onset of action and the possibility
of rapid withdrawal of corticosteroids.285 There is evidence of efficacy
Prednisone Starting dose Taperingb with anti-IL-1 agent (anakinra or rilonacept) monotherapy.108,275,282–284
dosea 0.20–0.50 mg/ However, concomitant use of colchicine could be helpful to reduce re-
kg/daya currences and prolong recurrence-free survival, providing a sequential
block of the pro-inflammatory pathway leading to the generation of
Prednisone >50 mg 10 mg/day every 1–2 weeks IL-1.286 Colchicine should be maintained and withdrawn as the last
daily dose drug only after stable remission. Moreover, colchicine has the safest car-
50–25 mg 5–10 mg/day every 1–2 weeks diovascular profile and is now proposed to prevent major adverse cardiac
25–15 mg 2.5 mg/day every 2–4 weeks events (MACE) in patients with atherosclerotic cardiovascular dis-
<15 mg 1.25–2.5 mg/day every 2–6 weeks eases.248 In patients obtaining stable remission with a chronic low dose
of corticosteroids (e.g. prednisone ≤5 mg or equivalent) plus colchicine,
aAvoid higher doses except for special cases, and only for a few days, with rapid tapering to
the decision of switching to IL-1 blocker treatment should be tailored to
25 mg/day. Prednisone 25 mg is equivalent to methylprednisolone 20 mg.
bEvery decrease in prednisone dose should be done only if the patient is asymptomatic and the patient on an individualized basis, taking into account several para-
C-reactive protein is normal, particularly for doses of <25 mg/day. meters (such as tolerability, age and sex issues, patient preference).
Calcium intake (supplement plus oral intake) of 1200–1500 mg/day and vitamin D The use of anti-IL-1 agents may be associated with a moderate increase
supplementation of 800–1000 IU/day should be offered to all patients receiving
in the overall risk of mild to moderate infections. Safety data on anti-IL-1
glucocorticoids. Moreover, bisphosphonates are recommended to prevent bone loss in
all men aged ≥50 years and postmenopausal women in whom long-term treatment with agents are reassuring when considering new malignancy risk, whereas
glucocorticoids is initiated at a dose of ≥5.0–7.5 mg/day of prednisone or equivalent.280 their safe administration in patients with known active malignancies has
not been well investigated to date.
There is limited evidence for other drugs for pericarditis.
Patients who develop a recurrence during corticosteroid tapering Azathioprine has been empirically used in patients with recurrences
should continue colchicine and receive an NSAID on top of this treat- and a lack of response to first- and second-level options such as as-
ment instead of increasing the dose of corticosteroids. Which medica- pirin/NSAID, colchicine, and corticosteroids.287 However, this drug
tion should be tapered first (corticosteroids or NSAID) depends on the seems more appropriate as a steroid-sparing agent, and has limited ef-
specific clinical scenario (age, kidney function, haemorrhagic risk, and ficacy for those with acute pain. Intravenous immunoglobulins have
use of oral anticoagulants). also been tested in patients with refractory RP after failure of first
For patients with corticosteroid dependence, colchicine resistance, and second options, as well as anti-IL-1 agents. These drugs may be
and evidence of elevated C-reactive protein (baseline or subsequent efficacious either for infectious or non-infectious aetiologies, since
episode), clinical trials and an international registry supported the use they are able to clear infectious agents and modulate the immune
of an anti-IL-1 agent (anakinra or rilonacept).108,275,282–284 An response.288 Both corticosteroids and immunoglobulins have been
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3992 E S C G u id e l in e s
Patient with acute pericarditis
Exercise-restriction and first level therapya:
ASA or NSAID (usually ibuprofen or indomethacin) plus colchicine
(Class I)
Response to medical therapy
If ASA/NSAID
contraindicated
or not tolerated
Tapering of ASA/NSAID
and colchicineb for 3–6 months Incessant/recurrent
to reduce recurrence risk
Low to moderate doses of corticosteroids plus colchicine
or triple medical therapy with corticosteroids, NSAID and colchicinec
(Class IIa)
Response to medical therapy
If corticosteroids
contraindicated
or not tolerated
Tapering of corticosteroids
and colchicineb for at least 6 months Incessant/recurrent
to reduce recurrence risk
Anti-IL-1 agents
(Anakinra or Rilonacept)
(Class I)d
Figure 16 Proposed algorithm of medical therapy for pericarditis in adults (not including interventional therapies and pericardiectomy). ASA, acetyl
salicylic acid; IL-1, interleukin-1; CRP, C-reactive protein; CMR, cardiovascular magnetic resonance; LOE, level of evidence; N, no; NSAID, non-steroidal
anti-inflammatory drug; Y, yes. aASA is the first option if patients are already on antiplatelet therapy with ASA. Ibuprofen is usually preferred as the first
NSAID. Try more than one agent to evaluate response. Gastroprotection with a proton pump inhibitor is always recommended with use of aspirin/
NSAID. bColchicine is recommended to prevent recurrence. Consider at least 3 months for the first episode of pericarditis and at least 6 months for
incessant/recurrent cases. Colchicine to be withdrawn as last drug only after stable remission. Tapering is recommended to reduce the persistence/
recurrence of symptoms. Tapering is slower for corticosteroids. Colchicine tapering is usually not performed due to the duration of >3–6 months
of therapy. Suggested schemes of tapering are reported in Table 12. For response to therapy we considered clinical remission. cLow to moderate
dose of corticosteroids (e.g. prednisone 0.2–0.5 mg/kg/day or equivalent doses of an alternative corticosteroid). dClass I LOE A, Class IIa LOE C re-
gardless of C-reactive protein levels if CMR evidence of pericardial inflammation.
proposed for a non-inflammatory presentation (so-called non- manner, and the tapering process should be slower than for a first epi-
inflammatory phenotype).288,289 sode of AP.1
More recently, hydroxychloroquine has shown a steroid-sparing ef- The dosing and duration of most common drugs used for pericarditis
fect and increased flare-free survival in RP in patients with colchicine re- is summarized in Table 13, while the proposed algorithm of medical
sistance and corticosteroid dependence.290 Treatment duration with therapy for pericarditis (not including interventional therapies and peri-
aspirin/NSAIDs and steroids should be extended in an individualized cardiectomy) is illustrated in Figure 16.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3993
Recommendation Table 10 — Recommendations for amongst those who respond best to temporary MCS.293 Among tem-
medical therapy in pericarditis (see Evidence Table 10) porary MCS, veno-arterial extracorporeal membrane oxygenation
(VA-ECMO) represents the most frequently applied or recommended
Recommendations Classa Levelb approach, ranging from 75% to 85% of AM cases.75,294–296 Despite the
high risk and markedly compromised state of patients undergoing
Colchicine is recommended as first-line therapy
VA-ECMO support for FM, the prognosis is rather favourable, with a
in patients with pericarditis as an adjunct
I A high rate of myocardial recovery and patient survival. Several national
to aspirin/NSAID or corticosteroid therapy
and international multicentre studies showed in-hospital survival ran-
to reduce subsequent recurrences.24,25,108,275–278
ging from 61% to 72%,297–300 but no freedom from HT in patients
Anti-IL-1 agents (anakinra or rilonacept) are with giant-cell FM.294 Temporary MCS should be performed early
recommended for patients with recurrent
and in a timely manner in patients with FM with refractory cardiogenic
pericarditis after failure of first-line therapies and
I A shock because of the high likelihood of recovery.
corticosteroids and elevation of C-reactive protein
levels to reduce recurrences and allow
corticosteroid withdrawal.108,275,282–284 6.3.1.2. Intra-aortic balloon pump
High-dose aspirin or NSAIDs with proton pump As mentioned, EMB should be performed as soon as possible, even in
inhibitors are recommended as first-line therapy in the presence of temporary MCS,212,295 and specific immunosuppres-
I B
patients with pericarditis to control symptoms and sive therapy should be considered at least as an initial option, while de-
reduce recurrences.291,292 termining the myocardial response.295 An intra-aortic balloon pump
A β-blocker should be considered in symptomatic (IABP) should be considered in cardiogenic shock as first-line MCS
with prompt escalation to more powerful MCS if haemodynamic and
patients, despite full anti-inflammatory therapy, and
IIa C end-organ perfusion improvement is not observed within a short
heart rate at rest >75 b.p.m. in order to improve
symptom control.274 time (1 h maximum).295
Anti-IL-1 agents (anakinra or rilonacept) should be
Recommendation Table 11 — Recommendations for
considered in cases of incessant/recurrent
interventional techniques including circulatory support
pericarditis with evidence of pericardial inflammation in myocarditis (see Evidence Table 11)
on CMR after failure, contraindications, and IIa C
intolerance to first-line therapies and corticosteroids Recommendations Classa Levelb
regardless of C-reactive protein levels to reduce
A timely and dedicated Shock Team discussion is
recurrences and allow corticosteroid withdrawal.
recommended in patients with myocarditis in the
Low- to medium-dosec corticosteroids should be
presence of haemodynamic compromise, to decide I C
considered for patients with pericarditis only in cases
on the need for escalation to MCS and to determine
of contraindication/failure of aspirin/NSAIDs and IIa C
a long-term management plan.
colchicine, or when there is a specific indication to
Temporary MCSc should be considered in patients
control symptoms and reduce recurrencesd.
with myocarditis and cardiogenic shock or acute
Hydroxychloroquine may be considered in patients IIa C
decompensation in chronic myocarditis to stabilize
with recurrent pericarditis refractory to standard IIb B the patients.
therapy (including corticosteroids and anti-IL-1
agents) to prolong recurrence-free survival.290 IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; PLVAD,
percutaneous left ventricular assist device; VA-ECMO, veno-arterial extracorporeal Corticosteroids are not recommended as the first membrane oxygenation.
option for patients with pericarditis therapy without III C aClass of recommendation.
a specific indicationd. bLevel of evidence.
cIABP, PLVAD, VA-ECMO.
b.p.m., beats per minute; CMR, cardiovascular magnetic resonance; IL, interleukin; NSAID,
non-steroidal anti-inflammatory drug.
aClass of recommendation.
bLevel of evidence. 6.3.2. Pericarditis
cSee Table 13. Pericardium-related interventional procedures are increasingly applied
dFor example, systemic inflammatory disease on maintenance therapy with corticosteroids, and require specific expertise.1,301 The use of percutaneous interven-
post-pericardiotomy syndromes, post-vaccine pericarditis, severe renal failure,
concomitant therapies interacting with NSAIDs such as oral anticoagulant. tional techniques for pericarditis is not limited to perform percutan-
eous drainage, but also to obtain fluid samples for cytology and other
pathological examinations (see Supplementary data online, Table S7).
Moreover, interventional techniques are used to provide alternative
6.3. Interventional techniques including treatment, such as balloon pericardiotomy or, less commonly, intraper-
circulatory support icardial drug administration (e.g. corticosteroids or chemotherapy).
6.3.1. Myocarditis
6.3.1.1. Short-term mechanical circulatory support 6.3.2.1. Pericardiocentesis and pericardial drainage
Myocarditis patients who present with rapid deterioration in haemo- Percutaneous pericardiocentesis guided by echocardiography or fluor-
dynamic status and rapidly progressive myocardial dysfunction are oscopy is indicated for CTP and symptomatic moderate to large PEffs
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3994 E S C G u id e l in e s
not responding to medical therapy, or when a search for aetiological 6.3.2.6. Circulatory support
agents is needed (e.g. suspicion of cancer, bacterial infection). Mechanical circulatory support has been shown to be applied in up to
Whenever possible, pericardiocentesis should not drain a large amount 12% of pericardiectomy patients with pre-procedural RV dilatation/
of pericardial fluid (usually <500 mL) to prevent pericardial decom- dysfunction,307–309 and is sometimes considered peri-operatively.307–
pression syndrome. Complete drainage of the PEff can be achieved, 309 The association of pre-procedural RV dilatation/dysfunction and re-
leaving a drain to be removed when the daily drainage is <30 mL. duced LV function also represent risk factors for a peri-procedural risk
Surgical drainage is required when percutaneous pericardiocentesis is of early mortality, calling for timely and prophylactic MCS.308
not feasible or purulent effusion is present, to allow complete drainage
of the effusion and prevent its organization. Clinical triage has been pro-
Recommendation Table 12 — Recommendations for
posed to indicate urgent management.118 An overall score of >6 indi-
interventional techniques in pericarditis (see Evidence
cates the need for urgent pericardiocentesis, whereas a lower score Table 12)
suggests delaying the intervention (see Figure 12).
Imaging is an essential component for guiding percutaneous peri- Recommendations Classa Levelb
cardiocentesis. Under echocardiography, CT, or fluoroscopic guidance,
Pericardiocentesis (echocardiography-, CT-, or
a needle (usually 16–20 gauge) should be introduced into the sub-
fluoroscopy-guided) is recommended for cardiac
xyphoid space, although an apical or left-lateral approach might be
tamponade, or suspected bacterial or neoplastic I C
used. The catheter should usually remain in situ for a few days, also
based on the type and efficacy of concomitant systemic and/or topic pericarditis, or symptomatic moderate to large
pharmacological treatment.1 pericardial effusion despite medical therapy.
Surgical pericardial drainage is recommended in
patients with pericardial effusion when percutaneous
6.3.2.2. Percutaneous balloon pericardiotomy
pericardiocentesis is not feasible or with purulent I C
Percutaneous balloon pericardiotomy represents a percutaneous alter-
pericardial effusion to allow complete drainage and
native to the endoscopic or surgical pleuro-pericardial window, which al-
to prevent constriction.
lows relapsing pericardial fluid to be absorbed through the ample pleural
serosa, especially as palliative and temporary relief.1 It should not be used Surgical pleuro-pericardial window is recommended
as a first- or second-line intervention, but rather reserved for very rare in patients with relapsing pericardial effusion despite I C
cases, such as recurrent neoplastic PEff and CTP, as well as for absolute medical therapy.
contraindications for surgery or in the case of a very poor quality of life in
CT, computed tomography.
terminal patients (see Supplementary data online, Table S8).1 aClass of recommendation.
bLevel of evidence.
6.3.2.3. Intrapericardial drug administration
Percutaneous access to the pericardium is done using an intrapericardial 6.4. Surgical therapy
catheter following pericardial drainage. It may be used to deliver drugs
6.4.1. Myocarditis
targeting different conditions. Anti-inflammatory agents have been deliv-
The surgical treatment of myocarditis mainly accounts for HT, when there
ered with some efficacy. Intrapericardial crystalloid triamcinolone,
is no myocardial recovery. In addition to infective or autoimmune aetiolo-
300 mg/m2 of body surface, can be used for autoreactive or recurrent
gies, radiation-induced myopericarditis (usually secondary to haemato-
PEffs that do not respond to other conventional therapies, and to avoid
logical cancer) may contribute to the indications for such an
or limit systemic side effects of oral corticosteroids. Chemotherapeutics
intervention. Limited series of HTs due to radiation-induced myocarditis
have also been delivered, such as cisplatin and thiotepa (usually for lung
have been described with satisfactory results. Secondary malignancy, lung
and breast cancer, respectively), with demonstrated reduction of PEff re-
and kidney failure are negative prognostic factors for post-operative mor-
lapse.302–304 Currently, due to improved chemotherapy, the systemic bidity and mortality.310 A durable ventricular assist device (VAD) or a total
route is favoured, and therapeutic planning should involve a multidiscip- artificial heart are other alternatives for advanced cardiac support.295
linary team with cardiologists and oncologists.
Sclerosing agents, such as talc, to enhance pericardium–epicardium
6.4.2. Pericarditis
adherence and to reduce relapsing PEff, should not be used, because
6.4.2.1. Surgical pericardiocentesis
of reduced efficacy compared with a pericardial window or pericar-
diectomy, and the risk of inducing constriction.305,306 Surgical pericardiocentesis is rarely performed for urgent/emergency
conditions, but for large PEff requiring expeditious drainage, not achiev-
able with percutaneous-based drainage (e.g. for purulent PEff or clot
6.3.2.4. Pericardioscopy
aspiration).
This procedure is sometimes considered as part of the diagnostic work-
up, allowing pericardial biopsy. Pericardial access is also increasingly
6.4.2.2. Pericardiotomy/pericardial window
used for mapping and ablation of the epicardial substrates of VA,
These surgical procedures are carried out to create a connection, namely
with an improved success rate and avoidance of a surgical procedure.
a pleuro-pericardial window, usually between the lateral or left posterior
pericardium and the left pleura. The indication is relapsing PEff with
6.3.2.5. Pericardial fluid analysis, pericardial and epicardial biopsy haemodynamic compromise despite conservative treatment or percutan-
Percutaneous pericardial access may be used also to provide fluid samples eous drainage. The pleuro-pericardial window is meant to promote drain-
for pathological and pathogen examinations (bacterial or viral aetiology), age from the pericardium to the left pleural space.1 Such a window may be
and/or to perform pericardial as well as epicardial biopsies, particularly created by a small thoracotomy or endoscopically. In selected cases, a
in cancer screening (see Supplementary data online, Table S7).1 pericardial window can also be created in the peritoneal cavity.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3995
6.4.2.3. Pericardiectomy critical regions, such as the posterior pericardium, may also preclude
Pericardiectomy is the mainstay treatment for chronic constriction or complete resection. In some patients, persistent heart failure symptoms
CP not responding to anti-inflammatory therapy.311 Complete pericar- and progressive functional deterioration may occur despite maximal
diectomy is recommended for the management of CP, as it offers su- medical therapy and attempted pericardiectomy. In these cases, heart
perior long-term outcomes and significantly reduces the risk of transplantation might be considered.
recurrences compared with partial anterior or anterophrenic pericar- It is also an option when coexistent myocardial disease or a mixed con-
diectomy, which may leave residual constrictive tissue and contribute strictive–restrictive physiology is present, where pericardial resection
to persistent or recurrent symptoms. Due to the relative rarity of would not be expected to improve symptoms or haemodynamic function.
the condition, and the complexity of patients, pericardiectomy should In CP, tricuspid regurgitation (TR) is a common finding due to chron-
be performed at high-volume centres that have the required expertise. ic elevated right-sided pressures, annular dilation secondary to long-
Early pericardiectomy within 6 months after the onset of symptoms is standing volume overload and atrial enlargement, tethering of leaflets
associated with the lowest operative mortality.312,313 The occurrence of due to pericardial constraint. When TR is present in patients undergo-
refractory RP and/or pericardial fluid formation, despite optimal medical ing pericardiectomy, leaving the valve unrepaired can lead to persistent
and interventional therapy, is also considered a possible indication for right HF symptoms (e.g. oedema, ascites, fatigue), poorer functional re-
surgical pericardiectomy. In the absence of a surgical plane for proper de- covery post-operatively, and higher long-term mortality, as shown in
cortication, a pragmatic approach, named the waffle procedure, can be retrospective observational studies. During pericardiectomy, the tri-
considered. This technique utilizes longitudinal and horizontal incisions cuspid valve is accessible, and repair (usually annuloplasty) can be safely
to allow some relief of constriction. However, it usually offers only tem- performed with minimal added risk—especially when CP surgery is
porary improvement, with a high rate of recurrent constriction.314,315 done under CPB. Thus, repair is recommended when TR is more
Extracorporeal circulation may be required in difficult operative condi- than mild, and anatomy is suitable, and the patient is already undergoing
tions, such as extensive calcifications with a high risk of marked bleeding pericardiectomy (i.e. no added surgery is required beyond access).
during pericardiectomy. Previous 2015 ESC guidelines recommended re- Supporting evidence is limited. While RCTs are lacking, the recommen-
section ‘of as much as possible’ of the pericardium with avoidance of car- dation is based on retrospective findings showing improved symptom
diopulmonary bypass (CBP), using this only in circumstances of difficult relief and outcomes with combined surgery, and surgical principles in
control of bleeding.1 Cardiopulmonary bypass can play an important valve disease management but also the practicality and safety of valve
role in enabling safe and complete pericardiectomy, particularly in se- repair when the chest is already open.311
lected complex or high-risk cases. Contraindications for pericardiectomy may include severe hepatic
Pericardiectomy is commonly performed without CPB. However, dysfunction with cirrhosis and ascites, uncontrolled infection or sepsis,
CPB may be necessary in specific clinical scenarios. These include and other life-limiting diseases. In some situations, advanced therapy,
dense adhesions between the pericardium and the myocardium, such as HT, might be the only solution due to unfeasible cardiac decor-
particularly involving the posterior surface of the heart. CPB is tication, because of extensive calcifications or a high risk of cardiac and
also indicated in cases of haemodynamic instability during dissection. major vascular injury during pericardiectomy (for predictors of out-
This is especially relevant when heart lifting is required to access the comes after pericardiectomy see also Supplementary data online,
diaphragmatic or posterior pericardium. Additional indications Table S8 and Section 3.2).
include calcific constrictive pericarditis with myocardial involve-
ment, challenging anatomical conditions, or the need for concomi- Recommendation Table 13 — Recommendations for
tant cardiac procedures, such as valve surgery or coronary artery surgical therapy (see Evidence Table 13)
bypass grafting.
Possible benefits of CPB include providing a bloodless field and im- Recommendations Classa Levelb
proved visibility for complete pericardial resection, especially posterior-
Surgical pericardiectomy is recommended in patients
ly, avoiding myocardial injury by decompressing the heart during
with chronic pericardial constriction or persistent
dissection, maintaining haemodynamic stability, particularly in patients I C
constrictive pericarditis despite medical therapy to
with borderline cardiac output or tamponade physiology. However,
improve symptoms and survival.312,313
the full heparinization required to perform CPB may, in some cases,
Tricuspid valve repair is recommended in patients
favour bleeding generated by pericardial resection. Therefore, the
with pericardial constriction and severe tricuspid
indication for the use of CPB must always be taken into consideration I C
valve regurgitation to improve symptoms and
intra-operatively and according to the anatomical as well as haemo-
survival.316
dynamic conditions encountered during the surgical procedure. It is,
however, self-explanatory that a radical pericardiectomy, including aClass of recommendation.
also the posterior site of the pericardium, would be usually possible bLevel of evidence.
and advisable with the application of CPB. However, diaphragmatic
pericardial resection may often be performed without CPB use, taking 6.5. Management of arrhythmias and
care to perform resection in a stepwise manner, without prolonging
prevention of sudden cardiac death in
heart lifting and avoiding marked haemodynamic compromise.
myocarditis
Heart transplantation is very rarely indicated in patients with CP.
However, it may be considered as a last-resort option in highly selected, Patients with myocarditis are known to be vulnerable to life-threatening
exceptional cases. This applies when pericardiectomy is not feasible or arrhythmias, and careful observation and management of patients ac-
cannot be completed due to extensive pericardial calcification with myo- cording to the risk stratification is needed. In the 2022 ESC Guidelines
cardial involvement, prior surgeries, radiation therapy, or infections that for the management of patients with ventricular arrhythmias and the pre-
have caused severe adhesions and scarring. Surgical inaccessibility of vention of sudden cardiac death, significant attention was paid to active
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

3996 E S C G u id e l in e s
and chronic myocarditis.58 In addition to these guidelines, our aim is to WCD in myocarditis
provide a special focus on several selected scenarios.
A WCD should be considered for 3–6 months in
patients with sustained ventricular arrhythmia during
6.5.1. Role of active devices (wearable and implanted IIa C
the acute phase of myocarditis as a bridge to
devices) in acute myocarditis recovery.323,325,327–330
In AM, AVB may be reversible, and temporary pacing is often necessary in
Ablation in myocarditis
cases of haemodynamic compromise as a bridge to recovery.317 In this
Catheter ablation, performed in specialized centres,
setting, temporary transvenous external pacing with an active lead can
should be considered in post-myocarditis patients
be used for patients who require prolonged temporary pacing.86,318–
with recurrent symptomatic SMVT or ICD shocks in IIa C
320 In the absence of recovery within a clinically reasonable period, defini-
whom AAD are ineffective, not tolerated, or not
tive cardiac pacing is usually necessary in patients with persistent high-
desired.58
degree AVB. In patients with LV dysfunction needing frequent ventricular
pacing, CRT or conduction system pacing may be helpful.86,321 ICD in myocarditis
Permanent pacemaker placement can be considered in patients with Secondary prevention
AM for persisting high-degree AVB despite medical therapy. ICD implantation is recommended in patients with
Sustained VA in the context of AM is a rare phenomenon,79 yet it non-activec myocarditis and haemodynamically
I C
poses a substantial risk of recurrence, persisting even after resolution not-tolerated sustained VT to prevent
of the acute phase. Studies indicate a high recurrence rate ranging SCD.78,79,322,336
from 28% to 60%, which appears higher in patients with monomorphic ICD implantation should be considered in patients
VT, chronically active myocarditis, anteroseptal LGE, and reduced with non-activec myocarditis and haemodynamically IIa C
LVEF.71,79,89,222,322–325 In myocarditis patients, polymorphic and irregular tolerated sustained VT to prevent SCD.78,79,322,336
VA are more common during the active inflammatory phase, whereas
ICD implantation may be considered in patients with
monomorphic and regular VA are associated with healed myocarditis
acute myocarditis and sustained VA (VT/VF) in the IIb C
and scars.79,83,325 An arrhythmic presentation may raise suspicion of an
acute phase to prevent SCD.71,79,89,222,323–325
underlying inherited CMP.95 GCM is associated with a high risk of life-
threatening VA and ICD implantation can be considered.326 The use of Primary prevention
a wearable cardioverter-defibrillator (WCD) is feasible in selected pa- ICD implantation may be considered in patients
tients with AM at higher risk of VA, when waiting for recovery or with with myocarditis after the acute phase (3–6 months)
IIb C
a temporary contraindication for ICD.327–330 The resolution of inflam- and persistent risk factors for VAd to prevent
mation does not necessarily indicate the absence of risk, because myo- SCD.89,332–334,336.
cardial fibrosis may constitute an arrhythmogenic substrate,
AAD, anti-arrhythmic drugs; CMR, cardiovascular magnetic resonance; ICD, implantable
predisposing a patient to VA long after the acute episode. On this basis,
cardioverter-defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular
arrhythmia risk stratification should be performed in patients with per- ejection fraction; NSVT, non-sustained ventricular tachycardia; PVS, programmed
sistent LGE after the acute phase.325 In patients with prior myocarditis, ventricular stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic
ventricular tachycardia; VA, ventricular arrhythmias; VF, ventricular fibrillation; VT,
sustained or non-sustained VT during an exercise test performed
ventricular tachycardia; WCD, wearable cardioverter-defibrillator.
6 months after the acute episode was found to be more common among aClass of recommendation.
those with an arrhythmic presentation, and was associated with subse- bLevel of evidence.
quent adverse events, including malignant VA.331 Late gadolinium en- cNon-active based on CMR evidence of activity (T2), see Figure 4. dNSVT, extensive LGE, unexplained syncope, positive PVS, reduced LVEF <50%.
hancement was also identified as a significant predictor of adverse
events, including malignant arrhythmias, irrespective of LVEF, especially
in an anteroseptal location.332–334 Implantable loop recorders can be use-
7. Prognosis
ful for early detection of VA in selected patients.89 Details regarding oral
anticoagulation can be found in the 2019 ESC Guidelines for the manage- The current literature focuses on the single condition, but one could
ment of patients with supraventricular tachycardia, the 2022 ESC expect that a patient with concomitant involvement of the myocardium
Guidelines for the management of patients with ventricular arrhythmias and pericardium will have a worse prognosis. However, current pub-
and the prevention of sudden cardiac death, and the 2024 ESC lished evidence suggests that patients with uncomplicated pericarditis
Guidelines for the management of atrial fibrillation.58,260,261 and myopericarditis have a good overall prognosis, despite combined
involvement of the pericardium and myocardium.4,337 The TF expects
Recommendation Table 14 — Recommendations for
that the introduction of the term IMPS will increase awareness and will
management of arrhythmias and prevention of sudden
lead to dedicated studies in this regard.
cardiac death in myocarditis (see Evidence Table 14)
Recommendations Classa Levelb 7.1. Complications and outcomes for
myocarditis
Pacing in myocarditis
One of the main prognostic factors is the initial clinical presentation of
Temporary transvenous external pacing should be
myocarditis (Figure 8). Low-risk myocarditis (about 75% of unselected
considered in patients with acute myocarditis and
IIa C c a s e s ) u s u a l l y h a s a c h e s t p a i n p r e s e n t a t io n w i t h p r e s e r v e d biventricular
high-degree conduction disorders as a bridge to
function, and an overall benign short- and long-term prognosis.28 Acute
recovery.86,317,335
complicated myocarditis with arrhythmic presentation, and especially
Continued HF presentation, has a worse prognosis.56 There is conflicting evidence
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3997
on the role of sex in the prognosis of IMPS.73 Women seem to have a present with acute HF symptoms, and frequently progress to
more favourable prognosis than men in myocarditis.338 Young age and a chronic HF.342
previous myocarditis were independent relapse predictors. Fulminant Arrhythmias during myocarditis range from mild conduction ab-
onset, lower LVEF at presentation, distinct autoimmune features, espe- normalities to life-threatening VT or VF, requiring medication and/
cially in women, and high-titre organ-specific anti-heart autoantibodies or device therapy (refer to Section 6.5). The risk of VA is independent
and antinuclear autoantibodies were independent predictors of death of LVEF.83,343
and HT.73 Genetic predisposition may also increase the risk (see Myocarditis may have a significant mortality. Initial complicated
Section 5.3). presentation and histological subtype predict the risk. Outcomes
The aetiology also plays a relevant role, e.g. EM, GCM and CS are are worse in patients with FM, with a reported mortality at 60 days
associated with a worse prognosis (Sections 9.2–9.4). Outcomes are of 24%.56,73 Mortality also depends on the underlying cause of FM.
worse in patients with FM, in the case of late diagnosis and delayed In a study of GCM survivors beyond 1 year, the combined rate of
interventions.57 Factors associated with increased mortality or HT death, HT, VAD implantation, or GCM recurrence was 47% at
are GCM, QRS duration of >120 ms on initial ECG, or the need 5 years.344 Reported in-hospital mortality and long-term outcomes
for temporary MCS other than IABP.56 Biventricular dysfunction after an episode of AM vary.345 In a multicentre registry of patients
has been described as the main predictor of death or HT in with AM, complicated AM occurred in 27%, including 9% cases of
myocarditis.63,66,73 FM. In-hospital mortality was 8.5%, compared with 0% in uncom-
Multimodality imaging contributes to the assessment of prognosis. plicated cases. Heart transplantation or LVAD was required in
For example, myocarditis patients with normal CMR have a good 3% and 4% of patients, respectively. Heart transplantation or death
prognosis.339 Late gadolinium enhancement on CMR at initial presen- occurred in 18% of complicated cases after 5 years. Recurrences
tation is an important prognostic finding.340 In a multicentre study or VA occurred in approximately 3%–9% of cases over a period
with AM and preserved EF, the presence of anteroseptal LGE in of 19–90 months.28 In the recently reported contemporary ESC
the mid-wall layer was the best independent predictor of the com- multicentre myocarditis registry of 581 patients with myocarditis,
bined endpoint of cardiac death, appropriate ICD interventions, re- 2.7% of patients died, 1.7% received a HT, 0.7% underwent VAD
suscitated cardiac arrest, and hospitalization for HF [odds ratio implantation, and 3.9% underwent ICD implantation at 1-year
(OR) 2.73; 95% confidence interval (CI) 1.2–5.9; P = .01]. At a median follow-up.62,63,73
follow-up of 4.3 years, 7.7% of these patients reached the combined
endpoint.3 Anteroseptal LGE was the best independent predictor
7.1.2. Follow-up
of SCD [hazard ratio (HR) 4.59; 95% CI 1.38–15.24; P = .01].
Patients with low-risk myocarditis with chest pain presentation can be
Myocardial fibrosis was present in 95% of patients with SCD, com-
pared with 41% in patients without SCD.341 Additionally, major ar- discharged when cardiac enzymes tend towards normalization. Time
to recovery in AM varies from a few days to a few months. Relapses
rhythmic onset (sustained VT or VF), presence of fibrosis at EMB,
occur in about 10% of cases, with a 1-year recurrence rate of around
and induction of major VA on PVS all predicted major arrhythmic
events.63,73,255
5%.10,73,346
Follow-up is recommended in all patients with myocarditis, with
In another study, including patients with AM and life-threatening
clinical assessment, ECG, Holter-ECG registration, exercise test (if
arrhythmias, positive LGE in two or more myocardial segments
no signs of ongoing inflammation), echocardiography, and CMR within
and absence of oedema on initial CMR were associated with an in-
at least 6 months after the index hospitalization (see Table 15).10,62
creased risk for recurrent major arrhythmic events, including SCD
The prognosis is determined by baseline and 6-month LV function, re-
[HR 4.51 (95% CI 2.39–8.53) and HR 2.59 (95% CI 1.40–4.79),
respectively].71 gardless of the initial clinical presentation.62,63,73 Cardiovascular mag-
netic resonance should be performed at least within the first
Large studies are needed in the future to develop a risk stratification
6 months in patients with definite myocarditis to guide the timepoint
with a high negative predictive value for SCD and the need for ICD im-
for return to work, based on the individual case.
plantation. Variables for risk stratification for the progression to DCM
It is generally accepted to wait 3–6 months after an acute episode
are given in Supplementary data online, Table S9.
of myocarditis to evaluate the need for an ICD. In some patients at
high risk for VA (see Section 6.5.1),71 a WCD should be considered
7.1.1. Sequela and mortality in myocarditis during follow-up as a bridge to recovery.58 Subsequently, after
The main long-term complications are evolution to DCM with sub- 3–6 months of follow-up, the decision on whether or not to implant
sequent HF and (recurrence of) VA, including SCD.76 LVEF recov- a definitive ICD is based on the individual patient, with increasing in-
ery after myocarditis can be complete or partial. Recovery rates dication based on risk factors including genetic predisposition (see
vary from 50% to 94% depending on the initial presentation.74 Section 5.3, Section 6.5.1; see Figure 17). In patients presenting with
These patients usually have a gradual deterioration of LVEF and symptomatic VA, or heart block in GCM or CS, early consideration
subsequent dilation and might remain unrecognized and asymp- of an ICD is warranted.58 Recommendations concerning arrhythmias
tomatic until development of overt HF. Myocarditis can cause and SCD in specific forms of myocarditis are discussed in Section 6.5.58
about 10% of DCM.66 Patients with B19V AM present most often In uncomplicated cases, a follow-up at 6, 12, and 24 months is suffi-
with an infarct-like syndrome, and may have a favourable long-term cient, while it should be prolonged and be lifelong in complicated cases
prognosis,342 but there is evidence describing cases with severe or with residuals.
fatal outcomes.228 In contrast, patients with HHV-6 myocarditis See Supplementary data online, Section 8 for patient communication
(and especially those with B19V and HHV-6 co-infection) usually advice.
Downloaded
from

by
guest
on
22
January
2026

3998 E S C G u id e l in e s
Recommendation Table 15 — Recommendations for prognostic markers in this setting with an infarct-like presentation and
risk stratification, complications, and outcomes of in- preserved biventricular function.4,35
flammatory myopericardial syndrome (see Evidence In the real world, approximately 25% of patients diagnosed with AP
Table 15)
present with at least one predictor of poor prognosis and require hos-
pitalization.130 The in-hospital mortality rate for AP is around 1% on
Recommendations Classa Levelb
average, but can be higher in older patients and those with severe
Follow-up with clinical assessment, biomarkersc, co-infections.23
ECG, exercise test, Holter-ECG monitoring, According to the clinical presentation, additional diagnostic work-up
echocardiography, and CMR at least within 6 months should be performed only for a specific clinical suspicion, the presence
I C
after the index hospitalization is recommended in all of high-risk features, or a lack/incomplete response to empirical anti-
inflammatory therapy (Table 16).
patients with myocarditis to identify a potential
progression or new risk factors.62 The usual course of AP is characterized by clinical remission
after medical therapy within 4–6 weeks. The most common and
Long-term follow-up is recommended for patients
problematic complication of pericarditis is RP, which affects
with complicated myocarditisd to identify a potential I C
20%–30% of patients not treated with colchicine. About 10% of
progression or new complications.28,74
patients may present with continued symptoms without clinical re-
Long-term follow-up is recommended for patients
mission. Such cases have been labelled as ‘incessant’, and may dir-
with incessant or recurrent pericarditis to identify a I C ectly progress to constriction in few months,104 while this
potential progression and new complications.104,347 complication is extremely rare in idiopathic RP.114,347 A course
with multiple recurrences is possible, but not usual in simple pre-
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram.
aClass of recommendation. sumed viral pericarditis, and should prompt a search for an under-
bLevel of evidence. lying cause (Figure 14).
cAt least troponin.
Cardiac tamponade is relatively rare in AP, as well as CP (<1% of
dSee definition of complicated myocarditis in Table 3.
cases). The risk for complications is related to the aetiology. For in-
stance, the risk of CP is low after presumed viral/idiopathic pericarditis,
intermediate for immune-mediated aetiologies, as well as PCIS and neo-
7.2. Complications and outcomes for
plastic pericarditis (2%–5%), and high for bacterial pericarditis (20%–
pericarditis 30%), especially if purulent.347
At least three scores43,44,348 have been proposed recently to iden-
Risk stratification of patients with pericarditis must be performed at the
tify patients at increased risk of developing complicated pericarditis
initial presentation at the emergency department or in an ambulatory
setting. Admission is recommended in high-risk cases.105,130 and chronicity, requiring close follow-up (see Supplementary data
online, Tables S2 and S3). However, these scores have not been va-
Non-high-risk cases can be managed as outpatients with a close follow-
lidated or replicated in additional larger studies, and remain
up within 1 to 2 weeks (Figure 7). ECG changes (mainly widespread
investigational.
ST-segment elevation) and troponin elevation were usually not negative
Table 15 Follow-up in inflammatory myopericardial syndrome after discharge
Within 1 month Within 3–6 months 12 months >1 year and long-term FUa
Clinical evaluation and ECG Myocarditis X X X X
Pericarditis X X X X
Biomarkers (TnI, C-reactive protein) Myocarditis X X (X) (X)
Pericarditis X X (X) (X)
Rhythm Myocarditis – X (X) (X)
(stress and/or Holter-ECG) Pericarditis – – – –
Imaging myocarditis TTE Xb Xc Xc
CMR Xb Xc Xc
Imaging pericarditis TTE Xb Xc X
CMR (X)b (X)d (X)d
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; FU, follow-up; IMPS, inflammatory myopericardial syndrome; TnI, troponin I; TTE, transthoracic echocardiography.
All follow-ups should be adapted to the clinical situation and severity. In round brackets, optional testing according to clinical presentation [(X), case-by-case decision].
aA long-term FU, e.g. after 2 years, is suggested only for complicated cases of IMPS, usually myocarditis.
bIn complicated cases or if abnormal at 1 month, imaging should be repeated between 3 and 6 months.
cIf abnormal at 6 months, imaging should be repeated within the next 6 months and/or in the next 12 months.
dFollow-up proposed for uncomplicated cases of acute pericarditis. Long-term follow-up, tailored to the single patient, is recommended for high-risk cases.
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 3999
(cid:141)(cid:15)(cid:14)(cid:23)(cid:18)(cid:20)(cid:23)(cid:11)(cid:30)(cid:25)(cid:12)(cid:3)(cid:21) (cid:16)(cid:15)(cid:14)
(cid:27)(cid:17)(cid:23)(cid:30)(cid:21)(cid:24)(cid:17)(cid:6)(cid:21)(cid:30)(cid:28)
(cid:31)(cid:11)(cid:19)(cid:17)(cid:30)(cid:26)(cid:18)(cid:10)(cid:23)(cid:9)(cid:8)
(cid:31)(cid:12)(cid:12)(cid:25)(cid:27)(cid:25)(cid:17)(cid:19)(cid:18)(cid:10)(cid:23)
(cid:30)(cid:25)(cid:20)(cid:5)(cid:23)(cid:4)(cid:18)(cid:24)(cid:27)(cid:17)(cid:30)(cid:20)(cid:18)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:30)(cid:27)
(cid:26)(cid:28)(cid:25)(cid:29)(cid:24)(cid:23)
(cid:22)(cid:28)(cid:21)(cid:21)(cid:28)(cid:20)(cid:19)(cid:18)(cid:17)
(cid:31)(cid:24)(cid:13)(cid:27)(cid:21) (cid:14)(cid:25)(cid:20)(cid:24)(cid:29)(cid:18)(cid:30)(cid:3)(cid:21)(cid:23)(cid:18)(cid:19)(cid:12)(cid:23)(cid:21)(cid:18)(cid:30)(cid:10)(cid:28) (cid:1)(cid:17)(cid:10)(cid:10)(cid:17)(cid:127)(cid:129)(cid:13)(cid:22)
(cid:26)(cid:28)(cid:17)(cid:24)(cid:18)(cid:30)(cid:12)(cid:25)(cid:27)(cid:25)(cid:20) (cid:30)(cid:25)(cid:20)(cid:5)(cid:23)(cid:20)(cid:27)(cid:30)(cid:18)(cid:27)(cid:25)(cid:2)(cid:24)(cid:18)(cid:27)(cid:25)(cid:17)(cid:19) (cid:30)(cid:25)(cid:20)(cid:5)(cid:23)(cid:20)(cid:27)(cid:30)(cid:18)(cid:27)(cid:25)(cid:2)(cid:24)(cid:18)(cid:27)(cid:25)(cid:17)(cid:19)
(cid:31)(cid:30)(cid:30)(cid:29)(cid:28)(cid:27)(cid:29)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:30)(cid:21)(cid:20)(cid:21)(cid:19)(cid:27)(cid:18)(cid:27)(cid:25)(cid:17)(cid:19) (cid:7)(cid:21)(cid:24)(cid:17)(cid:6)(cid:21)(cid:30)(cid:28)
(cid:143)(cid:21)(cid:12)(cid:25)(cid:24)(cid:18)(cid:10)(cid:23)(cid:27)(cid:29)(cid:21)(cid:30)(cid:18)(cid:22)(cid:28)
Figure 17 Follow-up and risk stratification after acute myocarditis with arrhythmic presentation. ICD, implantable cardioverter-defibrillator; LGE,
late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; PVS, programmed
ventricular stimulation; WCD, wearable cardioverter-defibrillator. Rarely for a high risk, cardioverter-defibrillator implantation may be considered be-
fore discharge (see text for detailed discussion). aAdditional risk factors (at least 1, increasing risk and indication with >1 or more): NSVT, extensive
LGE, unexplained syncope, positive PVS, reduced LVEF of <50%.327–329
Table 16 Indicators of non-viral aetiologies and 8. Inflammatory myopericardial
complications (high-risk features or red flags in acute
pericarditis) syndrome overlapping types:
myopericarditis and
Major
perimyocarditis
Fever >38°C (HR 3.56)
Subacute onset (HR 3.97) IMPS includes a spectrum of inflammatory diseases from isolated myo-
Large pericardial effusion (>20 mm on echocardiography) (HR 2.15) carditis to isolated pericarditis through a combination of both. IMPS
Cardiac tamponade (HR 2.15) should be used as an umbrella term, also covering overlapping forms
of myocarditis and pericarditis.1 The diagnosis of predominant pericar-
Lack of response to aspirin or NSAID after at least 1 week of therapy
ditis with myocardial involvement, or ‘myopericarditis’, can be clinically
(HR 2.50)
established if patients with definite criteria for AP show elevated bio-
Minor markers of myocardial injury, without newly developed focal or diffuse
impairment of LV function on TTE or CMR. The term myopericarditis
Pericarditis associated with myocarditis
indicates a primarily pericarditic syndrome with minor myocardial in-
Immunodepression
volvement, which describes the majority of combined pericarditis and
Trauma
myocarditis cases encountered in clinical practice. On the other
Oral anticoagulant therapy hand, evidence of new-onset focal or diffuse reduction of LV function
in patients with elevated myocardial biomarkers, and clinical criteria
HR, hazard ratio; NSAID, non-steroidal anti-inflammatory drug. Major features have been validated
in multivariable analysis in a prospective cohort study of patients with acute pericarditis.105 for AP, suggests predominant myocarditis with pericardial involvement,
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4000 E S C G u id e l in e s
termed ‘perimyocarditis’. The clinical management and outcomes of mediated by autoimmune mechanism, myocardial damage can be also
mixed forms follow the predominant involvement. At present, patients caused by microthrombotic phenomena.360,361
with myopericarditis can be treated as patients with pericarditis, while
patients with perimyocarditis should be managed as patients with pure 8.1.4. Sjögren’s syndrome
myocarditis. The knowledge in the field is rapidly evolving and ongoing
In Sjögren’s syndrome, the most common clinical manifestation of cardiac
trials and evidence will provide more updated guidance for clinical
damage is pericarditis, which has been reported in less than one-third of
management. cases. Myocarditis and myocardial fibrosis are also possible,362 and may
A common scenario with overlapping forms of myocarditis and peri-
occur associated with rhythm disturbances. Specific antibodies
carditis is represented by systemic immune disorders, which can affect (anti-Ro/SSA) could also be identified in unexplained heart blocks.363
either the myocardium or pericardium, or both.
Several systemic inflammatory and autoimmune diseases may present
8.1.5. Systemic sclerosis
with myocarditis, pericarditis, mixed forms, or PEff without pericarditis.
Inflammatory myopericardial syndrome is frequent in SSc,364 often clin-
Main conditions include RA, SLE, Sjögren’s syndrome, SSc, polymyositis
ically occult and, when symptomatic, the prognosis is poor. It may be
and dermatomyositis, and vasculitis (e.g. particularly EGPA).
related to ventricular dysfunction and/or structural damage of the
microvascular bed, leading to repeated focal ischaemic injuries and irre-
8.1. Inflammatory myopericardial
versible myocardial fibrosis. It can be also due to a primary systemic
syndrome in systemic disorders myositic disease.349,365 Damage usually follows two pathways.366 The
Inflammatory myopericardial syndrome may complicate several types first one is linked to the production of collagen by activated fibroblasts
of systemic diseases, generally immune-mediated,349,350 either with at the myopericardial level, especially at the subepicardial level, with
myocardial (myocarditis) or pericardial involvement (pericarditis and/ consequent fibrosis, valve stenosis, coronary spasms, and ischaemic
or PEff). Symptoms and signs that may raise the suspicion of a rheum- events. The second pathway is caused by renal and pulmonary involve-
atic autoimmune disease are family history, history of low-grade fever, ment, with severe cardiac consequences.367,368 Further research is
joint symptoms, dry eyes and mouth, headache, lymphadenopathy, needed to improve the understanding of IMPS in SSc.364
Raynaud phenomenon, skin rash, oral and genital aphthae, deep or
superficial vein thrombosis, recurrent foetal losses, lymphopenia, and 8.1.6. Polymyositis and dermatomyositis
chronic increase of CK and other inflammatory markers. Targeted
The myocardium can be affected in inflammatory myopathies, such as
therapy should be applied, if a specific diagnosis is reached during the polymyositis and dermatomyositis,369 with consequent myocardial
diagnostic work-up.
hypertrophy, ischaemia, cardiac enlargement, and systolic and diastolic
ventricular dysfunction.370 Cardiac involvement in inflammatory myop-
8.1.1. Rheumatoid arthritis athies is clinically occult in most patients, but may be suspected by multi-
Pericarditis can be seen as part of the inflammatory activity in RA, and is modality imaging371,372 and is related to poor outcome.370,372
often present concurrently with pleuritis. It is the most common cardiac Myocarditis occurs in up to 30% of autopsied patients, with or without
manifestation, affecting up to 50% of patients, as detected on post- concomitant coronary or vessel vasculitis. Pericarditis is rarely reported
mortem examination. Myocarditis may also be present, and generally re- in these patients.
solves if the disease is controlled.351 Anakinra, already registered for the
treatment of RA, can be used also for related pericardial involvement. 8.1.7. Vasculitis
Myocardial involvement is prognostically relevant in vasculitis, particu-
8.1.2. Systemic lupus erythematosus larly EGPA. In EGPA, about 15%–60% of patients present with cardiac
Pericarditis is the most common cardiac manifestation of SLE, reported disease350 including PEff, conduction disturbances, and motion abnor-
in approximately 25% of patients, and it is included in the American malities, as well as ACS, often due to coronary spasm, and EM (see
Rheumatism Association/American College of Rheumatology (ARA/ Section 9.2). While cardiac involvement in EGPA often occurs early, it
ACR) classification criteria.352 Myocardial involvement in SLE affects can be late in the course of the disease, and mainly affects anti-
about 5% of patients.353,354,355 Symptoms of IMPS are often non- neutrophil cytoplasmic antibody (ANCA)-negative patients with high
specific, including elevated troponin, alterations on the ECG, LVEF ab- eosinophil counts. Myocardial and pericardial involvement is also pos-
normalities, and PEff. These manifestations are usually associated with sible in other vasculitis, especially in Kawasaki’s disease, where myocar-
typical symptoms of SLE, including fever, arthritis, nephritis, and skin ditis is a common cardiovascular complication (see Supplementary data
rashes.356,357 The diagnosis can be supported by specific laboratory online, Figure S3).373
markers, as well as multimodality imaging, to guide the therapy.358,359 Cooperation with specialists is important in all these systemic condi-
Endomyocardial biopsy could be rarely considered in selected cases.349 tions to reach the correct diagnosis and to plan appropriate treatment.
Cardiac tamponade occurs in less than 2% of cases, and CP is extremely The diagnosis of EGPA may be particularly challenging.349
rare. Cardiomyopathy is uncommon clinically, but autopsy studies
found myocardial involvement in 40%–50% of patients. 8.2. Inflammatory myopericardial
syndrome in COVID-19 disease
8.1.3. Antiphospholipid syndrome The COVID-19 pandemic raised the awareness of IMPS, as in many pa-
Antiphospholipid syndrome is associated with the presence of tients the myocardium as well as the pericardium were affected. It is not
anti-cardiolipin and/or anti-β -glycoprotein antibodies, and/or lupus proven whether the SARS-CoV-2 virus can directly damage cardiomyo-
2
anticoagulant, and may be the cause of myocardial dysfunction through cytes or pericardiocytes, as it was suggested in cultivated human cardi-
various mechanisms. While myocarditis can manifest in this syndrome, omyocytes.374 Autopsy studies could only detect small amounts of virus
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4001
in the myocardium and pericardium.375–379 The true estimate of 9.2. Eosinophilic myocarditis
COVID-19-associated IMPS is variable depending on CMR/
Eosinophilic myocarditis is a rare form of myocarditis, characterized by
EMB-derived diagnosis ranging from 0.1–4.5/1000 cases380,381 up to
eosinophilic infiltration of the myocardium. Underlying disorders that
2%–8% of cases in symptomatic patients.382 Symptoms as well as diag-
should be evaluated during the work-up of EM include: hypersensitivity
nostic work-up are similar to those described for general IMPS (see and allergic reactions;271 immune-mediated disorders, in particular
Sections 4 and 5).
EGPA; undefined complex HES or its myeloproliferative variant; para-
The predominant management of symptomatic complicated sitic infections; and cancer.349 A meta-analysis of single cases or small
SARS-CoV-2-related IMPS is antiviral treatment for SARS-CoV-2 virus
case series reported a rate of in-hospital death of up to 22%, and a sig-
together with supportive therapy. Several immunosuppressive therap-
nificantly increased occurrence of the hypersensitivity form, up to
ies, such as anti-IL-1 (anakinra and canakinumab) and anti-IL-6 (tocilizu- 36%.271
mab and sarilumab), have demonstrated promising results in critically ill
patients hospitalized for COVID-19.383–385 In less severe cases, the key
9.2.1. Presentation
elements for treatments are those recommended for IMPS. More de-
tails can be found in Supplementary data online, Section 5.1.2. The clinical presentation of EM can be variable, ranging from oligosymp-
tomatic to acute FM, or chronic RCM (Loeffler CMP or endomyocar-
ditis).271 Nevertheless, prior study demonstrates that EM often has a
9. Specific types of myocarditis
fulminant presentation with abrupt impairment of LVEF, a high risk of
malignant arrhythmias, and a high risk of thromboembolic complica-
9.1. Lymphocytic myocarditis
tions, related to the formation of ventricular thrombi.271 Although
The diagnosis of LM is based on pathological criteria and reflects an in- EM is often accompanied by peripheral eosinophilia, it should be noted
flammatory disease that may be caused by viruses, but also by other in- that this finding is absent in up to 25% of patients with EM, and may con-
fectious agents, including bacteria (such as Borrelia spp.) and protozoa tribute to the underdiagnosis of EM.
(such as T. cruzi).10 Furthermore, contemporary single-centre and multi-
centre cohort studies suggest that LM is more commonly non-infectious
9.2.2. Diagnosis
or immune-mediated/autoimmune.63,73 It is important to note that the
The diagnosis of EM can be established by either the EMB-proven pres-
aetiopathogenesis and outcome of viral LM varies considerably, based
ence of eosinophilic infiltration of the myocardium, or the presence of
on the different infections. Cytolytic viruses, such as enteroviruses (e.g.
CMR-proven myocarditis with pathognomonic findings associated with
coxsackieviruses and echoviruses), destroy cardiomyocytes and induce
severe infiltration by macrophages and lymphocytes.386 In contrast to en- peripheral eosinophilia (Supplementary data online, Figure S3).
Furthermore, general clinical signs related to EGPA or HES disorders
teroviruses, vasculotropic B19V, which infects cardiac endothelial cells,
should be evaluated, such as an increased number of eosinophilic cells,
but not cardiomyocytes, can also induce severe LM, especially in young
children.228,387 High viral copy numbers (>500 viral DNA copies/µg of history of asthma and sinusitis, and characteristic skin lesions. Left ven-
tricular function may be preserved, and DCM can occur, but often the
cardiac DNA) were found to be associated with cardiac inflammation
and/or systemic infection.228,388 Low B19V DNA copy numbers in car- phenotype of RCM is present. On echocardiography, a typical finding is
Loeffler endocarditis. In the diagnostic work-up, systemic screening for
diac tissue rather reflect virus persistence, and are usually not related
the above-mentioned aetiologies should be carried out systematically.
to cardiac inflammation. Lymphotropic viruses of the Herpesviridae family
[HHV-6, EBV, human cytomegalovirus (CMV)], as well as HCV, influenza
viruses, and SARS-CoV-2 may indirectly trigger myocarditis by activating 9.2.3. Therapy
the immune system.389 Regarding the aetiology and pathogenesis of myo- The first-line therapy for EM is the administration of i.v. corticosteroids,
carditis, microRNAs (miRNAs) may be promising diagnostic markers, as but caution should be exercised if EM is caused by an infectious agent.
well as prognostic and therapeutic targets in myocarditis.141,390 The optimal dose and duration of corticosteroids are unclear, but it is
However, the precise role of miRNAs in myocarditis remains to be de- proposed to administer a daily i.v. bolus of corticosteroids followed by
termined.391 In addition to infectious agents, organ-specific autoimmun- dosage tapering in severe forms, while oral steroid administration (see
ity to heart autoantigens,66 different systemic immune-mediated Table 12) can be considered in patients with mild LV dysfunction.39,271
diseases, toxic substances, and drugs, including ICIs, are known to induce The identification of an EM-associated condition is crucial to administer
different forms of acute and chronic LM.66 Immune-mediated myocardi- specific treatments, such as cyclophosphamide or IL-5 inhibitors in
tis may occur with exclusive cardiac involvement or in the context of sys- EGPA-related EM,34 imatinib in the myeloproliferative variant of
temic immune-mediated diseases, such as SLE, SSc, and others.349,392 platelet-derived growth factor receptor alpha (PDGFRA)-associated
Interestingly, genetic host susceptibilities have also been linked to cardiac HES, or albendazole in Toxocara canis infection. In hypersensitivity/aller-
dysfunction following myocarditis.91,150 gic EM, first-line therapy is to withdraw the potential cause of
eosinophilia.
9.1.1. Presentation Since endocavitary thrombi were reported in 12% of EM cases, the
Since LM can be induced by various causes, there is no universal, specific use of anticoagulation during the acute phase could be considered for
clinical presentation. Instead, it must be considered in the context of the prevention of endocavitary thrombi.271
the different diseases, in line with the stages of myocarditis.
9.3. Giant-cell myocarditis
9.1.2. Diagnosis and therapy Giant-cell myocarditis is a very rare, but often rapidly progressive dis-
The diagnostic pathways were described above and vary depending on ease with a poor prognosis, with an ∼85% rate of death or HT at
the cause. The diagnostic and therapeutic approach has to follow the 3 years.56,82 The incidence of GCM was reported to range from
clinical situation and the stages as described in Section 4 (see Table 12). 0.007% to 0.051% in autopsy studies; however, this number might
Downloaded
from

by
guest
on
22
January
2026

4002 E S C G u id e l in e s
underestimate the true disease burden.393,394 Giant-cell myocarditis that the therapy should be initiated based on a strong clinical suspicion.
generally affects young and middle-aged adults without a sex predom- Historically, the survival of patients with GCM without immunosuppres-
inance. In a large multicentre registry of GCM cases, patients were aged sion was about 3 months from symptom onset to death or HT. Many
from 16 to 69 years at the time of diagnosis.82 studies have shown that immunosuppression is useful for the treatment
Giant-cell myocarditis is recognized as a non-infectious myosin-induced of GCM. Immunosuppressive therapy typically involves two or three
autoimmune form, as experimental models suggest,395 and an association drugs, including corticosteroids, and at least one, and usually two add-
with autoimmune disorders has been reported in ∼20% of cases.82 itional immunosuppressive agents (see Table 12). In GCM patients, im-
munosuppression with corticosteroid monotherapy is not associated
9.3.1. Presentation with a prolongation of transplant-free survival.82
Patients with GCM should receive the same guideline-based treat-
Early symptoms of GCM might not differ from other types of myocar-
ment for HF and arrhythmias as patients with heart disease from other
ditis and vary widely at the time of presentation. In an international
causes.12,58
registry of 63 GCM patients, HF was the presenting symptom in 75%
of cases.82 The initial manifestations might be progressive haemo- Cyclosporine is the most commonly used immunosuppressant. In
multiple retrospective and prospective studies, concomitant use of
dynamic deterioration or cardiogenic shock, intractable arrhythmias,
cyclosporine was associated with improved prognosis. Combining im-
and SCD. The condition often progresses rapidly to death, often within
munosuppressive therapy with corticosteroids and cyclosporine,
days to months. A systematic analysis including 51 patients with GCM
azathioprine, or both improved transplant-free survival on average to showed that the cumulative incidence of SCD (fatal or aborted) was
12 months, while patients treated with corticosteroids alone survived
22% at 1 year and 26% at 5 years after presentation, and the composite
incidence of SCD or VT was 41% at 1 year and 55% at 5 years.326 on average 4 months.82 A cases series of GCM reported that 1-year
transplant-free survival was 73% in patients who received corticoster-
Other early GCM manifestations include bradyarrhythmias and cardiac
oids and cyclosporine with or without muromonab-CD3, with a re-
conduction abnormalities, including complete AVB. In a study from
ported decrease of the degree of necrosis, cellular inflammation, and
Finland, 25% of individuals <55 years of age with clinically idiopathic
heart block had GCM or CS on heart biopsy.396 The presence of AM giant cells after 4 weeks of treatment.403 A systematic review of 27
studies with 43 biopsy-proven GCM cases requiring MCS showed
complicated by treatment-resistant HF or cardiogenic shock, VA, and
that the administration of immunosuppressive therapy prior to MCS
AVB should increase the clinical suspicion of GCM.
implantation was associated with significantly better survival than treat-
ment with MCS alone. Immunosuppression may reduce the severity of
9.3.2. Diagnosis
HF in these patients by preventing further autoimmune destruction of
Endomyocardial biopsy remains the gold-standard diagnostic modality the myocardium.404
for GCM and can identify these patients at an early stage.397,398 Patients
Cessation or reduction of immunosuppression is associated with
diagnosed with GCM through EMB had a shorter symptom-onset-to- GCM recurrence as long as 8 years after diagnosis.344,403
diagnosis time and milder heart damage than those diagnosed during
In a single-centre study, the risk of life-threatening VA in GCM pa-
HT.398
tients exceeded 50% at 5 years after admission. Permanent ICD effect-
The presence of multinucleated giant cells in the absence of well-
ively terminated life-threatening ventricular tachyarrhythmias, and no
organized granulomatous lesions in the myocardial biopsy specimen GCM patient with the device suffered from a SCD.326
is the hallmark of GCM. The giant cells are typically located in the inter-
Transplantation could be considered for GCM patients who fail to
stitium or around blood vessels and are characterized by their large size,
respond to GDMT and immunosuppression. A recent systematic re-
multinucleation, and cytoplasmic granules.
view and meta-analysis of 499 patients with CS and 69 with GCM
Giant-cell myocarditis is characterized by myocardial destruction
who underwent HT found that 1- and 5-year survival rates in GCM pa-
mediated by a large number of T cells, macrophages, multinucleated
tients were similar to those in transplant recipients with other HF
giant cells, and eosinophils in EMB.39 Generally, the histological diagno- aetiologies.405
sis of GCM is guided by myocyte necrosis, diffuse infiltration of inflam-
matory cells, and interstitial fibrosis.399,400 The severity of necrosis and
fibrosis in EMB predicts the outcome.401 It is important to understand Recommendation Table 16 — Recommendations for
giant-cell myocarditis (see Evidence Table 16)
that one set of non-diagnostic EMB samples does not exclude GCM.
The sensitivity of the first biopsy is 68% and increases to 93% when Recommendations Classa Levelb
the biopsy is performed up to three times. Thus, repeated EMB should
be considered when there is a high clinical suspicion of GCM.217 In a EMB is recommended in patients with suspected
single-centre case series of GCM, LGE on CMR was present in 96% GCM due to unexplained new-onset HF of up to
of cases, and its distribution correlated with the histology.401 Prompt 2 weeks associated with a normal or dilated left
EMB in the setting of suspected GCM can affect the choice of MCS, ventricle and new ventricular arrhythmias, second- I C
leading to an early listing for HT and consideration of cyclosporine-
or third-degree AVB, or failure to respond to usual
based immunosuppression.402 Administration of i.v. steroids prior to
care within 1 to 2 weeks to initiate specific
EMB may reduce the diagnostic yield of EMB. There should be an agree- treatment.402
ment in specialized centres to prioritize the evaluation of EMB, and to
Combined immunosuppressive therapy is
provide the results at least within 3 days, optimally within 8 h. I C
recommended in patients with a diagnosed GCM.217
9.3.3. Therapy AVB, atrioventricular block; EMB, endomyocardial biopsy; GCM, giant-cell myocarditis; HF,
heart failure.
As soon as GCM is suspected, immunosuppressive therapy should be in- aClass of recommendation.
itiated promptly to avoid disease progression and delay HT. It is crucial bLevel of evidence.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4003
9.4. Myocarditis in sarcoidosis not necessarily located in the same region as the 18F-FDG uptake.427
Hybrid PET-CMR may enable better detection of cardiac inflammation
Cardiac sarcoidosis is a form of inflammatory heart disease, coexisting
with systemic sarcoidosis in 5%–10% of cases,406 or rarely, in isolation. in a more comprehensive manner,440,442,443 but its availability is limited.
Both CMR and PET may be used for imaging-guided EMB.
The aetiology of sarcoidosis is not well understood, but may involve an
The intensity and extent of FDG uptake on PET is of prognostic rele-
autoimmune response after certain trigger(s) and genetic predisposition,
vance.443–449 In a meta-analysis of 37 studies of patients with CS, LGE on
which leads to the formation of non-caseating granulomas in multiple or-
gans, typically in the lungs.407 On histopathology, the granuloma consists CMR and FDG uptake on PET were both predictive of MACE (all-cause
of CD68+ macrophages, CD68+ giant cells, CD3+ T lymphocytes, and death, cardiac death and aborted SCD, VA, and HF hospitalization).
CD20+ B lymphocytes. It is characterized by inflammation, oedema, Fluorodeoxyglucose-positron emission tomography has proved to
lymphocytic infiltration, and replacement fibrosis.408 Cardiac sarcoidosis be useful in predicting and monitoring the anti-inflammatory therapy
response in sarcoidosis;204,450 however, the optimal timing for repeat-
is often subclinical, with an estimated cardiac involvement in around 25%
of cases on autopsy series in patients with sarcoidosis.409,410 ing PET studies for the assessment of treatment response is not well
established.
In addition to clinical assessment, imaging modalities should be used
9.4.1. Presentation
for the short- and long-term management of patients with CS.
Manifestations of CS may range from cardiac inflammation, conduction
system disease, frequent ectopy, tachyarrhythmia, and HF, to SCD.407
Cardiac sarcoidosis may mimic different cardiac phenotypes, including 9.4.3. Therapy
ARVC,254,411–413 DCM, and hypertrophic CMP (HCM), but may also The treatment of CS is currently not standardized, and is based on
occur in patients with normal cardiac function.414 Symptoms are non- patient-tailored assessment, often with multidisciplinary input.451
specific, and often related to arrhythmias, especially AVBs and VTs. The Treatment is targeted at controlling cardiac inflammation, myocardial
challenge is to identify patients at risk, since SCD due to malignant ar- scarring and dysfunction.13,431–436 First-line therapy includes corticos-
rhythmia is common.415,416 teroids (see Table 12).
Since resolution of conduction abnormalities with anti-inflammatory
9.4.2. Diagnosis treatment remains unpredictable, definitive cardiac pacing is usually
The diagnostic algorithm of CS is different in patients with or without needed. AVB and the need for cardiac pacing are associated with a high-
known extracardiac sarcoidosis. Pathognomonic findings in non- er risk of sustained VA, which reached 31% at 5 years in the Finnish
invasive imaging are sufficient for the diagnosis of CS in cases with registry.416,452,453 Thus, it appears reasonable to propose an ICD
known systemic sarcoidosis.417 In contrast, the diagnostic pathway in with pacing ability rather than a pacemaker in CS patients with pacing
primary CS is more challenging, but typical multimodality imaging pat- indications. The risk of VA during follow-up is high in observational
terns are usually sufficient. Cardiac sarcoidosis can manifest as abnor- studies, in patients with low LVEF,416,452,454,455 presence of LGE on
malities on ECG, echocardiography, CMR, PET, EMB, and cardiac and CMR,434,456–459 and positive PVS.456,460–464 There is a lack of data on
inflammatory blood biomarkers (see Section 5.4). Electrocardiogram the relationship between scarring extent and arrhythmia risk.
or cardiac rhythm monitoring may demonstrate conduction system ab- Positron emission tomography-computed tomography may also help
normalities (such as AVB or bundle-branch block) and arrhythmias, in- to stratify patients.465
cluding VT.418 Echocardiography may reveal regional WMA in a Heart transplantation could be considered in a subgroup of patients
non-coronary distribution, septal thinning, and ventricular aneurysms. with CS, similarly to GCM.405
Endomyocardial biopsy may be helpful in selected patients, but negative
results do not rule out CS due to potential sampling errors.419
Recommendation Table 17 — Recommendations for
Endomyocardial biopsy guided by imaging or EAM may improve the
myocarditis in sarcoidosis (see Evidence Table 17)
diagnostic yield (see Section 5.12).
Multimodality advanced cardiac imaging, such as CMR and FDG-PET, Recommendations Classa Levelb
plays an increasing role in the management of suspected CS. Overall,
compared with FDG-PET, CMR has higher sensitivity of 89%–95% vs Diagnosis
84%, respectively, but similar specificity of 78%–85% vs 82%, respect- CMR, using tissue characterization techniques, is
ively, for the diagnosis of CS.408,420–428 recommended in patients with suspected CS to
I B
On CMR, CS has a wide range of potential findings, and is often con- assess cardiac inflammation and myocardial
sidered the ‘great mimicker’ of various cardiac conditions, but the inter- involvement.408,421–425
ventricular septum is often involved408 and the ‘hook sign’429 is 18F-FDG-PET is recommended for the diagnostic
recognized to be associated with a high probability of CS. For more de- work-up, including detection of inflammation, as well
I B
tails, see Supplementary data online, Figure S3. A heavy burden of LGE is
as for follow-up and assessment of therapeutic
associated with a poorer prognosis and predisposes to VA, HF, and death response in patients with CS.426–428
in CS, and may guide clinical decision-making.430–436 Aside from LGE, the
Therapy
identification of ongoing myocardial inflammation is possible.30,437–441
ICD implantation is recommended in patients with
Fluorodeoxyglucose-positron emission tomography also allows detec-
tion of cardiac inflammation in CS.426 It requires careful patient prepar- CS and sustained ventricular arrhythmia (VT/VF) or I B
ation to suppress physiological 18F-FDG uptake. The classical finding is aborted CA to prevent SCD.58,396,416,454,455,466
focal 18F-FDG uptake in the basal septum, with a concordant perfusion ICD implantation is recommended in patients with
I C
defect. Perfusion defects in the active stage of CS may be due to micro- CS and LVEF ≤35% to prevent SCD.416,452,454,455
vascular obstruction by inflammatory oedema, necrosis, or both, and are Continued
Downloaded
from

by
guest
on
22
January
2026

4004 E S C G u id e l in e s
ICD implantation should be considered in patients myocarditis.10 Treatment with type I IFN in patients with enterovirus
with CS and LVEF >35% after resolution of the active has been suggested to increase viral clearance, but large trials are miss-
ing.273,473–475 Antiviral therapies have to be prescribed and managed in
phase with significant LGE, a history of arrhythmias,
IIa C collaboration with an infectious diseases expert with shared decision-
unexplained syncope, inducible sustained VA at PVS,
making in the IMPS team.1,472
or with persistent high-degree AVB to prevent
SCD.416,434,452,453,456–464,467
9.5.1.3.1. Influenza virus. Supportive management is the backbone of
AVB, atrioventricular block; CA, cardiac arrest; CMR, cardiovascular magnetic resonance;
severe influenza treatment. Myocardial involvement is rare, but should
CS, cardiac sarcoidosis; 18F-FDG-PET, [18F]-fluorodeoxyglucose positron emission
be considered in patients of any age with chest pain, tachycardia, and
tomography; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium
enhancement; LVEF, left ventricular ejection fraction; PVS, programmed ventricular haemodynamic instability within 2–4 weeks from symptom onset.
stimulation; SCD, sudden cardiac death; VA, ventricular arrhythmias; VF, ventricular The effect of antiviral therapy on myocarditis is not clear, although osel-
fibrillation; VT, ventricular tachycardia.
tamivir is utilized in both inpatient and outpatient settings. Peramivir
aClass of recommendation.
bLevel of evidence. and zanamivir are used only for hospitalized patients. There are individ-
ual case reports of successful treatment with neuraminidase inhibi-
tors.476–479 Peramivir has often been used in combination with either
oseltamivir480,481 or zanamivir.482
9.5. Specific infectious myocarditis
(Viruses, Lyme, Chagas)
9.5.1.3.2. Human immunodeficiency virus. The pathogenesis of
9.5.1. Viruses HIV-associated myocarditis involves direct viral infection, co-infection
A large variety of infectious agents (Supplementary data online, Table S1) with other viruses or bacteria, cytokine activity, side effects of highly
can cause myocardial inflammation, but viruses are considered the most active antiretroviral therapy (HAART), immune system dysregulation,
common cause among infectious forms of myocarditis. Data on the true and/or ischaemia. If HIV-associated myocarditis is diagnosed, therapy
prevalence of viral myocarditis are difficult to determine, since EMB is for HIV infection has to be started or continued. Highly active anti-
performed only in a subgroup of high-risk patients and in complicated retroviral therapy has been reported to significantly decrease the in-
cases. Moreover, a positive viral serological test does not imply myocar- cidence of cardiac involvement, especially pericarditis, arrhythmias,
dial infection and is not routinely recommended. Exceptions are HIV and and DCM compared with patients treated with nucleoside reverse
HCV and for specific infections such as Lyme disease.10 The epidemi- transcriptase inhibitors in a retrospective study of 1042 patients.483
ology of viral myocarditis has changed during the past three decades;
while enteroviruses and adenoviruses have been considered the most 9.5.2. Lyme carditis
common causes of viral myocarditis,468 vasculotropic viruses such as Lyme carditis may be an early manifestation of Lyme borreliosis, a tick-
B19V,63,66,468 and lymphotropic viruses such as HHV-6 are increasingly borne disease, caused by Borrelia spp., which is one of the most com-
found in EMB samples.342,469 The prognostic relevance of persistent mon vector-borne diseases in the northern hemisphere.
B19V infection with low viral copy numbers remains controversial be-
cause its presence in myocardial tissue may not have direct pathogenetic
9.5.2.1. Presentation
significance,470,471 in contrast to acute B19V infection.228
In cases of early disseminated infection, AM with possible associated
pericarditis may occur, but LC is typically characterized by varying de-
9.5.1.1. Presentation grees of AVB, with third-degree AVB in approximately 25% of cases.484
Symptoms vary according to the underlying cause and severity of dis- Chronic LC often shows manifested persistent symptoms and signs,
ease. However, it generally follows the presentation of acute and such as fatigue, cognitive dysfunction, headaches, sleep disturbance,
chronic stages, as presented in Section 4. neuropsychiatric and musculoskeletal symptoms, electrical conduction
delays, and DCM.
9.5.1.2. Diagnosis
The diagnostic approach should follow the description outlined in 9.5.2.2. Diagnosis
Section 4 (Figures 5 and 6). The presence of more than 500 copies/μg The suspicious index in LC score has been proposed to evaluate the like-
of DNA in EMB is considered as the threshold for virus-related myocar- lihood of high-degree AVB to be caused by LC. It allows categorization
dial inflammation, and usually guides therapeutic choices (e.g. starting of patients into low-, intermediate- and high-risk categories.485
immunosuppression). Viral PCR analysis in EMB samples is performed Continuous ECG monitoring is required for patients presenting with
to better characterize the pathological substrate causing myocarditis. syncope or with a PR interval of >300 ms, since this is a high-risk marker
If immunosuppression is needed, viral presence has to be ruled out of progression to complete AVB.484 Serological tests are recommended
by EMB.10 Contemporary PCR analysis for viral presence in EMB speci- for patients presenting with high-degree AVB and suspected LC.
mens and blood samples is utilized to rule out possible tissue
contamination.10,469
9.5.2.3. Therapy
Atrioventricular block is often transient and typically resolves within
9.5.1.3. Therapy 1–2 weeks of antibiotic treatment, therefore permanent pacemaker
Data are insufficient to support antiviral therapy for AM, as well as treat- placement is not warranted for AVB associated with LC before starting
ment with IVIG for presumed viral myocarditis.472 Anti-herpesvirus therapy. Intravenous therapy with ceftriaxone is the recommended
drugs in patients with CMV or HHV-6 infection can be considered, al- first-line treatment for patients with LC and AV disturbances,486 fol-
though their efficacy has not been directly studied in patients with lowed by oral antibiotics (doxycycline, amoxicillin, or cefuroxime) for
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4005
at least 14 days and up to 21 days (total antibiotic course), depending 9.6. Drug- or vaccine-induced myocarditis
on the severity of clinical presentation and response to treatment.
9.6.1. Drug-induced myocarditis
The prognosis for early-treated disseminated LC is favourable,
9.6.1.1. Immune checkpoint inhibitor-induced myocarditis
with complete recovery occurring in most patients treated with
Immune checkpoint inhibitors have revolutionized cancer treatment
antibiotics.484,487
and are approved in multiple cancer types. These agents are monoclo-
Although LC may resolve spontaneously, antibiotic therapy shortens
nal antibodies blocking specific molecules that inhibit the immune
the disease duration and prevents further complications.
response—CTLA-4 (cytotoxic T-lymphocyte antigen 4), PD-1 (pro-
grammed cell death protein 1) and its ligand PD-L1 (programmed
9.5.3. Chagas disease
death ligand 1), and LAG-3 (lymphocyte activation gene 3)—strongly
Chagas disease (CD) is a systemic disorder caused by the protozoan enhancing T-cell responses against cancer. By activating the immune
parasite T. cruzi, which is transmitted through a haematophagous tria- system, ICIs may induce immune-related adverse events, which can af-
tomine insect vector in endemic areas, such as Latin America, and fect any organ. Myocarditis is one of the most feared complica-
can be transmitted transplacentally, by infected blood, or even orally tions,495–497 although rare, as it affects approximately 1% of treated
through ingestion of contaminated food and drinks. Current migration patients, within the first weeks following the initiation of therapy.495
has made CD a global disease, and congenital transmission has become Since a growing number of patients are eligible for ICI treatment,
relevant in non-endemic areas, including Europe. the absolute number of cases is increasing. One of the largest case ser-
ies, including 122 patients with ICI-associated myocarditis, recorded
9.5.3.1. Presentation early onset after treatment initiation (median 30 days), and up to
Acutely infected individuals remain asymptomatic or show mild and 50% mortality.496 A systematic analysis of the World Health
non-specific symptoms. Intense direct tissue parasitism may result in Organization (WHO) pharmacovigilance database confirmed a high
AM in less than 5% of cases. Chagas disease may evolve into CMP in mortality rate up to 33%.498
20%–30% of cases. Common findings in patients with Chagas CMP in- The main risk factor for ICI-induced AM is combination therapy with
clude brady- or tachyarrhythmias, dilated ventricles with regional two types of ICI, such as an anti-CTLA-4, e.g. ipilimumab, combined
(mainly inferior, inferolateral, or apical) or global systolic dysfunction, with an anti-PD-1, e.g. nivolumab.499
and thromboembolism. This complication affects mostly men495 and older patients (median
age 65 years) with more comorbidities.28,495 Furthermore, if ICIs are
combined with other cancer therapies, their toxicity aggravates.
9.5.3.2. Diagnosis
Diagnosis of CD requires a high clinical suspicion. Polymerase chain
9.6.1.1.1. Presentation. Immune checkpoint inhibitor-induced myo-
reaction testing is the most sensitive test in acute infection while,
carditis is especially arrhythmogenic, including a risk of conduction
for diagnosing chronic CD, the combination of two serological tests
disorders, and HF with reduced EF occurs in about half of patients.500
with antigens that detect different antibodies against T. cruzi is prefer-
Myocarditis is frequently associated with peripheral myositis, which,
able. Multimodality imaging is able to support the diagnosis, as often
when associated with respiratory failure, can negatively affect
apical aneurysms with and without thrombi can be detected by
CMR.488 survival.
9.5.3.3. Therapy 9.6.1.1.2. Diagnosis. When suspected, rapid diagnostic triage is
needed.495–497 Early diagnosis is extremely important, usually including la- Eradication of the parasite is a target in early phases, and anti-parasitic
boratory tests and multimodality imaging (Section 5). The detection of a treatment should be provided as soon as possible, following detection
coexisting CAD in older patients should not refrain from further work-up
of an acute infection. In the BENEFIT (Benznidazole Evaluation for
for myocarditis (Table 4). In inconclusive cases an EMB can be necessary.
Interrupting Trypanosomiasis) trial, 2854 patients with Chagas CMP
For more details, see the 2022 ESC cardio-oncology guidelines.501
were randomized to either benznidazole or placebo for 80 days.
Benznidazole significantly reduced serum parasite detection, but there
was no significant reduction in clinical cardiac deterioration at 9.6.1.1.3. Therapy. After diagnosis, immediate discontinuation of ICI
5 years.489 Therefore, anti-trypanosomal treatment should not be rou- and early (within the first 24 h) initiation of corticosteroids is war-
tinely used in adult patients with chronic CMP, but it can be considered ranted. Up to 50% of patients will be refractory to corticosteroids. In
in early and mild forms490,491 (see Table 12). Patients with Chagas CMP this situation, second-line immunosuppression treatments are neces-
should be treated according to HF guidelines. Chagas disease is asso- sary (see Table 12).502 In a prospective registry, the combination of rux-
ciated with high morbidity and mortality, with an annual rate of cardio- olitinib and high doses of abatacept, and screening for concurrent
vascular death of 6%.492 In this population, the benefit of ICD in primary respiratory muscle failure, was associated with improved survival.502
and secondary prevention is controversial, since observational studies Long-term cardiovascular effects of ICIs become more and more rele-
did not demonstrate a mortality benefit compared with amiodarone.493 vant since a growing number of cancer patients are exposed to this
However, a systematic review and meta-analysis showed that, in pa- therapy.503,504 Rechallenge with an ICI has to be considered following
tients with previous VT, appropriate ICD interventions and electric a multidisciplinary team discussion, based on factors such as the severity
storms were frequent, occurring at a rate of 25% and 9% per year, re- of the myocarditis, cancer prognosis, oncology treatment options, and
spectively, with an overall mortality of 9% per year.494 A case-based de- patient preference.504,505 Details are given in the 2022 ESC guidelines
cision is warranted. for cardio-oncology.501
Downloaded
from

by
guest
on
22
January
2026

4006 E S C G u id e l in e s
Recommendation Table 18 — Recommendations for neurohormonal changes of late pregnancy and delivery, as well as the
immune checkpoint inhibitor-associated myocarditis role of genetic predisposition.524
(see Evidence Table 18)
9.7.1. Presentation
Recommendations Classa Levelb
There is no clear distinction between the phenotype of PaM and PPCM.
Diagnostic triage within 24 h is recommendedc in Women develop symptoms of HF during late pregnancy or after deliv-
patients with suspected myocarditis induced by ICI I C ery, with the majority being diagnosed after delivery, typically in the first
to initiate treatment rapidly.495,496,501,504 month post-partum. A minority of patients may present with pulmon-
Immediate disruption of ICI and administration of ary oedema, cardiogenic shock, severe arrhythmias,525 cardio-
high-dosage corticosteroids are recommended in pulmonary arrest, thromboembolic complications, and brain injury.
patients with ICI-associated myocarditis in order to I C
stop the inflammatory reaction and stabilize the 9.7.2. Diagnosis
patient.504 There are no specific studies for PaM, therefore the guidance for PPCM
Second-line immunosuppression treatment should should be followed. Transthoracic echocardiography should be per-
be considered in patients with steroid-refractory IIa C formed in any suspected case. In PPCM, LVEF is typically <45%.526
ICI-associated myocarditis.501,504 Careful examination should be undertaken to clearly view the LV
apex to detect intracardiac thrombi. Brain natriuretic peptide/
Second-line immunosuppression treatment may be
N-terminal prohormone of brain natriuretic peptide are usually mark- considered in patients with fulminant/severe IIb C
edly elevated.527–529
ICI-associated myocarditis.501,504
Cardiovascular magnetic resonance imaging is an advanced imaging
ICI, immune checkpoint inhibitor. modality if echocardiogram is inadequate, but gadolinium-based contrast
aClass of recommendation. agents should be avoided during pregnancy.530–532 Cardiovascular mag-
bLevel of evidence. netic resonance is crucial to differentiate underlying causes.533 The detec-
cSee Figure 5.
tion of active inflammation can be performed without application of
contrast media in CMR (Figure 4).
Peripartum CMP has been associated with a higher rate of recovery
9.6.1.2. Other drugs associated with myocarditis than other forms of HF with reduced EF,534 and remission frequently
Many drugs have been associated with myocarditis (see Supplementary occurs within the first 3 to 6 months.535 Delayed recovery can also oc-
data online, Table S10), especially clozapine.506 The reported incidence cur after 2 years.536,537
of clozapine-associated myocarditis ranges from 0.1% to 5%.507,508
Drug-induced myocarditis may be associated with drug reaction with eo- 9.7.3. Therapy
sinophilia and systemic symptoms (DRESS) syndrome.509 Treatment is
There are no dedicated studies for PaM, so advice is based on published
based on discontinuation of the drug and use of corticosteroids.
literature for PPCM.
Treatment of HF is essential, with modifications to ensure foetal
9.6.2. Vaccine-induced myocarditis safety during pregnancy.521,538–540
Low-molecular-weight heparins do not cross the placenta, and are
In 2002 the ‘Brighton collaboration’ was established with the aim to pro-
vide standards for the definition of adverse events after vaccination.510 preferred during pregnancy if the thromboembolic risk is high.541
Direct oral anticoagulants are less well studied in pregnancy, and should
In a clinical context, different vaccines, apart from the SARS-CoV-2
be avoided. Anticoagulation should be continued until recovery of LV
vaccine, have been associated with myocarditis. The main association
is with smallpox vaccine,511 with data deriving mainly from the US mili- function.
Bromocriptine has been shown to improve LVEF at 6 months, but
tary population.
the results are contradictory.521,542–545
A systematic review reported cardiac events including IMPS after in-
fluenza vaccination, pneumococcal vaccine, and tetanus toxoid.512 Following delivery, most HF medications are compatible with breast-
feeding. Many patients may also relapse. Treatment withdrawal and in-
Few data reported myocarditis after receiving different vaccines (e.g.
complete recovery of LV function are risk factors for recurrences.546,547
meningococcus, hepatitis A and B, diphtheria, poliovirus) (see
Supplementary data online, Table S11).513–518 Lifelong treatment has not been proven to be necessary.
Pre-conception counselling should include discussion of the potential
A recent multicentre study reported good mid-term outcomes after
risks of recurrent myocardial dysfunction, even after recovery.547
COVID-19 vaccine-associated myocarditis without death or need for
HT.519 More detailed information can be found in Supplementary Multidisciplinary teams are warranted for patient management.548,549
data online, Section 5.1.2.
10. Inflammatory cardiomyopathy
9.7. Pregnancy-associated myocarditis
Inflammatory CMP is defined by chronic myocarditis in association with
Peripartum CMP (PPCM) is sometimes associated with myocardial in- cardiac dysfunction and ventricular remodelling, with a clinical hypoki-
flammation, more common particularly in patients presenting with ar- netic phenotype, either dilated or non-dilated, with or without arrhyth-
rhythmias.520 Pregnancy-associated myocarditis (PaM) is a rare mogenic substrate. It can also manifest as the evolution of a prior
condition, and its incidence and prognosis varies regionally.521–523 myocarditis, whether treated or untreated. Inflammatory CMP is in-
Nutritional deficiencies, viral myocarditis, and autoimmune processes volved in the pathogenesis of DCM. It includes immune-mediated/auto-
have been postulated as triggers. Recent data support the role of immune forms and infectious subtypes.12,550 A genetic predisposition is
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4007
also important for the pathogenesis of inflammatory CMP.9 However, 11. Specific types of pericarditis
the rates, risk factors, and other characteristics of cases progressing
from AM to chronic myocarditis or inflammatory CMP remain unknown. 11.1. Tuberculous pericarditis
In high-income countries, TB pericarditis accounts for up to 4% of pericar-
10.1. Presentation dial disease, but it is increasing due to immigration. On the other hand, TB
is the cause of clinically significant PEff in approximately 90% of
Patients with inflammatory CMP may present with new-onset/acute,
HIV-infected and 50%–70% of non-HIV-infected individuals living in devel-
subacute, or chronic HF. Although myocarditis resolves in >50% of
oping countries with a high prevalence of TB.556 It should be emphasized
cases, even spontaneously, approximately 25% of cases may present
that most of the information on TB pericarditis comes from endemic
with persistent ventricular dysfunction, and more severe cases may
areas in low-income countries and immunosuppressed patients.1
progress to DCM.10
Notably, the disease can occur at any age, and men are affected more fre-
quently than women.48 Tuberculous pericarditis has an overall mortality
10.2. Diagnosis rate of 17%–40% at 6 months after diagnosis.557
A variety of clinical assessment, ECG, multimodality imaging, and, if
needed, EMB can be used to reach a diagnosis. Persistent or chronic
11.1.1. Presentation
myocardial inflammation should be suspected in cases with non-
Clinical presentations of TB pericardial involvement include AP (most
ischaemic ventricular dysfunction associated with low QRS voltages,
commonly with PEff), ECP, and CP, with these manifestations repre-
and persistent mild elevation of hs-TnT/TnI. The absence of significant
senting consecutive stages of a unique process rather than independent
remodelling may be observed in the early phase of the disease. This sus-
conditions.558,559 Specifically, the evolution of TB pericarditis encom-
picion can be confirmed by multimodality imaging (echocardiography
passes four stages (Figure 18). The first stage or dry stage of AP is with-
and CMR) and EMB, especially in the presence of myocardial oedema
out effusion, the second stage with PEff (this is the form most
observed at CMR. Inflammatory CMP may be familial in rare cases. In
commonly encountered in clinical practice) in up to 80% of cases, the
these patients, genetic testing should be discussed.
third stage with progressive absorption of effusion, and the fourth stage
with pericardial constriction. In the effusive phase, pericardiocentesis
10.3. Therapy
usually yields bloody effusion, and effusive–constrictive physiology
Guideline HF treatment is recommended in patients with inflammatory may emerge after pericardial drainage. At this stage, lymphocytic exud-
CMP.12,259 Medical therapy should be tailored to the underlying cause ate is mainly observed.560 The duration of each stage varies and de-
in case of systemic disorders, especially in autoimmune diseases. Only pends on individual factors (e.g. HIV status), and early treatment may
one RCT showed an improvement of cardiac function with immuno- prevent progression.
suppressive treatment in patients with virus-negative inflammatory
CMP.551 Other non-randomized studies, often derived from single-
centre and/or retrospective studies,34,131,551–555 suggest the efficacy 11.1.2. Diagnosis
of immunosuppression on top of optimized HF therapy, and support The diagnosis of TB pericarditis is challenging and in 15%–20% of cases
its safety. In patients with different immune-mediated myocarditis the diagnosis may be missed.561 A ‘definite’ diagnosis of TB is based on
and HF, immunosuppressive therapy was safe.34,131,552–555 Therefore, the presence of tubercle bacilli in the pericardial fluid or on a histologic-
the treatment should be based on histological/immunohistological al sample of the pericardium, by culture or by PCR (Xpert MTB/RIF and
and viral PCR examination of the biopsy specimens. RIF ultra) testing. A ‘probable’ diagnosis is made when there is proof of
In untreated cases, progression to DCM and transplantation or death TB elsewhere in a patient with unexplained pericarditis, a lymphocytic
are observed.10,39 pericardial exudate with elevated unstimulated IFN-γ (uIFN-γ), adeno-
sine deaminase or lysozyme levels, and/or an appropriate response to
antituberculosis therapy in endemic areas.558 In a meta-analysis, the
Recommendation Table 19 — Recommendations for sensitivity and specificity of adenosine deaminase, which is probably
inflammatory cardiomyopathy (see Evidence Table 19)
the most widely used biomarker, were 90% and 86%, respectively,
for the diagnosis of TB pericarditis.562 Xpert MTB/RIF is highly specific
Recommendations Classa Levelb (100%); however, it has a sensitivity of 64%, which increases to 78%
Guideline-directed heart failure treatments are when pericardial biopsy samples are employed.563,564 Pericardial fluid
recommended in patients with inflammatory culture shows low sensitivity (53%–75%) and it is also time-consuming,
I C
needing more than 3 weeks to yield results. Interferon gamma offers su-
cardiomyopathy to improve and/or stabilize left
perior accuracy for the diagnosis of microbiologically confirmed TB peri-
ventricular function.
carditis compared with the adenosine deaminase (ADA) assay and the
Specific medical therapy for the potentially
Xpert MTB/RIF test.563 In a meta-analysis, values of uIFN-γ in the pericar-
underlying systemic disease is recommended in I C
dial fluid from studies using thresholds of 14–200 pg/mL showed very
inflammatory cardiomyopathy.
high sensitivity (97%) and specificity (99%) for the diagnosis of TB peri-
Immunosuppressive therapy, guided by
carditis, with a positive likelihood ratio of 187 and a negative likelihood
endomyocardial biopsy, should be considered in IIa B ratio of 0.03.565 On the other hand, the tuberculin skin test and IFN-γ
virus-negative inflammatory cardiomyopathies to release assays are of limited value, especially in areas with a high burden
suppress the autoimmune response.34,131,551–555 of TB, since they cannot discriminate between previous exposure to
aClass of recommendation. Mycobacterium and active disease.566 A detailed approach is outlined
bLevel of evidence. in Supplementary data online, Table S12.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4008 E S C G u id e l in e s
Figure 18 Stages of tuberculous pericarditis.
11.1.3. Therapy Recommendation Table 20 — Recommendations for
Medical treatment consists of a regimen including rifampicin, isoniazid, tuberculous pericarditis (see Evidence Table 20)
pyrazinamide, and ethambutol for at least 2 months, followed by isoni-
azid and rifampicin for an additional 4 months, which is effective in Recommendations Classa Levelb
treating extrapulmonary TB.1,567 Treatment for ≥9 months gives no
Diagnosis and treatment of tuberculous pericarditis and effusion
better results and has the disadvantages of increased cost and poor
Diagnostic pericardiocentesis is recommended in all
compliance.567
patients with suspected tuberculous pericarditis
However, it should be emphasized that, excluding isoniazid, poor I C
when diagnosis is not confirmed by non-invasive tests
drug penetration into the pericardial space is a matter of concern,
to identify the aetiological agent in pericardial fluid.570
also considering the emerging evidence of intrapericardial bacillary
load and mortality.568 Empirical antituberculosis chemotherapy is
With the prompt use of antitubercular medications, steroids (oral recommended in patients living in endemic areas I C
or intrapericardial), and the widespread use of pericardial drainage with exudative pericardial effusion after excluding
with or without intrapericardial fibrinolysis, the currently reported other causes to treat the most likely cause.567,570
rates of CP are between 5% and 25%.569 Moreover, contemporary Standard antituberculosis multidrug treatment for
treatment has accounted for a 20% reduction in all-cause mortal- 6 months is recommended in patients with
I C
ity.567,569–572 tuberculous pericarditis for the prevention of
Pericardial drainage by any means (pericardiocentesis or pericardial pericardial constriction.570
window) is recommended as an essential part of the work-up in pa- Pericardiectomy is recommended in patients with
tients with suspected TB pericarditis, both for diagnostic and thera-
tuberculous pericarditis if the condition is not improving
peutic purposes.1 I C
or is deteriorating after 4–8 weeks of antituberculosis
Constriction generally develops in up to 50% of patients with-
therapy to change the course of disease.
in 6 months of presentation prior to the introduction of effect-
Adjunctive steroid therapy should be considered in
ive TB therapy.1 Appropriate antibiotic therapy is essential to
HIV-negative cases to prevent the development of IIa C
prevent this progression.570 In addition, two interventions
constrictive TB pericarditis.569
may reduce the incidence of constriction: (i) intrapericardial
In non-endemic areas a pericardial biopsy may be
urokinase; and (ii) high-dose adjunctive prednisolone for
6 weeks.569,573 considered in patients with >3 weeks of illness IIb C
However, the coexistence of TB and HIV infection requires spe- without aetiologic diagnosis.
cial attention. Prednisolone was associated with an increased risk of Empirical antituberculosis treatment is not
III C
HIV-associated malignancies.569 On this basis, it may be reasonable recommended in patients living in non-endemic areas.
to use adjunctive corticosteroids in patients with TB pericarditis
HIV, human immunodeficiency virus; TB, tuberculosis.
without HIV infection and to avoid them in HIV-infected aClass of recommendation.
individuals.569 bLevel of evidence.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4009
11.2. Pericardial involvement in neoplastic Recommendation Table 21 — Recommendations for
neoplastic pericardial involvement (see Evidence
disease
Table 21)
11.2.1. Presentation
Neoplastic pericardial involvement is occasionally manifested by peri- Recommendations Classa Levelb
carditis or, more commonly, an isolated PEff (usually moderate to
Pericardiocentesis is recommended for patients with
large, or CTP) with or without evident masses on imaging. It is usually
cardiac tamponade to relieve symptoms and
related to metastatic lymphatic involvement (especially for lung can- I C
establish the diagnosis of malignant pericardial
cer) or haematogenous spread (especially for breast cancer). In add-
effusion.576,583
ition, lymphomas, leukaemias, and melanoma may affect the
Extended pericardial drainage (3–6 days) is
pericardium, as may cancer of contiguous organs (e.g. oesophageal
cancer).574,575 Primary neoplastic disease of the pericardium is rare. recommended in patients with suspected or definite I B
Pericardial mesothelioma is the most common form, and it may pre- neoplastic pericardial effusion to prevent effusion
sent as ECP or CP in advanced cases. On this basis, the term ‘neoplas-
recurrence.576,583
tic pericarditis’ is often used incorrectly instead of ‘neoplastic Cytological analysis of pericardial fluid is
pericardial effusion’. recommended in patients with neoplastic pericarditis
I C
for the confirmation of malignant pericardial
disease.581
11.2.2. Diagnosis
Systemic antineoplastic treatment is recommended
The definitive diagnosis is based on the confirmation of malignant in-
in confirmed cases of neoplastic aetiology to treat
filtration within the pericardial fluid by cytology (pericardiocentesis) I C
the primary and secondary metastatic neoplastic
or pericardial biopsy. A probable diagnosis may be achieved by the
detection of tumour markers in the pericardial fluid (e.g. CEA,
involvement.582
CYFRA 21-1, NSE, CA-19-9, CA-72-4, SCC, GATA3, and VEGF), al- Pericardiocentesis should be considered in patients
though none of these tumour markers has been proven to be accur- with moderate to large pericardial effusion to
ate enough for distinguishing malignant from benign effusions.576,577 establish the diagnosis of malignant pericardial IIa C
Evidence of malignant disease elsewhere and concomitant pericardi- effusion when the diagnosis cannot be reached by
tis or PEff is also suggestive, although in almost two-thirds of patients multimodality imaging.584
with documented malignancy, pericardial involvement is caused by Pericardial or epicardial biopsy may be considered in
non-malignant diseases,15 e.g. radiation,578,579 chemotherapy,580 or patients with suspected malignant pericardial disease
infections. Cytological analyses of pericardial fluid are mandatory when the diagnosis cannot be reached by IIb C
for the confirmation of malignant pericardial disease.581 Analyses
multimodality imaging or cytological analysis, to
of pericardial fluid and less commonly pericardial or epicardial biop-
confirm the diagnosis.
sies are essential for the confirmation of malignant pericardial
Intrapericardial therapy, in agreement with the
disease.
oncologist, may be considered in cases refractory to IIb C
systemic antineoplastic treatment.
11.2.3. Therapy
aClass of recommendation.
The management of these patients requires a multidisciplinary ap- bLevel of evidence.
proach involving oncologists, cardiologists, and radiotherapists, as
well as other specific subspecialty experts according to the type of
cancer.
11.3. Post-cardiac injury syndrome
General principles of treatment include systemic antineoplastic
treatment as baseline therapy. Local antineoplastic treatment is based The term PCIS is an umbrella term indicating a group of inflamma-
on tailored intrapericardial therapy according to the type of tumour tory pericardial syndromes, including late post-acute myocardial
(e.g. cisplatin is efficacious in lung cancer, thiotepa in breast cancer),582 infarction (post-AMI) pericarditis (or Dressler syndrome), post-
and intrapericardial instillation of cytostatic/sclerosing agents to pre- pericardiotomy syndrome (PPS), and post-traumatic pericarditis
vent recurrences. Malignant PEffs show a high recurrence rate with or without bleeding. Currently several post-traumatic cases
(>50%). Extended pericardial drainage can be necessary in patients are iatrogenic and related to cardiovascular interventions.585,586
with suspected or definite neoplastic PEff to prevent effusion recur- Nowadays, Dressler syndrome appears in <1% of cases, mainly in
rence and provide a route for intrapericardial therapy. Additional inter- larger infarctions and/or late reperfusion, typically 1–2 weeks after
ventions for recurrent effusions may include pericardiotomy, AMI.587 Notably, patients with a post-AMI PEff of >10 mm at end-
pericardial window, and percutaneous balloon pericardiotomy. All diastole should be investigated for a possible subacute heart
techniques are palliative and aimed at improving the quality of life of pa- rupture.588,589
tients with a poor short-term outcome. In contrast, cases developing after cardiac device implantation or ar-
Radiation therapy is very effective in controlling malignant PEff in pa- rhythmia ablation (e.g. pericarditis appears in ∼10% of cases after AF
tients with radiosensitive tumours, such as lymphomas and leukaemias. ablation) are becoming increasingly common due to the growing
In clinical practice, management is often palliative at late stages with number of invasive procedures.586,587,590,591
advanced disease, and it is aimed only at the relief of symptoms rather Such syndromes are presumed to have an autoimmune pathogenesis
than treatment of the underlying disease, considering the prognosis, triggered by pericardial bleeding and/or pleura incision.47,592 An
and the overall quality of life of the patient. immune-mediated pathogenesis is supported by a latent period,
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4010 E S C G u id e l in e s
generally a few weeks, until the appearance of the first manifestations, Recommendation Table 22 — Recommendations for
the positive response to anti-inflammatory drugs, and the possibility of post-cardiac injury syndrome (see Evidence Table 22)
recurrences.
Recommendations Classa Levelb
11.3.1. Diagnosis Anti-inflammatory therapy is recommended in
According to proposed diagnostic criteria, the diagnosis of PCIS may be patients with PCIS to hasten symptom remission and I B
reached in the presence of at least two of the following five criteria: (i) reduce recurrences.292,600
fever without alternative causes; (ii) pericardial or pleuritic chest pain; IL-1 antagonists are recommended in patients with
(iii) pericardial or pleural rubs; (iv) evidence of PEff; and/or (v) pleural refractory PCIS to prevent recurrences and I B
effusion with elevated C-reactive protein.593–595 progression to constriction.604
The rationale for proposing specific criteria is that these syndromes
High-dose aspirin is recommended as the first-choice
may have concomitant pleuro-pericardial involvement and possible pul-
anti-inflammatory therapy for post-myocardial
monary infiltrates, and are not simply pericarditis.595 Moreover, it is I C
infarction pericarditis and in patients being already on
sometimes difficult to differentiate PCIS from the simple mechanical
antiplatelet therapy.
consequences of surgery (such as early pericardial or pleural effusion).
Colchicine, started 48 to 72 h before cardiac surgery,
The demonstration of inflammatory activity (e.g. C-reactive protein ele-
should be considered for 1 month in patients after
vation) is essential to establish the diagnosis. Multimodality imaging can IIa A
cardiac surgery for the prevention of PCIS if there
be helpful for the diagnosis of complicated cases (e.g. loculated effu-
are no contraindications and if it is tolerated.594,596
sions, evidence of inflammation).
Careful follow-up should be considered in patients
with PCIS to exclude possible evolution towards IIa C
11.3.2. Therapy
constrictive pericarditis.347
The same therapeutic scheme adopted for AP, essentially based on em-
pirical anti-inflammatory therapy, is effective for all forms of PCIS, and IL, interleukin; PCIS, post-cardiac injury syndrome.
aClass of recommendation.
may improve remission rates and reduce the risk of recurrences. In
bLevel of evidence.
early post-AMI pericarditis, a 5–7-day course of aspirin seems the
most reasonable option, in association with colchicine.587
Different treatment strategies (namely aspirin, methylprednisolone, 11.4. Pericarditis and autoinflammatory
dexamethasone, and colchicine) have been adopted for the primary diseases
prevention of PPS, and the effects of such treatments have been ad-
Compared with the previous guidelines, it has become evident that some
dressed in a meta-analysis that showed that only colchicine was asso-
inflammatory forms of RP share similarities with genetic autoinflamma-
ciated with a decreased risk of PPS (OR 0.38), sometimes, however,
with an increased risk of gastrointestinal side effects.593,594,596–600 tory diseases characterized by periodic fevers, e.g. FMF and TRAPS.50,51
These are genetic disorders characterized by mutations of genes in-
Preventive administration of colchicine can be given after cardiac sur-
volved in the regulation of the inflammatory response, without involve-
gery using weight-adjusted doses (i.e. 0.5 mg once for patients
ment of specific T cells or autoantibodies.605 These disorders are
≤70 kg and 0.5 mg twice daily for patients >70 kg) and without a load-
ing dose for the prevention of PPS and continued for 1 month.596 usually detected in the paediatric population, although some patients ex-
perience disease onset during adulthood. The most common monogenic
In this guideline document, the LOE for colchicine recommendation
autoinflammatory syndromes include FMF, in which serositis episodes last
for the prevention of PPS is based on analysis of the available evidence
only 1–3 days, and TRAPS, in which fever and symptoms last for weeks.605
from more than one RCT, systematic reviews and the consensus opin-
Mutations associated with these disorders have been reported in up to
ion of the TF members.
10% of patients with multiple recurrences, especially with a positive family
Neither NSAIDs nor colchicine have to be administered for post- operative effusions in the absence of systemic inflammation.601,602 history, and a poor response to colchicine.152 Recently, rare deleterious
MEFV variants were observed more frequently in idiopathic RP than
Early post-operative PEffs are relatively common after cardiac surgery,
and usually disappear spontaneously in 7–10 days.1 Asymptomatic small in ancestry-matched controls (allele frequency 9/200 vs 2932/129 200,
P = 0.040).50 These conditions are characterized by the exaggerated pro-
PEffs do not require treatment; however, moderate to large effusions
duction of IL-1 by the inflammasome. Familial occurrence of pericarditis
(observed in one-third of cases) can progress to CTP at a rate of
has been reported among the relatives of idiopathic RP patients, ranging
10% within 1 month after surgery and need pericardial decompres-
sion.603 Treatment of these asymptomatic effusions by NSAIDs has from 4%50 to 10%.113 These data suggest a genetic predisposition in at
least a subset of patients; counselling may be warranted in these cases.
been shown to be ineffective [e.g. diclofenac in the Post-Operative
Pericardial Effusion (POPE) trial], and may be associated with an in-
creased risk of side effects.601 11.5. Purulent pericarditis
The prognosis of PPS is generally good.600 In the largest published Purulent pericarditis, namely the most serious manifestation of bacter-
series on PPS patients after cardiac surgery, complication rates were ial pericarditis, is characterized by the macro- or microscopic presence
low: <4% for recurrences; <2% for CTP; and no cases of constriction, of purulent PEff. It is an exceedingly rare form of pericarditis in the
although hospital stay may be prolonged in these patients.592 Western world, accounting for <1% of AP cases.606 It has a high mor-
Moreover, the development of CP has been reported in ∼3% of tality in untreated cases while, in optimally treated patients, the re-
cases.347 Both early post-AMI pericarditis and Dressler syndrome are ported survival rate is approximately 15%–40%.606
markers of larger infarct size, but without independent prognostic In developed countries, the most common organisms isolated in
significance.587 purulent pericarditis include staphylococci and streptococci, while
5202CSE©
Downloaded
from

by
guest
on
22 January
2026

ESC Guidelines 4011
the predominant associated lesions are empyema (50%) or pneumonia 11.6. Incessant and recurrent pericarditis
(33%). In immunosuppressed patients or following thoracic surgery, the
The TF proposes to adopt the term ‘incessant’ for cases of persistent
most frequently encountered bacterial/fungal agents are Staphylococcus
symptoms without clear remission, and thus also to include cases of
aureus (30%) and fungi (20%), while anaerobic bacteria, originating from
symptom persistence/recurrence during drug tapering. Recognition of
the oropharynx, have also been reported.607,608
these cases is of paramount importance, since they can directly progress
It should be stressed that in the modern era of iatrogenic and to CP within a few months.104 Recurrent pericarditis is defined as a re-
HIV-associated immunosuppression, more unusual organisms may ac-
lapse after a documented first episode of AP, a symptom-free interval,
count for pericardial infection.1,607
complete discontinuation of anti-inflammatory therapy, and evidence
of subsequent recurrence of pericarditis. Recurrence usually occurs with-
11.5.1. Presentation in 18 months from the index episode, and is the most common and
Purulent pericarditis has generally manifested as a serious febrile disease, problematic complication of AP, ranging from 15% to 30% of cases after
and the underlying sepsis may predominate, including septic shock.606–608 a first episode of pericarditis. It may increase to 50% after a first recur-
Constrictive pericarditis complicates 20%–30% of cases.347 rence in patients with inadequate treatment of the first episode (e.g.
too fast tapering, not treated with colchicine, treated with corticoster-
oids).25,611 In developed countries, the aetiology of recurrences is poorly
11.5.2. Diagnosis
known, and most cases are labelled as idiopathic. Historically, most cases
Suspicion of purulent pericarditis is an indication for pericardial drainage were probably related to an autoinflammatory/autoimmune pathogen-
independently from the haemodynamic status. Surgical pericardial drain-
esis. This is based on the inflammatory/non-inflammatory phenotype,
age is recommended to allow complete removal of the fluid and prevent
the latency from the acute attack (several weeks after the index episode),
its organization and progression to constriction. Low pericardial-to-serum
the presence of autoantibodies, and the response to anti-inflammatory/
glucose ratio (mean 0.3) and elevated pericardial fluid white cell count immunosuppressive treatments.52,283,284,287
with a high proportion of neutrophils (mean cell count 2.8/mL, 92% neu-
trophils) differentiate purulent from tuberculous (glucose ratio 0.7, mean
11.7. Inflammatory and non-inflammatory
cell count 1.7/mL, 50% neutrophils) and neoplastic pericarditis (glucose
pericardial effusion
ratio 0.8, mean cell count 3.3/mL, 55% neutrophils).
Fluid must be sent for bacterial, fungal, and tuberculous studies along The normal pericardial sac contains 10–50 mL of pericardial fluid, a
with blood and tissue samples, as guided by the clinical presentation.1 plasma ultrafiltrate that acts as a lubricant between the pericardial
layers. Any pathological process that causes pericardial inflammation in-
11.5.3. Therapy creases the amount of fluid, causing PEff (exudate). Alternative mechan-
isms causing PEff include decreased reabsorption following increased
Intravenous antimicrobial therapy should be started empirically until
systemic venous pressure, as observed in congestive HF or pulmonary
microbiological results are available. Afterwards, pathogen-directed anti-
biotic therapy is warranted based on antibiotic susceptibility.1 The dur- hypertension (transudate) or alternatively, decreased lymphatic drain-
age.612 The regimen of pressures in the epicardium and pericardial cav-
ation of antibiotic therapy should be individualized until fever and clinical
ity is shown in Supplementary data online, Figure S4.
signs resolve, with the minimum period of administration being 3 weeks.
Purulent effusions are often heavily loculated and likely to rapidly re-
accumulate. Subxiphoid pericardiotomy and rinsing of the pericardial cav- 11.7.1. Classification and aetiology
ity should be considered.15 This allows more complete drainage of the The reported incidence and prevalence of PEff in developed countries is
effusion, since loculations can be manually lysed. Intrapericardial fibrinoly- estimated at 3% and 6%–9%, respectively, based on echocardiographic
sis is a possible treatment for cases of loculated effusions to achieve ad- laboratory records.613 Pericardial effusion was detected in 14% of sub-
equate drainage.609 Fibrinolysis has been shown to prevent complications jects in a prospective registry of consecutive patients who underwent
in approximately 86% of cases without fatal complications.573,609,610 In chest CT.198
the unfortunate case that percutaneous measures fail to control infec- The classification of PEff is shown in Table 10. Echocardiography pro-
tion, and worsening HF occurs along with constrictive physiology fea- vides semiquantitative assessment of the effusion size, which is useful for
tures, referral to surgical pericardiectomy is advised.610 estimating the risk of having a non-idiopathic aetiology and complications
(see Supplementary data online, Figure S5).105 In the past three decades,
six major surveys have been published on the characteristics of moderate
Recommendation Table 23 — Recommendations for to large PEff (see Supplementary data online, Table S13).556,614–618
purulent pericarditis (see Evidence Table 23)
According to these series, many cases remain idiopathic in developed
Recommendations Classa Levelb countries (up to 50%), while additional aetiologies include cancer
(10%–32%), infections (15%–30%), iatrogenic causes (15%–20%), and
Urgent pericardiocentesis and/or a surgical window connective tissue diseases (5%–15%), whereas TB is the dominant cause
is recommended in patients with suspicion of I C in developing countries (>60%), where TB is endemic.558
purulent pericarditis to establish a diagnosis.606
Intrapericardial fibrinolysis should be considered in 11.7.2. Presentation
patients with purulent pericarditis to allow complete
IIa B A significant proportion of patients with PEff are asymptomatic, and PEff is
drainage of purulent fluid and to prevent an incidental finding during routine examination. The clinical presentation
constriction.573,610
of PEff varies according to the speed of accumulation of fluid (see
aClass of recommendation. Supplementary data online, Figure S4). Classic symptoms include exertional
bLevel of evidence. dyspnoea progressing to orthopnoea, chest pain, and feeling of fullness.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4012 E S C G u id e l in e s
Additional symptoms due to the compression of adjacent structures in- (see Supplementary data online, Figure S5).115,124 Advanced imaging
clude nausea (diaphragm), dysphagia (oesophagus), hoarseness (recur- (CT and CMR) provides valuable information concerning local inflam-
rent laryngeal nerve), and hiccups (phrenic nerve).118,619 mation, masses, associated chest abnormalities (e.g. pectus excavatum),
loculated effusions, and systemic diseases.196,198,620 Pericardial effusion
11.7.3. Diagnosis is often associated with known or unknown medical conditions (e.g.
Physical examination may be normal in patients without haemodynamic hypothyroidism) in up to 60% of cases, especially if moderate/large.615
compromise. Echocardiography is the primary diagnostic tool for A practical routine evaluation for the triage of PEff is presented in
diagnosis, sizing, assessment of haemodynamic effects, and follow-up Figure 19.1
Pericardial effusion
First-line assessment with history, physical examination, ECG,
chest X-ray transthoracic echocardiography, laboratory assessment
Cardiac tamponade, symptomatic moderate to large pericardial
effusion with suspicion of neoplastic or bacterial aetiology
Admission,
pericardiocentesis
Treat as pericarditis Concomitant pericarditis and aetiology search
Treat the systemic
Associated systemic disease
condition
Large (>20 mm) and chronic (>3 months) effusion
Symptomatic Oupatient follow-up
Pericardiocentesis with drainage
Empiric anti-inflammatory therapy
Outpatient follow-up
and treatment
Improvement Pericardial window
according to
specific aetiology
Fluid re-accumulation Symptomatic
Outpatient follow-up and treatment
according to specific aetiology
Figure 19 Triage and management of pericardial effusion. ECG, electrocardiogram; N, no; Y, yes.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4013
Patients presenting with PEff without inflammatory marker elevation syndrome, and the aspiration of small amounts of pericardial fluid with
have an increased risk of a neoplastic aetiology (likelihood ratio 2.9).615 pericardiocentesis may greatly improve the clinical condition.118
In chronic effusions with no definite aetiology, and without inflamma- Pericardial effusions are usually circumferential, but after trauma or
tory markers, empirical anti-inflammatory treatment is futile.1,621 In cardiac surgery, they may be loculated and even be responsible for lo-
worsening large effusions without evidence of systemic inflammation, calized compression and the development of CTP.
the exclusion of cancer with advanced imaging (mainly CT) is war-
ranted.196 C-reactive protein should be measured before pericardio-
11.8.1. Presentation
centesis, since it can increase after the procedure.622 Notably, the
classical Light criteria used for the classification of pleural effusions Beck identified a triad of signs, consisting of hypotension, increased JVP,
should not be applied to PEff due to the high rate of misclassification and quiet heart sounds as presenting symptoms.118,619
of fluids as exudates, since pericardial fluid is rich in mesothelial cells, This triad was classically identified in ‘surgical tamponade’ with acute
proteins, albumin, and lactate dehydrogenase (LDH).623,624 CTP due to intrapericardial haemorrhage because of trauma, or myo-
cardial/aortic rupture. Beck’s triad may be lacking in patients with ‘med-
ical tamponade’ with slowly accumulating pericardial fluid. Acute CTP is
11.7.4. Therapy
usually associated with tachycardia and low blood pressure
The treatment of PEff is shown in Figure 19. Therapy of PEff should be (<90 mmHg) that is only slightly reduced in subacute, chronic tampon-
targeted at the aetiology, as much as possible. In the absence of pericar- ade.118,619 On physical examination, classical signs include neck vein dis-
dial inflammation (namely in the absence of C-reactive protein elevation tention with elevated JVP, pulsus paradoxus, and diminished heart
and evidence of pericardial inflammation by an imaging technique) anti- sounds. Pulsus paradoxus is defined as an inspiratory reduction of the
inflammatory treatment is not recommended. According to recent systolic blood pressure by at least 10 mmHg.118,619 Pulsus paradoxus
data, the usefulness of pericardial drainage in asymptomatic or oligo- is due to exaggerated ventricular interdependence occurring in CTP,
symptomatic, large, chronic, idiopathic effusions without evidence of when the overall volume of ventricles becomes unable to expand,
pericarditis has been revised.49,621 Conservative treatment improves and any change in the volume on one side of the heart causes opposite
outcomes, the risk of CTP being only 2.2%/year without reported changes on the other side. On ECG, the patient usually shows tachycar-
deaths.625 In addition, survival after recurrence or complications is dia, low QRS voltages, and electrical alternans due to the damping effect
significantly better in patients treated conservatively without interven- of pericardial fluid and swinging heart.118,619
tions. Nevertheless, if during follow-up the PEff becomes symptomatic
and haemodynamic impairment is observed by echocardiography,
11.8.2. Aetiology and diagnosis
drainage is warranted.
Cardiac tamponade shares the same causes of PEff. In clinical practice,
the most common aetiologies include cancer, TB, purulent infections,
11.7.5. Prognosis and follow-up
trauma, iatrogenic complications of cardiovascular interventions (e.g.
The prognosis of PEff is essentially related to its aetiology.626 Moderate ablation of arrhythmias, device implantation, PCIS), acute aortic disease,
to large effusions are more common for specific aetiologies.105,615 In systemic inflammatory diseases, and renal failure.118 In the setting of AP
general, PEff should be considered as a marker of the severity of the with a viral or idiopathic aetiology, CTP is rare (1%–2% of cases) and is
underlying disease.584 Small, idiopathic, asymptomatic PEff have an more common with pericarditis associated with a non-idiopathic aeti-
overall good prognosis with a very low risk of complications, although ology (20%).347 The diagnosis of CTP is a clinical diagnosis based on
not all studies concur.613 Those individuals should be reassured about the combination of a suggestive history, symptoms, signs, and imaging
the benign nature of the condition, and should not restrict their physical confirmation by echocardiography (Table 17).118
activity if C-reactive protein is normal.11 The follow-up of PEff is mainly
based on the evaluation of symptoms, using focused echocardiography
to assess size changes, and haemodynamic issues, as well as C-reactive Table 17 Echocardiographic signs of cardiac tamponade
protein. Asymptomatic patients with mild idiopathic effusions do not
Echocardiographic feature Sensitivity Specificity generally require specific monitoring. In asymptomatic patients with
at least moderate effusions, a reasonable follow-up is every 6 months,
Large pericardial effusion with swinging n.a. n.a.
ideally in specialized centres. The latter patients should be instructed to
heart
seek medical advice in case of symptom appearance, such as dyspnoea
Diastolic collapse of the RA 50%–100% 33%–100%
or fatigue, and/or chest pain suggesting pericarditis.
Duration of diastolic collapse of the RA as >90% 100%
a ratio of the cardiac cycle length >0.34
11.8. Cardiac tamponade
Diastolic collapse of the RV 48%–100% 72%–100%
Cardiac tamponade is a pericardial syndrome occurring when PEff im- Respiratory changes of the mitral E n.a. n.a.
pairs diastolic filling of the heart until cardiac output is reduced. The
velocity >25%–30%, tricuspid E velocity
size of the effusion as well as its distribution may vary. Since the pericar-
>40%–60%
dium is relatively stiff, if pericardial fluid collects quickly, such as in haemo-
Inferior vena cava plethora (dilatation 97% 40%
pericardium, the limit of pericardial stretching is reached quickly with
>20 mm and <50% reduction of diameter
volumes of 200–300 mL. In contrast, slowly accumulating PEff may reach
with respiratory phases), as well as hepatic
1 to 2 L before the development of CTP (Supplementary data online,
vein dilatation
Figure S4). This pathophysiology explains that CTP is a last-drop phenom-
enon. Thus, a small increase of pericardial volume may precipitate the n.a., not available; RA, right atrium, RV, right ventricle.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4014 E S C G u id e l in e s
The diagnosis of CTP identifies high-risk patients with an increased constriction associated with pericarditis.114,119,347 There is a high risk
risk of complications during follow-up and a high probability of a non- of progression in bacterial pericarditis (20%–30%), especially purulent
viral aetiology. The patients should be admitted for therapy and pericarditis, intermediate risk in immune-mediated pericarditis and
monitoring.1,105 neoplastic pericardial diseases (2%–5%), and a low risk in viral and idio-
The definitive therapy is pericardiocentesis, which should be per- pathic pericarditis (<1%).347 Cases of CP after pericardiectomy have
formed urgently according to the clinical presentation. been reported, especially after partial pericardiectomy.627–630 In devel-
oped countries, the most common reported causes are: viral or idio-
11.8.3. Therapy pathic (42%–49%); post-cardiac surgery (11%–37%); post-radiation
therapy, mostly for breast cancer or Hodgkin’s disease (9%–31%); con-
The treatment for CTP is drainage of the pericardial fluid, preferably by
nective tissue disorders (3%–7%); post-infectious causes (purulent peri-
needle pericardiocentesis with the use of echocardiographic or fluoro-
carditis or TB in 3%–6%); and miscellaneous causes (<10%). TB is a
scopic guidance, and should be performed without delay in unstable pa-
major cause of CP in developing countries.630,631
tients. Alternatively, drainage is performed by a surgical approach,
especially in situations such as purulent pericarditis, or urgent situations
with bleeding into the pericardium. 11.9.2. Presentation
Pericardiocentesis should be performed by experienced operators The classical clinical presentation comprises signs and symptoms of
trained/certified in acute cardiovascular care and carries a variable right HF with preserved biventricular function without previous or con-
risk of complications from 4% to 10%, depending on type of monitor- comitant myocardial disease. Subacute/chronic inflammatory pericardi-
ing, operator’s skill, and setting (emergent vs urgent vs elective). The tis can evolve into CP, and the duration of progression from initial
most common complications include arrhythmias, coronary artery or pericardial inflammation and the onset of constriction is variable.347
cardiac chamber puncture, haemothorax, pneumothorax, pneumoper- Systolic dysfunction due to myocardial fibrosis or atrophy can aggravate
icardium, and hepatic injury.1 Mechanical ventilation with positive air- the haemodynamic impairment in more advanced cases.
way pressure should be avoided in CTP. In addition, diuretic therapy In up to 20% of cases, constriction might be present with normal
should be avoided, and temporary fluid administration can be helpful pericardial thickness, while advanced and classic cases demonstrate
to stabilize the patient while waiting for urgent pericardiocentesis. prominent pericardial thickening and calcifications.119
11.8.4. Outcomes and prognosis 11.9.3. Diagnosis
The prognosis of CTP is essentially related to its aetiology. Cardiac tam- The diagnosis is made by multimodality imaging methods, such as echo-
ponade in patients with cancer and metastatic involvement of the peri- cardiography, CT, and CMR (Figure 13). Cardiac catheterization should
cardium has a bad short-term prognosis, since this is a sign of advanced be considered only if non-invasive multimodality imaging methods are
disease. In contrast, patients with CTP and a final diagnosis of idiopathic inconclusive.115,124,632,633 The Mayo Clinic has proposed specific diag-
pericarditis generally have a good long-term prognosis.1,105 nostic criteria, based on echocardiography to diagnose CP, that have
been confirmed by other centres. They include the presence of septal
11.9. Pericardial constriction and bounce or ventricular septal shift with either medial e’ of >8 cm/s or
constrictive pericarditis (calcified and hepatic vein expiratory diastolic reversal ratio of >0.78 (sensitivity
87%, specificity 91%; specificity may increase to 97% if all criteria are
non-calcified)
present with a corresponding decrease of sensitivity to 64%). In add-
11.9.1. Introduction ition, respirophasic variation E-wave mitral inflow of >25%/tricuspid in-
Pericardial constriction is a chronic condition usually characterized by a flow of >40% can be recorded in these patients632,634 (see
thickened, fibrotic, and often calcified pericardium that leads to im- Supplementary data online, Figures S1, S5, and Table S14). The main re-
paired diastolic filling of the heart. Constrictive pericarditis is ported constrictive syndromes are shown in Table 18.
Table 18 Definitions and therapy of main constrictive pericardial syndromes
Syndrome Definition Therapy
Transient constriction Reversible pattern of constriction following A 3–6 month course of empirical
(d.d. permanent constrictive pericarditis, restrictive CMP) spontaneous recovery or anti-inflammatory anti-inflammatory medical therapy
therapy
Effusive–constrictive pericarditis Failure of the right atrial pressure to fall by 50% or Pericardiocentesis followed by medical therapy
(d.d. cardiac tamponade, constrictive pericarditis) to a level <10 mmHg after pericardiocentesis Surgery for persistent cases
May be diagnosed also by non-invasive imaging
Chronic constriction Persistent constriction after 3–6 months Radical pericardiectomy, medical therapy for
(d.d. transient constriction, restrictive CMP) advanced cases or high risk of surgery or mixed
forms with myocardial involvement
CMP, cardiomyopathy; d.d., differential diagnosis.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4015
11.9.4. Therapy 11.10. Effusive–constrictive pericarditis
Medical therapy is considered for specific aetiologies, such as TB, 11.10.1. Introduction
to prevent progression to constriction.558 Antituberculosis drugs
In ECP, pericardial fluid is present, and the scarred pericardium puts
may significantly reduce the risk of constriction from >80%
pericardial fluid under increased pressure, constricts the cardiac vo-
to <10%.569 Anti-inflammatory therapy may help to resolve tran- lumes, and leads to signs of CTP.116,117 Classically it is defined haemo-
sient constriction in 10%–20% of cases of AP.121,122 In such cases,
dynamically as failure of the RAP to fall by 50% or to a level below
to identify patients with potentially reversible forms of constric- 10 mmHg after pericardiocentesis.117 Modern multimodality imaging
tion, pericarditis should be excluded by testing markers of inflam-
allows a non-invasive diagnosis without cardiac catheterization.
mation (e.g. C-reactive protein) or looking for imaging evidence of
pericardial inflammation (e.g. pericardial oedema and/or LGE on
11.10.2. Aetiology
CMR).
Limited data have been published on ECP, and it appears to be a com-
In advanced cases, medical therapy is supportive of controlling symp-
mon condition in developing countries.117 Idiopathic cases are most
toms of congestion, but surgery should never be delayed to improve
commonly found in developed countries, while TB appears to be the
outcomes.
most common cause in developing countries. The other reported
Pericardiectomy is the standard therapy for symptomatic chronic
causes are neoplasia, radiation, chemotherapy, infections (mainly TB
constriction without inflammation or not responding to anti-
and purulent type), and post-surgical pericardial disease.641
inflammatory therapy (see Section 6.4.2). For milder disease or more
advanced disease, or for those with radiation-induced disease, reduced
11.10.3. Presentation
EF, or advanced renal disease, caution is necessary. Radical pericardiect-
omy rather than anterior phrenic-to-phrenic pericardiectomy is war- Clinical features of either CP or CTP, or sometimes both, are typically
ranted for the best outcomes.311,635–637 present in patients with ECP. In patients who appear to have uncompli-
In general, pericardiectomy has been seen as a high-risk surgery with cated CTP, the diagnosis usually becomes evident during pericardiocen-
operative mortality of 6%–10%. However, recent studies show better tesis.117 Tricuspid regurgitation or right HF may cause persistently
results for early surgery in high-volume centres. The risk is related to elevated RAP after efficient pericardiocentesis.
the aetiologies and other comorbidities. Idiopathic causes have the low-
est risk of <1.5%.638–640 11.10.4. Diagnosis
To diagnose ECP, non-invasive imaging may be valuable.641 Thickening of
the epicardial–pericardial layer is responsible for the constrictive compo-
nent. After pericardiocentesis for CTP, careful detection of constriction
Recommendation Table 24 — Recommendations for
constrictive pericarditis (see Evidence Table 24) on Doppler findings can be reported.124 Without haemodynamic mon-
itoring, ECP can also be suspected on echocardiography and CMR (see
Recommendations Classa Levelb Supplementary data online, Table S14). Cardiovascular magnetic reson-
ance may provide helpful information, especially in differentiating con-
Diagnosis
striction from RCM (Table S14). An accurate evaluation of ventricular
Multimodality imaging is recommended in all interdependence and septal bounce can be made by assessing ventricular
patients with suspected constrictive pericarditis to coupling with echocardiography and/or real-time cine CMR.115
make the diagnosis and assess pericardial I C Echo-Doppler findings indicating effusive constriction may be detected
thickening, calcifications, and active prior to pericardiocentesis.116,124 Currently, the diagnosis can be made
inflammation.632 using multimodality imaging without cardiac catheterization.
Cardiac catheterization for haemodynamic
assessment should be considered in patients with 11.10.5. Treatment
IIa C
suspected constrictive pericarditis when Effusive constriction can often resolve spontaneously or be treated with
multimodality imaging is inconclusive.633 anti-inflammatory therapies in the case of evidence of transient constric-
Therapy tion.641 In resistant cases, visceral pericardiectomy must be performed,
since the epicardial layer is responsible for constricting the heart. The visceral
Anti-inflammatory therapy is recommended in
component of pericardiectomy requires sharp dissection of many small frag-
haemodynamically stable patients with a transient or
ments until ventricular motion is improved. Only pericardial centres with ex-
new diagnosis of constriction with concomitant
I C perience and competency should perform pericardiectomy for CP.
evidence of pericardial inflammationc to prevent
progression to constriction and avoid
pericardiectomy.122,123 12. Age- and sex-related aspects in
Pericardiectomy is recommended in patients with inflammatory myopericardial
permanent constriction if there is no active
I C syndrome
inflammation or anti-inflammatory treatment is not
successful after 3–6 months.635,636
12.1. Sex distribution
CMR, cardiovascular magnetic resonance. Acute myocarditis is more prevalent in males (75%–84%).17,28,73,78,642
aClass of recommendation.
bLevel of evidence. On the contrary, the male-to-female ratio is similar in fulminant cases
ci.e. C-reactive protein elevation or pericardial enhancement on CMR. (46% females).56,75,643 Sex differences in pericarditis are less evident,
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4016 E S C G u id e l in e s
with some studies showing a mild prevalence in males of 59% in AP.37 often difficult to withdraw these drugs when clinical remission is achieved;
Males aged 16–65 years are at higher risk of pericarditis (relative risk for instance, in one study only 15% of children were able to stop anti-IL-1
2.02) than females. On the other hand, the probability of pericarditis agents after a mean follow-up of 2.6 years.658 Few paediatric patients were
recurrence is higher in females (HR 1.67), probably due to the higher enrolled in RCTs testing anakinra and rilonacept.283,284
frequency of specific causes (e.g. autoimmune diseases).105
12.3. Pregnancy, lactation, and
12.2. Paediatric patients
reproductive issues
12.2.1. Myocarditis
There is very limited published evidence on this topic. There are only
The annual incidence of myocarditis during childhood is between 1 and
case reports for myocarditis,659–663 and one case series describing
2 cases per 100 000 children.21,644,645 In children <6 years of age, the
pregnant women with RP.664 Pregnancy-associated myocarditis is de-
sex distribution was balanced, 50% each,20 but boys had a significantly
scribed in Section 9.7. Pericardial effusion is the most common manifest-
higher incidence at ages 6 to 15 years.21
ation of pericardial diseases during pregnancy. Effusions during
The proposed diagnostic approach in adults applies also for children,
pregnancy are typically benign, mild or moderate, and well tolerated,
including CMR (e.g. in the MYKKE registry).646
with spontaneous resolution after delivery, and no specific treatment
There are conflicting data regarding the complication rates of EMB in
is required in such cases. However, PEff may be associated with pre-
children, with some studies reporting similar incidence of complications
eclampsia.665 Acute pericarditis is the second most common condition. as in adults, both around 5%, mainly from RV sampling.40,63 Particular
Pre-conception counselling is essential in women of childbearing age
care should be taken in children aged <1 year and in the case of LV bi- with RP or previous myocarditis. In such cases, pregnancy should be
opsies with reported complication rates up to 30%.213
planned in a phase of disease remission, and therapy should be re-
In particular, very young children are predisposed to severe myocar-
viewed. Pre-conception assessment should include multidisciplinary
ditis. Critically ill children admitted to the intensive care unit (ICU)
evaluation. Echocardiography is the preferred imaging method, while
mostly survived, if receiving high-resource therapies, including
X-ray, CT scan, and CMR can be used in selected cases.666
MCS.647 In a prospective multicentre registry it was shown that in acute
In patients with IMPS, vaginal delivery is not excluded in uncompli-
HF and FM, MCS including VAD improved survival.648 Similar results
cated cases, while Caesarean section may be required in the presence
have also been reported from Japan.649
of haemodynamic instability.666 Appropriate follow-up with a multidis-
In infants, enteroviruses, such as Coxsackievirus, were found more
ciplinary team with experience in the field is recommended throughout
commonly than in adults.649 A presumed viral aetiology was identified
pregnancy to ensure good maternal and foetal outcomes.
in 11%–50%,40,63 with a death or HT rate of 2%, similar to adults.21 In
High-dose aspirin or NSAIDs, such as ibuprofen and indomethacin,
biopsy-proven myocarditis, the HT rate rises to 7%, and the mortality
can be used up to the 20th week of gestation. Corticosteroids at the
rate increases to 4%–6%.40
minimal effective dose can be given in patients with active pericarditis
Therapy for myocarditis in children is not well defined. In a
throughout pregnancy along with NSAIDs and in selected cases colchi-
meta-analysis evaluating corticosteroids, no mortality reduction was
cine. Azathioprine and IVIG are compatible with pregnancy and breast-
observed, but a significant improvement in LVEF was reached with
feeding. All these medications, apart from high-dose aspirin, may be
the use of steroids in other studies.650–652 In a meta-analysis evaluating
used during lactation. Colchicine is compatible with pregnancy and
IVIG,628 treatment was not associated with better survival. This was
breastfeeding, and it can be continued throughout pregnancy to pre-
also supported by a prospective trial653 and a multicentre cohort
vent recurrences.664,667–669 The use of IL-1 blockers during pregnancy
study.654 On the contrary, another meta-analysis655 in FM concluded
is controversial. Available literature data seem encouraging; however,
that IVIG therapy (usually 1–2 g/kg over 24–48 h) significantly reduced
the relevant studies are scant and retrospective. Despite the limited evi-
in-hospital mortality and improved LVEF.
dence, anakinra may be continued through conception, pregnancy, and
Genetic evaluation might help in the future in differentiating subsets
lactation in women with rheumatic and musculoskeletal diseases who of children and tailoring therapies.93
are not able to use alternative therapies.668–670 More details regarding
drug dosages can be found in Supplementary data online, Table S16.
12.2.2. Pericarditis There are no specific limitations for men with pericarditis who are
In children aged 12 years or less, the incidence of AP was 2.8/100 000 in a planning to have children because they can safely continue
population study from 2009 to 2021.644 The diagnostic criteria (see therapy.667,668
Table 4), aetiologies, and risk of recurrences (see Tables S2 and S3) are
similar to those reported in adults (see Supplementary data online,
Recommendation Table 25 — Recommendations for
Table S1). Most paediatric cases of pericarditis are related to PPS, particu- pregnancy, lactation, and reproductive issues (see
larly after atrial septal defect closure. Compared with adults, children more Evidence Table 25)
commonly have an inflammatory phenotype.656 Non-steroidal anti-
inflammatory drugs remain the mainstay of therapy at high dosages (see Recommendations Classa Levelb
Supplementary data online, Table S15). Most paediatricians avoid aspirin.
Pre-conception counselling is recommended in
Colchicine halved recurrences in children, similarly as for adults.656,657
women with recurrent pericarditis or myocarditis to I C
The use of corticosteroids should be restricted even more than in adults,
assess disease activity and to review therapy.
given that their side effects (including striae rubrae and growth impair-
ment) are particularly deleterious in growing children. Anti-interleukin-1 NSAIDs should be considered in pregnant patients
agents have been used for the first time in children with autoinflammatory with pericarditis until the 20th week to treat an IIa C
diseases and then adopted for RP in them, representing a new therapeutic incessant/recurrent course.664
option, especially if they are corticosteroid-dependent. However, it is Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4017
Anti-inflammatory therapies should be considered in SCD. To ensure resolution of the disease, recovery should be moni-
patients with pericarditis during lactation to treat and tored, including clinical assessment, rhythm control, laboratory analysis,
IIa C
prevent pericarditis with timing adjusted to reduce and multimodality imaging (see Table 15). A personalized prescription
of exercise should be performed, based on the patient (athletes, non-
drug exposure of the breastfed infant.
athletes), and type of exercise.
During pregnancy and breastfeeding, corticosteroids
at the minimal effective dose (preferably up to 20 mg
12.5.1. Mental health effect of restricting exercise
prednisone daily) should be considered in patients IIa C
with active pericarditis, despite NSAID (if feasible), to Exercise restriction can affect patient mental health, especially in chil-
prevent an incessant/recurrent course.664 dren and young adults. It can lead to frustration, sadness, and depres-
sion in patients. Freedom to exercise should be approached with
Colchicine may be considered in pregnant patients
shared decision-making, taking into account the risk vs benefit ratio in
with pericarditis, especially in patients already IIb C
the single case.
receiving this drug to prevent recurrences.
Anakinra may be considered through pregnancy and
lactation in pregnant patients with recurrent Recommendation Table 26 — Recommendations for
IIb C
pericarditis who are not able to use alternative physical activity and myocarditis/pericarditis (see
Evidence Table 26)
therapies to prevent an incessant/recurrent course.
NSAID, non-steroidal anti-inflammatory drug. Recommendation Classa Levelb
aClass of recommendation.
bLevel of evidence. Restriction of physical exercise until remission, for at
least 1 month, is recommended in athletes and
I C
non-athletes after IMPS using an individualized
approach to accelerate recovery.
12.4. The elderly
Myocarditis is more prevalent in young people, with a median age be- IMPS, inflammatory myopericardial syndrome.
tween 20 and 40 years.28,55,63,73 In a Swedish study, 64% patients aClass of recommendation.
bLevel of evidence.
were younger than 50 years of age. In this study, HF/DCM and deaths
occurred more commonly in patients aged >50 years.17 Myocarditis is
probably more commonly related to drugs in the elderly, e.g. ICIs28,495 12.6. Multidisciplinary teams for the
and clozapine.508 Age- and sex-based differences have been evaluated in
management of inflammatory
two studies with AP, and one study with RP.45,102,671 In these studies,
myopericardial syndrome
elderly patients less often had chest pain, fever, ST elevation, and PR de-
pression. They had lower C-reactive protein values but dyspnoea, AF, It is recommended to have a multidisciplinary team for high-risk cases
and PEff were more common. Moreover, they received glucocorticoids with IMPS. The team should be composed of a clinical cardiologist, a
more commonly, and had a lower risk of recurrences compared with CMR imaging specialist with expertise in IMPS, a pathologist with ex-
younger patients. In the elderly, therapy compliance may be problem- pertise in cardiovascular diseases, and additionally, depending on the
atic, because of cognitive impairment and comorbidities, but the stron- case, a rheumatologist (or clinical immunologist), an infectious disease
gest predictor of non-adherence is the number of medications.672 specialist, a geneticist (or a cardiologist with expertise in genetics),
Non-steroidal anti-inflammatory drugs should be used cautiously; dos- interventional cardiologists (including electrophysiologists), and a car-
ing should be adapted (e.g. colchicine dose should be halved in some diac intensive care specialist. A cardiac surgeon might be involved sub-
cases), and attention should be paid to evaluate renal impairment and sequently when interventional or surgical decisions are anticipated.
drug interactions. More details are given in Figure 20. It is of paramount importance
that physicians develop competence and skills in IMPS to allow timely
diagnosis and therapy for patients, since mixed forms are common in
12.5. Physical activity in inflammatory
clinical practice. Patient involvement is important, particularly when
myopericardial syndrome the evidence is scarce to foster shared decision-making.375,673,674
Patients with active IMPS are advised to restrict physical activity. It has
been proposed that exercise can aggravate myocardial and pericardial
Recommendation Table 27 — Recommendations for
inflammation through several mechanisms, including a tachycardia-
multidisciplinary teams in myopericardial syndromes
mediated process. The importance of controlling heart rate is con-
(see Evidence Table 27)
firmed by observational studies, in which the empirical use of
β-blockers to control heart rate in patients with pericarditis improved Recommendations Classa Levelb
symptom control.274 Previous recommendations have made distinc-
tions between athletes and non-athletes, providing arbitrary times for A multidisciplinary team discussion at a referral
abstention from 3 to 6 months. This TF recommends an individualized centre is recommended in patients with high-risk/
I C
approach, based on remission times. A complete clinical remission complicated IMPS to provide a patient-tailored
should be considered in athletes/non-athletes with normalization of approach.375,673
symptoms, biomarkers, and imaging.
IMPS, inflammatory myopericardial syndrome.
During the acute stage of myocarditis, patients are advised to rest aClass of recommendation.
completely, since exercise has been associated with arrhythmias and bLevel of evidence.
5202CSE©
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4018 E S C G u id e l in e s
(cid:31)(cid:30)(cid:29)(cid:28)(cid:29)(cid:27)(cid:26)(cid:30)(cid:25)(cid:27)(cid:26)(cid:24)(cid:23)(cid:29)(cid:22)(cid:30)(cid:22)(cid:21)(cid:29)(cid:20)(cid:19)
(cid:31)(cid:26)(cid:24)(cid:23)(cid:29)(cid:26)(cid:27)(cid:25)(cid:29)(cid:8)(cid:26)(cid:21)(cid:29)(cid:28)(cid:21)(cid:25)(cid:20)(cid:12)(cid:17)(cid:27)(cid:29)(cid:26)(cid:30)(cid:29)(cid:20)(cid:19) (cid:11)(cid:26)(cid:19)(cid:14)(cid:22)(cid:30)(cid:22)(cid:21)(cid:29)(cid:20)(cid:19)
(cid:18)(cid:28)(cid:19)(cid:17)(cid:24)(cid:16)(cid:17)(cid:28)(cid:19)(cid:29)(cid:22)(cid:28)(cid:26)(cid:30)
(cid:10)(cid:30)(cid:17)(cid:27)(cid:19)(cid:24)(cid:22)(cid:12)(cid:14)(cid:9)(cid:20)(cid:29)(cid:22)(cid:30)(cid:22)(cid:21)(cid:29)(cid:20)(cid:19)
(cid:27)(cid:26)(cid:24)(cid:23)(cid:29)(cid:22)(cid:30)(cid:22)(cid:21)(cid:29)(cid:20)(cid:19)
(cid:18)(cid:5)(cid:11)(cid:4)
(cid:5)(cid:13)(cid:30)(cid:19)(cid:29)(cid:23)(cid:29)(cid:20)(cid:27)(cid:29)(cid:12)(cid:30)(cid:29)(cid:28)(cid:26)(cid:24)(cid:9)
(cid:31)(cid:26)(cid:24)(cid:23)(cid:29)(cid:26)(cid:27)(cid:25)(cid:29)(cid:28)(cid:19)(cid:17)(cid:28)(cid:20)(cid:29)(cid:16)(cid:17) (cid:31)(cid:26)(cid:24)(cid:23)(cid:29)(cid:26)(cid:27)(cid:15)(cid:19)(cid:14)(cid:22)(cid:24)(cid:26)(cid:27)(cid:29)(cid:27)
(cid:19)(cid:17)(cid:26)(cid:8)(cid:26)(cid:25)
(cid:27)(cid:26)(cid:24)(cid:17)(cid:25)(cid:20)(cid:12)(cid:17)(cid:27)(cid:29)(cid:26)(cid:30)(cid:29)(cid:20)(cid:19) (cid:20)(cid:13)(cid:24)(cid:21)(cid:17)(cid:22)(cid:28)
(cid:18)(cid:8)(cid:8)(cid:13)(cid:28)(cid:22)(cid:30)(cid:22)(cid:21)(cid:29)(cid:20)(cid:19)(cid:15)
(cid:11)(cid:20)(cid:9)(cid:27)(cid:14)(cid:22)(cid:30)(cid:22)(cid:21)(cid:29)(cid:20)(cid:19)
(cid:24)(cid:14)(cid:17)(cid:13)(cid:8)(cid:26)(cid:19)(cid:22)(cid:30)(cid:22)(cid:21)(cid:29)(cid:20)(cid:19)
(cid:18)(cid:28)(cid:7)(cid:17)(cid:27)(cid:19)(cid:29)(cid:22)(cid:13)(cid:20)(cid:25)(cid:23)(cid:29)(cid:20)(cid:17)(cid:26)(cid:20)(cid:17) (cid:6)(cid:17)(cid:28)(cid:17)(cid:19)(cid:29)(cid:27)(cid:29)(cid:20)(cid:19)
(cid:20)(cid:12)(cid:17)(cid:27)(cid:29)(cid:26)(cid:30)(cid:29)(cid:20)(cid:19)
Figure 20 Multidisciplinary teams for inflammatory myopericardial syndrome. aFull team—tailored to the specific case.
13. Advice for patients manage patients with IMPS. Leading institutions are recognized for their
cardiovascular expertise and often handle patients with complex dis-
Specific patient education is mandatory for patients with IMPS. Advice ease.674 Such centres have significant expertise in the diagnosis and
should address the causes, rationale for treatment, possible complica- therapy of myocarditis and pericarditis and are actively involved in re-
tions, and outcomes. Inflammatory myopericardial syndrome affects search. They should be the referral centre of choice for complicated
young patients and may severely affect their quality of life. Specific ad- cases that cannot be managed by regional centres. Endomyocardial bi-
vice should be provided on the need for rest during the acute phase of opsy referral centres for deep investigation of EMB samples, including
the disease, and the timing for return to physical activity and work, as immunochemistry and molecular testing, should be identified at region-
well as benefits and risks associated with tailored immunosuppres- al or national level.
sive/immunomodulatory therapies, and when to contact the multidis-
ciplinary team. Advice must be tailored to the specific social situation.
14.2. Inflammatory myopericardial
Suitable language should be used, recognizing the patient’s educational
status. Clarification based on images is preferrable. Care should be ta- syndrome in regional centres
ken not to aggravate anxiety unnecessarily. An additional description Most uncomplicated cases can be handled by regional centres, and de-
and advice for patients with IMPS is provided in Supplementary data pending on the healthcare systems, in outpatient departments.
online, Section 8, Figure S6, and Table S17. A separate document dedi- However, the crucial factor is the local expertise. At the same time,
cated to patients has been developed. those with more severe pericarditis or myocarditis might need treat-
ment at a hospital or tertiary care referral centre that has advanced
multimodality imaging capacity and access to new therapeutic
14. Tertiary referral centres for agents.674
inflammatory myopericardial
14.3. Hub-and-spoke model
syndrome: feature and volume of
These centres should be capable of managing all care levels and adopt a
activity
hub-and-spoke model. Regardless of where care is provided, the goal is
to sustain communication and collaboration throughout all healthcare
14.1. Tertiary care centres
system levels. The hub-and-spoke model aims to ease patient access
Tertiary care centres of excellence are extensive, renowned healthcare to suitable care levels, promote care co-ordination, and drive quality
facilities that house specialized cardiology departments equipped to enhancement for all patients with IMPS.674,675
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4019
14.4. Teamwork, competencies, and drugs and colchicine are useful to control chest pain, while additional
advances in imaging techniques therapies should be guideline-directed for specific complicated courses.
If a specific aetiology is identified, treatment should be targeted at the
Building a contemporary multidisciplinary team requires knowledge of
specific cause. In all cases of IMPS, restriction of physical activity is re-
recent advancements in imaging techniques, as well as evidence-based
commended in the acute phase, while return to work and physical ac-
strategies for drug, interventional, and surgical therapies.63,674–676
tivity should be individualized according to clinical remission times.
The conventional organization of academic or practice departments of-
ten operates in isolation, hindering the requirements of diseases that
demand the insights and skills of a diverse expert panel. These centres 15.4. Prognosis and outcomes
should endorse a comprehensive team setup that encourages regular, The prognosis of IMPS varies. Most patients presenting with chest pain
ongoing communication among all members. The role of physician-led have a favourable outcome, although recurrences, especially for peri-
vs nurse-led tertiary centres should be explored further674,675 in view carditis, may severely affect the quality of life of patients and require
of the increasing number and complexity of these patients, and the util- long-term follow-up. For complicated cases of myocarditis with HF
ity of monitoring inflammatory markers and serial monitoring of cardiac and arrhythmias, a tailored and individualized approach is warranted.
imaging, even in an outpatient setting. Such patients require long-term follow-up, usually lifetime monitoring.
15. Key messages 15.5. Multidisciplinary team
Management of patients with IMPS should usually be guided by a multi- The recognition of the whole spectrum of IMPS is increasing within the
disciplinary team, which should be tailored to the specific patient. This
medical community. This is based on a deeper understanding leading to
team should be composed of different clinicians, all with expertise in
a more systematic evaluation, as well as more data being generated by
cardiovascular diseases (e.g. imaging experts, a pathologist, a rheuma-
prospective trials. Although these entities have been explored for some
tologist, an infectious disease specialist, a geneticist, interventional car-
time, the COVID-19 pandemic was the main trigger to increase the
diologists, intensive care specialists, and surgeons). It is of paramount
awareness on the spectrum of disease. Advanced multimodality imaging
importance that physicians develop competence and skills either in
technologies, including CMR, allow a patient-tailored diagnostic and
myocarditis or pericarditis to allow timely diagnosis and therapy for pa-
therapeutic approach. A major diagnostic paradigm change is the cap-
tients, because mixed forms are common in clinical practice.
ability of reaching a clinical diagnosis of certainty by non-invasive multi-
modality imaging (CMR for myocarditis), while EMB remains important
in selected intermediate- and high-risk cases, if a targeted specific ther-
16. Gaps in evidence
apy, based on specific histotypes or aetiologies, is needed.
The field of IMPS has significant knowledge gaps across all aspects, from
15.1. Aetiology
pathogenesis to therapy. However, growing awareness has led to nu-
Inflammatory myopericardial syndrome is a spectrum of inflammatory merous ongoing studies. Advances in multimodality imaging have en-
diseases with some common aetiologies, either infectious or non- abled a more comprehensive and non-invasive understanding of
infectious, that can affect either the myocardium (myocarditis) or peri- disease progression, opening the way to patient-tailored approaches.
cardium (pericarditis) in isolated forms, or combined (myopericarditis Despite these advancements, large-scale prospective multicentre trials
and perimyocarditis). with predefined outcome measures are lacking. These uncertainties are
especially pronounced in chronic conditions, as well as in specific pa-
15.2. Clinical presentation and diagnosis tient groups, such as children, women of childbearing age, during preg-
nancy, lactating women, and in the elderly.
In a large percentage of cases, myocarditis and pericarditis have a chest
A further challenge is the handling of the return to work and physical
pain presentation, and generally preserved biventricular function with
activity as there is a need for a patient-specific approach, taking into
good outcomes. For myocarditis, complicated forms include those pre-
consideration the individual risk. Lessons learned from other diseases
senting with severe HF and arrhythmias. Nevertheless, uncomplicated
should lead to less restrictive guidance in comparison with previous
presentations may also develop life-threatening complications, albeit
advice.
less commonly, and therefore also may need fast management.
For pericarditis, complicated cases include those with an incessant or
recurrent course. Many cases with persistent symptoms may show 16.1. Myocarditis
constrictive physiology, which can be reversible after appropriate med-
Knowledge about myocarditis has evolved during recent years, as the
ical therapy. The diagnosis of non-high-risk cases is based on clinical
different mechanisms are better understood. Several causes, such as
evaluation, including ECG and biomarkers, with non-invasive confirm-
viral and toxic ones, including chemotherapy, as well as systemic disor-
ation of the clinical suspicion by evidence of inflammatory involvement
ders, have been investigated, and targeted therapeutic approaches
using multimodality imaging (mainly echocardiography and CMR).
were proposed. However, further research into specific therapy is
Endomyocardial biopsy is recommended for intermediate- and high-
needed based on advanced diagnostic approaches.
risk cases on a case-by-case decision, only when results are expected
Nevertheless, a specific challenge for myocarditis is related to the
to change management.
low frequency of complications and the high rate of spontaneous remis-
sion. On this basis, clinical trials on medical therapy for myocarditis
15.3. Therapy
might be currently underpowered to assess the clinical benefit of a spe-
The treatment of uncomplicated IMPS is empirical, aiming at the control cific treatment with small sample sizes. In addition, many antiviral ther-
of symptoms and prevention of complications. Anti-inflammatory apies are off-label for myocarditis and controlled trials are missing.
Downloaded
from

by
guest
on
22
January
2026

4020 E S C G u id e l in e s
Currently, quantitative immunohistochemistry criteria for the diag- A significant management issue is the treatment of patients not re-
nosis of LM are under discussion among cardio-pathologists to present sponding to colchicine and anti-IL-1 agents, as well as the causes of
more definite criteria for EMB. drug dependence to maintain stable clinical remission, such as for cor-
Furthermore, a better understanding of the pathogenic and prognos- ticosteroids and anti-IL-1 agents.
tic role of viral loads is needed (e.g. active/causative vs latent/innocent Additional research is also warranted to understand the prognostic
bystanders in cardiac viral infections). significance of persistent LGE of the pericardium.
Moreover, the role of genetic predisposition in recurrent myocardi- There are limited data to support the best timing of return to work
tis is not thoroughly clarified. Research into the role of genetic predis- and physical activity, and further research is needed on this topic with
position is evolving to change the classification of disease and may appropriate clinical trials or observational studies.
influence therapeutic pathways in the future. An increase of ‘overlap-
ping’ conditions, especially DCM and ARVC, can be expected and
17. Sex differences
may change our understanding of the disease in the future.
That means, more research is warranted on the prognosis and SCD
There is limited published evidence on this topic. Inflammatory myo-
risk stratification.
pericardial syndrome seems to affect males more than females from
a young age. Myocarditis complicated by VA is more common in males,
while in females, a relatively higher proportion of cases presents with
16.2. Pericarditis
complicated forms compared with males, and systemic autoimmune
There are significant knowledge gaps in individualized treatment and disorders are more commonly diagnosed. This was addressed in the
pathogenesis of various types of pericarditis, as well as the understand- relevant sections. The diagnostic approaches are similar, but care
ing of the interaction among genetic background, inflammation, and should be taken when applying normal values, especially in imaging.
autoimmune mechanisms. Better knowledge of the pathogenesis of re- Medication should be adapted in women of childbearing age, pregnancy,
currences may also help to develop more targeted and individualized and during lactation (more details are specified in specific sections).
therapies.
The genetic background requires further evaluation in complicated,
18. ‘What to do’ and ‘What not to
recurrent cases and could be helpful to elucidate the mechanisms lead-
ing to incessant/recurrent forms. New therapeutic options should also do’ messages from the Guidelines
be considered and evaluated in clinical trials to explore new drugs for
more complicated, incessant, or recurrent cases to develop a more in- Table 19 lists all Class I and Class III recommendations from the text
dividualized and efficacious approach for the treatment of pericarditis. alongside their level of evidence.
Table 19 ‘What to do’ and ‘What not to do’
Recommendations Classa Levelb
Recommendations for clinical evaluation of myocarditis and pericarditis
Complete clinical evaluation, including history, physical examination, chest X-ray, biomarkers, ECG, and echocardiography is recommended
I C
in all patients with a suspicion of myocarditis and/or pericarditis for the initial diagnostic assessment.
CMR is recommended in patients with the clinical suspicion of myocarditis (using updated LL criteria) and/or pericarditis for the I B
non-invasive diagnosis of inflammatory reaction.
Hospital admission is recommended for patients with high-risk pericarditis for monitoring and treatment. I B
Hospital admission is recommended for patients with moderate- to high-risk myocarditis for monitoring and treatment. I C
EMB is recommended in patients with high-risk myocarditis and/or haemodynamic instability, and/or in patients with intermediate-risk
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral I C
genome for treatment.
Invasive coronary angiography or coronary CT, depending on clinical likelihood, is recommended in patients with IMPS if an acute coronary
I C
syndrome is suspected to rule out obstructive coronary artery disease.
Routine serology is not recommended in patients with myocarditis and/or pericarditis for the evaluation of viral aetiology except for
III C
hepatitis C, HIV and Lyme disease.
Recommendations for genetic testing
It is recommended to obtain family history including pedigrees in cases of recurrent IMPS to provide clues to the underlying aetiology,
I C
determine inheritance pattern, and identify relatives at risk.
Recommendations for the use of cardiovascular magnetic resonance imaging
Myocarditis
CMR is recommended in patients with suspected myocarditis to reach a clinical diagnosis and to determine the cause of acute myocardial
I B
injury, including assessment of oedema, ischaemia, and necrosis/fibrosis/scarring.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4021
CMR is recommended for follow-up at least within the first 6 months in patients with myocarditis to identify a healed or ongoing process,
I C
for risk stratification and personalized therapy, and to enable a return to exercise.
Pericarditis
CMR is recommended in patients with suspected pericarditis when a diagnosis cannot be made using clinical criteria to assess evidence of
I B
pericardial thickening, oedema, LGE, and to assess the persistence of disease during follow-up in selected cases.
Recommendations for computed tomography
CT is recommended to evaluate pericardial thickness, calcifications, masses, and loculated pericardial effusions, as well as concomitant
I C
pleuropulmonary diseases and chest abnormalities.
Recommendations for endomyocardial biopsy
EMB is recommended in patients with high-risk myocarditis, and/or haemodynamic instability, and/or in patients with intermediate-risk
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral I C
genome for treatment.
Recommendations for autopsy
Comprehensive autopsy is recommended in all patients <50 years of age with SCD to evaluate the presence of acute myocarditis as a cause
I B
and to detect potential underlying inherited cardiac diseases.
Retaining samples suitable for DNA extraction and consulting a cardiac pathologist is recommended in cases of SCD, when an inherited
I B
cause is suspected, or the cause of death remains unexplained.
Recommendations for medical therapy in myocarditis
Management of heart failure
Adherence to the ESC HF guidelines is recommended in cases of myocarditis with LV systolic dysfunction and/or HF to reduce symptoms
I C
and to improve LV function.
Immunosuppressive therapy
Routine use of immunosuppressive therapy is not recommended in acute myocarditis with preserved LV function because no outcome
III C
benefit has been shown.
Recommendations for medical therapy in pericarditis
Colchicine is recommended as first-line therapy in patients with pericarditis as an adjunct to aspirin/NSAID or corticosteroid therapy to
I A
reduce subsequent recurrences.
Anti-IL-1 agents (anakinra or rilonacept) are recommended for patients with recurrent pericarditis after failure of first-line therapies and
I A
corticosteroids, and elevation of C-reactive protein levels to reduce recurrences and allow corticosteroid withdrawal.
High-dose aspirin or NSAIDs with proton pump inhibitors are recommended as first-line therapy in patients with pericarditis to control
I B
symptoms and reduce recurrences.
Corticosteroids are not recommended as the first option for patients with pericarditis therapy without a specific indication. III C
Recommendations for interventional techniques, including circulatory support in myocarditis
A timely and dedicated Shock Team discussion is recommended in patients with myocarditis in the presence of haemodynamic
I C
compromise, to decide on the need for escalation to MCS and to determine a long-term management plan.
Recommendations for interventional techniques in pericarditis
Pericardiocentesis (echocardiography CT-, or fluoroscopy-guided) is recommended for cardiac tamponade, or suspected bacterial or
I C
neoplastic pericarditis, or symptomatic moderate to large pericardial effusion despite medical therapy.
Surgical pericardial drainage is recommended in patients with pericardial effusion when percutaneous pericardiocentesis is not feasible or
I C
with purulent pericardial effusion to allow complete drainage and to prevent constriction.
Surgical pleuro-pericardial window is recommended in patients with relapsing pericardial effusion despite medical therapy. I C
Recommendations for surgical therapy
Surgical pericardiectomy is recommended in patients with chronic pericardial constriction or persistent constrictive pericarditis despite
I C
medical therapy to improve symptoms and survival.
Tricuspid valve repair is recommended in patients with pericardial constriction and severe tricuspid valve regurgitation to improve
I C
symptoms and survival.
Recommendations for management of arrhythmias and prevention of sudden cardiac death in myocarditis
ICD in myocarditis—secondary prevention
ICD implantation is recommended in patients with non-active myocarditis and haemodynamically not-tolerated sustained VT to prevent
I C
SCD.
Continued
Downloaded
from

by
guest
on
22
January
2026

4022 E S C G u id e l in e s
Recommendations for risk stratification, complications, and outcomes of inflammatory myopericardial syndrome
Follow-up with clinical assessment, biomarkers, ECG, exercise test, Holter-ECG monitoring, echocardiography, and CMR at least within
6 months after the index hospitalization is recommended in all patients with myocarditis to identify a potential progression or new risk I C
factors.
Long-term follow-up is recommended for patients with complicated myocarditis to identify a potential progression or new complications. I C
Long-term follow-up is recommended for patients with incessant or recurrent pericarditis to identify a potential progression and new
I C
complications.
Recommendations for giant-cell myocarditis
EMB is recommended in patients with suspected GCM due to unexplained new-onset HF of up to 2 weeks associated with a normal or
dilated left ventricle and new ventricular arrhythmias, second- or third-degree AVB, or failure to respond to usual care within 1 to 2 weeks I C
to initiate specific treatment.
Combined immunosuppressive therapy is recommended in patients with a diagnosed GCM. I C
Recommendations for myocarditis in sarcoidosis
Diagnosis
CMR, using tissue characterization techniques, is recommended in patients with suspected CS to assess cardiac inflammation and
I B
myocardial involvement.
18F-FDG-PET is recommended for the diagnostic work-up, including detection of inflammation, as well as for follow-up and assessment of
I B
therapeutic response in patients with CS.
Therapy
ICD implantation is recommended in patients with CS and sustained ventricular arrhythmia (VT/VF) or aborted CA to prevent SCD. I B
ICD implantation is recommended in patients with CS and LVEF ≤35% to prevent SCD. I C
Recommendations for immune checkpoint inhibitor-associated myocarditis
Diagnostic triage within 24 h is recommended in patients with suspected myocarditis induced by ICI to initiate treatment rapidly. I C
Immediate disruption of ICI and administration of high-dosage corticosteroids are recommended in patients with ICI-associated myocarditis
I C
in order to stop the inflammatory reaction and stabilize the patient.
Recommendations for inflammatory cardiomyopathy
Guideline-directed HF treatments are recommended in patients with inflammatory cardiomyopathy to improve and/or stabilize left
I C
ventricular function.
Specific medical therapy for the potentially underlying systemic disease is recommended in inflammatory cardiomyopathy. I C
Recommendations for tuberculous pericarditis
Diagnosis and treatment of tuberculous pericarditis and effusion
Diagnostic pericardiocentesis is recommended in all patients with suspected tuberculous pericarditis when diagnosis is not confirmed by
I C
non-invasive tests to identify the aetiological agent in pericardial fluid.
Empirical antituberculosis chemotherapy is recommended in patients living in endemic areas with exudative pericardial effusion after
I C
excluding other causes to treat the most likely cause.
Standard antituberculosis multidrug treatment for 6 months is recommended in patients with tuberculous pericarditis for the prevention of
I C
pericardial constriction.
Pericardiectomy is recommended in patients with tuberculous pericarditis if the condition is not improving or is deteriorating after
I C
4–8 weeks of antituberculosis therapy to change the course of disease.
Empirical antituberculosis treatment is not recommended in patients living in non-endemic areas. III C
Recommendations for neoplastic pericardial involvement
Pericardiocentesis is recommended for patients with cardiac tamponade to relieve symptoms and establish the diagnosis of malignant
I C
pericardial effusion.
Extended pericardial drainage (3–6 days) is recommended in patients with suspected or definite neoplastic pericardial effusion to prevent
I B
effusion recurrence.
Cytological analysis of pericardial fluid is recommended in patients with neoplastic pericarditis for the confirmation of malignant pericardial
I C
disease.
Systemic antineoplastic treatment is recommended in confirmed cases of neoplastic aetiology to treat the primary and secondary metastatic
I C
neoplastic involvement.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4023
Recommendations for post-cardiac injury syndrome
Anti-inflammatory therapy is recommended in patients with PCIS to hasten symptom remission and reduce recurrences. I B
IL-1 antagonists are recommended in patients with refractory PCIS to prevent recurrences and progression to constriction. I B
High-dose aspirin is recommended as the first-choice anti-inflammatory therapy for post-myocardial infarction pericarditis and in patients
I C
already on antiplatelet therapy.
Recommendations for purulent pericarditis
Urgent pericardiocentesis and/or a surgical window is recommended in patients with suspicion of purulent pericarditis to establish a
I C
diagnosis.
Recommendations for constrictive pericarditis
Diagnosis
Multimodality imaging is recommended in all patients with suspected constrictive pericarditis to make the diagnosis and assess pericardial
I C
thickening, calcifications, and active inflammation.
Therapy
Anti-inflammatory therapy is recommended in haemodynamically stable patients with a transient or new diagnosis of constriction with
I C
concomitant evidence of pericardial inflammation to prevent progression to constriction and avoid pericardiectomy.
Pericardiectomy is recommended in patients with permanent constriction if there is no active inflammation or anti-inflammatory treatment
I C
is not successful after 3–6 months.
Recommendations for pregnancy, lactation, and reproductive issues
Pre-conception counselling is recommended in women with recurrent pericarditis or myocarditis to assess disease activity and to review
I C
therapy.
Recommendations for physical activity and myocarditis/pericarditis
Restriction of physical exercise until remission, for at least 1 month, is recommended in athletes and non-athletes after IMPS using an
I C
individualized approach to accelerate recovery.
Recommendations for multidisciplinary teams in myopericardial syndromes
A multidisciplinary team discussion at a referral centre is recommended in patients with high-risk/complicated IMPS to provide a
I C
patient-tailored approach.
AVB, atrioventricular block; CA, cardiac arrest; CMR, cardiovascular magnetic resonance; CS, cardiac sarcoidosis; CT, computed tomography; DNA, deoxyribonucleic acid; ECG,
electrocardiogram; EMB, endomyocardial biopsy; ESC, European Society of Cardiology; 18F-FDG-PET, [18F]-fluorodeoxyglucose positron emission tomography; GCM, giant-cell
myocarditis; HF, heart failure; HIV, human immunodeficiency virus; ICD, implantable cardioverter-defibrillator; ICI, immune checkpoint inhibitor; IL, interleukin; IMPS; inflammatory
myopericardial syndrome; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; NSAID, non-steroidal
anti-inflammatory drug; PCIS, post-cardiac injury syndrome; SCD; sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
19. Evidence tables Kardiologie, Angiologie und Intensivmedizin, Berlin, Germany;
Yehuda Adler, Sackler Medical School, Tel Aviv University, Tel
Evidence tables are available at the European Heart Journal online. Aviv, Israel; Antonio Brucato, Department of biomedical and clin-
ical sciences, University of Milano, Fatebenefratelli Hospital, Milano,
Italy; Vanessa Christian (United Kingdom), ESC Patient Forum,
20. Data availability statement
Sophia Antipolis, France; Vanessa M. Ferreira, Oxford Centre
for Clinical Magnetic Resonance Research (OCMR), University of
No new data were generated or analysed in support of this research.
Oxford, Oxford, United Kingdom; Estelle Gandjbakhch,
Cardiology Departement, Sorbonne Université, APHP, Hôpital
21. Author information Pitié Salpêtrière, Paris, France, and Referral Center for Inherited
Cardiac Diseases, APHP, Hôpital Pitié Salpêtrière, Paris, France,
Author/Task Force Member Affiliations: Valentino Collini, and Inserm 1166, IHU ICAN, Paris, France; Bettina Heidecker,
Cardiology, Cardiothoracic Department, Santa Maria della Deutsches Herzzentrum der Charité, Universitätsmedizin Berlin,
Misericordia University Hospital, Udine, Italy; Jan Gröschel, Charité Berlin, Germany, and Berlin Institute of Health (BIH), Charité,
—Universitätsmedizin Berlin, corporate member of Freie Universität Universitätsmedizin Berlin, Berlin, Germany, and DZHK (German
Berlin and Humboldt-Universität zu Berlin, ECRC Experimental and Centre for Cardiovascular Research), partner site Berlin, Berlin,
Clinical Research Center, Berlin, Germany, and DZHK (German Germany; Mathieu Kerneis, Sorbonne Université, Paris, France,
Centre for Cardiovascular Research), partner site Berlin, Berlin, and ACTION Group, Paris, France, and UMRS 1166 Inserm, Paris,
Germany, and Deutsches Herzzentrum der Charité, Klinik für France, and Institute of Cardiology, Hôpital Pitié-Salpêtrière,
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4024 E S C G u id e l in e s
Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Allan Sannino (Germany), Franziska Seidel (Germany), Felix C. Tanner
L. Klein, Center for the diagnosis of pericardial disease, department (Switzerland), Witold Zbyszek Tomkowski (Poland), Ilonca
of cardiovascular medicine, heart, vascular and thoracic institute, Vaartjes (Netherlands), Sophie Van Linthout (Germany), Christiaan
Cleveland clinic, Cleveland, Ohio, United States of America; Karin Vrints (Belgium), Romuald Wojnicz (Poland), Katja Zeppenfeld
Klingel, Institute for Pathology and Neuropathology, University (Netherlands)
Hospital Tuebingen, Tuebingen, Germany; George Lazaros, ESC National Cardiac Societies actively involved in the review
Cardiology, School of medicine, Hippokration General Hospital, process of the ESC Guidelines for the management of myocarditis and
National and Kapodistrian University of Athens, Athens, Greece; pericarditis:
Roberto Lorusso, Cardio-Thoracic Surgery, Maastricht University Albania: Albanian Society of Cardiology, Albana Doko Banushi;
Medical Centre, Maastricht, Netherlands, and Cardiovascular Research Algeria: Algerian Society of Cardiology, Mohammed Chettibi;
Institute Maastricht, Maastricht, Netherlands; Elena G. Nesukay, Armenia: Armenian Cardiologists Association, Hamayak S. Sisakian;
Department of non-coronary heart diseases, rheumatology and therapy, Azerbaijan: Azerbaijan Society of Cardiology, Ogtay Musayev;
National scientific center “The M.D. Strazhesko institute of cardiology, Belgium: Belgian Society of Cardiology, Bernard P. Paelinck; Bosnia
clinical and regenerative medicine”, Kiev, Ukraine; Kazem Rahimi, and Herzegovina: Association of Cardiologists of Bosnia and
Nuffield department of women’s and reproductive health, University Herzegovina, Alden Begić; Bulgaria: Bulgarian Society of Cardiology,
of Oxford, Oxford, United Kingdom; Arsen D. Ristić, Department Yvaylo Daskalov; Croatia: Croatian Cardiac Society, Bosko Skoric;
of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia, Cyprus: Cyprus Society of Cardiology, Marios Ioannides; Czechia:
and Faculty of Medicine, Belgrade University, Belgrade, Serbia; Marcin Czech Society of Cardiology, Tomas Palecek; Denmark: Danish
Rucinski (Poland), ESC Patient Forum, Sophia Antipolis, France; Society of Cardiology, Kasper Rossing; Egypt: Egyptian Society of
Leyla Elif Sade, School of Medicine, University of Pittsburgh, Cardiology, Haytham Soliman Ghareeb; Estonia: Estonian Society of
Pittsburgh, PA, United States of America, and Department of Cardiology, Ulvi Hinto; Finland: Finnish Cardiac Society, Markku
Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, Kupari; France: French Society of Cardiology, Emmanuelle
United States of America; Hannah Schaubroeck, Intensive Care Berthelot; Georgia: Georgian Society of Cardiology, Vaja Agladze;
Unit, Ghent University Hospital, Ghent, Belgium; Anne Grete Germany: German Cardiac Society, Brenda Gerull; Greece:
Semb, Department of research and innovation, REMEDY centre, Hellenic Society of Cardiology, Alexandros Kasiakogias; Hungary:
Diakonhjemmet Hospital, Oslo, Norway; Gianfranco Sinagra, Hungarian Society of Cardiology, Hajnalka Vágó; Iceland: Icelandic
Center for Diagnosis and Treatment of Cardiomyopathies, Society of Cardiology, Inga Jóna Ingimarsdóttir; Ireland: Irish
Cardiothoracovascular Department, Azienda Sanitaria Universitaria Cardiac Society, Emer Joyce; Israel: Israel Heart Society, Sorel
Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy; Jens Goland; Italy: Italian Federation of Cardiology, Enrico Fabris;
Jakob Thune, Department of cardiology, Copenhagen University Kazakhstan: Association of Cardiologists of Kazakhstan, Murat
Hospital—Bispebjerg and Frederiksberg, Copenhagen, Denmark, and Amanzholovich Mukarov; Kosovo (Republic of): Kosovo Society
Department of clinical medicine, University of Copenhagen, of Cardiology, Ibadete Bytyçi; Kyrgyzstan: Kyrgyz Society
Copenhagen, Denmark. of Cardiology, Erkin Mirrakhimov, Latvia: Latvian Society of
Cardiology, Ginta Kamzola; Lebanon: Lebanese Society of
Cardiology, Naji J. Abirached; Libya: Libyan Cardiac Society, Aiman
22. Appendix
M. Smer; Lithuania: Lithuanian Society of Cardiology, Vaida
Mizariene; Luxembourg: Luxembourg Society of Cardiology,
ESC Scientific Document Group
Andrei Codreanu; Malta: Maltese Cardiac Society, Tiziana Felice;
Includes Document Reviewers and ESC National Cardiac Societies. Moldova (Republic of): Moldavian Society of Cardiology,
Document Reviewers: Elena Arbelo (CPG Review Eleonora Boris Vataman; Morocco: Moroccan Society of
Co-ordinator) (Spain), Cristina Basso (CPG Review Co-ordinator) Cardiology, Aida Soufiani; Netherlands: Netherlands Society of
(Italy), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), Cardiology, Geertruida Petronella Bijvoet; North Macedonia:
Enrico Ammirati (Italy), Lisa Anderson (United Kingdom), Eloisa National Society of Cardiology of North Macedonia, Irena Mitevska;
Arbustini (Italy), Emanuele Bobbio (Sweden), Giuseppe Boriani (Italy), Norway: Norwegian Society of Cardiology, Haavard Ravnestad;
Margarita Brida (Croatia), Robert A. Byrne (Ireland), Alida L.P. Poland: Polish Cardiac Society, Karol Kamiński; Portugal:
Caforio (Italy), Gh.-Andrei Dan (Romania), Fernando Domínguez Portuguese Society of Cardiology, Nuno Cardim; Romania:
(Spain), Suzanne Fredericks (Canada), Geeta Gulati (Norway), Borja Romanian Society of Cardiology, Oliviana Geavlete; San Marino:
Ibanez (Spain), Stefan James (Sweden), Alexander Kharlamov San Marino Society of Cardiology, Emidio Troiani; Serbia:
(Netherlands), Sabine Klaassen (Germany), Jolanda Kluin Cardiology Society of Serbia, Marija Zdravkovic; Slovakia: Slovak
(Netherlands), Konstantinos C. Koskinas (Switzerland), Petr Society of Cardiology, Marcela Dankova; Slovenia: Slovenian Society
Kuchynka (Czech Republic), Vijay Kunadian (United Kingdom), Ulf of Cardiology, Andreja Černe Čerček; Spain: Spanish Society
Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), of Cardiology, Fernando Domínguez; Sweden: Swedish Society of
Bernhard Maisch (Germany), Federica Marelli-Berg (United Cardiology, Gabriel Arefalk; Switzerland: Swiss Society of
Kingdom), Pilar Martin (Spain), John William McEvoy (Ireland), Cardiology, Philip Haaf; Syrian Arab Republic: Syrian
Borislava Mihaylova (United Kingdom), Richard Mindham (United Cardiovascular Association, Mohammed Yassin Bani Marjeh;
Kingdom), Inge Moelgaard (Denmark), Saidi A. Mohiddin (United Türkiye: Turkish Society of Cardiology, Baris Kilicaslan; Ukraine:
Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet Ukrainian Association of Cardiology, Sergii Cherniuk; United
(Belgium), Giovanni Peretto (Italy), Kalliopi Pilichou (Italy), Nicolas Kingdom of Great Britain and Northern Ireland: British
Piriou (France), Eva Prescott (Denmark), Amina Rakisheva Cardiovascular Society, Saidi A. Mohiddin, Uzbekistan: Association
(Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna of Cardiologists of Uzbekistan, Amayak Kevorkov
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4025
ESC Clinical Practice Guidelines (CPG) Committee: Ulf Heart Association. Circulation 2021;144:e123–35. 
Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson) 0000000000001001
15.Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y, et al. Guidelines on
(Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom),
the diagnosis and management of pericardial diseases executive summary: the task
Folkert W. Asselbergs (Netherlands), Colin Baigent (United Kingdom), force on the diagnosis and management of pericardial diseases of the European
Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida Society of Cardiology. Eur Heart J 2004;25:587–610. 
(Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France), 2004.02.002
16.Patriki D, Gresser E, Manka R, Emmert MY, Lüscher TF, Heidecker B. Approximation
Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja
of the incidence of myocarditis by systematic screening with cardiac magnetic reson-
Ibanez (Spain), Peter Jüni (United Kingdom), Gregory Y.H. Lip (United
ance imaging. JACC Heart Fail 2018;6:573–9. 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United 17.Fu M, Kontogeorgos S, Thunström E, Zverkova Sandström T, Kroon C, Bollano E, et al.
Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom), Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to
2014. Sci Rep 2022;12:1810. 
Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain),
18.Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al.
Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek
Global burden of cardiovascular diseases and risk factors, 1990–2019: update from
Wojakowski (Poland), Katja Zeppenfeld (Netherlands) the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. 
Contributor either withdrew or was engaged in only a part of the re- jacc.2020.11.010
view process: Gerhard Poelzl (Austria) 19.Global Burden of Disease Study 2013 Collaborators. Global, regional, and national in-
cidence, prevalence, and years lived with disability for 301 acute and chronic diseases
and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden
of Disease Study 2013. Lancet 2015;386:743–800. 
23. References
6736(15)60692-4
20.Messroghli DR, Pickardt T, Fischer M, Opgen-Rhein B, Papakostas K, Böcker D, et al.
1.Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Toward evidence-based diagnosis of myocarditis in children and adolescents: rationale,
Guidelines for the diagnosis and management of pericardial diseases: the task force for
design, and first baseline data of MYKKE, a multicenter registry and study platform. Am
the diagnosis and management of pericardial diseases of the European Society of
Heart J 2017;187:133–44. 
Cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic
21.Arola A, Pikkarainen E, Sipilä JO, Pykäri J, Rautava P, Kytö V. Occurrence and features
Surgery (EACTS). Eur Heart J 2015;36:2921–64. 
of childhood myocarditis: a nationwide study in Finland. J Am Heart Assoc 2017;6:
ehv318
e005306. 
2.Adamopoulos S, Miliopoulos D, Karavidas A, Nikolaou M, Lazaros G, Gkouziouta A,
22.Imazio M, Cecchi E, Demichelis B, Chinaglia A, Ierna S, Demarie D, et al.
et al. HEllenic Registry on Myocarditis SyndromES on behalf of Hellenic Heart
Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008;94:498–501.
Failure Association: the HERMES-HF registry. ESC Heart Fail 2020;7:3676–84.

23.Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hos-
3.Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, et al. Cardiac
pitalized for acute pericarditis. Circulation 2014;130:1601–6. 
MR with late gadolinium enhancement in acute myocarditis with preserved systolic
function: ITAMY study. J Am Coll Cardiol 2017;70:1977–87.  CIRCULATIONAHA.114.010376
24.Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized
jacc.2017.08.044
4.Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, et al. Good prog- trial of colchicine for acute pericarditis. N Engl J Med 2013;369:1522–8. 
nosis for pericarditis with and without myocardial involvement: results from a multi- org/10.1056/NEJMoa1208536
center, prospective cohort study. Circulation 2013;128:42–9.  25.Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of
1161/CIRCULATIONAHA.113.001531 colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicen-
5.Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes tre, double-blind, placebo-controlled, randomised trial. Lancet 2014;383:2232–7.
of cardiovascular magnetic resonance imaging in patients recently recovered from cor- 
onavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–73.  26.Charpentier S, Beaune S, Joly LM, Khoury A, Duchateau F-X, Briot R, et al.
1001/jamacardio.2020.3557 Management of chest pain in the French emergency healthcare system: the prospect-
6.Keren A, Asleh R, Birati EY, Ben Gal T, Arad M. Definition and diagnosis of acute myo- ive observational EPIDOULTHO study. Eur J Emerg Med 2018;25:404–10. 
carditis: a position statement of the Israel Heart Society. Isr Med Assoc J 2023;25: org/10.1097/MEJ.0000000000000481
519–24. 27.Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N,
7.Montera MW, Marcondes-Braga FG, Simões MV, Moura LAZ, Fernandes F, Mangine S, et al. Myocarditis and pericarditis: case definition and guidelines for data collection, ana-
et al. Brazilian Society of Cardiology guideline on myocarditis—2022. Arq Bras Cardiol lysis, and presentation of immunization safety data. Vaccine 2022;40:1499–511. https://
2022;119:143–211.  doi.org/10.1016/j.vaccine.2021.11.074
8.Nagai T, Inomata T, Kohno T, Sato T, Tada A, Kubo T, et al. JCS 2023 guideline on the 28.Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al. Clinical presenta-
diagnosis and treatment of myocarditis. Circ J 2023;87:674–754.  tion and outcome in a contemporary cohort of patients with acute myocarditis:
1253/circj.CJ-22-0696 Multicenter Lombardy Registry. Circulation 2018;138:1088–99. 
9.Writing Committee; Drazner MH, Bozkurt B, Cooper LT, Aggarwal NR, Basso C, et al.
1161/CIRCULATIONAHA.118.035319
2024 ACC expert consensus decision pathway on strategies and criteria for the diag-
29.Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023
nosis and management of myocarditis: a report of the American College of Cardiology
ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44:
Solution Set Oversight Committee. J Am Coll Cardiol 2025;85:391–431. 
3948–4042. 
10.1016/j.jacc.2024.10.080
30.Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al.
10.Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al.
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert
Current state of knowledge on aetiology, diagnosis, management, and therapy of myo-
recommendations. J Am Coll Cardiol 2018;72:3158–76. 
carditis: a position statement of the European Society of Cardiology Working Group
2018.09.072
on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–48, 2648a–48d.
31.Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987;18:619–24. 

10.1016/s0046-8177(87)80363-5
11.Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines
32.Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al.
on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J
Myocarditis and inflammatory cardiomyopathy: current evidence and future direc-
2021;42:17–96. 
12.McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. tions. Nat Rev Cardiol 2021;18:169–93. 
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic 33.Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus
heart failure. Eur Heart J 2021;42:3599–726.  statement on endomyocardial biopsy from the Association for European
ehab368 Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc
13.Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. Pathol 2012;21:245–74. 
2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 34.Caforio ALP, Giordani AS, Baritussio A, Marcolongo D, Vicenzetto C, Tarantini G,
44:3503–626.  et al. Long-term efficacy and safety of tailored immunosuppressive therapy in immune-
14.Law YM, Lal AK, Chen S, Čiháková D, Cooper LT, Deshpande S, et al. Diagnosis and mediated biopsy-proven myocarditis: a propensity-weighted study. Eur J Heart Fail
management of myocarditis in children: a scientific statement from the American 2024;26:1175–85. 
Downloaded
from

by
guest
on
22
January
2026

4026 E S C G u id e l in e s
35.Imazio M, Squarotti GB, Andreis A, Agosti A, Millesimo M, Frea S, et al. Diagnostic and 56.Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Fulminant
prognostic role of the electrocardiogram in patients with pericarditis. Heart 2022;108: versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunc-
1474–8.  tion. J Am Coll Cardiol 2019;74:299–311. 
36.Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G, et al. Prevalence 57.Huang F, Ammirati E, Ponnaiah M, Montero S, Raimbault V, Abrams D, et al. Fulminant
of C-reactive protein elevation and time course of normalization in acute pericarditis: myocarditis proven by early biopsy and outcomes. Eur Heart J 2023;44:5110–24.
implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 2011; 
123:1092–7.  58.Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022
37.Pisacreta AM, Mascolo R, Nivuori M, Dominioni CC, Gabiati C, Trotta L, et al. Acute ESC Guidelines for the management of patients with ventricular arrhythmias and
pericarditis with pleuropulmonary involvement, fever and elevated C-reactive protein: the prevention of sudden cardiac death: developed by the task force for the manage-
a systemic autoinflammatory disease? A cohort study. Eur J Intern Med 2023;113:45–8. ment of patients with ventricular arrhythmias and the prevention of sudden cardiac
 death of the European Society of Cardiology (ESC) Endorsed by the Association for
38.Tombetti E, Casarin F, Bizzi E, Bezer S, Mascolo R, Pallini G, et al. Relapsing pericarditis: European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2022;43:
peripheral blood neutrophilia, lymphopenia and high neutrophil-to-lymphocyte ratio 3997–4126. 
herald acute attacks, high-grade inflammation, multiserosal involvement, and predict 59.Berg J, Kottwitz J, Baltensperger N, Kissel CK, Lovrinovic M, Mehra T, et al. Cardiac
multiple recurrences. Int J Rheum Dis 2023;26:337–43.  magnetic resonance imaging in myocarditis reveals persistent disease activity despite
185X.14523 normalization of cardiac enzymes and inflammatory parameters at 3-month follow-up.
39.Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Circ Heart Fail 2017;10:e004262. 
Management of acute myocarditis and chronic inflammatory cardiomyopathy: an ex- 004262
pert consensus document. Circ Heart Fail 2020;13:e007405.  60.Schwuchow-Thonke S, Göbel S, Emrich T, Schmitt VH, Fueting F, Klank C, et al.
CIRCHEARTFAILURE.120.007405 Increased C reactive protein, cardiac troponin I and GLS are associated with myocar-
40.Seidel F, Opgen-Rhein B, Rentzsch A, Boehne M, Wannenmacher B, Boecker D, et al. dial inflammation in patients with non-ischemic heart failure. Sci Rep 2021;11:3008.
Clinical characteristics and outcome of biopsy-proven myocarditis in children—results 
of the German prospective multicentre registry ‘MYKKE’. Int J Cardiol 2022;357: 61.Krumm P, Brendel JM, Klingel K, Müller KAL, Kübler J, Gräni C, et al. Using multipara-
95–104.  metric cardiac magnetic resonance to phenotype and differentiate biopsy-proven
41.Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High preva- chronic from healed myocarditis and dilated cardiomyopathy. J Clin Med 2022;11:
lence of viral genomes and multiple viral infections in the myocardium of adults with 5047. 
‘idiopathic’ left ventricular dysfunction. Circulation 2005;111:887–93.  62.Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, et al.
10.1161/01.CIR.0000155616.07901.35 Long-term evolution and prognostic stratification of biopsy-proven active myocarditis.
42.Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis associated with influenza A Circulation 2013;128:2384–94. 
H1N1pdm2009. Influenza Res Treat 2012;2012:351979.  003092
2012/351979 63.Caforio ALP, Kaski JP, Gimeno JR, Elliott PM, Laroche C, Tavazzi L, et al.
43.Lazarou E, Lazaros G, Antonopoulos AS, Imazio M, Vasileiou P, Karavidas A, et al. A Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis
risk score for pericarditis recurrence. Eur J Clin Invest 2021;51:e13602.  in the European Society of Cardiology EURObservational Research Programme
org/10.1111/eci.13602 Cardiomyopathy and Myocarditis Long-Term Registry. Eur Heart J 2024;45:
44.Imazio M, Andreis A, Lubian M, Lazaros G, Lazarou E, Brucato A, et al. The Torino 2548–69. 
Pericarditis Score: a new-risk stratification tool to predict complicated pericarditis. 64.Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D,
Intern Emerg Med 2021;16:1921–6.  Sanchez-Munoz JJ, Oliva-Sandoval MJ, et al. Genetics of myocarditis in arrhythmogenic
45.Lazaros G, Antonopoulos AS, Lazarou E, Vlachopoulos C, Vogiatzi G, Vassilopoulos D, right ventricular dysplasia. Heart Rhythm 2015;12:766–73. 
et al. Age- and sex-based differences in patients with acute pericarditis. Eur J Clin Invest hrthm.2015.01.001
2021;51:e13392.  65.Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC
46.Vecchié A, Chiabrando JG, Dell MS, Bonaventura A, Mauro AG, Wohlford G, et al. Guidelines for the management of acute coronary syndromes in patients presenting
Clinical presentation and outcomes of acute pericarditis in a large urban hospital in without persistent ST-segment elevation. Eur Heart J 2021;42:1289–367. 
the United States of America. Chest 2020;158:2556–67.  org/10.1093/eurheartj/ehaa575
chest.2020.07.039 66.Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, et al. A prospective
47.Gouriet F, Levy P-Y, Casalta J-P, Zandotti C, Collart F, Lepidi H, et al. Etiology of peri- study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathoge-
carditis in a prospective cohort of 1162 cases. Am J Med 2015;128:784.e1–e8. https:// netic features at diagnosis. Eur Heart J 2007;28:1326–33. 
doi.org/10.1016/j.amjmed.2015.01.040 eurheartj/ehm076
48.Mayosi BM, Wiysonge CS, Ntsekhe M, Volmink JA, Gumedze F, Maartens G, et al. 67.Buiatti A, Merlo M, Pinamonti B, De Biasio M, Bussani R, Sinagra G. Clinical presenta-
Clinical characteristics and initial management of patients with tuberculous pericarditis tion and long-term follow-up of perimyocarditis. J Cardiovasc Med (Hagerstown) 2013;
in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI 14:235–41. 
Africa) registry. BMC Infect Dis 2006;6:2.  68.Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al.
49.Conte E, Tamanini S, Bizzi E, Maestroni S, Cumetti D, Novembre ML, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with sus-
Post-cardiac injury syndrome and pericardial effusion recurrence after pericardial ef- pected acute myocarditis: comparison of different approaches. J Am Coll Cardiol
fusion drainage in chronic idiopathic pericardial effusion. Eur J Intern Med 2024;123: 2005;45:1815–22. 
132–7.  69.Zagrosek A, Abdel-Aty H, Boyé P, Wassmuth R, Messroghli D, Utz W, et al. Cardiac
50.Peet CJ, Rowczenio D, Omoyinmi E, Papadopoulou C, Mapalo BRR, Wood MR, et al. magnetic resonance monitors reversible and irreversible myocardial injury in myocar-
Pericarditis and autoinflammation: a clinical and genetic analysis of patients with idio- ditis. JACC Cardiovasc Imaging 2009;2:131–8. 
pathic recurrent pericarditis and monogenic autoinflammatory diseases at a national 014
referral center. J Am Heart Assoc 2022;11:e024931.  70.Gröschel J, Bhoyroo Y, Blaszczyk E, Trauzeddel RF, Viezzer D, Saad H, et al. Different
121.024931 impacts on the heart after COVID-19 infection and vaccination: insights from cardio-
51.Imazio M, Faletra F, Zucco J, Mio C, Carraro M, Gava AM, et al. Genetic variants in pa- vascular magnetic resonance. Front Cardiovasc Med 2022;9:916922. 
tients with recurrent pericarditis. J Cardiovasc Med (Hagerstown) 2024;25:799–804. 3389/fcvm.2022.916922
 71.Gentile P, Merlo M, Peretto G, Ammirati E, Sala S, Della Bella P, et al. Post-discharge
52.Caforio ALP, Brucato A, Doria A, Brambilla G, Angelini A, Ghirardello A, et al. arrhythmic risk stratification of patients with acute myocarditis and life-threatening
Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in ventricular tachyarrhythmias. Eur J Heart Fail 2021;23:2045–54. 
idiopathic recurrent acute pericarditis. Heart 2010;96:779–84.  1002/ejhf.2288
1136/hrt.2009.187138 72.Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC
53.Basso C. Myocarditis. N Engl J Med 2022;387:1488–500.  Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:
NEJMra2114478 3720–826. 
54.Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA 73.Baritussio A, Schiavo A, Basso C, Giordani AS, Cheng C-Y, Pontara E, et al. Predictors
2023;329:1098–113.  of relapse, death or heart transplantation in myocarditis before the introduction of im-
55.Younis A, Matetzky S, Mulla W, Masalha E, Afel Y, Chernomordik F, et al. Epidemiology munosuppression: negative prognostic impact of female gender, fulminant onset, low-
characteristics and outcome of patients with clinically diagnosed acute myocarditis. Am er ejection fraction and serum autoantibodies. Eur J Heart Fail 2022;24:1033–44.
J Med 2020;133:492–9.  
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4027
74.Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, et al. Survival and left systematic review and meta-analysis. JACC Heart Fail 2024;12:1101–11. 
ventricular function changes in fulminant versus nonfulminant acute myocarditis. org/10.1016/j.jchf.2024.02.012
Circulation 2017;136:529–45.  96.Belkaya S, Kontorovich AR, Byun M, Mulero-Navarro S, Bajolle F, Cobat A, et al.
75.Kondo T, Okumura T, Shibata N, Imaizumi T, Dohi K, Izawa H, et al. Differences in Autosomal recessive cardiomyopathy presenting as acute myocarditis. J Am Coll
prognosis and cardiac function according to required percutaneous mechanical circu- Cardiol 2017;69:1653–65. 
latory support and histological findings in patients with fulminant myocarditis: insights 97.Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al.
from the CHANGE PUMP 2 study. J Am Heart Assoc 2022;11:e023719.  Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy
10.1161/JAHA.121.023719 distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy.
76.Peretto G, Sala S, Rizzo S, De Luca G, Campochiaro C, Sartorelli S, et al. Arrhythmias in Circulation 2020;141:1872–84. 
myocarditis: state of the art. Heart Rhythm 2019;16:793–801.  044934
hrthm.2018.11.024 98.Peretto G, De Luca G, Villatore A, Di Resta C, Sala S, Palmisano A, et al. Multimodal
77.Imazio M, Lazaros G, Picardi E, Vasileiou P, Orlando F, Carraro M, et al. Incidence and detection and targeting of biopsy-proven myocardial inflammation in genetic cardio-
prognostic significance of new onset atrial fibrillation/flutter in acute pericarditis. Heart myopathies: a pilot report. JACC Basic Transl Sci 2023;8:755–65. 
2015;101:1463–7.  1016/j.jacbts.2023.02.018
78.Shah Z, Mohammed M, Vuddanda V, Ansari MW, Masoomi R, Gupta K. National 99.Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, et al. ‘Hot phase’
trends, gender, management, and outcomes of patients hospitalized for myocarditis. clinical presentation in arrhythmogenic cardiomyopathy. Europace 2021;23:907–17.
Am J Cardiol 2019;124:131–6.  
79.Rosier L, Zouaghi A, Barré V, Martins R, Probst V, Marijon E, et al. High risk of sustained 100. Bariani R, Rigato I, Cipriani A, Bueno Marinas M, Celeghin R, Basso C, et al.
ventricular arrhythmia recurrence after acute myocarditis. J Clin Med 2020;9:848. Myocarditis-like episodes in patients with arrhythmogenic cardiomyopathy: a system-
 atic review on the so-called hot-phase of the disease. Biomolecules 2022;12:1324.
80.Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS ex- 
pert consensus statement on the diagnosis and management of arrhythmias associated 101. Bassetto G, Merlo M, Dal Ferro M, Setti M, Paldino A, Collesi C, et al. Apoptosis, a use-
with cardiac sarcoidosis. Heart Rhythm 2014;11:1305–23.  ful marker in the management of hot-phase cardiomyopathy? Eur J Heart Fail 2024;26:
hrthm.2014.03.043 590–7. 
81.Bobbio E, Hjalmarsson C, Björkenstam M, Polte CL, Oldfors A, Lindström U, et al. 102. Collini V, Siega Vignut L, Angriman F, Braidotti G, De Biasio M, Imazio M. Age-stratified
patterns in clinical presentation, treatment and outcomes in acute pericarditis: a retro-
Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis:
spective cohort study. Heart 2024;110:1139–44. 
a Swedish single center experience. BMC Cardiovasc Disord 2022;22:192. 
2024-324214
org/10.1186/s12872-022-02639-0
103. Lazaros G, Antonopoulos AS, Imazio M, Solomou E, Lazarou E, Vassilopoulos D, et al.
82.Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis—natural history
Clinical significance of pleural effusions and association with outcome in patients hos-
and treatment. N Engl J Med 1997;336:1860–66. 
pitalized with a first episode of acute pericarditis. Intern Emerg Med 2019;14:745–51.
NEJM199706263362603

83.Peretto G, Sala S, Rizzo S, Palmisano A, Esposito A, De Cobelli F, et al. Ventricular ar-
104. Imazio M, Pivetta E, Andreis A, Serra C, Carbone F, Masoero M, et al. Incessant peri-
rhythmias in myocarditis: characterization and relationships with myocardial inflamma-
carditis as a risk factor for complicated pericarditis and hospital admission. Circulation
tion. J Am Coll Cardiol 2020;75:1046–57. 
2021;143:401–2. 
84.Peretto G, Sala S, Basso C, Rizzo S, Radinovic A, Frontera A, et al. Inflammation as a
105. Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, et al. Indicators of
predictor of recurrent ventricular tachycardia after ablation in patients with myocar-
poor prognosis of acute pericarditis. Circulation 2007;115:2739–44. 
ditis. J Am Coll Cardiol 2020;76:1644–56. 
10.1161/CIRCULATIONAHA.106.662114
85.van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. Scand J Infect Dis
106. Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, et al.
Suppl 1991;77:81–4. 
Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized ob-
86.Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021
servation. Circulation 2008;118:667–71. 
ESC guidelines on cardiac pacing and cardiac resynchronization therapy: developed by
107.761064
the Task Force on cardiac pacing and cardiac resynchronization therapy of the
107. Lazaros G, Antonopoulos AS, Vlachopoulos C, Oikonomou E, Karavidas A,
European Society of Cardiology (ESC) With the special contribution of the
Chrysochoou C, et al. Predictors of switching from nonsteroidal anti-inflammatory
European Heart Rhythm Association (EHRA). Eur Heart J 2021;42:3427–520.
drugs to corticosteroids in patients with acute pericarditis and impact on clinical out-

come. Hellenic J Cardiol 2019;60:357–63. 
87.Bhatia RT, Finocchiaro G, Westaby J, Chatrath N, Behr ER, Papadakis M, et al.
108. Melendo-Viu M, Marchán-Lopez Á, Guarch CJ-L, Roubín SR, Abu-Assi E, Meneses RT,
Myocarditis and sudden cardiac death in the community: clinical and pathological in-
et al. A systematic review and meta-analysis of randomized controlled trials evaluating
sights from a national registry in the United Kingdom. Circ Arrhythm Electrophysiol
pharmacologic therapies for acute and recurrent pericarditis. Trends Cardiovasc Med
2023;16:e012129.  2023;33:319–26. 
88.Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J. Sudden cardiac
109. Artom G, Koren-Morag N, Spodick DH, Brucato A, Guindo J, Bayes-de-Luna A, et al.
death caused by myocarditis in persons aged 1–49 years: a nationwide study of 14 Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing
294 deaths in Denmark. Forensic Sci Res 2019;4:247–56.  recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 2005;26:723–27.
20961790.2019.1595352 
89.Peretto G, Mazzone P, Paglino G, Marzi A, Tsitsinakis G, Rizzo S, et al. Continuous elec- 110. Klein AL, Wang TKM, Cremer PC, Abbate A, Adler Y, Asher C, et al. Pericardial dis-
trical monitoring in patients with arrhythmic myocarditis: insights from a referral cen- eases: international position statement on new concepts and advances in multimodal-
ter. J Clin Med 2021;10:5142.  ity cardiac imaging. JACC Cardiovasc Imaging 2024;17:937–88. 
90.Baritussio A, Cheng C-Y, Simeti G, Ocagli H, Lorenzoni G, Giordani AS, et al. CMR jcmg.2024.04.010
predictors of favorable outcome in myocarditis: a single-center experience. J Clin 111. Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH, et al.
Med 2024;13:1229.  Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll
91.Ammirati E, Raimondi F, Piriou N, Sardo Infirri L, Mohiddin SA, Mazzanti A, et al. Acute Cardiol 2020;75:76–92. 
myocarditis associated with desmosomal gene variants. JACC Heart Fail 2022;10: 112. Cremer PC, Tariq MU, Karwa A, Alraies MC, Benatti R, Schuster A, et al. Quantitative
714–27.  assessment of pericardial delayed hyperenhancement predicts clinical improvement in
92.Kontorovich AR, Tang Y, Patel N, Georgievskaya Z, Shadrina M, Williams N, et al. patients with constrictive pericarditis treated with anti-inflammatory therapy. Circ
Burden of cardiomyopathic genetic variation in lethal pediatric myocarditis. Circ Cardiovasc Imaging 2015;8:e003125. 
Genom Precis Med 2021;14:e003426.  003125
93.Seidel F, Holtgrewe M, Al-Wakeel-Marquard N, Opgen-Rhein B, Dartsch J, Herbst C, 113. Brucato A, Brambilla G, Moreo A, Alberti A, Munforti C, Ghirardello A, et al.
et al. Pathogenic variants associated with dilated cardiomyopathy predict outcome in Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J
pediatric myocarditis. Circ Genom Precis Med 2021;14:e003250.  Cardiol 2006;98:267–71. 
1161/CIRCGEN.120.003250 114. Imazio M, Brucato A, Adler Y, Brambilla G, Artom G, Cecchi E, et al. Prognosis of idio-
94.Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic pathic recurrent pericarditis as determined from previously published reports. Am J
architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Cardiol 2007;100:1026–8. 
Circulation 2022;146:1123–34.  115. Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B, et al. American Society
058457 of Echocardiography clinical recommendations for multimodality cardiovascular im-
95.Monda E, Bakalakos A, Cannie D, O’Mahony C, Syrris P, Kaski JP, et al. Prevalence of aging of patients with pericardial disease: endorsed by the Society for
pathogenic variants in cardiomyopathy-associated genes in acute myocarditis: a Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed
Downloaded
from

by
guest
on
22
January
2026

4028 E S C G u id e l in e s
Tomography. J Am Soc Echocardiogr 2013;26:965–1012.e15.  136. Ukena C, Mahfoud F, Kindermann I, Kandolf R, Kindermann M, Böhm M. Prognostic
echo.2013.06.023 electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart
116. Miranda WR, Newman DB, Sinak LJ, Espinosa RE, Anavekar NS, Goel K, et al. Pre- and Fail 2011;13:398–405. 
post-pericardiocentesis echo-Doppler features of effusive-constrictive pericarditis 137. Jhamnani S, Fuisz A, Lindsay J. The spectrum of electrocardiographic manifestations of
compared with cardiac tamponade and constrictive pericarditis. Eur Heart J acute myocarditis: an expanded understanding. J Electrocardiol 2014;47:941–7. https://
Cardiovasc Imaging 2019;20:298–306.  doi.org/10.1016/j.jelectrocard.2014.07.018
117. Sagristà-Sauleda J, Angel J, Sánchez A, Permanyer-Miralda G, Soler-Soler J. 138. Baritussio A, Cheng C-Y, Lorenzoni G, Basso C, Rizzo S, De Gaspari M, et al. A
Effusive-constrictive pericarditis. N Engl J Med 2004;350:469–75.  machine-learning model for the prognostic role of C-reactive protein in myocarditis.
1056/NEJMoa035630 J Clin Med 2022;11:7068. 
118. Ristić AD, Imazio M, Adler Y, Anastasakis A, Badano LP, Brucato A, et al. Triage strat- 139. Lazaros G, Vlachakis PK, Theofilis P, Dasoula FE, Imazio M, Lazarou E, et al. D-dimer as
egy for urgent management of cardiac tamponade: a position statement of the a diagnostic and prognostic plasma biomarker in patients with a first episode of acute
European Society of Cardiology Working Group on Myocardial and Pericardial pericarditis. Eur J Intern Med 2023;19:2133–9. 
Diseases. Eur Heart J 2014;35:2279–84.  017
119. Talreja DR, Edwards WD, Danielson GK, Schaff HV, Tajik AJ, Tazelaar HD, et al. 140. Mauro A, Bizzi E, Wu MA, Mascolo R, Chirico C, Conte E, et al. D-dimer and procal-
Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. citonin in patients with recurrent pericarditis: a prospective study. Intern Emerg Med
Circulation 2003;108:1852–7.  2024;19:2133–9. 
120. Sagristà-Sauleda J, Permanyer-Miralda G, Candell-Riera J, Angel J, Soler-Soler J. 141. Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, Jiménez-Borreguero LJ,
Transient cardiac constriction: an unrecognized pattern of evolution in effusive acute Matesanz-Marín A, Relaño M, et al. A novel circulating microRNA for the detection
idiopathic pericarditis. Am J Cardiol 1987;59:961–6.  of acute myocarditis. N Engl J Med 2021;384:2014–27. 
9149(87)91134-9 NEJMoa2003608
121. Haley JH, Tajik AJ, Danielson GK, Schaff HV, Mulvagh SL, Oh JK. Transient constrictive 142. Caforio ALP, De Luca G, Baritussio A, Seguso M, Gallo N, Bison E, et al. Serum organ-
pericarditis: causes and natural history. J Am Coll Cardiol 2004;43:271–75.  specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers
org/10.1016/j.jacc.2003.08.032 of cardiac involvement in systemic sclerosis: frequency, clinical and prognostic correlates.
122. Sato K, Ayache A, Kumar A, Cremer PC, Griffin B, Popovic ZB, et al. Improvement in Diagnostics (Basel) 2021;11:2165. 
left ventricular mechanics following medical treatment of constrictive pericarditis. 143. Coronado MJ, Bruno KA, Blauwet LA, Tschöpe C, Cunningham MW, Pankuweit S,
Heart 2021;107:828–35.  et al. Elevated sera sST2 is associated with heart failure in men ≤50 years old with myo-
123. Feng D, Glockner J, Kim K, Martinez M, Syed IS, Araoz P, et al. Cardiac magnetic res- carditis. J Am Heart Assoc 2019;8:e008968. 
onance imaging pericardial late gadolinium enhancement and elevated inflammatory 144. Müller I, Vogl T, Kühl U, Krannich A, Banks A, Trippel T, et al. Serum alarmin S100A8/
markers can predict the reversibility of constrictive pericarditis after antiinflammatory S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Fail 2020;7:
medical therapy: a pilot study. Circulation 2011;124:1830–7.  1442–51. 
CIRCULATIONAHA.111.026070 145. Müller I, Vogl T, Pappritz K, Miteva K, Savvatis K, Rohde D, et al. Pathogenic role of the
124. Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ, et al. damage-associated molecular patterns S100A8 and S100A9 in Coxsackievirus
European Association of Cardiovascular Imaging (EACVI) position paper: multimodal- B3-induced myocarditis. Circ Heart Fail 2017;10:e004125. 
ity imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 2015;16:12–31. https:// CIRCHEARTFAILURE.117.004125
doi.org/10.1093/ehjci/jeu128 146. Ader F, Surget E, Charron P, Redheuil A, Zouaghi A, Maltret A, et al. Inherited cardio-
125. Lopalco G, Venerito V, Brucato A, Emmi G, Giacomelli R, Cauli A, et al. Anakinra ef- myopathies revealed by clinically suspected myocarditis: highlights from genetic testing.
fectiveness in refractory polyserositis: an Italian multicenter study. Joint Bone Spine Circ Genom Precis Med 2020;13:e002744. 
2022;89:105299.  002744
126. Kilic A, Varkal MA, Durmus MS, Yildiz I, Yıldırım ZNY, Turunc G, et al. Relationship 147. Poller W, Haas J, Klingel K, Kühnisch J, Gast M, Kaya Z, et al. Familial recurrent myo-
between clinical findings and genetic mutations in patients with familial carditis triggered by exercise in patients with a truncating variant of the desmoplakin
Mediterranean fever. Pediatr Rheumatol Online J 2015;13:59.  gene. J Am Heart Assoc 2020;9:e015289. 
s12969-015-0057-1 148. Ollitrault P, Al Khoury M, Troadec Y, Calcagno Y, Champ-Rigot L, Ferchaud V, et al.
127. Kumar S, Khubber S, Reyaldeen R, Agrawal A, Cremer PC, Imazio M, et al. Advances in Recurrent acute myocarditis: an under-recognized clinical entity associated with the
imaging and targeted therapies for recurrent pericarditis: a review. JAMA Cardiol 2022; later diagnosis of a genetic arrhythmogenic cardiomyopathy. Front Cardiovasc Med
7:975–85.  2022;9:998883. 
128. Habib G, Bucciarelli-Ducci C, Caforio ALP, Cardim N, Charron P, Cosyns B, et al. 149. Piriou N, Marteau L, Kyndt F, Serfaty JM, Toquet C, Le Gloan L, et al. Familial screening
Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardio-
document in collaboration with the ‘Working group on myocardial and pericardial dis- myopathies. ESC Heart Fail 2020;7:1520–33. 
eases’ of the European Society of Cardiology Endorsed by The Indian Academy of 150. Artico J, Merlo M, Delcaro G, Cannatà A, Gentile P, De Angelis G, et al. Lymphocytic
Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:1090–121.  myocarditis: a genetically predisposed disease? J Am Coll Cardiol 2020;75:3098–100.
10.1093/ehjci/jex034 
129. Imazio M, Pivetta E, Palacio Restrepo S, Sormani P, Pedrotti P, Quarta G, et al. 151. Verdonschot JAJ, Heymans SRB. Dilated cardiomyopathy: second hits knock-down the
Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am J Cardiol heart. Eur Heart J 2024;45:500–1. 
2020;125:146–51.  152. Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F, et al. Clues to
130. Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, et al. Day-hospital detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among
treatment of acute pericarditis: a management program for outpatient therapy. J Am patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin
Coll Cardiol 2004;43:1042–46.  Res Cardiol 2012;101:525–31. 
131. Chimenti C, Russo MA, Frustaci A. Immunosuppressive therapy in virus-negative in- 153. Brucato A, Shinar Y, Brambilla G, Robbiolo L, Ferrioli G, Patrosso MC, et al. Idiopathic
flammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur Heart J 2022; recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolu-
43:3463–73.  tion in a large cohort of Caucasian patients. Lupus 2005;14:670–4. 
132. Rao K, De Silva K, Sood A, Denniss AR, Hsu C-J. Predicting patients with troponin posi- 1191/0961203305lu2197oa
tive chest pain and unobstructed coronary arteries with electrocardiogram, troponin 154. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, et al.
kinetics and GRACE score. Heart Lung Circ 2022;31:1219–27.  Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol
j.hlc.2022.05.040 2000;36:227–32. 
133. De Lazzari M, Zorzi A, Baritussio A, Siciliano M, Migliore F, Susana A, et al. Relationship 155. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, et al. Echocardiographic
between T-wave inversion and transmural myocardial edema as evidenced by cardiac findings in myocarditis. Am J Cardiol 1988;62:285–91. 
magnetic resonance in patients with clinically suspected acute myocarditis: clinical and 9149(88)90226-3
prognostic implications. J Electrocardiol 2016;49:587–95.  156. Uppu SC, Shah A, Weigand J, Nielsen JC, Ko HH, Parness IA, et al. Two-dimensional
jelectrocard.2016.04.002 speckle-tracking-derived segmental peak systolic longitudinal strain identifies regional
134. Nucifora G, Miani D, Di Chiara A, Piccoli G, Artico J, Puppato M, et al. Infarct-like acute myocardial involvement in patients with myocarditis and normal global left ventricular
myocarditis: relation between electrocardiographic findings and myocardial damage as systolic function. Pediatr Cardiol 2015;36:950–9. 
assessed by cardiac magnetic resonance imaging. Clin Cardiol 2013;36:146–52. https:// 1105-9
doi.org/10.1002/clc.22088 157. Sperlongano S, D’Amato A, Tagliamonte E, Russo V, Desiderio A, Ilardi F, et al. Acute
135. Wang Z, Wang Y, Lin H, Wang S, Cai X, Gao D. Early characteristics of fulminant myo- myocarditis: prognostic role of speckle tracking echocardiography and comparison
carditis vs non-fulminant myocarditis: a meta-analysis. Medicine (Baltimore) 2019;98: with cardiac magnetic resonance features. Heart Vessels 2022;37:121–31. 
e14697.  org/10.1007/s00380-021-01893-0
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4029
158. Ben-Joya D, Kaplan A, Baruch G, Rothschild E, Beer G, Banai S, et al. The prevalence of 176. Blissett S, Chocron Y, Kovacina B, Afilalo J. Diagnostic and prognostic value of cardiac
abnormal right ventricle speckle strain in the setting of acute myocarditis and pre- magnetic resonance in acute myocarditis: a systematic review and meta-analysis. Int J
served left ventricle function. Int J Cardiovasc Imaging 2023;39:1231–8.  Cardiovasc Imaging 2019;35:2221–9. 
org/10.1007/s10554-023-02829-7 177. Pan JA, Lee YJ, Salerno M. Diagnostic performance of extracellular volume, native T1,
159. Meindl C, Paulus M, Poschenrieder F, Hamer OW, Zeman F, Maier LS, et al. Left atrial and T2 mapping versus Lake Louise criteria by cardiac magnetic resonance for detec-
strain parameters derived by echocardiography are impaired in patients with acute tion of acute myocarditis: a meta-analysis. Circ Cardiovasc Imaging 2018;11:e007598.
myocarditis and preserved systolic left ventricular function. Int J Cardiovasc Imaging 
2023;39:1157–65.  178. Wei S, Fu J, Chen L, Yu S. Performance of cardiac magnetic resonance imaging for diag-
160. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in nosis of myocarditis compared with endomyocardial biopsy: a meta-analysis. Med Sci
addition to conventional therapy for acute pericarditis: results of the COlchicine for Monit 2017;23:3687–96. 
acute PEricarditis (COPE) trial. Circulation 2005;112:2012–6.  179. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al.
1161/CIRCULATIONAHA.105.542738 Cardiovascular magnetic resonance and single-photon emission computed tomog-
161. Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological val- raphy for diagnosis of coronary heart disease (CE-MARC): a prospective trial.
Lancet 2012;379:453–60. 
idation of cardiac magnetic resonance analysis of regional and diffuse interstitial myo-
180. Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, et al.
cardial fibrosis. Eur Heart J Cardiovasc Imaging 2015;16:14–22. 
Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scin-
ehjci/jeu182
tigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the
162. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, et al. Comprehensive val-
CE-MARC 2 randomized clinical trial. JAMA 2016;316:1051–60. 
idation of cardiovascular magnetic resonance techniques for the assessment of myo-
1001/jama.2016.12680
cardial extracellular volume. Circ Cardiovasc Imaging 2013;6:373–83. 
181. Nagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST, et al.
1161/CIRCIMAGING.112.000192
Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl
163. Voigt A, Elgeti T, Durmus T, Idiz ME, Butler C, Beling M, et al. Cardiac magnetic res-
J Med 2019;380:2418–28. 
onance imaging in dilated cardiomyopathy in adults—towards identification of myo-
182. Arai AE, Schulz-Menger J, Berman D, Mahrholdt H, Han Y, Bandettini WP, et al.
cardial inflammation. Eur Radiol 2011;21:925–35. 
Gadobutrol-enhanced cardiac magnetic resonance imaging for detection of coronary
010-1985-2
artery disease. J Am Coll Cardiol 2020;76:1536–47. 
164. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al. Comprehensive car-
07.060
diac magnetic resonance imaging in patients with suspected myocarditis: the 183. Kwong RY, Ge Y, Steel K, Bingham S, Abdullah S, Fujikura K, et al. Cardiac magnetic
MyoRacer-Trial. J Am Coll Cardiol 2016;67:1800–11.  resonance stress perfusion imaging for evaluation of patients with chest pain. J Am
2016.02.013 Coll Cardiol 2019;74:1741–55. 
165. Zurick AO, Bolen MA, Kwon DH, Tan CD, Popovic ZB, Rajeswaran J, et al. Pericardial 184. Bohm P, Scharhag J, Meyer T. Data from a nationwide registry on sports-related sud-
delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis den cardiac deaths in Germany. Eur J Prev Cardiol 2016;23:649–56. 
undergoing surgical pericardiectomy: a case series with histopathological correlation. 1177/2047487315594087
JACC Cardiovasc Imaging 2011;4:1180–91.  185. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, et al.
166. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Recommendations for participation in competitive and leisure time sport in athletes
Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 up- with cardiomyopathies, myocarditis, and pericarditis: position statement of the
date. J Cardiovasc Magn Reson 2020;22:17.  Sport Cardiology Section of the European Association of Preventive Cardiology
00607-1 (EAPC). Eur Heart J 2019;40:19–33. 
167. Muehlberg F, Blaszczyk E, Will K, Wilczek S, Brederlau J, Schulz-Menger J. 186. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM, et al.
Characterization of critically ill patients with septic shock and sepsis-associated cardio- Eligibility and disqualification recommendations for competitive athletes with cardiovascu-
myopathy using cardiovascular MRI. ESC Heart Fail 2022;9:2147–56.  lar abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ven-
1002/ehf2.13938 tricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific
168. Gröschel J, Ammann C, Zange L, Viezzer D, Forman C, Schmidt M, et al. Fast acquisi- statement from the American Heart Association and American College of Cardiology.
tion of left and right ventricular function parameters applying cardiovascular magnetic Circulation 2015;132:e273–80. 
resonance in clinical routine—validation of a 2-shot compressed sensing cine se- 187. Sechtem U, Tscholakoff D, Higgins CB. MRI of the normal pericardium. AJR Am J
quence. Scand Cardiovasc J 2022;56:266–75.  Roentgenol 1986;147:239–44. 
2099010 188. Stark DD, Higgins CB, Lanzer P, Lipton MJ, Schiller N, Crooks LE, et al. Magnetic res-
169. Mileva N, Paolisso P, Gallinoro E, Fabbricatore D, Munhoz D, Bergamaschi L, et al. onance imaging of the pericardium: normal and pathologic findings. Radiology 1984;
Diagnostic and prognostic role of cardiac magnetic resonance in MINOCA: systematic 150:469–74. 
review and meta-analysis. JACC Cardiovasc Imaging 2023;16:376–89.  189. Tscholakoff D, Sechtem U, de Geer G, Schmidt H, Higgins CB. Evaluation of pleural
1016/j.jcmg.2022.12.029 and pericardial effusions by magnetic resonance imaging. Eur J Radiol 1987;7:169–74.
170. Machanahalli Balakrishna A, Ismayl M, Thandra A, Walters R, Ganesan V, Anugula D, 190. Power JA, Thompson DV, Rayarao G, Doyle M, Biederman RWW. Cardiac magnetic
resonance radiofrequency tissue tagging for diagnosis of constrictive pericarditis: a et al. Diagnostic value of cardiac magnetic resonance imaging and intracoronary optical
proof of concept study. J Thorac Cardiovasc Surg 2016;151:1348–55.  coherence tomography in patients with a working diagnosis of myocardial infarction
10.1016/j.jtcvs.2015.12.035
with non-obstructive coronary arteries—a systematic review and meta-analysis.
191. Gastl M, Sokolska JM, Polacin M, Gotschy A, von Spiczak Brzezinski J, Alkadhi H, et al.
Curr Probl Cardiol 2023;48:101126. 
Parametric mapping CMR for the measurement of inflammatory reactions of the peri-
171. Hausvater A, Smilowitz NR, Li B, Redel-Traub G, Quien M, Qian Y, et al. Myocarditis in
cardium. Open Heart 2022;9:e001919. 
relation to angiographic findings in patients with provisional diagnoses of MINOCA.
192. Conte E, Agalbato C, Lauri G, Mushtaq S, Cia AD, Bonomi A, et al. Cardiac MRI after
JACC Cardiovasc Imaging 2020;13:1906–13. 
first episode of acute pericarditis: a pilot study for better identification of high risk pa-
172. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E, et al.
tients. Int J Cardiol 2022;354:63–7. 
Myocarditis or ‘true’ infarction by cardiac magnetic resonance in patients with a clinical
193. Young PM, Glockner JF, Williamson EE, Morris MF, Araoz PA, Julsrud PR, et al. MR im-
diagnosis of myocardial infarction without obstructive coronary disease: a
aging findings in 76 consecutive surgically proven cases of pericardial disease with CT
meta-analysis of individual patient data. Atherosclerosis 2015;241:87–91. 
and pathologic correlation. Int J Cardiovasc Imaging 2012;28:1099–109. 
org/10.1016/j.atherosclerosis.2015.04.816 10.1007/s10554-011-9916-0
173. Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, et al. 194. Taylor AM, Dymarkowski S, Verbeken EK, Bogaert J. Detection of pericardial inflam-
Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect ac- mation with late-enhancement cardiac magnetic resonance imaging: initial results. Eur
tive myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging Radiol 2006;16:569–74. 
2015;8:e003073.  195. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019
174. Khanna S, Amarasekera AT, Li C, Bhat A, Chen HHL, Gan GCH, et al. The utility of ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur
cardiac magnetic resonance imaging in the diagnosis of adult patients with acute myo- Heart J 2020;41:407–77. 
carditis: a systematic review and meta-analysis. Int J Cardiol 2022;363:225–39. https:// 196. Maggiolini S, De Carlini CC, Ferri LA, Colombo GI, Gentile G, Meles E, et al. The role of
doi.org/10.1016/j.ijcard.2022.06.047 early contrast-enhanced chest computed tomography in the aetiological diagnosis of
175. Jia Z, Wang L, Jia Y, Liu J, Zhao H, Huo L, et al. Detection of acute myocarditis using T1 patients presenting with cardiac tamponade or large pericardial effusion. Eur Heart J
and T2 mapping cardiovascular magnetic resonance: a systematic review and Cardiovasc Imaging 2016;17:421–8. 
meta-analysis. J Appl Clin Med Phys 2021;22:239–48.  197. Lee Y-H, Kim SM, Kim EK, Park S-J, Lee S-C, Park SW, et al. Pattern of pericardial cal-
13365 cification determines mid-term postoperative outcomes after pericardiectomy in
Downloaded
from

by
guest
on
22
January
2026

4030 E S C G u id e l in e s
chronic constrictive pericarditis. Int J Cardiol 2023;387:131133.  219. Casella M, Pizzamiglio F, Dello Russo A, Carbucicchio C, Al-Mohani G, Russo E, et al.
1016/j.ijcard.2023.131133 Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of en-
198. Conte E, Agalbato C, Lauri G, Mushtaq S, Carollo C, Bonomi A, et al. Prevalence and domyocardial biopsy. Circ Arrhythm Electrophysiol 2015;8:625–32. 
prognosis of pericardial effusion in patients affected by pectus excavatum: a case- 1161/CIRCEP.114.002216
control study. Int J Cardiol 2021;344:179–83.  220. Ezzeddine FM, Kapa S, Rosenbaum A, Blauwet L, Deshmukh AJ, AbouEzzeddine OF,
005 et al. Electrogram-guided endomyocardial biopsy yield in patients with suspected car-
199. Bogaert J, Meyns B, Dymarkowski S, Sinnaeve P, Meuris B. Calcified constrictive peri- diac sarcoidosis and relation to outcomes. J Cardiovasc Electrophysiol 2021;32:2486–95.
carditis: prevalence, distribution patterns, and relationship to the myocardium. JACC 
Cardiovasc Imaging 2016;9:1013–4.  221. Vaidya VR, Abudan AA, Vasudevan K, Shantha G, Cooper LT, Kapa S, et al. The efficacy
200. Azzu A, Morosin M, Antonopoulos AS, Capoccia M, Rosendahl U, Mohiaddin R. and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic
Cardiac decompression by pericardiectomy for constrictive pericarditis: multimodality review. J Interv Card Electrophysiol 2018;53:63–71. 
imaging to identify patients at risk for prolonged inotropic support. J Cardiovasc Imaging 018-0410-7
2021;29:361–72.  222. Pelargonio G, Pinnacchio G, Narducci ML, Pieroni M, Perna F, Bencardino G, et al. long-
201. Peretto G, Busnardo E, Ferro P, Palmisano A, Vignale D, Esposito A, et al. Clinical ap- term arrhythmic risk assessment in biopsy-proven myocarditis. JACC Clin Electrophysiol
plications of FDG-PET scan in arrhythmic myocarditis. JACC Cardiovasc Imaging 2022; 2020;6:574–82. 
15:1771–80.  223. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, et al.
202. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol
Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with per- 1987;1:3–14.
sisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:288–92. https:// 224. Schnitt SJ, Ciano PS, Schoen FJ. Quantitation of lymphocytes in endomyocardial biop-
doi.org/10.1016/j.jcmg.2020.03.009 sies: use and limitations of antibodies to leukocyte common antigen. Hum Pathol 1987;
203. Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A, et al. Initial experience with 18:796–800. 
simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis. 225. Linder J, Cassling RS, Rogler WC, Wilson JE, Markin RS, Sears TD, et al.
Clin Nucl Med 2017;42:e328–34.  Immunohistochemical characterization of lymphocytes in uninflamed ventricular myo-
204. Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. cardium. Implications for myocarditis. Arch Pathol Lab Med 1985;109:917–20.
Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in 226. Ohta-Ogo K, Sugano Y, Ogata S, Nakayama T, Komori T, Eguchi K, et al. Myocardial
T-lymphocytes as a prognostic risk-stratifying marker of dilated cardiomyopathy—re-
cardiac sarcoid detection and therapy monitoring. J Nucl Med 2017;58:1341–53.
sults of the multicenter registry to investigate inflammatory cell infiltration in dilated

cardiomyopathy in tissues of endomyocardial biopsy (INDICATE study). Circ J 2022;
205. Salomäki SP, Hohenthal U, Kemppainen J, Pirilä L, Saraste A. Visualization of pericar-
86:1092–101. 
ditis by fluorodeoxyglucose PET. Eur Heart J Cardiovasc Imaging 2014;15:291. https://
227. Katzmann JL, Schlattmann P, Rigopoulos AG, Noutsias E, Bigalke B, Pauschinger M,
doi.org/10.1093/ehjci/jet179
et al. Meta-analysis on the immunohistological detection of inflammatory cardiomyop-
206. Nensa F, Kloth J, Tezgah E, Poeppel TD, Heusch P, Goebel J, et al. Feasibility of
athy in endomyocardial biopsies. Heart Fail Rev 2020;25:277–94. 
FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl
1007/s10741-019-09835-9
Cardiol 2018;25:785–94. 
228. Pelzl L, Mantino S, Sauter M, Manuylova T, Vogel U, Klingel K. Lymphocytic myocarditis
207. Basso C, Calabrese F, Angelini A, Carturan E, Thiene G. Classification and histological,
in children with parvovirus B19 infection: pathological and molecular insights.
immunohistochemical, and molecular diagnosis of inflammatory myocardial disease.
Biomedicines 2024;12:1909. 
Heart Fail Rev 2013;18:673–81. 
229. Stiermaier T, Föhrenbach F, Klingel K, Kandolf R, Boudriot E, Sandri M, et al.
208. Murphy L, McGuckin M, Giblin G, Keogh A, McGovern B, Fabre A, et al. The role of
Biventricular endomyocardial biopsy in patients with suspected myocarditis: feasibility,
endomyocardial biopsy in suspected myocarditis in the contemporary era: a 10-year
complication rate and additional diagnostic value. Int J Cardiol 2017;230:364–70.
National Transplant Centre experience. Cardiovasc Pathol 2021;54:107366. https://

doi.org/10.1016/j.carpath.2021.107366
230. Mahfoud F, Gärtner B, Kindermann M, Ukena C, Gadomski K, Klingel K, et al. Virus
209. Lu ZA, Aubry MC, Fallon JT, Fishbein MC, Giordano C, Klingel K, et al. Myocarditis and
serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011;
endomyocardial biopsy: achieving consensus diagnosis on 100 cases. Cardiovasc Pathol
32:897–903. 
2023;62:107492. 
231. Heidecker B, Williams SH, Jain K, Oleynik A, Patriki D, Kottwitz J, et al. Virome sequen-
210. Seferović PM, Tsutsui H, McNamara DM, Ristić AD, Basso C, Bozkurt B, et al. Heart
cing in patients with myocarditis. Circ Heart Fail 2020;13:e007103. 
Failure Association of the ESC, Heart Failure Society of America and Japanese Heart
1161/CIRCHEARTFAILURE.120.007103
Failure Society position statement on endomyocardial biopsy. Eur J Heart Fail 2021;
232. Maisch B, Rupp H, Ristic A, Pankuweit S. Pericardioscopy and epi- and pericardial bi-
23:854–71. 
opsy—a new window to the heart improving etiological diagnoses and permitting tar-
211. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al.
geted intrapericardial therapy. Heart Fail Rev 2013;18:317–28. 
Comparative evaluation of left and right ventricular endomyocardial biopsy: differ- s10741-013-9382-y
ences in complication rate and diagnostic performance. Circulation 2010;122:900–9.
233. Ding Z, Yang M, Wang Y, Wu S, Qiu X, Liu Q. Retrospective analysis of 769 cases of
 sudden cardiac death from 2006 to 2015: a forensic experience in China. Forensic Sci
212. van der Boon R, den Dekker W, Meuwese CL, Lorusso R, von der Thüsen J,
Med Pathol 2017;13:336–41. 
Constantinescu AC, et al. Safety of endomyocardial biopsy in new-onset acute heart 234. Vassalini M, Verzeletti A, Restori M, De Ferrari F. An autopsy study of sudden cardiac
failure requiring veno-arterial extracorporeal membrane oxygenation. Circ Heart Fail death in persons aged 1–40 years in Brescia (Italy). J Cardiovasc Med (Hagerstown) 2016;
2021;14:e008387.  17:446–53. 
213. Mueller GC, Michel-Behnke I, Knirsch W, Haas NA, Abdul-Khaliq H, Gitter R, et al. 235. Wu Y, Ai M, Bardeesi ASA, Zhang L, Wu Q, Yin K, et al. The forensic pathological ana-
Feasibility, safety and diagnostic impact of endomyocardial biopsies for the diagnosis lysis of sport-related sudden cardiac death in Southern China. Forensic Sci Res 2020;5:
of myocardial disease in children and adolescents. EuroIntervention 2018;14: 47–54. 
1089–95.  236. Wang H, Yao Q, Zhu S, Zhang G, Wang Z, Li Z, et al. The autopsy study of 553 cases of
214. De Gaspari M, Larsen BT, d’Amati G, Kreutz K, Basso C, Michaud K, et al. Diagnosing sudden cardiac death in Chinese adults. Heart Vessels 2014;29:486–95. 
myocarditis in endomyocardial biopsies: survey of current practice. Cardiovasc Pathol 10.1007/s00380-013-0388-0
2023;64:107494.  237. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young
215. Gartshteyn Y, Tamargo M, Fleischer S, Kapoor T, Li J, Askanase A, et al. Australians. Med J Aust 2004;180:110–2. 
Endomyocardial biopsies in the diagnosis of myocardial involvement in systemic lupus tb05830.x
erythematosus. Lupus 2020;29:199–204.  238. Harris KM, Mackey-Bojack S, Bennett M, Nwaudo D, Duncanson E, Maron BJ. Sudden
216. Heymans S, Lakdawala NK, Tschöpe C, Klingel K. Dilated cardiomyopathy: causes, me- unexpected death due to myocarditis in young people, including athletes. Am J Cardiol
chanisms, and current and future treatment approaches. Lancet 2023;402:998–1011. 2021;143:131–4. 
 239. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al. Guidelines for
217. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M. autopsy investigation of sudden cardiac death: 2017 update from the Association for
Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined European Cardiovascular Pathology. Virchows Arch 2017;471:691–705. 
immunosuppression. Circ Heart Fail 2013;6:15–22.  10.1007/s00428-017-2221-0
CIRCHEARTFAILURE.112.969261 240. Ekström K, Lehtonen J, Nordenswan H-K, Mäyränpää MI, Räisänen-Sokolowski A,
218. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al. Diagnostic Kandolin R, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical
yield of electroanatomic voltage mapping in guiding endomyocardial biopsies. Circulation and cause-of-death registries. Eur Heart J 2019;40:3121–8. 
2020;142:1249–60.  eurheartj/ehz428
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4031
241. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA 261. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. 2019
expert consensus statement on the state of genetic testing for the channelopathies ESC guidelines for the management of patients with supraventricular tachycardia. The
and cardiomyopathies. This document was developed as a partnership between the Task Force for the management of patients with supraventricular tachycardia of the
Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). European Society of Cardiology (ESC). Eur Heart J 2020;41:655–720. 
Heart Rhythm 2011;8:1308–39.  10.1093/eurheartj/ehz467
242. Wilhelm M, Bolliger SA, Bartsch C, Fokstuen S, Gräni C, Martos V, et al. Sudden cardiac 262. Berg J, Lovrinovic M, Baltensperger N, Kissel CK, Kottwitz J, Manka R, et al.
death in forensic medicine—Swiss recommendations for a multidisciplinary approach. Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical
Swiss Med Wkly 2015;145:w14129.  follow-up. Open Heart 2019;6:e000990. 
243. de Noronha SV, Behr ER, Papadakis M, Ohta-Ogo K, Banya W, Wells J, et al. The im- 263. Collini V, De Martino M, Andreis A, De Biasio M, Gaspard F, Paneva E, et al. Efficacy and
portance of specialist cardiac histopathological examination in the investigation of safety of colchicine for the treatment of myopericarditis. Heart 2024;110:735–9.
young sudden cardiac deaths. Europace 2014;16:899–907.  
europace/eut329 264. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al.
244. De Gaspari M, Fedeli U, Saia M, Carturan E, Pilichou K, Corrado D, et al. Rate and cause Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:
of sudden cardiac death in the young during the COVID-19 pandemic and vaccination. 639–48. 
Circulation 2023;148:2069–71.  265. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology,
066270 pathophysiology and contemporary management of cardiogenic shock—a position
245. du Long R, Fronczek J, Niessen HWM, van der Wal A, de Boer H. The histopathologic- statement from the Heart Failure Association of the European Society of
al spectrum of myocardial inflammation in relation to circumstance of death: a retro- Cardiology. Eur J Heart Fail 2020;22:1315–41. 
spective cohort study in clinical and forensic autopsies. Forensic Sci Res 2022;7:238–46. 266. Heymans S, Van Linthout S, Kraus SM, Cooper LT, Ntusi NAB. Clinical characteristics
 and mechanisms of acute myocarditis. Circ Res 2024;135:397–411. 
246. Li L, Zhang Y, Burke A, Xue A, Zhao Z, Fowler D, et al. Demographic, clinical and 1161/CIRCRESAHA.124.324674
pathological features of sudden deaths due to myocarditis: results from a state-wide 267. Pappritz K, Lin J, El-Shafeey M, Fechner H, Kühl U, Alogna A, et al. Colchicine prevents
population-based autopsy study. Forensic Sci Int 2017;272:81–6.  disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the
1016/j.forsciint.2016.12.037 cardiosplenic axis. ESC Heart Fail 2022;9:925–41. 
247. Gulino SP, Burns K, Gunther WM, MacLeod H. Improving forensic pathologic investi- 268. Kerneis M, Cohen F, Combes A, Amoura Z, Pare C, Brugier D, et al. Rationale and de-
gation of sudden death in the young: tools, guidance, and methods of cardiovascular
sign of the ARAMIS trial: anakinra versus placebo, a double blind randomized con-
dissection from the sudden death in the young case registry. Acad Forensic Pathol
trolled trial for the treatment of acute myocarditis. Arch Cardiovasc Dis 2023;116:
2018;8:347–91. 
460–6. 
248. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC
269. Li Y, Yu Y, Chen S, Liao Y, Du J. Corticosteroids and intravenous immunoglobulin in
guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;
pediatric myocarditis: a meta-analysis. Front Pediatr 2019;7:342. 
45:3415–537. 
3389/fped.2019.00342
249. Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, et al. Coronary
270. Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane
artery disease and revascularization associated with immune checkpoint blocker myo-
Database Syst Rev 2013;2013:CD004471. 
carditis: report from an international registry. Eur J Cancer 2022;177:197–205. https://
CD004471.pub3
doi.org/10.1016/j.ejca.2022.07.018
271. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic
250. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association be-
myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol 2017;70:
tween immune checkpoint inhibitors with cardiovascular events and atherosclerotic pla-
2363–75. 
que. Circulation 2020;142:2299–311. 
272. Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al.
049981
A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333:
251. Zöller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with
269–75. 
cancer: a nationwide follow-up study from Sweden. Eur J Cancer 2012;48:121–8.
273. Schultheiss H-P, Piper C, Sowade O, Waagstein F, Kapp J-F, Wegscheider K, et al.

Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-β treat-
252. Jain CC, Miranda WR, El Sabbagh A, Nishimura RA. A simplified method for the diag-
ment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016;105:
nosis of constrictive pericarditis in the cardiac catheterization laboratory. JAMA Cardiol
763–73. 
2022;7:100–4. 
274. Imazio M, Andreis A, Agosti A, Piroli F, Avondo S, Casula M, et al. Usefulness of beta-
253. Casella M, Gasperetti A, Compagnucci P, Narducci ML, Pelargonio G, Catto V, et al.
blockers to control symptoms in patients with pericarditis. Am J Cardiol 2021;146:
Different phases of disease in lymphocytic myocarditis: clinical and electrophysiological
115–9. 
characteristics. JACC Clin Electrophysiol 2023;9:314–26. 
275. Avondo S, Andreis A, Casula M, Biondi-Zoccai G, Imazio M. Pharmacologic treatment
2022.10.004
of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled 254. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al.
clinical trials. Panminerva Med 2021;63:314–23. 
Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis
from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol 21.04263-4
276. Lutschinger LL, Rigopoulos AG, Schlattmann P, Matiakis M, Sedding D, Schulze PC,
2020;6:696–707. 
255. Peretto G, Sala S, Basso C, Della Bella P. Programmed ventricular stimulation in pa- et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of
tients with active vs previous arrhythmic myocarditis. J Cardiovasc Electrophysiol postpericardiotomy syndrome. BMC Cardiovasc Disord 2019;19:207. 
2020;31:692–701.  10.1186/s12872-019-1190-4
256. Haanschoten DM, Adiyaman A, ‘t Hart NA, Jager PL, Elvan A. Value of 3D mapping- 277. Li Y-L, Qiao S-B, Wang J-Y, Chen Y-M, Luo J, Zhang H-F. Colchicine in addition to con-
guided endomyocardial biopsy in cardiac sarcoidosis: case series and narrative review ventional therapy for pericarditis recurrence: an update meta-analysis. Herz 2016;41:
on the value of electro-anatomic mapping-guided endomyocardial biopsies. Eur J Clin 630–8. 
Invest 2021;51:e13497.  278. Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for pre-
257. Muser D, Santangeli P, Liang JJ, Castro SA, Magnani S, Hayashi T, et al. Characterization vention and treatment of cardiac diseases: a meta-analysis. Cardiovasc Ther 2017;35:
of the electroanatomic substrate in cardiac sarcoidosis: correlation with imaging find- 10–18. 
ings of scar and inflammation. JACC Clin Electrophysiol 2018;4:291–303.  279. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastropro-
10.1016/j.jacep.2017.09.175 tectant drugs for the prevention and treatment of peptic ulcer disease and its compli-
258. Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, et al. Electrogram guid- cations: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3:
ance: a method to increase the precision and diagnostic yield of endomyocardial biopsy 231–41. 
for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail 2014;2:466–73. 280. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022
 American College of Rheumatology guideline for the prevention and treatment of
259. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2023;75:2088–102. https://
Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute doi.org/10.1002/art.42646
and chronic heart failure. Eur Heart J 2023;44:3627–39.  281. Sambola A, Roca Luque I, Mercé J, Alguersuari J, Francisco-Pascual J, García-Dorado D,
eurheartj/ehad195 et al. Colchicine administered in the first episode of acute idiopathic pericarditis: a ran-
260. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. domized multicenter open-label study. Rev Esp Cardiol (Engl Ed) 2019;72:709–16.
2024 ESC Guidelines for the management of atrial fibrillation developed in collabor- 
ation with the European Association for Cardio-Thoracic Surgery (EACTS). Eur 282. Imazio M, Andreis A, Piroli F, Lazaros G, Gattorno M, Lewinter M, et al.
Heart J 2024;45:3314–414.  Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic
Downloaded
from

by
guest
on
22
January
2026

4032 E S C G u id e l in e s
review and meta-analysis. Heart 2021;107:1240–5.  pericardial effusions with thiotepa. Chest 2004;126:1412–6. 
2020-318869 chest.126.5.1412
283. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. Phase 3 trial of 304. Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, et al. Intracavitary
interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 2021;384:31–41. chemotherapy with thiotepa in malignant pericardial effusions: an active and well-
 tolerated regimen. J Clin Oncol 1998;16:2371–6. 
284. Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of 16.7.2371
anakinra on recurrent pericarditis among patients with colchicine resistance and cor- 305. Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, et al. A randomised
ticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA 2016;316: trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer
1906–12.  (JCOG9811). Br J Cancer 2009;100:464–9. 
285. Brucato A, Wheeler A, Luis SA, Abbate A, Cremer PC, Zou L, et al. Transition to ri- 306. Shepherd FA, Morgan C, Evans WK, Ginsberg JF, Watt D, Murphy K. Medical manage-
lonacept monotherapy from oral therapies in patients with recurrent pericarditis. ment of malignant pericardial effusion by tetracycline sclerosis. Am J Cardiol 1987;60:
Heart 2023;109:297–304.  1161–6. 
286. Collini V, Andreis A, De Biasio M, De Martino M, Isola M, Croatto N, et al. Efficacy of 307. Beckmann E, Ismail I, Cebotari S, Busse A, Martens A, Shrestha M, et al. Right-sided
colchicine in addition to anakinra in patients with recurrent pericarditis. Open Heart heart failure and extracorporeal life support in patients undergoing pericardiectomy
2024;11:e002599.  for constrictive pericarditis: a risk factor analysis for adverse outcome. Thorac
287. Vianello F, Cinetto F, Cavraro M, Battisti A, Castelli M, Imbergamo S, et al. Azathioprine Cardiovasc Surg 2017;65:662–70. 
in isolated recurrent pericarditis: a single centre experience. Int J Cardiol 2011;147: 308. Busch C, Penov K, Amorim PA, Garbade J, Davierwala P, Schuler GC, et al. Risk factors
477–8.  for mortality after pericardiectomy for chronic constrictive pericarditis in a large
288. Imazio M, Lazaros G, Picardi E, Vasileiou P, Carraro M, Tousoulis D, et al. Intravenous single-centre cohort. Eur J Cardiothorac Surg 2015;48:e110–6. 
human immunoglobulins for refractory recurrent pericarditis: a systematic review of 1093/ejcts/ezv322
all published cases. J Cardiovasc Med (Hagerstown) 2016;17:263–9.  309. Vondran M, Rylski B, Berezowski M, Polycarpou A, Born F, Guenther S, et al.
2459/JCM.0000000000000260 Preemptive extracorporeal life support for surgical treatment of severe constrictive
289. Marcolongo R, Russo R, Laveder F, Noventa F, Agostini C. Immunosuppressive ther- pericarditis. Ann Thorac Surg 2019;108:1376–81. 
apy prevents recurrent pericarditis. J Am Coll Cardiol 1995;26:1276–9. 
2019.03.105
10.1016/0735-1097(95)00302-9
310. Saxena P, Joyce LD, Daly RC, Kushwaha SS, Schirger JA, Rosedahl J, et al. Cardiac trans-
290. Lazaros G, Antonopoulos AS, Antonatou K, Skendros P, Ritis K, Hadziyannis E, et al.
plantation for radiation-induced cardiomyopathy: the Mayo Clinic experience. Ann
Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic re-
Thorac Surg 2014;98:2115–21. 
current pericarditis: a pilot observational prospective study. Int J Cardiol 2020;311:
311. Al-Kazaz M, Klein AL, Oh JK, Crestanello JA, Cremer PC, Tong MZ, et al. Pericardial
77–82. 
diseases and best practices for pericardiectomy: JACC state-of-the-art review. J Am
291. Lotrionte M, Biondi-Zoccai G, Imazio M, Castagno D, Moretti C, Abbate A, et al.
Coll Cardiol 2024;84:561–80. 
International collaborative systematic review of controlled clinical trials on pharmaco-
312. Vistarini N, Chen C, Mazine A, Bouchard D, Hebert Y, Carrier M, et al. Pericardiectomy
logic treatments for acute pericarditis and its recurrences. Am Heart J 2010;160:
for constrictive pericarditis: 20 years of experience at the Montreal Heart Institute. Ann
662–70. 
Thorac Surg 2015;100:107–13. 
292. Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective
313. Lee S, Lee J, Joo S, Park YK, Kim KM, Jung JC, et al. Impact of pericardial calcification on
treatment of postpericardiotomy syndrome after cardiac operations. A randomized
early postoperative outcomes after pericardiectomy: a retrospective observational
placebo-controlled trial. J Thorac Cardiovasc Surg 1990;100:292–6. 
study. J Cardiothorac Surg 2024;19:449. 
1016/S0022-5223(19)35571-0
314. Yamamoto N, Ohara K, Nie M, Torii S, Inoue N, Miyaji K. For what type of constrictive
293. Atluri P, Ullery BW, MacArthur JW, Goldstone AB, Fairman AS, Hiesinger W, et al.
pericarditis is the waffle procedure effective? Asian Cardiovasc Thorac Ann 2011;19:
Rapid onset of fulminant myocarditis portends a favourable prognosis and the ability
115–8. 
to bridge mechanical circulatory support to recovery. Eur J Cardiothorac Surg 2013;
315. Matsuura K, Mogi K, Takahara Y. Off-pump waffle procedure using an ultrasonic scal-
43:379–82. 
pel for constrictive pericarditis. Eur J Cardiothorac Surg 2015;47:e220–2. 
294. Montero S, Aissaoui N, Tadié J-M, Bizouarn P, Scherrer V, Persichini R, et al. Fulminant
10.1093/ejcts/ezu554
giant-cell myocarditis on mechanical circulatory support: management and outcomes
316. Calderon-Rojas RD, Greason KL, King KS, Luis SA, Oh JK, Stulak JM, et al. Outcomes of
of a French multicentre cohort. Int J Cardiol 2018;253:105–12. 
tricuspid valve operation at the time of pericardiectomy for constrictive pericarditis.
j.ijcard.2017.10.053
Ann Thorac Surg 2021;111:1252–7. 
295. Bernhardt AM, Copeland H, Deswal A, Gluck J, Givertz MM; Task Force 1; et al. The
317. Li T-T, Cheng J. Clinical analysis of temporary pacemaker implantation in 13 children.
International Society for Heart and Lung Transplantation/Heart Failure Society of
Transl Pediatr 2022;11:174–82. 
America Guideline on Acute Mechanical Circulatory Support. J Heart Lung
318. Suarez K, Banchs JE. A review of temporary permanent pacemakers and a comparison
Transplant 2023;42:e1–e64. 
with conventional temporary pacemakers. J Innov Card Rhythm Manag 2019;10: 296. Lorusso R, Shekar K, MacLaren G, Schmidt M, Pellegrino V, Meyns B, et al. ELSO interim
3652–61. 
guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac pa-
319. Braun MU, Rauwolf T, Bock M, Kappert U, Boscheri A, Schnabel A, et al. Percutaneous
tients. ASAIO J 2021;67:827–44. 
lead implantation connected to an external device in stimulation-dependent patients
297. Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, et al.
Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis with systemic infection—a prospective and controlled study. Pacing Clin
in adult patients: a 5-year multi-institutional experience. Ann Thorac Surg 2016;101: Electrophysiol 2006;29:875–9. 
919–26.  320. Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using transvenous
298. Mirabel M, Luyt C-E, Leprince P, Trouillet J-L, Léger P, Pavie A, et al. Outcomes, long- active fixation leads and external re-sterilized pulse generators. J Am Coll Cardiol 2006;
term quality of life, and psychologic assessment of fulminant myocarditis patients res- 47:1487–9. 
cued by mechanical circulatory support. Crit Care Med 2011;39:1029–35.  321. Chung MK, Patton KK, Lau C-P, Forno ARJD, Al-Khatib SM, Arora V, et al. 2023 HRS/
org/10.1097/CCM.0b013e31820ead45 APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitiga-
299. Diddle JW, Almodovar MC, Rajagopal SK, Rycus PT, Thiagarajan RR. Extracorporeal tion of heart failure. Heart Rhythm 2023;20:e17–91. 
membrane oxygenation for the support of adults with acute myocarditis. Crit Care 2023.03.1538
Med 2015;43:1016–25.  322. Casella M, Bergonti M, Narducci ML, Persampieri S, Gasperetti A, Conte E, et al. Prior
300. Nunez JI, Grandin EW, Reyes-Castro T, Sabe M, Quintero P, Motiwala S, et al. myocarditis and ventricular arrhythmias: the importance of scar pattern. Heart Rhythm
Outcomes with peripheral venoarterial extracorporeal membrane oxygenation for 2021;18:589–96. 
suspected acute myocarditis: 10-year experience from the extracorporeal life support 323. Rav-Acha M, Shah K, Hasin T, Gumuser E, Tovia-Brodie O, Shauer A, et al. Incidence
organization registry. Circ Heart Fail 2023;16:e010152.  and predictors for recurrence of ventricular arrhythmia presenting during acute myo-
CIRCHEARTFAILURE.122.010152 carditis: a multicenter study. JACC Clin Electrophysiol 2024;10:1161–74. 
301. Strobbe A, Adriaenssens T, Bennett J, Dubois C, Desmet W, McCutcheon K, et al. 10.1016/j.jacep.2024.02.027
Etiology and long-term outcome of patients undergoing pericardiocentesis. J Am 324. Sasko B, Patschan D, Nordbeck P, Seidlmayer L, Andresen H, Jänsch M, et al. Secondary
Heart Assoc 2017;6:e007598.  prevention of potentially life-threatening arrhythmia using implantable cardioverter
302. Maisch B, Ristić AD, Pankuweit S, Neubauer A, Moll R. Neoplastic pericardial effusion. defibrillators in patients with biopsy-proven viral myocarditis and preserved ejection
Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 2002;23: fraction. Cardiology 2021;146:213–21. 
1625–31.  325. Peretto G, Sala S, Carturan E, Rizzo S, Villatore A, De Luca G, et al. Clinical profiling and
303. Martinoni A, Cipolla CM, Cardinale D, Civelli M, Lamantia G, Colleoni M, et al. outcomes of viral myocarditis manifesting with ventricular arrhythmias. Eur Heart J
Long-term results of intrapericardial chemotherapeutic treatment of malignant Open 2023;3:oead132. 
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4033
326. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M. 347. Imazio M, Brucato A, Maestroni S, Cumetti D, Belli R, Trinchero R, et al. Risk of con-
Incidence, risk factors, and outcome of life-threatening ventricular arrhythmias in giant strictive pericarditis after acute pericarditis. Circulation 2011;124:1270–5. 
cell myocarditis. Circ Arrhythm Electrophysiol 2016;9:e004559.  org/10.1161/CIRCULATIONAHA.111.018580
CIRCEP.116.004559 348. Yesilyaprak A, Kumar AK, Agrawal A, Furqan MM, Verma BR, Syed AB, et al. Predicting
327. Tscholl V, Wielander D, Kelch F, Stroux A, Attanasio P, Tschöpe C, et al. Benefit of a long-term clinical outcomes of patients with recurrent pericarditis. J Am Coll Cardiol
wearable cardioverter defibrillator for detection and therapy of arrhythmias in pa- 2024;84:1193–204. 
tients with myocarditis. ESC Heart Fail 2021;8:2428–37.  349. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, et al. Diagnosis
13353 and management of myocardial involvement in systemic immune-mediated diseases: a
328. Blaschke F, Lacour P, Dang PL, Parwani AS, Hohendanner F, Walter T, et al. Wearable position statement of the European Society of Cardiology Working Group on
cardioverter-defibrillator: friend or foe in suspected myocarditis? ESC Heart Fail 2021; Myocardial and Pericardial Disease. Eur Heart J 2017;38:2649–62. 
8:2591–6.  1093/eurheartj/ehx321
329. Wäßnig NK, Günther M, Quick S, Pfluecke C, Rottstädt F, Szymkiewicz SJ, 350. Cheng C-Y, Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP.
et al. Experience with the wearable cardioverter-defibrillator in patients at high risk Myocarditis in systemic immune-mediated diseases: prevalence, characteristics and
for sudden cardiac death. Circulation 2016;134:635–43.  prognosis. A systematic review. Autoimmun Rev 2022;21:103037. 
CIRCULATIONAHA.115.019124 1016/j.autrev.2022.103037
330. El-Battrawy I, Koepsel K, Tenbrink D, Kovacs B, Dreher TC, Blockhaus C, et al. Use of 351. Mavrogeni S, Bratis K, Sfendouraki E, Papadopoulou E, Kolovou G. Myopericarditis,
the wearable cardioverter-defibrillator among patients with myocarditis and reduced as the first sign of rheumatoid arthritis relapse, evaluated by cardiac magnetic reson-
ejection fraction or ventricular tachyarrhythmia: data from a multicenter registry. J Am ance. Inflamm Allergy Drug Targets 2013;12:206–11. 
Heart Assoc 2023;12:e030615.  1871528111312030008
331. Peretto G, Gulletta S, Slavich M, Campochiaro C, Vignale D, De Luca G, et al. Exercise 352. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al.
stress test late after arrhythmic versus nonarrhythmic presentation of myocarditis. 2019 European League Against Rheumatism/American College of Rheumatology clas-
J Pers Med 2022;12:1702.  sification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:
332. Yang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gado- 1400–12. 
linium enhancement in myocarditis and clinically suspected myocarditis: systematic re- 353. Jia E, Geng H, Liu Q, Xiao Y, Zhang Y, Xie J, et al. Cardiac manifestations of Han
Chinese patients with systemic lupus erythematosus: a retrospective study. Ir J Med
view and meta-analysis. Eur Radiol 2020;30:2616–26. 
Sci 2019;188:801–6. 
019-06643-5
354. Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB. Lupus myocarditis: a single center
333. Georgiopoulos G, Figliozzi S, Sanguineti F, Aquaro GD, di Bella G, Stamatelopoulos K,
experience and a comparative analysis of observational cohort studies. Lupus 2018;27:
et al. Prognostic impact of late gadolinium enhancement by cardiovascular magnetic
1296–302. 
resonance in myocarditis. Circ Cardiovasc Imaging 2021;14:e011492. 
355. Thomas G, Cohen Aubart F, Chiche L, Haroche J, Hié M, Hervier B, et al. Lupus myo-
10.1161/CIRCIMAGING.120.011492
carditis: initial presentation and longterm outcomes in a multicentric series of 29 pa-
334. Schumm J, Greulich S, Wagner A, Grün S, Ong P, Bentz K, et al. Cardiovascular mag-
tients. J Rheumatol 2017;44:24–32. 
netic resonance risk stratification in patients with clinically suspected myocarditis.
356. Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L,
J Cardiovasc Magn Reson 2014;16:14. 
et al. Ultrasensitive serum interferon-α quantification during SLE remission identifies
335. Salamanca J, Díez-Villanueva P, Martínez P, Cecconi A, González de Marcos B, Reyes G,
patients at risk for relapse. Ann Rheum Dis 2019;78:1669–76. 
et al. COVID-19 ‘fulminant myocarditis’ successfully treated with temporary mechan-
1136/annrheumdis-2019-215571
ical circulatory support. JACC Cardiovasc Imaging 2020;13:2457–9. 
357. Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Barnabei L, Ben Salah E, et al.
1016/j.jcmg.2020.05.003
Monitoring disease activity in systemic lupus erythematosus with single-molecule array
336. Pavlicek V, Kindermann I, Wintrich J, Mahfoud F, Klingel K, Böhm M, et al. Ventricular
digital enzyme-linked immunosorbent assay quantification of serum interferon-α.
arrhythmias and myocardial inflammation: long-term follow-up of patients with sus-
Arthritis Rheumatol 2019;71:756–65. 
pected myocarditis. Int J Cardiol 2019;274:132–7. 
358. du Toit R, Herbst PG, Ackerman C, Pecoraro AJ, Claassen D, Cyster HP, et al.
2018.07.142
Outcome of clinical and subclinical myocardial injury in systemic lupus erythemato-
337. Imazio M, Brucato A, Spodick DH, Adler Y. Prognosis of myopericarditis as deter-
sus—a prospective cohort study. Lupus 2021;30:256–68. 
mined from previously published reports. J Cardiovasc Med (Hagerstown) 2014;15:
0961203320976960
835–9. 
359. Hinojar R, Foote L, Sangle S, Marber M, Mayr M, Carr-White G, et al. Native T1 and T2
338. Castrichini M, Porcari A, Baggio C, Gagno G, Maione D, Barbati G, et al. Sex differences
mapping by CMR in lupus myocarditis: disease recognition and response to treatment.
in natural history of cardiovascular magnetic resonance- and biopsy-proven lympho-
Int J Cardiol 2016;222:717–26. 
cytic myocarditis. ESC Heart Fail 2022;9:4010–9. 
360. Sacré K, Brihaye B, Hyafil F, Serfaty J-M, Escoubet B, Zennaro M-C, et al. Asymptomatic
339. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term
myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac mag-
follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete netic resonance imaging study. Arthritis Rheum 2010;62:2093–100. 
recovery. J Am Coll Cardiol 2012;59:1604–15. 
1002/art.27488
007 361. Pineton de Chambrun M, Larcher R, Pène F, Argaud L, Mayaux J, Jamme M, et al.
340. Ammirati E, Varrenti M, Sormani P, Bernasconi D, Moro C, Grosu A, et al. Long-term In-hospital mortality-associated factors in patients with thrombotic antiphospholipid
prognostic performance of cardiac magnetic resonance imaging markers versus com- syndrome requiring ICU admission. Chest 2020;157:1158–66. 
plicated clinical presentation after an acute myocarditis. Int J Cardiol 2024;417:132567. 1016/j.chest.2019.11.010
 362. Yong WC, Sanguankeo A, Upala S. Association between primary Sjogren’s syndrome,
341. Greulich S, Seitz A, Müller KAL, Grün S, Ong P, Ebadi N, et al. Predictors of mortality in arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis.
patients with biopsy-proven viral myocarditis: 10-year outcome data. J Am Heart Assoc Clin Rheumatol 2019;38:447–55. 
2020;9:e015351.  363. Lazzerini PE, Murthy Ginjupalli VK, Srivastava U, Bertolozzi I, Bacarelli MR, Verrengia
342. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. D, et al. Anti-Ro/SSA antibodies blocking calcium channels as a potentially reversible
Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. cause of atrioventricular block in adults. JACC Clin Electrophysiol 2023;9:1631–48.
Circulation 2006;114:1581–90.  
606509 364. Bruni C, Buch MH, Furst DE, De Luca G, Djokovic A, Dumitru RB, et al. Primary sys-
343. Narducci ML, Pelargonio G, La Rosa G, Inzani F, d’Amati G, Novelli V, et al. Role of temic sclerosis heart involvement: a systematic literature review and preliminary data-
extensive diagnostic workup in young athletes and nonathletes with complex ventricu- driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord 2022;7:24–32.
lar arrhythmias. Heart Rhythm 2020;17:230–7.  
08.022 365. Krumm P, Mueller KAL, Klingel K, Kramer U, Horger MS, Zitzelsberger T, et al.
344. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss H-P, Cooper LT. Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement
Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J in systemic sclerosis. J Cardiovasc Magn Reson 2016;18:70. 
Cardiol 2015;115:1733–8.  s12968-016-0289-3
345. Kim M-J, Jung HO, Kim H, Bae Y, Lee SY, Jeon DS. 10-Year survival outcome after clin- 366. De Luca G, Campochiaro C, De Santis M, Sartorelli S, Peretto G, Sala S, et al. Systemic
ically suspected acute myocarditis in adults: a nationwide study in the pre-COVID-19 sclerosis myocarditis has unique clinical, histological and prognostic features: a com-
era. PLoS One 2023;18:e0281296.  parative histological analysis. Rheumatology (Oxford) 2020;59:2523–33. 
346. Kytö V, Sipilä J, Rautava P. Rate and patient features associated with recurrence of org/10.1093/rheumatology/kez658
acute myocarditis. Eur J Intern Med 2014;25:946–50.  367. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic
2014.11.001 sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian
Downloaded
from

by
guest
on
22
January
2026

4034 E S C G u id e l in e s
patients. Medicine (Baltimore) 2002;81:139–53.  388. Bock C-T, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J
200203000-00004 Med 2010;362:1248–9. 
368. Bruni C, Buch MH, Djokovic A, De Luca G, Dumitru RB, Giollo A, et al. Consensus on 389. Huang C-H, Vallejo JG, Kollias G, Mann DL. Role of the innate immune system in acute
the assessment of systemic sclerosis-associated primary heart involvement: World viral myocarditis. Basic Res Cardiol 2009;104:228–37. 
Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, 008-0765-5
and follow-up assessment. J Scleroderma Relat Disord 2023;8:169–82.  390. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, et al.
10.1177/23971983231163413 MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury
369. Fairley JL, Wicks I, Peters S, Day J. Defining cardiac involvement in idiopathic inflamma- and dysfunction during acute viral myocarditis. Circ Res 2012;111:415–25. 
tory myopathies: a systematic review. Rheumatology (Oxford) 2021;61:103–20. https:// org/10.1161/CIRCRESAHA.112.267443
doi.org/10.1093/rheumatology/keab573 391. Goldberg L, Tirosh-Wagner T, Vardi A, Abbas H, Pillar N, Shomron N, et al. Circulating
370. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients microRNAs: a potential biomarker for cardiac damage, inflammatory response, and
with idiopathic inflammatory myopathies according to clinical features: a longitudinal left ventricular function recovery in pediatric viral myocarditis. J Cardiovasc Transl
study of 162 cases. Medicine (Baltimore) 2004;83:35–42.  Res 2018;11:319–28. 
md.0000109755.65914.5e 392. Mueller KAL, Mueller II, Eppler D, Zuern CS, Seizer P, Kramer U, et al. Clinical and
371. Allanore Y, Vignaux O, Arnaud L, Puéchal X, Pavy S, Duboc D, et al. Effects of corti- histopathological features of patients with systemic sclerosis undergoing endomyocar-
costeroids and immunosuppressors on idiopathic inflammatory myopathy related dial biopsy. PLoS One 2015;10:e0126707. 
myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65: 0126707
249–52.  393. Wakafuji S, Okada R. Twenty year autopsy statistics of myocarditis incidence in Japan.
372. Zhang L, Wang G, Ma L, Zu N. Cardiac involvement in adult polymyositis or dermato- Jpn Circ J 1986;50:1288–93. 
myositis: a systematic review. Clin Cardiol 2012;35:686–91.  394. Vaideeswar P, Cooper LT. Giant cell myocarditis: clinical and pathological features in
22026 an Indian population. Cardiovasc Pathol 2013;22:70–4. 
373. Groh M, Masciocco G, Kirchner E, Kristen A, Pellegrini C, Varnous S, et al. Heart trans- carpath.2012.06.003
plantation in patients with eosinophilic granulomatosis with polyangiitis (Churg– 395. Caforio ALP, Angelini A, Blank M, Shani A, Kivity S, Goddard G, et al. Passive transfer of
Strauss syndrome). J Heart Lung Transplant 2014;33:842–50.  affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocardi-
j.healun.2014.02.023 tis induces experimental myocarditis in mice. Int J Cardiol 2015;179:166–77. 
374. Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Saleem U, Hansen A, et al.
org/10.1016/j.ijcard.2014.10.165
SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes.
396. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as
Cardiovasc Res 2020;116:2207–15. 
causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm
375. Peretto G, Villatore A, Rizzo S, Esposito A, De Luca G, Palmisano A, et al. The spec-
Electrophysiol 2011;4:303–9. 
trum of COVID-19-associated myocarditis: a patient-tailored multidisciplinary ap-
397. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diag-
proach. J Clin Med 2021;10:1974. 
nostic and treatment strategies for specific dilated cardiomyopathies: a scientific state-
376. Weckbach LT, Curta A, Bieber S, Kraechan A, Brado J, Hellmuth JC, et al. Myocardial
ment from the American Heart Association. Circulation 2016;134:e579–e646. https://
inflammation and dysfunction in COVID-19-associated myocardial injury. Circ
doi.org/10.1161/CIR.0000000000000455
Cardiovasc Imaging 2021;14:e012220. 
398. Liu S, Zheng L, Shen L, Wu L, Yao Y. Clinical identification and characteristic analysis of
011713
giant cell myocarditis in 12 cases. Front Cardiovasc Med 2021;8:649094. 
377. Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal A, Aubry M-C, et al.
10.3389/fcvm.2021.649094
Pathological features of COVID-19-associated myocardial injury: a multicentre cardio-
399. Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, et al. A clinical and
vascular pathology study. Eur Heart J 2020;41:3827–35. 
histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis.
eurheartj/ehaa664
J Am Coll Cardiol 2003;41:322–9. 
378. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovas-
400. Berthelot-Richer M, O’Connor K, Bernier M, Trahan S, Couture C, Dubois M, et al.
cular findings across 277 postmortem examinations. Cardiovasc Pathol 2021;50:
When should we consider the diagnosis of giant cell myocarditis? Revisiting ‘classic’
107300. 
echocardiographic and clinical features of this rare pathology. Exp Clin Transplant
379. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al.
2014;12:565–8. 
Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy
401. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M.
cases. JAMA Cardiol 2020;5:1281–5. 
Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail
380. Aquaro GD, Licordari R, Todiere G, Ianni U, Dellegrotaglie S, Restivo L, et al. Incidence
2016;18:1452–8. 
of acute myocarditis and pericarditis during the coronavirus disease 2019 pandemic:
402. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of
comparison with the prepandemic period. J Cardiovasc Med (Hagerstown) 2022;23:
endomyocardial biopsy in the management of cardiovascular disease: a scientific state-
447–53. 
ment from the American Heart Association, the American College of Cardiology, and 381. Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, et al. Association be-
the European Society of Cardiology. Endorsed by the Heart Failure Society of America
tween COVID-19 and myocarditis using hospital-based administrative data—United
States, March 2020–January 2021. MMWR Morb Mortal Wkly Rep 2021;70:1228–32. and the Heart Failure Association of the European Society of Cardiology. J Am Coll
 Cardiol 2007;50:1914–31. 
382. Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, et al. 403. Cooper LT, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al.
Prevalence of clinical and subclinical myocarditis in competitive athletes with recent Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102:
SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA 1535–9. 
Cardiol 2021;6:1078–87.  404. Patel PM, Saxena A, Wood CT, O’Malley TJ, Maynes EJ, Entwistle JWC, et al.
383. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Outcomes of mechanical circulatory support for giant cell myocarditis: a systematic
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute re- review. J Clin Med 2020;9:3905. 
spiratory distress syndrome, and hyperinflammation: a retrospective cohort study. 405. Bobbio E, Björkenstam M, Nwaru BI, Giallauria F, Hessman E, Bergh N, et al. Short- and
Lancet Rheumatol 2020;2:e325–31.  long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell
384. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol myocarditis: a systematic review and meta-analysis. Clin Res Cardiol 2022;111:
AD, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N 125–40. 
Engl J Med 2021;384:1491–502.  406. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al.
385. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir
between early treatment with tocilizumab and mortality among critically ill patients Crit Care Med 2001;164:1885–9. 
with COVID-19. JAMA Intern Med 2021;181:41–51.  407. Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. Cardiac sarcoidosis:
jamainternmed.2020.6252 phenotypes, diagnosis, treatment, and prognosis. Eur Heart J 2023;44:1495–510.
386. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, et al. Ongoing 
enterovirus-induced myocarditis is associated with persistent heart muscle infection: 408. Okasha O, Kazmirczak F, Chen K-HA, Farzaneh-Far A, Shenoy C. Myocardial involve-
quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl ment in patients with histologically diagnosed cardiac sarcoidosis: a systematic review
Acad Sci U S A 1992;89:314–8.  and meta-analysis of gross pathological images from autopsy or cardiac transplantation
387. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, et al. cases. J Am Heart Assoc 2019;8:e011253. 
Association of parvovirus B19 genome in children with myocarditis and cardiac allo- 409. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitalchi M, Kawabata Y. Pathological stud-
graft rejection: diagnosis using the polymerase chain reaction. Circulation 1997;96: ies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol
3549–54.  Jpn 1993;43:372–6. 
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4035
410. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 431. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging pre-
38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119: dicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc
167–72. Imaging 2013;6:501–11. 
411. Philips B, Madhavan S, James CA, te Riele ASJM, Murray B, Tichnell C, et al. 432. Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identi-
Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: fied with cardiac magnetic resonance imaging in sarcoidosis patients is associated with
distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc
2014;7:230–6.  Imaging 2015;16:634–41. 
412. Gasperetti A, Rossi VA, Chiodini A, Casella M, Costa S, Akdis D, et al. Differentiating 433. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of
hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis myocardial damage in sarcoidosis patients with preserved left ventricular ejection frac-
fulfilling 2010 ARVC task force criteria. Heart Rhythm 2021;18:231–8.  tion: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging
10.1016/j.hrthm.2020.09.015 2016;9:e003738. 
413. Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari MD, et al. 434. Coleman GC, Shaw PW, Balfour PC, Gonzalez JA, Kramer CM, Patel AR, et al.
Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020; Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis.
319:106–14.  JACC Cardiovasc Imaging 2017;10:411–20. 
414. Bagwan IN, Hooper LVB, Sheppard MN. Cardiac sarcoidosis and sudden death. The 435. Smedema J-P, van Geuns R-J, Ector J, Heidbuchel H, Ainslie G, Crijns HJGM. Right ven-
heart may look normal or mimic other cardiomyopathies. Virchows Arch 2011;458: tricular involvement and the extent of left ventricular enhancement with magnetic res-
671–8.  onance predict adverse outcome in pulmonary sarcoidosis. ESC Heart Fail 2018;5:
415. Athwal PSS, Chhikara S, Ismail MF, Ismail K, Ogugua FM, Kazmirczak F, et al. 157–71. 
Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in 436. Velangi PS, Chen K-HA, Kazmirczak F, Okasha O, von Wald L, Roukoz H, et al. Right
patients with suspected cardiac sarcoidosis. JAMA Cardiol 2022;7:1057–66. https:// ventricular abnormalities on cardiovascular magnetic resonance imaging in patients
doi.org/10.1001/jamacardio.2022.2981 with sarcoidosis. JACC Cardiovasc Imaging 2020;13:1395–405. 
416. Azoulay L-D, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors associated 1016/j.jcmg.2019.12.011
with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: 437. Greulich S, Kitterer D, Latus J, Aguor E, Steubing H, Kaesemann P, et al.
a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:17–23.  Comprehensive cardiovascular magnetic resonance assessment in patients with sar-
36141/svdld.v37i1.8271 coidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging
417. Sharma R, Kouranos V, Cooper LT, Metra M, Ristic A, Heidecker B, et al. Management 2016;9:e005022. 
of cardiac sarcoidosis. Eur Heart J 2024;45:2697–726.  438. Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping
eurheartj/ehae356 in recognition of early cardiac involvement in systemic sarcoidosis. Radiology 2017;285:
418. Selan JC, Michaelson M, Fanburg BL, Estes NAM. Evaluation and management of heart 63–72. 
rhythm disturbances due to cardiac sarcoidosis. Heart Lung Circ 2014;23:1100–9. 439. Crouser ED, Ruden E, Julian MW, Raman SV. Resolution of abnormal cardiac MRI T2
 signal following immune suppression for cardiac sarcoidosis. J Investig Med 2016;64:
419. Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive 1148–50. 
endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients 440. Greulich S, Gatidis S, Gräni C, Blankstein R, Glatthaar A, Mezger K, et al. Hybrid cardiac
with initially unexplained cardiomyopathy. Am Heart J 2005;150:459–63.  magnetic resonance/fluorodeoxyglucose positron emission tomography to differenti-
org/10.1016/j.ahj.2004.10.006 ate active from chronic cardiac sarcoidosis. JACC Cardiovasc Imaging 2022;15:445–56.
420. Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, et al. 
Complementary role of CMR to conventional screening in the diagnosis and prognosis 441. Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoid-
of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017;10:1437–47.  osis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med
1016/j.jcmg.2016.11.019 2014;189:109–12. 
421. Adhaduk M, Paudel B, Khalid MU, Ashwath M, Mansour S, Liu K. Comparison of car- 442. Cheung E, Ahmad S, Aitken M, Chan R, Iwanochko RM, Balter M, et al. Combined sim-
diac magnetic resonance imaging and fluorodeoxyglucose positron emission tomog- ultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the
raphy in the assessment of cardiac sarcoidosis: meta-analysis and systematic review. diagnosis and prognosis of suspected cardiac sarcoidosis. Eur J Hybrid Imaging 2021;
J Nucl Cardiol 2023;30:1574–87.  5:24. 
422. Orii M, Tanimoto T, Ota S, Takagi H, Tanaka R, Fujiwara J, et al. Diagnostic accuracy of 443. Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC, et al. Diagnostic
cardiac magnetic resonance imaging for cardiac sarcoidosis in complete heart block pa- accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose posi-
tients implanted with magnetic resonance-conditional pacemaker. J Cardiol 2020;76: tron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur
191–7.  Heart J Cardiovasc Imaging 2018;19:757–67. 
423. Stanton KM, Ganigara M, Corte P, Celermajer DS, McGuire MA, Torzillo PJ, et al. The 444. Aitken M, Davidson M, Chan MV, Urzua Fresno C, Vasquez LI, Huo YR, et al.
utility of cardiac magnetic resonance imaging in the diagnosis of cardiac sarcoidosis. Prognostic value of cardiac MRI and FDG PET in cardiac sarcoidosis: a systematic re-
Heart Lung Circ 2017;26:1191–9.  view and meta-analysis. Radiology 2023;307:e222483. 
424. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of 222483
myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77. 445. Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, et al. Is there an
 association between clinical presentation and the location and extent of myocardial
425. Zhang J, Li Y, Xu Q, Xu B, Wang H. Cardiac magnetic resonance imaging for diagnosis involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron
of cardiac sarcoidosis: a meta-analysis. Can Respir J 2018;2018:7457369.  emission tomography? Circ Cardiovasc Imaging 2013;6:617–26. 
org/10.1155/2018/7457369 1161/CIRCIMAGING.112.000289
426. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 446. Muser D, Santangeli P, Castro SA, Liang JJ, Enriquez A, Werner TJ, et al. Prognostic role
18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaana- of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in pa-
lysis including the Ontario experience. J Nucl Med 2012;53:241–8.  tients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl
2967/jnumed.111.090662 Med Mol Imaging 2018;45:1394–404. 
427. Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Hybrid 447. Ahmed AI, Abebe AT, Han Y, Alnabelsi T, Agrawal T, Kassi M, et al. The prognostic role
magnetic resonance imaging and positron emission tomography with fluorodeoxyglu- of cardiac positron emission tomography imaging in patients with sarcoidosis: a sys-
cose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11:94–107. tematic review. J Nucl Cardiol 2021;28:1545–52. 
 02681-z
428. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 448. Flores RJ, Flaherty KR, Jin Z, Bokhari S. The prognostic value of quantitating and local-
18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989–98. izing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol 2020;27:2003–10. https://
 doi.org/10.1007/s12350-018-01504-y
429. Vita T, Okada DR, Veillet-Chowdhury M, Bravo PE, Mullins E, Hulten E, et al. 449. Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R, et al.
Complementary value of cardiac magnetic resonance imaging and positron emission Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F–
tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11:
Cardiovasc Imaging 2018;11:e007030.  336–45. 
007030 450. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al.
430. Agoston-Coldea L, Kouaho S, Sacre K, Dossier A, Escoubet B, Chillon S, et al. High Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tom-
mass (>18 g) of late gadolinium enhancement on CMR imaging is associated with ma- ography is associated with improved left ventricular ejection fraction in patients with
jor cardiac events on long-term outcome in patients with biopsy-proven extracardiac cardiac sarcoidosis. J Nucl Cardiol 2014;21:166–74. 
sarcoidosis. Int J Cardiol 2016;222:950–6.  013-9828-6
Downloaded
from

by
guest
on
22
January
2026

4036 E S C G u id e l in e s
451. Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, et al. Cardiac 471. Stewart GC, Lopez-Molina J, Gottumukkala RVSRK, Rosner GF, Anello MS, Hecht JL,
sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic
2020;220:246–52.  phenotype in adults with heart failure. Circ Heart Fail 2011;4:71–8. 
452. Nordenswan H-K, Lehtonen J, Ekström K, Kandolin R, Simonen P, Mäyränpää M, et al. 1161/CIRCHEARTFAILURE.110.958249
Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ 472. Robinson J, Hartling L, Vandermeer B, Sebastianski M, Klassen TP. Intravenous im-
Arrhythm Electrophysiol 2018;11:e006145.  munoglobulin for presumed viral myocarditis in children and adults. Cochrane
006145 Database Syst Rev 2020;8:CD004370. 
453. Halawa A, Jain R, Turagam MK, Kusumoto FM, Woldu HG, Gautam S. Outcome of pub4
implantable cardioverter defibrillator in cardiac sarcoidosis: a systematic review and 473. Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al.
meta-analysis. J Interv Card Electrophysiol 2020;58:233–42.  Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular
s10840-020-00705-1 function in patients with myocardial persistence of viral genomes and left ventricular dys-
454. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable cardi- function. Circulation 2003;107:2793–8. 
overter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc 67150.51
Electrophysiol 2012;23:925–9.  474. Kühl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss H-P. Interferon-beta im-
455. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. proves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012;60:
Long-term follow-up of patients with cardiac sarcoidosis and implantable 1295–6. 
cardioverter-defibrillators. Heart Rhythm 2012;9:884–91.  475. Schultheiss H-P, Bock C-T, Aleshcheva G, Baumeier C, Poller W, Escher F.
hrthm.2012.02.010 Interferon-β suppresses transcriptionally active parvovirus B19 infection in viral car-
456. Franke KB, Marshall H, Kennewell P, Pham H-D, Tully PJ, Rattanakosit T, et al. Risk and diomyopathy: a subgroup analysis of the BICC-trial. Viruses 2022;14:444. 
predictors of sudden death in cardiac sarcoidosis: a systematic review and org/10.3390/v14020444
meta-analysis. Int J Cardiol 2021;328:130–40.  476. Cobas M, Abbo L, Santos M, Baccini-Jauregui C, Pham S. Successful management of
044 fulminant influenza A subtype H1N1 myocarditis. BMJ Case Rep 2010;2010:
457. Mathijssen H, Bakker ALM, Balt JC, Akdim F, van Es HW, Veltkamp M, et al. Predictors bcr0220102763. 
of appropriate implantable cardiac defibrillator therapy in cardiac sarcoidosis. J 477. Baik SH, Jeong HS, Kim SJ, Yoon YK, Sohn JW, Kim MJ. A case of influenza associated
Cardiovasc Electrophysiol 2022;33:1272–80.  fulminant myocarditis successfully treated with intravenous peramivir. Infect
458. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, et al. Magnetic Chemother 2015;47:272–7. 
478. Jahns F-P, Ben-Hamouda N, Kirsch M, Roumy A, Liaudet L. Intravenous zanamivir for
resonance imaging for identifying patients with cardiac sarcoidosis and preserved or
influenza myocarditis and enteral malabsorption. Crit Care 2018;22:332. 
mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ
org/10.1186/s13054-018-2263-y
Arrhythm Electrophysiol 2014;7:1109–15. 
479. Mazzitelli M, Garofalo E, Bruni A, Barreca GS, Quirino A, Giancotti A, et al. Severe
459. Shafee MA, Fukuda K, Wakayama Y, Nakano M, Kondo M, Hasebe Y, et al. Delayed
myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman suc-
enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in pa-
cessfully treated with intravenous zanamivir: a case report. Clin Case Rep 2019;7:
tients with cardiac sarcoidosis. J Cardiol 2012;60:448–53. 
2336–40. 
2012.08.002
480. Yoshimizu N, Tominaga T, Ito T, Nishida Y, Wada Y, Sohmiya K, et al. Repetitive ful-
460. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary preven-
minant influenza myocarditis requiring the use of circulatory assist devices. Intern Med
tion of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricu-
2014;53:109–14. 
lar stimulation. Circ Arrhythm Electrophysiol 2011;4:43–8. 
481. Khouzam RN, Parizianu C, Hafiz AM, Chawla S, Schwartz R. Fulminant myocarditis as-
CIRCEP.110.958322
sociated with novel H1N1 influenza A. Heart Lung 2011;40:566–8. 
461. Okada DR, Smith J, Derakhshan A, Gowani Z, Zimmerman SL, Misra S, et al.
1016/j.hrtlng.2011.01.004
Electrophysiology study for risk stratification in patients with cardiac sarcoidosis and
482. Ito N, Sato M, Momoi N, Aoyagi Y, Endo K, Chishiki M, et al. Influenza A H1N1
abnormal cardiac imaging. Int J Cardiol Heart Vasc 2019;23:100342. 
pdm09-associated myocarditis during zanamivir therapy. Pediatr Int 2015;57:1172–4.
1016/j.ijcha.2019.03.002

462. Adhaduk M, Paudel B, Liu K, Ashwath M, Giudici M. The role of electrophysiology
483. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active
study in risk stratification of cardiac sarcoidosis patients: meta-analyses and systemic
antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000;
review. Int J Cardiol 2022;349:55–61. 
40:282–4. 
463. Zipse MM, Tzou WS, Schuller JL, Aleong RG, Varosy PD, Tompkins C, et al.
484. Steere AC, Batsford WP, Weinberg M, Alexander J, Berger HJ, Wolfson S, et al. Lyme
Electrophysiologic testing for diagnostic evaluation and risk stratification in patients
carditis: cardiac abnormalities of Lyme disease. Ann Intern Med 1980;93:8–16. https://
with suspected cardiac sarcoidosis with preserved left and right ventricular systolic
doi.org/10.7326/0003-4819-93-1-8
function. J Cardiovasc Electrophysiol 2019;30:1939–48. 
485. Besant G, Wan D, Yeung C, Blakely C, Branscombe P, Suarez-Fuster L, et al. Suspicious
14058 index in Lyme carditis: systematic review and proposed new risk score. Clin Cardiol
464. Tandon P, Mosleh T, Mustafa A, Miodownik H, Miller M, Morgenthau AS. Utility of
2018;41:1611–6. 
electrophysiologic testing for sudden death risk stratification in cardiac sarcoidosis pa- 486. Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME,
tients with mildly impaired left ventricular function. Respir Med 2022;191:106712. Auwaerter PG, et al. Clinical Practice Guidelines by the Infectious Diseases Society
 of America (IDSA), American Academy of Neurology (AAN), and American
465. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac posi- College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and
tron emission tomography enhances prognostic assessments of patients with sus- treatment of Lyme disease. Arthritis Care Res (Hoboken) 2021;73:1–9. 
pected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329–36.  10.1002/acr.24495
1016/j.jacc.2013.09.022 487. Costello JM, Alexander ME, Greco KM, Perez-Atayde AR, Laussen PC. Lyme carditis in
466. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efficacy and safety of children: presentation, predictive factors, and clinical course. Pediatrics 2009;123:
implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients e835–841. 
with cardiac sarcoidosis. Europace 2013;15:347–54.  488. Nunes MCP, Badano LP, Marin-Neto JA, Edvardsen T, Fernández-Golfín C,
eus316 Bucciarelli-Ducci C, et al. Multimodality imaging evaluation of Chagas disease: an ex-
467. Stevenson A, Bray JJH, Tregidgo L, Ahmad M, Sharma A, Ng A, et al. Prognostic value of pert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the
late gadolinium enhancement detected on cardiac magnetic resonance in cardiac sar- European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc
coidosis. JACC Cardiovasc Imaging 2023;16:345–57.  Imaging 2018;19:459–60. 
10.018 489. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al.
468. Veronese G, Ammirati E, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Viral gen- Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med
ome search in myocardium of patients with fulminant myocarditis. Eur J Heart Fail 2015;373:1295–306. 
2020;22:1277–80.  490. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J,
469. Sinagra G, Porcari A, Gentile P, Artico J, Fabris E, Bussani R, et al. Viral presence-guided López-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic re-
immunomodulation in lymphocytic myocarditis: an update. Eur J Heart Fail 2021;23: view with a meta-analysis. J Antimicrob Chemother 2009;64:1139–47. 
211–6.  1093/jac/dkp357
470. Moimas S, Zacchigna S, Merlo M, Buiatti A, Anzini M, Dreas L, et al. Idiopathic dilated 491. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term car-
cardiomyopathy and persistent viral infection: lack of association in a controlled study diac outcomes of treating chronic Chagas disease with benznidazole versus no treat-
using a quantitative assay. Heart Lung Circ 2012;21:787–93.  ment: a nonrandomized trial. Ann Intern Med 2006;144:724–34. 
hlc.2012.07.013 7326/0003-4819-144-10-200605160-00006
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4037
492. Chadalawada S, Rassi A, Samara O, Monzon A, Gudapati D, Vargas Barahona L, et al. 513. Thanjan MT, Ramaswamy P, Lai WW, Lytrivi ID. Acute myopericarditis after multiple
Mortality risk in chronic Chagas cardiomyopathy: a systematic review and vaccinations in an adolescent: case report and review of the literature. Pediatrics 2007;
meta-analysis. ESC Heart Fail 2021;8:5466–81.  119:e1400–3. 
493. Carmo AAL, de Sousa MR, Agudelo JF, Boersma E, Rocha MOC, Ribeiro ALP, et al. 514. Dilber E, Karagöz T, Aytemir K, Ozer S, Alehan D, Oto A, et al. Acute myocarditis as-
Implantable cardioverter-defibrillator in Chagas heart disease: a systematic review sociated with tetanus vaccination. Mayo Clin Proc 2003;78:1431–3. 
and meta-analysis of observational studies. Int J Cardiol 2018;267:88–93.  4065/78.11.1431-a
org/10.1016/j.ijcard.2018.05.091 515. Boccara F, Benhaiem-Sigaux N, Cohen A. Acute myopericarditis after diphtheria, tet-
494. Rassi FM, Minohara L, Rassi A, Correia LCL, Marin-Neto JA, Rassi A, et al. Systematic anus, and polio vaccination. Chest 2001;120:671–2. 
review and meta-analysis of clinical outcome after implantable cardioverter- 2.671
defibrillator therapy in patients with Chagas heart disease. JACC Clin Electrophysiol 516. Barton M, Finkelstein Y, Opavsky MA, Ito S, Ho T, Ford-Jones LE, et al. Eosinophilic
2019;5:1213–23.  myocarditis temporally associated with conjugate meningococcal C and hepatitis B
495. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. vaccines in children. Pediatr Infect Dis J 2008;27:831–5. 
Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 0b013e31816ff7b2
2018;71:1755–64.  517. Lu J, Zhang X, Xu H, Li Z. Inspiration to mRNA-based COVID-19 vaccination: serious
496. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. adverse case reports with hepatitis B vaccine in real-world. Front Pediatr 2022;10:
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observa- 888686. 
tional, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579–89. 518. Nagano N, Yano T, Fujita Y, Koyama M, Hasegawa R, Nakata J, et al. Hemodynamic
 collapse after influenza vaccination: a vaccine-induced fulminant myocarditis? Can J
497. Suzuki Y, Kaneko H, Tamura Y, Okada A, Fujiu K, Michihata N, et al. Cardiovascular Cardiol 2020;36:1554.e5–e7. 
events after the initiation of immune checkpoint inhibitors. Heliyon 2023;9:e16373. 519. Jain SS, Anderson SA, Steele JM, Wilson HC, Muniz JC, Soslow JH, et al. Cardiac man-
 ifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in
498. Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, et al. the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV)
Systematic analysis of drug-associated myocarditis reported in the World Health multicenter study. EClinicalMedicine 2024;76:102809. 
Organization pharmacovigilance database. Nat Commun 2022;13:25.  2024.102809
10.1038/s41467-021-27631-8 520. Peretto G, Micaglio E, Ciconte G, Maia M, Luzzi M, Cariello M, et al. The ‘arrhythmic’
499. Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J. Cardiotoxicity of immune checkpoint presentation of peripartum cardiomyopathy: case series and critical review of the lit-
inhibitors: a frequency network meta-analysis. Front Immunol 2022;13:1006860. erature. Front Cardiovasc Med 2024;11:1362692. 
 1362692
500. Pradhan R, Nautiyal A, Singh S. Diagnosis of immune checkpoint inhibitor-associated 521. Hoevelmann J, Engel ME, Muller E, Hohlfeld A, Böhm M, Sliwa K, et al. A global perspec-
myocarditis: a systematic review. Int J Cardiol 2019;296:113–21.  tive on the management and outcomes of peripartum cardiomyopathy: a systematic
1016/j.ijcard.2019.07.025 review and meta-analysis. Eur J Heart Fail 2022;24:1719–36. 
501. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ejhf.2603
2022 ESC Guidelines on cardio-oncology developed in collaboration with the 522. Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of
European Hematology Association (EHA), the European Society for Therapeutic peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 2011;118:583–91. 
(IC-OS). Eur Heart J 2022;43:4229–361.  523. Karaye KM, Ishaq NA, Sa’idu H, Balarabe SA, Talle MA, Isa MS, et al. Incidence, clinical
502. Salem J-E, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to miti- the PEACE Registry. ESC Heart Fail 2020;7:235–43. 
gate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 2023;13: 524. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic
1100–15.  landscape of peripartum cardiomyopathy. Circulation 2021;143:1852–62. 
503. L’Orphelin J-M, Dollalille C, Akroun J, Alexandre J, Dompmartin A. Cardiovascular im- org/10.1161/CIRCULATIONAHA.120.052395
munotoxicity associated with immune checkpoint inhibitors in metastatic melanoma. 525. Mallikethi-Reddy S, Akintoye E, Trehan N, Sharma S, Briasoulis A, Jagadeesh K, et al.
Cancers (Basel) 2023;15:2170.  Burden of arrhythmias in peripartum cardiomyopathy: analysis of 9841 hospitaliza-
504. Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, et al. tions. Int J Cardiol 2017;235:114–7. 
Cardiovascular toxicities of immune therapies for cancer—a scientific statement of 526. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current
the Heart Failure Association (HFA) of the ESC and the ESC Council of state of knowledge on aetiology, diagnosis, management, and therapy of peripartum
Cardio-Oncology. Eur J Heart Fail 2024;26:2055–76.  cardiomyopathy: a position statement from the Heart Failure Association of the
505. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune check- European Society of Cardiology Working Group on peripartum cardiomyopathy.
point inhibitor rechallenge after immune-related adverse events in patients with can- Eur J Heart Fail 2010;12:767–78. 
cer. JAMA Oncol 2020;6:865–71.  527. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natriuretic
506. Clapham E, Reutfors J, Linder M, Brandt L, Sundström J, Bodén R. The association be- peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56:1247–53.
tween exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyo- 
carditis and heart failure: a population-based cohort study. Psychiatry Res 2023;326: 528. Esbrand FD, Zafar S, Panthangi V, Cyril Kurupp AR, Raju A, Luthra G, et al. Utility of
115336.  N-terminal (NT)-brain natriuretic peptide (proBNP) in the diagnosis and prognosis of
507. Sandarsh S, Bishnoi RJ, Shashank RB, Miller BJ, Freudenreich O, McEvoy JP. Monitoring pregnancy associated cardiovascular conditions: a systematic review. Cureus 2022;14:
for myocarditis during treatment initiation with clozapine. Acta Psychiatr Scand 2021; e32848. 
144:194–200.  529. Li W, Li H, Long Y. Clinical characteristics and long-term predictors of persistent left
508. Siskind D, Sidhu A, Cross J, Chua Y-T, Myles N, Cohen D, et al. Systematic review and ventricular systolic dysfunction in peripartum cardiomyopathy. Can J Cardiol 2016;32:
meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N 362–8. 
Z J Psychiatry 2020;54:467–81.  530. Arora NP, Mahajan N, Mohamad T, Kottam A, Afonso LC, Danrad R, et al. Cardiac
509. Seree-aphinan C, Assanangkornchai N, Nilmoje T. Prolonged extracorporeal mem- magnetic resonance imaging in peripartum cardiomyopathy. Am J Med Sci 2014;347:
brane oxygenation support in a patient with drug reaction with eosinophilia and sys- 112–7. 
temic symptoms syndrome-associated fulminant myocarditis—a case report and 531. Ordovas KG, Baldassarre LA, Bucciarelli-Ducci C, Carr J, Fernandes JL, Ferreira VM,
literature review. Heart Int 2020;14:112–7.  et al. Cardiovascular magnetic resonance in women with cardiovascular disease: pos-
510. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton ition statement from the Society for Cardiovascular Magnetic Resonance (SCMR). J
Collaboration: addressing the need for standardized case definitions of adverse events Cardiovasc Magn Reson 2021;23:52. 
following immunization (AEFI). Vaccine 2002;21:298–302.  532. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI
s0264-410x(02)00449-8 exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316:
511. Engler RJM, Montgomery JR, Spooner CE, Nelson MR, Collins LC, Ryan MA, et al. 952–61. 
Myocarditis and pericarditis recovery following smallpox vaccine 2002–2016: a com- 533. Schelbert EB, Elkayam U, Cooper LT, Givertz MM, Alexis JD, Briller J, et al. Myocardial
parative observational cohort study in the military health system. PLoS One 2023;18: damage detected by late gadolinium enhancement cardiac magnetic resonance is un-
e0283988.  common in peripartum cardiomyopathy. J Am Heart Assoc 2017;6:e005472. https://
512. Parmar K, Subramanyam S, Del Rio-Pertuz G, Sethi P, Argueta-Sosa E. Cardiac adverse doi.org/10.1161/JAHA.117.005472
events after vaccination—a systematic review. Vaccines (Basel) 2022;10:700. https:// 534. Cooper LT, Mather PJ, Alexis JD, Pauly DF, Torre-Amione G, Wittstein IS, et al.
doi.org/10.3390/vaccines10050700 Myocardial recovery in peripartum cardiomyopathy: prospective comparison with
Downloaded
from

by
guest
on
22
January
2026

4038 E S C G u id e l in e s
recent onset cardiomyopathy in men and nonperipartum women. J Card Fail 2012;18: 555. Peretto G, Sala S, De Luca G, Marcolongo R, Campochiaro C, Sartorelli S, et al.
28–33.  Immunosuppressive therapy and risk stratification of patients with myocarditis pre-
535. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical out- senting with ventricular arrhythmias. JACC Clin Electrophysiol 2020;6:1221–34. https://
comes for peripartum cardiomyopathy in North America: results of the IPAC study doi.org/10.1016/j.jacep.2020.05.013
(investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol 2015;66: 556. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large aca-
905–14.  demic hospital in South Africa. Epidemiol Infect 2005;133:393–9. 
536. Biteker M, Özlek B, Özlek E, Çil C, Çelik O, Doğan V, et al. Predictors of early and de- 1017/s0950268804003577
layed recovery in peripartum cardiomyopathy: a prospective study of 52 patients. J 557. Mayosi BM, Wiysonge CS, Ntsekhe M, Gumedze F, Volmink JA, Maartens G, et al.
Matern Fetal Neonatal Med 2020;33:390–7.  Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr
1494146 Med J 2008;98:36–40.
537. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the in- 558. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 2005;112:
cidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin 3608–16. 
Proc 2005;80:1602–6.  559. Isiguzo G, Du Bruyn E, Howlett P, Ntsekhe M. Diagnosis and management of tubercu-
538. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, et al. Long-term lous pericarditis: what is new? Curr Cardiol Rep 2020;22:2. 
follow-up in peripartum cardiomyopathy patients with contemporary treatment: low s11886-020-1254-1
mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J 560. Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Fail Rev
Heart Fail 2019;21:1534–42.  2013;18:367–73. 
539. Sliwa K, Azibani F, Baard J, Osman A, Zühlke L, Lachmann A, et al. Reducing late ma- 561. Noubiap JJ, Agbor VN, Ndoadoumgue AL, Nkeck JR, Kamguia A, Nyaga UF, et al.
ternal death due to cardiovascular disease—a pragmatic pilot study. Int J Cardiol 2018; Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart
272:70–6.  2019;105:180–8. 
540. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJS, Crespo-Leiro MG, 562. Xie DL, Cheng B, Sheng Y, Jin J. Diagnostic accuracy of adenosine deaminase for tuber-
et al. Current management of patients with severe acute peripartum cardiomyopathy: culous pericarditis: a meta-analysis. Eur Rev Med Pharmacol Sci 2015;19:4411–8. https://
practical guidance from the Heart Failure Association of the European Society of doi.org/10.18632/eurrev_2015_19_22_4411
Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016;18: 563. Pandie S, Peter JG, Kerbelker ZS, Meldau R, Theron G, Govender U, et al. Diagnostic
1096–105.  accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared
541. Fu K, Zhang H, Chen N, Hu Y, Xiao J, Zhang X, et al. Risk factors for intracardiac to adenosine deaminase and unstimulated interferon-γ in a high burden setting: a pro-
thrombus in peripartum cardiomyopathy: a retrospective study in China. ESC Heart spective study. BMC Med 2014;12:101. 
Fail 2023;10:148–58.  564. Yu G, Ye B, Chen D, Zhong F, Chen G, Yang J, et al. Comparison between the diag-
542. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. nostic validities of Xpert MTB/RIF and interferon-γ release assays for tuberculous peri-
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre rando- carditis using pericardial tissue. PLoS One 2017;12:e0188704. 
mized study. Eur Heart J 2017;38:2671–9.  journal.pone.0188704
543. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J-P, Becker A, et al. Evaluation of 565. Liu C, Cui Y-L, Ding C-M, Wu Y-H, Li H-L, Liu X-F, et al. Diagnostic accuracy of
bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a interferon-gamma in pericardial effusions for tuberculous pericarditis: a meta-analysis.
proof-of-concept pilot study. Circulation 2010;121:1465–73.  J Thorac Dis 2018;10:854–60. 
CIRCULATIONAHA.109.901496 566. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al.
544. Kumar A, Ravi R, Sivakumar RK, Chidambaram V, Majella MG, Sinha S, et al. Prolactin Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in
inhibition in peripartum cardiomyopathy: systematic review and meta-analysis. Curr HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune
Probl Cardiol 2023;48:101461.  Defic Syndr 2011;56:230–38. 
545. Trongtorsak A, Kittipibul V, Mahabir S, Ibrahim M, Saint Croix GR, Hernandez GA, 567. Wiysonge CS, Ntsekhe M, Thabane L, Volmink J, Majombozi D, Gumedze F, et al.
et al. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2017;
and meta-analysis. Heart Fail Rev 2022;27:533–43.  9:CD000526. 
021-10185-8 568. Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, Gumedze F, et al.
546. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality.
of pharmacological treatment for heart failure in patients with recovered dilated car- EBioMedicine 2015;2:1634–9. 
diomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393: 569. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al. Prednisolone and
61–73.  Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014;371:
547. Codsi E, Rose CH, Blauwet LA. Subsequent pregnancy outcomes in patients with peri- 1121–30. 
partum cardiomyopathy. Obstet Gynecol 2018;131:322–7.  570. Reuter H, Burgess LJ, Louw VJ, Doubell AF. The management of tuberculous pericar-
AOG.0000000000002439 dial effusion: experience in 233 consecutive patients. Cardiovasc J S Afr 2007;18:20–5.
548. Meng M-L, Arendt KW, Banayan JM, Bradley EA, Vaught AJ, Hameed AB, et al. 571. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of pred-
Anesthetic care of the pregnant patient with cardiovascular disease: a scientific state- nisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei.
ment from the American Heart Association. Circulation 2023;147:e657–73.  Lancet 1987;2:1418–22. 
org/10.1161/CIR.0000000000001121 572. Strang JIG, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ. Management of
549. De Backer J, Haugaa K. 2025 ESC Guidelines for the management of cardiovascular tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: re-
disease and pregnancy. Eur Heart J. 2011;32:3147–97.  sults at 10 years follow-up. QJM 2004;97:525–35. 
eurheartj/ehr218 573. Cui H-B, Chen X-Y, Cui C-C, Shou X-L, Liu X, Yao X-W, et al. Prevention of pericar-
550. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, et al. Report dial constriction by transcatheter intrapericardial fibrinolysis with urokinase. Chin Med
of the 1995 World Health Organization/International Society and Federation of Sci J 2005;20:5–10. 
Cardiology Task Force on the definition and classification of cardiomyopathies. 574. Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in
Circulation 1996;93:841–2.  patients with neoplastic disease. Prog Cardiovasc Dis 2010;53:157–63. 
551. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosup- 10.1016/j.pcad.2010.06.003
pressive therapy in patients with virus-negative inflammatory cardiomyopathy: the 575. Imazio M, Demichelis B, Parrini I, Favro E, Beqaraj F, Cecchi E, et al. Relation of acute
TIMIC study. Eur Heart J 2009;30:1995–2002.  pericardial disease to malignancy. Am J Cardiol 2005;95:1393–4. 
ehp249 1016/j.amjcard.2005.01.094
552. Escher F, Kühl U, Lassner D, Poller W, Westermann D, Pieske B, et al. Long-term out- 576. Pawlak Cieślik A, Szturmowicz M, Fijałkowska A, Gątarek J, Gralec R,
come of patients with virus-negative chronic myocarditis or inflammatory cardiomy- Błasińska-Przerwa K, et al. Diagnosis of malignant pericarditis: a single centre experi-
opathy after immunosuppressive therapy. Clin Res Cardiol 2016;105:1011–20. ence. Kardiol Pol 2012;70:1147–53. 
 577. Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in ma-
553. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, lignant and non-malignant pericardial effusion. Heart Fail Rev 2013;18:337–44. https://
et al. Immunosuppressive therapy improves both short- and long-term prognosis in doi.org/10.1007/s10741-012-9327-x
patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart 578. Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, et al. Cardiac toxicity after
Fail 2018;11:e004228.  radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation
554. De Luca G, Campochiaro C, Sartorelli S, Peretto G, Sala S, Palmisano A, et al. Efficacy trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387–94. 
and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myo- JCO.2016.70.0229
carditis: a prospective cohort study. J Autoimmun 2020;106:102330.  579. Takata N, Kataoka M, Hamamoto Y, Tsuruoka S, Kanzaki H, Uwatsu K, et al. Risk fac-
1016/j.jaut.2019.102330 tors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4039
comparison of four-field technique and traditional two opposed fields technique. J Surgery substudy. Am Heart J 2014;168:126–31.e1. 
Radiat Res 2018;59:291–7.  03.017
580. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. 600. Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH, et al. Meta-analysis
Evaluation and management of cancer patients presenting with acute cardiovascular of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J
disease: a Consensus Document of the Acute CardioVascular Care (ACVC) associ- Cardiol 2011;108:575–9. 
ation and the ESC Council of Cardio-Oncology—Part 1: acute coronary syndromes 601. Meurin P, Tabet JY, Thabut G, Cristofini P, Farrokhi T, Fischbach M, et al. Nonsteroidal
and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;10:947–59. anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter
 randomized, double-blind trial. Ann Intern Med 2010;152:137–43. 
581. Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, et al. Diagnostic yield of 7326/0003-4819-152-3-201002020-00004
cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 spe- 602. Meurin P, Lelay-Kubas S, Pierre B, Pereira H, Pavy B, Iliou MC, et al. Colchicine for post-
cimens. Cancer Cytopathol 2017;125:128–37.  operative pericardial effusion: a multicentre, double-blind, randomised controlled trial.
582. Numico G, Cristofano A, Occelli M, Sicuro M, Mozzicafreddo A, Fea E, et al. Prolonged Heart 2015;101:1711–6. 
drainage and intrapericardial bleomycin administration for cardiac tamponade second- 603. Meurin P, Weber H, Renaud N, Larrazet F, Tabet JY, Demolis P, et al. Evolution of the
ary to cancer-related pericardial effusion. Medicine (Baltimore) 2016;95:e3273. https:// postoperative pericardial effusion after day 15: the problem of the late tamponade.
doi.org/10.1097/MD.0000000000003273 Chest 2004;125:2182–7. 
583. Kim SR, Kim EK, Cho J, Chang S-A, Park S-J, Lee S-C, et al. Effect of anti-inflammatory 604. Andreis A, Imazio M, Giustetto C, Brucato A, Adler Y, De Ferrari GM. Anakinra for
drugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll constrictive pericarditis associated with incessant or recurrent pericarditis. Heart
Cardiol 2020;76:1551–61.  2020;106:1561–5. 
584. De Filippo O, Gatti P, Rettegno S, Iannaccone M, D’Ascenzo F, Lazaros G, et al. Is peri- 605. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification
cardial effusion a negative prognostic marker? Meta-analysis of outcomes of pericardial criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019;78:1025–32.
effusion. J Cardiovasc Med (Hagerstown) 2019;20:39–45.  
0000000000000720 606. Sagristà-Sauleda J, Barrabés JA, Permanyer-Miralda G, Soler-Soler J. Purulent pericar-
585. Gatzoulis K, Archontakis S, Tsiachris D, Lazaros G, Apostolopoulos T, Zervopoulos G, ditis: review of a 20-year experience in a general hospital. J Am Coll Cardiol 1993;22:
et al. Post-cardiac injury syndrome after permanent electronic cardiac device implant- 1661–5. 
ation. Incidence, presentation, management and long-term prognosis. Int J Cardiol 607. Rubin RH, Moellering RC. Clinical, microbiologic and therapeutic aspects of purulent
2014;174:163–4.  pericarditis. Am J Med 1975;59:68–78. 
586. Nakhla S, Mentias A, Rymer C, Hussein A, Wazni O, Rickard J, et al. Acute pericarditis 608. Brook I, Frazier EH. Microbiology of acute purulent pericarditis. A 12-year experience
after atrial fibrillation ablation: incidence, characteristics, and risk factors. Heart Rhythm
in a military hospital. Arch Intern Med 1996;156:1857–60. 
2022;3:248–51. 
archinte.1996.00440150113013
587. Imazio M, Negro A, Belli R, Beqaraj F, Forno D, Giammaria M, et al. Frequency and
609. Wiyeh AB, Ochodo EA, Wiysonge CS, Kakia A, Awotedu AA, Ristic A, et al. A system-
prognostic significance of pericarditis following acute myocardial infarction treated
atic review of the efficacy and safety of intrapericardial fibrinolysis in patients with peri-
by primary percutaneous coronary intervention. Am J Cardiol 2009;103:1525–9.
cardial effusion. Int J Cardiol 2018;250:223–8. 

049
588. Figueras J, Juncal A, Carballo J, Cortadellas J, Soler JS. Nature and progression of peri-
610. Augustin P, Desmard M, Mordant P, Lasocki S, Maury J-M, Heming N, et al. Clinical re-
cardial effusion in patients with a first myocardial infarction: relationship to age and free
view: intrapericardial fibrinolysis in management of purulent pericarditis. Crit Care
wall rupture. Am Heart J 2002;144:251–8. 
2011;15:220. 
589. Figueras J, Barrabés JA, Serra V, Cortadellas J, Lidón R-M, Carrizo A, et al. Hospital
611. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for re-
outcome of moderate to severe pericardial effusion complicating ST-elevation
current pericarditis (CORP): a randomized trial. Ann Intern Med 2011;155:409–14.
acute myocardial infarction. Circulation 2010;122:1902–9. 

1161/CIRCULATIONAHA.109.934968
612. Vogiatzidis K, Zarogiannis SG, Aidonidis I, Solenov EI, Molyvdas P-A, Gourgoulianis KI,
590. Mohanty S, Mohanty P, Kessler D, Gianni C, Baho KK, Morris T, et al. Impact of col-
et al. Physiology of pericardial fluid production and drainage. Front Physiol 2015;6:62.
chicine monotherapy on the risk of acute pericarditis following atrial fibrillation abla-

tion. JACC Clin Electrophysiol 2023;9:1051–9. 
613. Mitiku TY, Heidenreich PA. A small pericardial effusion is a marker of increased mor-
037
tality. Am Heart J 2011;161:152–7. 
591. Lehto J, Kiviniemi T, Gunn J, Airaksinen J, Rautava P, Kytö V. Occurrence of postper-
614. Corey GR, Campbell PT, Van Trigt P, Kenney RT, O’Connor CM, Sheikh KH, et al.
icardiotomy syndrome: association with operation type and postoperative mortality
Etiology of large pericardial effusions. Am J Med 1993;95:209–13. 
after open-heart operations. J Am Heart Assoc 2018;7:e010269. 
1016/0002-9343(93)90262-n 1161/JAHA.118.010269
615. Sagristà-Sauleda J, Mercé J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the
592. Imazio M, Brucato A, Rovere ME, Gandino A, Cemin R, Ferrua S, et al. Contemporary
causes of large pericardial effusions. Am J Med 2000;109:95–101. 
features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol
1016/s0002-9343(00)00459-9
2011;108:1183–7. 
616. Levy P-Y, Corey R, Berger P, Habib G, Bonnet J-L, Levy S, et al. Etiologic diagnosis of
593. Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, et al. Colchicine for
204 pericardial effusions. Medicine (Baltimore) 2003;82:385–91. 
the prevention of postpericardiotomy syndrome. Herz 2002;27:791–4. 
1097/01.md.0000101574.54295.73 10.1007/s00059-002-2376-5
617. Ma W, Liu J, Zeng Y, Chen S, Zheng Y, Ye S, et al. Causes of moderate to large peri-
594. Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, et al. COlchicine
for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, ran- cardial effusion requiring pericardiocentesis in 140 Han Chinese patients. Herz 2012;
domized, double-blind, placebo-controlled trial. Eur Heart J 2010;31:2749–54. https:// 37:183–7. 
doi.org/10.1093/eurheartj/ehq319 618. Abdallah R, Atar S. Etiology and characteristics of large symptomatic pericardial effu-
595. Imazio M, Brucato A, Ferrazzi P, Spodick DH, Adler Y. Postpericardiotomy syndrome: sion in a community hospital in the contemporary era. QJM 2014;107:363–8. https://
a proposal for diagnostic criteria. J Cardiovasc Med (Hagerstown) 2013;14:351–3. doi.org/10.1093/qjmed/hct255
 619. Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial
596. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al. Colchicine for pre- effusion have cardiac tamponade? JAMA 2007;297:1810–8. 
vention of postpericardiotomy syndrome and postoperative atrial fibrillation: the jama.297.16.1810
COPPS-2 randomized clinical trial. JAMA 2014;312:1016–23.  620. Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, et al. Complicated
1001/jama.2014.11026 pericarditis: understanding risk factors and pathophysiology to inform imaging and
597. Gill PJ, Forbes K, Coe JY. The effect of short-term prophylactic acetylsalicylic acid on treatment. J Am Coll Cardiol 2016;68:2311–28. 
the incidence of postpericardiotomy syndrome after surgical closure of atrial septal 785
defects. Pediatr Cardiol 2009;30:1061–7.  621. Lazaros G, Antonopoulos AS, Lazarou E, Vlachopoulos C, Foukarakis E, Androulakis A,
598. Mott AR, Fraser CD, Kusnoor AV, Giesecke NM, Reul GJ, Drescher KL, et al. The ef- et al. Long-term outcome of pericardial drainage in cases of chronic, large, hemo-
fect of short-term prophylactic methylprednisolone on the incidence and severity of dynamically insignificant, C-reactive protein negative, idiopathic pericardial effusions.
postpericardiotomy syndrome in children undergoing cardiac surgery with cardiopul- Am J Cardiol 2020;126:89–93. 
monary bypass. J Am Coll Cardiol 2001;37:1700–6.  622. Lazaros G, Oikonomou V, Oikonomou E, Aznaouridis K, Vlachopoulos C, Vogiatzi G,
1097(01)01223-2 et al. Recurrence of pericardial effusion after pericardiocentesis: does catheter-
599. Bunge JJH, van Osch D, Dieleman JM, Jacob KA, Kluin J, van Dijk D, et al. Dexamethasone induced acute pericardial inflammation play a role? Am J Med Sci 2021;361:676–8.
for the prevention of postpericardiotomy syndrome: a DExamethasone for Cardiac 
Downloaded
from

by
guest
on
22
January
2026

4040 E S C G u id e l in e s
623. Buoro S, Tombetti E, Ceriotti F, Simon C, Cugola D, Seghezzi M, et al. What is the nor- practice and applicability of adult protocols. Cardiol Young 2022;32:1957–65. https://
mal composition of pericardial fluid? Heart 2021;107:1584–90.  doi.org/10.1017/S1047951121005291
1136/heartjnl-2020-317966 647. Peng DM, Kwiatkowski DM, Lasa JJ, Zhang W, Banerjee M, Mikesell K, et al.
624. Imazio M, Biondo A, Ricci D, Boffini M, Pivetta E, Brucato A, et al. Contemporary bio- Contemporary care and outcomes of critically-ill children with clinically diagnosed
chemical analysis of normal pericardial fluid. Heart 2020;106:541–4.  myocarditis. J Card Fail 2023;30:350–8. 
1136/heartjnl-2018-314574 648. Schubert S, Opgen-Rhein B, Boehne M, Weigelt A, Wagner R, Müller G, et al. Severe
625. Imazio M, Lazaros G, Valenti A, De Carlini CC, Maggiolini S, Pivetta E, et al. Outcomes heart failure and the need for mechanical circulatory support and heart transplantation
of idiopathic chronic large pericardial effusion. Heart 2019;105:477–81.  in pediatric patients with myocarditis: results from the prospective multicenter registry
10.1136/heartjnl-2018-313532 ‘MYKKE’. Pediatr Transplant 2019;23:e13548. 
626. Fröhlich GM, Keller P, Schmid F, Wolfrum M, Osranek M, Falk C, et al. 649. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, et al. Clinical features of acute
Haemodynamically irrelevant pericardial effusion is associated with increased mortality and fulminant myocarditis in children – 2nd Nationwide Survey by Japanese Society of
in patients with chronic heart failure. Eur Heart J 2013;34:1414–23.  Pediatric Cardiology and Cardiac Surgery. Circ J 2016;80:2362–8. 
1093/eurheartj/eht006 1253/circj.CJ-16-0234
627. Porta-Sánchez A, Sagristà-Sauleda J, Ferreira-González I, Torrents-Fernández A, 650. Yao Q, Zhan S. Corticosteroid in anti-inflammatory treatment of pediatric acute myo-
Roca-Luque I, García-Dorado D. Constrictive pericarditis: etiologic spectrum, pat- carditis: a systematic review and meta-analysis. Ital J Pediatr 2023;49:30. 
terns of clinical presentation, prognostic factors, and long-term follow-up. Rev Esp 10.1186/s13052-023-01423-w
Cardiol (Engl Ed) 2015;68:1092–100.  651. Camargo PR, Snitcowsky R, da Luz PL, Mazzieri R, Higuchi ML, Rati M, et al. Favorable
628. Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB, et al. Constrictive effects of immunosuppressive therapy in children with dilated cardiomyopathy and ac-
pericarditis in the modern era: evolving clinical spectrum and impact on outcome after tive myocarditis. Pediatr Cardiol 1995;16:61–8. 
pericardiectomy. Circulation 1999;100:1380–6.  652. Aziz KU, Patel N, Sadullah T, Tasneem H, Thawerani H, Talpur S. Acute viral myocar-
629. Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, ditis: role of immunosuppression: a prospective randomised study. Cardiol Young 2010;
et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiect- 20:509–15. 
omy. J Am Coll Cardiol 2004;43:1445–52.  653. Lin M-S, Tseng Y-H, Chen M-Y, Chung C-M, Tsai M-H, Wang P-C, et al. In-hospital and
630. Mutyaba AK, Balkaran S, Cloete R, du Plessis N, Badri M, Brink J, et al. Constrictive peri- post-discharge outcomes of pediatric acute myocarditis underwent after high-dose
carditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South steroid or intravenous immunoglobulin therapy. BMC Cardiovasc Disord 2019;19:10.
Africa: causes and perioperative outcomes in the HIV era (1990–2012). J Thorac

Cardiovasc Surg 2014;148:3058–65.e1. 
654. Butts RJ, Boyle GJ, Deshpande SR, Gambetta K, Knecht KR, Prada-Ruiz CA, et al.
631. Yang J, Xiang W, He R, Zhang P. Tuberculous constrictive pericarditis: ‘armored heart’.
Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi-
QJM 2024;117:679–80. 
center cohort. Pediatr Cardiol 2017;38:1175–82. 
632. Welch TD, Ling LH, Espinosa RE, Anavekar NS, Wiste HJ, Lahr BD, et al.
1638-1
Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ
655. Huang X, Sun Y, Su G, Li Y, Shuai X. Intravenous immunoglobulin therapy for acute
Cardiovasc Imaging 2014;7:526–34. 
myocarditis in children and adults. Int Heart J 2019;60:359–65. 
633. Talreja DR, Nishimura RA, Oh JK, Holmes DR. Constrictive pericarditis in the modern
1536/ihj.18-299
era: novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll
656. Imazio M, Brucato A, Pluymaekers N, Breda L, Calabri G, Cantarini L, et al. Recurrent
Cardiol 2008;51:315–9. 
pericarditis in children and adolescents: a multicentre cohort study. J Cardiovasc Med
634. Qamruddin S, Alkharabsheh SK, Sato K, Kumar A, Cremer PC, Chetrit M, et al.
(Hagerstown) 2016;17:707–12. 
Differentiating constriction from restriction (from the Mayo Clinic echocardiographic
657. Alsabri M, Elsayed SM, Elsnhory AB, Abouelmagd K, Ayyad M, Alqeeq BF, et al. Efficacy
criteria). Am J Cardiol 2019;124:932–8. 
and safety of colchicine in pediatric pericarditis: a systematic review and future direc-
635. Saito T, Fukushima S, Yamasaki T, Kawamoto N, Tadokoro N, Kakuta T, et al.
tions. Pediatr Cardiol 2024; 
Pericardiectomy for constrictive pericarditis at a single Japanese center: 20 years of ex-
658. Caorsi R, Insalaco A, Bovis F, Martini G, Cattalini M, Chinali M, et al. Pediatric recurrent
perience. Gen Thorac Cardiovasc Surg 2022;70:430–8. 
pericarditis: appropriateness of the standard of care and response to IL-1 blockade. J
021-01718-x
Pediatr 2023;256:18–26.e8. 
636. Choi MS, Jeong DS, Oh JK, Chang S-A, Park S-J, Chung S. Long-term results of radical
659. Sunohara D, Motoki H, Saigusa T, Ebisawa S, Okada A, Ando H, et al. Biopsy detection
pericardiectomy for constrictive pericarditis in Korean population. J Cardiothorac Surg
and clinical management of acute lymphocytic myocarditis in pregnancy. J Cardiol Cases
2019;14:32. 
2019;20:164–7. 
637. George TJ, Arnaoutakis GJ, Beaty CA, Kilic A, Baumgartner WA, Conte JV.
660. Veronese G, Nonini S, Cannata A, Aresta F, Olivieri G, Montrasio E, et al. Fulminant
Contemporary etiologies, risk factors, and outcomes after pericardiectomy. Ann
lymphocytic myocarditis during pregnancy treated with temporary mechanical circu-
Thorac Surg 2012;94:445–51. 
latory supports and aggressive immunosuppression. Circ Heart Fail 2022;15:
638. Tzani A, Doulamis IP, Tzoumas A, Avgerinos DV, Koudoumas D, Siasos G, et al.
e009810.  Meta-analysis of population characteristics and outcomes of patients undergoing peri-
661. Moore RC, Briery CM, Rose CH, Skelton TN, Martin JN. Lymphocytic myocarditis
cardiectomy for constrictive pericarditis. Am J Cardiol 2021;146:120–7. 
presenting as nausea, vomiting, and hepatic dysfunction in the first trimester of preg-
10.1016/j.amjcard.2021.01.033
639. Faiza Z, Prakash A, Namburi N, Johnson B, Timsina L, Lee LS. Fifteen-year experience nancy. Obstet Gynecol 2006;108:815–7. 
with pericardiectomy at a tertiary referral center. J Cardiothorac Surg 2021;16:180. 91685.52
 662. Marceau A, McGinnis JM, Derakhshan F, Liu YA, Sathananthan G, Sosa Cazales AC,
640. Gillaspie EA, Stulak JM, Daly RC, Greason KL, Joyce LD, Oh J, et al. A 20-year experi- et al. Interdisciplinary approach to an unusual case of myocarditis in pregnancy. CJC
ence with isolated pericardiectomy: analysis of indications and outcomes. J Thorac Open 2019;1:103–5. 
Cardiovasc Surg 2016;152:448–58.  663. Movva R, Brown SB, Morris DL, Figueredo VM. Anakinra for myocarditis in juvenile
641. Ntsekhe M, Shey Wiysonge C, Commerford PJ, Mayosi BM. The prevalence and out- idiopathic arthritis. Tex Heart Inst J 2013;40:623–5.
come of effusive constrictive pericarditis: a systematic review of the literature. 664. Brucato A, Pluymaekers N, Tombetti E, Rampello S, Maestroni S, Lucianetti M, et al.
Cardiovasc J Afr 2012;23:281–5.  Management of idiopathic recurrent pericarditis during pregnancy. Int J Cardiol 2019;
642. Thevathasan T, Kenny MA, Gaul AL, Paul J, Krause FJ, Lech S, et al. Sex and age char- 282:60–5. 
acteristics in acute or chronic myocarditis. a descriptive, multicenter cohort study. 665. Pouta AM, Räsänen JP, Airaksinen KE, Vuolteenaho OJ, Laatikainen TJ. Changes in ma-
JACC Adv 2024;3:100857.  ternal heart dimensions and plasma atrial natriuretic peptide levels in the early puer-
643. Kanaoka K, Onoue K, Terasaki S, Nakano T, Nakai M, Sumita Y, et al. Features and out- perium of normal and pre-eclamptic pregnancies. Br J Obstet Gynaecol 1996;103:
comes of histologically proven myocarditis with fulminant presentation. Circulation 988–92. 
2022;146:1425–33.  666. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková
644. Conte E, Leoni O, Ammirati E, Imazio M, Brucato A. Incidence of myocarditis and peri- R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis-
carditis considered as separate clinical events over the years and post-SARS-CoV2 vac- eases during pregnancy. Eur Heart J 2018;39:3165–241. 
cination in adults and children. Eur J Intern Med 2023;115:140–2.  eurheartj/ehy340
1016/j.ejim.2023.06.002 667. Schreiber K, Frishman M, Russell MD, Dey M, Flint J, Allen A, et al. British Society for
645. Klugman D, Berger JT, Sable CA, He J, Khandelwal SG, Slonim AD. Pediatric patients Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: co-
hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 2010;31: morbidity medications used in rheumatology practice. Rheumatology 2023;62:
222–8.  e89–e104. 
646. Pitak B, Opgen-Rhein B, Schubert S, Reineker K, Wiegand G, Boecker D, et al. 668. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin
Cardiovascular magnetic resonance in children with suspected myocarditis: current MD, et al. 2020 American College of Rheumatology Guideline for the management
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4041
of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 673. Peretto G, De Luca G, Campochiaro C, Palmisano A, Busnardo E, Sartorelli S, et al.
2020;72:529–56.  Telemedicine in myocarditis: evolution of a mutidisciplinary ‘disease unit’ at the time
669. Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers of COVID-19 pandemic. Am Heart J 2020;229:121–6. 
C, et al. The EULAR points to consider for use of antirheumatic drugs before preg- 2020.07.015
nancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810. https:// 674. Aldajani A, Bérubé M, Mardigyan V. How and why to set up a pericardial disease clinic.
doi.org/10.1136/annrheumdis-2015-208840
Can J Cardiol 2023;39:1149–51. 
670. Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society for
675. Mizia-Stec K, Charron P, Gimeno Blanes JR, Elliott P, Kaski JP, Maggioni AP, et al.
Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immu-
Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis
nomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology 2023;62:
of cardiomyopathy: the ESC EORP cardiomyopathy/myocarditis registry. Eur Heart J
e48–e88. 
Cardiovasc Imaging 2021;22:781–9. 
671. Bizzi E, Cavaleri F, Mascolo R, Conte E, Maggiolini S, Decarlini CC, et al. Recurrent peri-
676. Kaski JP, Norrish G, Gimeno Blanes JR, Charron P, Elliott P, Tavazzi L, et al.
carditis in older adults: clinical and laboratory features and outcome. J Am Geriatr Soc
2024;72:3467–75.  Cardiomyopathies in children and adolescents: aetiology, management, and outcomes
672. Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, et al. Medication in the European Society of Cardiology EURObservational Research Programme
non-adherence among elderly patients newly discharged and receiving polypharmacy. Cardiomyopathy and Myocarditis Registry. Eur Heart J 2024;45:1443–54. 
Drugs Aging 2014;31:283–9.  org/10.1093/eurheartj/ehae109
Downloaded
from

by
guest
on
22
January
2026
